

5

APPENDICES



Biennial Report of the Director
National Institutes of Health
Fiscal Years 2008 & 2009

Volume V

NIH Publication No. 11-7701
U.S. Department of Health and Human Services
National Institutes of Health

An electronic version of this report is available at:
<http://biennialreport.nih.gov> and contains many live links
to NIH programs, plans, and publications.

Volume V Contents

Chapter 5: Appendices

Appendix A: Legal Mandates for this Report	5-1
Appendix B: Priorities and Plans of the Institutes and Centers and the Program Offices in the Office of the Director.....	5-7
Appendix C: Common Fund Strategic Planning Report, 2009	5-13
Appendix D: Monitoring Adherence to the NIH Policy on the Inclusion of Women and Minorities as Subjects in Clinical Research (excerpt)	5-27
Appendix E: Research Training and Graduate Medical Education Data	5-37
Appendix F: Report of the Advisory Committee on Research on Women’s Health FYs 2007-2008 (excerpt).....	5-45
Comprehensive Table of Contents	5-51
Index	5-53

Contents of Other Volumes

Volume I

Preface

Chapter 1: About NIH

Volume II

Chapter 2: Summary of Research Activities by Disease Category

Volume III

Chapter 3: Summary of Research Activities by Key Approach and Resource

Volume IV

Chapter 4: NIH Centers of Excellence

Appendix A: Legal Mandates for this Report

Pub. L. No. 109-482: The National Institutes of Health Reform Act of 2006 (Relevant Provisions)

An Act

To amend title IV of the Public Health Service Act to revise and extend the authorities of the National Institutes of Health, and for other purposes.

Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

This Act may be cited as the "National Institutes of Health Reform Act of 2006".

TITLE I—NIH REFORM

SEC. 102. AUTHORITY OF DIRECTOR OF NIH.

(b) **ADDITIONAL AUTHORITIES.**—Section 402(b) of the Public Health Service Act, as amended by subsection (a) of this section, is amended by striking paragraphs (2) and (3) and inserting the following:

“(7)(A) shall, through the Division of Program Coordination, Planning, and Strategic Initiatives—

“ (i) identify research that represents important areas of emerging scientific opportunities, rising public health challenges, or knowledge gaps that deserve special emphasis and would benefit from conducting or supporting additional research that involves collaboration between 2 or more national research institutes or national centers, or would otherwise benefit from strategic coordination and planning;

“(ii) include information on such research in reports under section 403;

SEC. 104. REPORTS

(a) **REPORT OF DIRECTOR OF NIH.**—The Public Health Service Act (42 U.S.C. 201 et seq.), as amended by section 103(a) of this Act, is amended—

(3) by striking section 403 and inserting the following sections:

“SEC. 403. BIENNIAL REPORTS OF DIRECTOR OF NIH.

“(a) **IN GENERAL.**—The Director of NIH shall submit to the Congress on a biennial basis a report in accordance with this section. The first report shall be submitted not later than 1 year after the date of the enactment of the National Institutes of Health Reform Act of 2006. Each such report shall include the following information:

“(1) An assessment of the state of biomedical and behavioral research.

“(2) A description of the activities conducted or supported by the agencies of the National Institutes of Health and policies respecting the programs of such agencies.

“(3) Classification and justification for the priorities established by the agencies, including a strategic plan and recommendations for future research initiatives to be carried out under section 402(b)(7) through the Division of Program Coordination, Planning, and Strategic Initiatives.

“(4) A catalog of all the research activities of the agencies, prepared in accordance with the following:

“(A) The catalog shall, for each such activity—

“(i) identify the agency or agencies involved;

“(ii) state whether the activity was carried out directly by the agencies or was supported by the agencies and describe to what extent the agency was involved; and

“(iii) identify whether the activity was carried out through a center of excellence.

“(B) In the case of clinical research, the catalog shall, as appropriate, identify study populations by demographic variables and other variables that contribute to research on minority health and health disparities.

“(C) Research activities listed in the catalog shall include, where applicable, the following:

“(i) Epidemiological studies and longitudinal studies.

“(ii) Disease registries, information clearinghouses, and other data systems.

“(iii) Public education and information campaigns.

“(iv) Training activities, including—

“(I) National Research Service Awards and Clinical Transformation Science Awards;

“(II) graduate medical education programs, including information on the number and type of graduate degrees awarded during the period in which the programs received funding under this title;

“(III) investigator-initiated awards for postdoctoral training;

“(IV) a breakdown by demographic variables and other appropriate categories; and

“(V) an evaluation and comparison of outcomes and effectiveness of various training programs.

“(v) Clinical trials, including a breakdown of participation by study populations and demographic variables and such other information as may be necessary to demonstrate compliance with section 492B (regarding inclusion of women and minorities in clinical research).

“(vi) Translational research activities with other agencies of the Public Health Service.

“(5) A summary of the research activities throughout the agencies, which summary shall be organized by the following categories, where applicable:

“(A) Cancer.

“(B) Neurosciences.

“(C) Life stages, human development, and rehabilitation.

“(D) Organ systems.

“(E) Autoimmune diseases.

Appendix A: Legal Mandates for this Report

“(F) Genomics.

“(G) Molecular biology and basic science.

“(H) Technology development.

“(I) Chronic diseases, including pain and palliative care.

“(J) Infectious diseases and bioterrorism.

“(K) Minority health and health disparities.

“(L) Such additional categories as the Director determines to be appropriate.

“(6) A review of each entity receiving funding under this title in its capacity as a center of excellence (in this paragraph referred to as a ‘center of excellence’), including the following:

“(A) An evaluation of the performance and research outcomes of each center of excellence.

“(B) Recommendations for promoting coordination of information among the centers of excellence.

“(C) Recommendations for improving the effectiveness, efficiency, and outcomes of the centers of excellence.

“(D) If no additional centers of excellence have been funded under this title since the previous report under this section, an explanation of the reasons for not funding any additional centers.

“(b) Requirement Regarding Disease-Specific Research Activities.— In a report under subsection (a), the Director of NIH, when reporting on research activities relating to a specific disease, disorder, or other adverse health condition, shall—

“(1) present information in a standardized format;

“(2) identify the actual dollar amounts obligated for such activities; and

“(3) include a plan for research on the specific disease, disorder, or other adverse health condition, including a statement of objectives regarding the research, the means for achieving the objectives, a date by which the objectives are expected to be achieved, and justifications for revisions to the plan.

SEC. 106. ENHANCING THE CLINICAL AND TRANSLATIONAL SCIENCE AWARD.

(a) IN GENERAL.—In administering the Clinical and Translational Science Award, the Director of NIH shall establish a mechanism to preserve independent funding and infrastructure for pediatric clinical research centers by—

(b) REPORT.—As part of the biennial report under section 403 of the Public Health Service Act, the Director of NIH shall provide an evaluation and comparison of outcomes and effectiveness of training programs under subsection (a).

Public Law 110-85: The Food and Drug Administration Act of 2007 (Relevant Provisions)

An Act

To amend the Federal Food, Drug, and Cosmetic Act to revise and extend the user-fee programs for prescription drugs and for medical devices, to enhance the post market authorities of the Food and Drug Administration with respect to the safety of drugs, and for other purposes.

Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

This Act may be cited as the "Food and Drug Administration Amendments Act of 2007."

TITLE XI—OTHER PROVISIONS

Subtitle A—In General

SEC. 1104. NIH TECHNICAL AMENDMENTS.

The Public Health Service Act (42 U.S.C. 201 et seq.) is amended—

(3) in section 403(a)(4)(C)(iv)(III), by inserting "and postdoctoral training funded through research grants" before the semicolon;

Appendix A: Legal Mandates for this Report

Public Law 110-204: The Newborn Screening Saves Lives Act of 2007 (Relevant Provisions)

An Act

To amend the Public Health Service Act to establish grant programs to provide for education and outreach on newborn screening and coordinated follow-up care once newborn screening has been conducted, to reauthorize programs under part A of title XI of such Act, and for other purposes.

Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

This act may be cited as the “Newborn Screening Saves Lives Act of 2007”.

SECTION 7. CONTINGENCY PLANNING.

Part A of title XI of the Public Health Service Act (42 U.S.C. 300b-1 et seq.) as amended by section 6, is further amended by adding at the end the following:

“SEC. 1116. HUNTER KELLY RESEARCH PROGRAM.

(a) NEWBORN SCREENING ACTIVITIES. —

“(1) IN GENERAL. —The Secretary , in conjunction with the Director of the National Institutes of Health and taking into consideration the recommendations of the Advisory Committee, may continue carrying out, coordinating, and expanding research in newborn screening (to be known as ‘Hunter Kelly Newborn Screening Research Program’) including —

“(c) REPORTS .—The Director is encouraged to include information about the activities carried out under this section in the biennial report required under section 403 of the National Institutes of Health Reform Act of 2006.

Appendix B: Priorities and Plans of the Institutes and Centers and the Program Offices in the Office of the Director

This appendix provides brief descriptions of the missions of the NIH Institutes and Centers (ICs) and the program offices in the Office of the Director. Links to strategic plans (or strategic planning Web sites) are embedded in the names of the ICs and offices. The ICs are presented in the order in which they appear on the appropriation table in the Congressional Justification. The mission statements and strategic plans presented here classify and justify NIH priorities.

NIH Institutes and Centers

National Cancer Institute (NCI). NCI leads a national effort to reduce the burden of cancer. The National Cancer Act of 1971 broadened the scope and responsibilities of NCI and created the National Cancer Program, which conducts and supports basic and clinical biomedical research; training; health information dissemination; and other programs with respect to the cause, diagnosis, prevention, and treatment of cancer and HIV/AIDS; rehabilitation from cancer; and the continuing care of cancer patients and their families. NCI aims for a future in which we can prevent cancer before it starts, identify cancers that do develop at the earliest stage, eliminate cancers through innovative treatment interventions, and biologically control those cancers that we cannot eliminate so they become manageable, chronic diseases.

National Heart, Lung, and Blood Institute (NHLBI). NHLBI provides leadership for a national research program in diseases of the heart, blood vessels, lung, and blood; sleep disorders; and blood resources management. The Institute plans, conducts, fosters, and supports an integrated and coordinated program of basic research, clinical investigations and trials, observational studies, and demonstration and education projects. In addition, NHLBI plans and directs research in the development and evaluation of interventions and devices related to the prevention of diseases and disorders within its purview and the treatment and rehabilitation of patients who suffer from them. Also, the NHLBI oversees management of the NIH Women's Health Initiative.

National Institute of Dental and Craniofacial Research (NIDCR). NIDCR's mission is to improve oral, dental, and craniofacial health through research, research training, and the dissemination of health information. The Institute accomplishes its mission through basic and clinical research; training and career development programs that ensure an adequate number of talented, well-prepared, and diverse investigators; coordination across all sectors of the research community; and the timely transfer of knowledge gained from research and its implications for health to the public, health professionals, researchers, and policymakers.

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). NIDDK conducts and supports basic and applied research and provides leadership for national programs in diabetes, endocrinology, and metabolic diseases; digestive diseases and nutrition; and kidney, urologic, and hematologic diseases. Several of these diseases are among the leading causes of disability and death and all can seriously affect the quality of life of those who have them.

National Institute of Neurological Disorders and Stroke (NINDS). NINDS aims to reduce the burden of neurological diseases and disorders. To accomplish this goal, the Institute conducts and supports basic, translational, and clinical research on the normal and diseased nervous system, fosters the training of investigators in the neurosciences, and seeks to better understand, diagnose, treat, and prevent neurological disorders. The NINDS research portfolio encompasses hundreds of neurological disorders, from diseases such as stroke that affect millions of people and are among the leading causes of death and disability, to rare disorders that individually affect a few people but collectively have an enormous impact on patients and families.

National Institute of Allergy and Infectious Diseases (NIAID). NIAID's mission is to conduct and support research to understand, treat, and prevent infectious and immune-related diseases. Infectious diseases include well-known killers such as HIV/AIDS, tuberculosis, and malaria; emerging or reemerging threats such as influenza and extensively drug-resistant tuberculosis (XDR-TB); and "deliberately emerging" threats from potential agents of bioterrorism. Immune-related disorders include autoimmune diseases such as rheumatoid arthritis as well as asthma, allergies, and problems associated with transplantation.

National Institute of General Medical Sciences (NIGMS). NIGMS supports basic biomedical research that increases the understanding of life processes and lays the foundation for advances in disease diagnosis, treatment, and prevention. The Institute's programs encompass the areas of cell biology, biophysics, genetics, developmental biology, pharmacology, physiology, biological chemistry, bioinformatics, computational biology, and minority biomedical research and training.

National Institute of Child Health and Human Development (NICHD). NICHD conducts and supports research on all stages of human development, from preconception to adulthood, to better understand the health of children, adults, families, and communities. This includes research on fertility, pregnancy, growth, developmental disabilities, and medical rehabilitation.

National Eye Institute (NEI). NEI conducts and supports research that helps prevent and treat eye diseases and other disorders of vision. This research leads to sight-saving treatments, reduces visual impairment and blindness, and improves the quality of life for people of all ages. NEI-supported research has advanced our knowledge of how the eye functions in health and disease.

National Institute of Environmental Health Sciences (NIEHS). The mission of NIEHS is to reduce the burden of human illness and disability by understanding how the environment influences the development and progression of human disease.

National Institute on Aging (NIA). NIA leads a broad scientific effort to understand the nature of aging and to extend the healthy, active years of life. The Institute provides leadership in aging research, training, health information dissemination, and other programs relevant to aging and older people and serves as the primary Federal agency on Alzheimer's disease research.

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). NIAMS supports research to address the causes, treatment, and prevention of arthritis and musculoskeletal and skin diseases; the training of basic and clinical scientists to carry out this research; and the dissemination of information on research progress in these diseases.

National Institute on Deafness and Other Communication Disorders (NIDCD). NIDCD conducts and supports biomedical research and research training on normal mechanisms as well as diseases and disorders of hearing, balance, smell, taste, voice, speech, and language. In addition, NIDCD conducts and supports research and research training related to disease prevention and health promotion; addresses special biomedical and behavioral problems associated with persons who have communication impairments or disorders; and supports efforts to create devices that substitute for lost and impaired sensory and communication function.

National Institute of Mental Health (NIMH). The mission of NIMH is to transform the understanding and treatment of mental illness through basic and clinical research, paving the way for prevention, recovery, and cure. NIMH supports research and research training to fulfill the following four objectives: (1) Promote discovery in the brain and behavioral sciences to fuel research on the causes of mental disorders; (2) Chart mental illness trajectories to determine when, where, and how to intervene; (3) Develop new and better interventions that incorporate the diverse needs and circumstances of people with mental illness; and (4) Strengthen the public health impact of NIMH-supported research.

Appendix B: Priorities and Plans of the Institutes and Centers and the Program Offices in the Office of the Director

National Institute on Drug Abuse (NIDA). NIDA's mission is to lead the Nation in bringing the power of science to bear on drug abuse and addiction. This charge has two critical components. The first is the strategic support and conduct of research across a broad range of disciplines. The second is ensuring the rapid and effective dissemination and use of the results of that research to significantly improve prevention and treatment, and to inform policy as it relates to drug abuse and addiction.

National Institute on Alcohol Abuse and Alcoholism (NIAAA). NIAAA supports and conducts research focused on improving the treatment and prevention of alcoholism and alcohol-related problems to reduce the enormous health, social, and economic consequences of this disease. NIAAA conducts and supports research in a wide range of scientific areas including genetics, neuroscience, epidemiology, health risks and benefits of alcohol consumption, prevention, and treatment; coordinates and collaborates with international, national, State, and local institutions, organizations, agencies, and programs engaged in alcohol-related work; and communicates research findings to health care providers, researchers, policymakers, and the public.

National Institute of Nursing Research (NINR). NINR supports clinical and basic research to build the scientific foundation for clinical practice, prevent disease and disability, manage and eliminate symptoms caused by illness, enhance end-of-life and palliative care, and develop the next generation of scientists. The Institute's scientific focus spans multiple disciplines and unites the biological and behavioral sciences to better understand the complex interactions between the physiological factors of health and disease and an individual's knowledge, beliefs, and behavior.

National Human Genome Research Institute (NHGRI). NHGRI's mission has expanded since the initiation of the International Human Genome Project to encompass a broad range of studies aimed at understanding the structure and function of the human genome and its role in health and disease. A critical part of the NHGRI mission continues to be the study of the ethical, legal, and social implications of genome research. NHGRI also supports the training of investigators and the dissemination of genome-related information to the public and health professionals.

National Institute of Biomedical Imaging and Bioengineering (NIBIB). NIBIB's mission is to improve health by leading the development and accelerating the application of biomedical technologies. The Institute is committed to integrating the physical and engineering sciences with the life sciences to advance research and medical care.

National Center for Research Resources (NCRR). NCRR provides laboratory scientists and clinical researchers with the environments and tools needed to make biomedical discoveries, translate these findings to animal-based studies, and then apply them to patient-oriented research. NCRR connects researchers with one another and with patients and communities across the Nation. These connections bring together innovative research teams and the power of shared resources, multiplying the opportunities to improve human health. Together, NCRR's four integrated and complementary divisions biomedical technology, clinical and translational research, comparative medicine, and research infrastructure accelerate and enhance research along the entire continuum of biomedical science.

National Center for Complementary and Alternative Medicine (NCCAM). NCCAM is dedicated to exploring complementary and alternative healing practices in the context of rigorous science; training complementary and alternative medicine researchers; and disseminating authoritative information to the public and professionals. To fulfill its mission, NCCAM supports a broad-based portfolio of research, research training, and educational grants and contracts, as well as various outreach mechanisms to disseminate information.

National Center on Minority Health and Health Disparities (NCMHD).¹ NCMHD promotes minority health and leads, coordinates, supports, and assesses NIH efforts to reduce and ultimately eliminate health disparities. In this effort, NCMHD supports and partners with other ICs to support basic, clinical, social, and behavioral research; promote research

infrastructure and training; foster emerging programs; disseminate health information; and reach out to minority and other communities that suffer from disparities in health.

John E. Fogarty International Center (FIC). FIC strengthens human and institutional capacity to confront complex global health challenges through innovative and collaborative research and training programs. It builds the knowledge and skills of developing country foreign scientists, identifies crucial gaps in global health research, and supports and advances the NIH mission through international partnerships.

National Library of Medicine (NLM). NLM is the world's largest research library of the health sciences, serving scientists, health professionals, and the public by collecting, organizing, and providing access to biomedical information. NLM also carries out programs designed to strengthen existing and develop new medical library services in the United States. It conducts research in health communications, supports medical informatics, and provides information services and sophisticated tools in the areas of molecular biology and toxicology/environmental health. NLM creates Web-based services for the general public containing information from NIH and other reliable sources. (Also see "The National Library of Medicine" in the section on "Capitalizing on Discovery," in Chapter 1.)

NIH Clinical Center. The Clinical Center is the NIH facility that provides the patient care, medical services, and environment necessary for NIH scientists to conduct clinical research. Clinical and laboratory research is conducted shoulder-to-shoulder at the Clinical Center and this tandem approach drives all aspects of its operations. (Also see "NIH Clinical Center" in the section on "Extramural and Intramural Research Programs" in Chapter 1)

Center for Information Technology (CIT). CIT incorporates the power of modern computers into NIH's biomedical and behavioral research programs and administrative procedures by focusing on three primary activities: conducting computational biosciences research, developing computer systems, and providing computer facilities. (Also see "Information and Information Technology" in the section on "Providing the Platform for Discovery" in Chapter 1.)

Center for Scientific Review (CSR). CSR carries out peer review of the majority of research and fellowship applications submitted to NIH; serves as the central receipt point for all such Public Health Service applications; makes referrals to scientific review groups for scientific and technical merit review of applications and to funding components for potential award; and develops and implements innovative, flexible ways to conduct referral and review for all grant applications. (Also see "NIH Peer Review Process" under the section on "Extramural and Intramural Research Programs" in Chapter 1.)

Office of the Director

Division of Program Coordination, Planning and Strategic Initiatives (DPCPSI). DPCPSI was established by mandate of the NIH Reform Act of 2006. DPCPSI's role is to identify emerging scientific opportunities, rising public health challenges, and scientific knowledge gaps that merit further research; assist NIH in effectively addressing identified areas; and develop and apply resources (databases, analytic tools, and methodologies) that will support priority setting and analyses of the NIH portfolio. DPCPSI now incorporates the functions of the former Office of Portfolio Analysis and Strategic Initiatives. The primary components within DPCPSI are the Office of Strategic Coordination, which manages the NIH Common Fund (including the Roadmap), and the four OD program offices. DPCPSI also is the locus for NIH planning and reporting required by the Government Performance and Results Act and other government-wide performance assessment endeavors. (Also see the section on *NIH Strategic Planning and the NIH Roadmap and Common Fund* in Chapter 1).


As detailed below, the four OD Program Offices are in the areas of disease prevention; behavioral and social sciences research; women's health; and AIDS research.

Appendix B: Priorities and Plans of the Institutes and Centers and the Program Offices in the Office of the Director

- Office of Disease Prevention (ODP). ODP fosters, coordinates, and assesses research related to disease prevention and health promotion, and disseminates related information that aims to improve the health of the U.S. population. ODP advises the NIH Director and collaborates with other Federal agencies, academic institutions, the private sector, nongovernmental organizations, and international organizations in the formulation and implementation of research initiatives and policies that promote public health. There are three additional offices within ODP: Office of Rare Diseases Research (ORDR), Office of Dietary Supplements (ODS), and Office of Medical Applications of Research (OMAR):
 - ORDR stimulates, coordinates, and supports research on rare diseases to advance research opportunities and to respond to the needs of approximately 25 to 30 million people who have one of the approximately 6,500 known rare diseases. (Also see the section on the Rare Diseases Clinical Research Network in Chapter 4, which addresses NIH Centers of Excellence.)
 - ODS promotes and supports, through collaboration with the ICs, basic and clinical research to increase understanding of the impact of dietary supplements (e.g., plant extracts, enzymes, vitamins, minerals, amino acids, hormonal extracts) on disease prevention and health maintenance. The mission is to strengthen knowledge and understanding of dietary supplements by evaluating scientific information, stimulating and supporting research, disseminating research results, and educating the public.
 - OMAR is the focal point for evidence-based assessments of medical practice and state-of-the-science conferences key mechanisms for assessing, translating, and disseminating the results of biomedical research to improve the delivery of health services to the public. The office also conducts an annual course to train journalists on how to critically evaluate and report on medical research.
- Office of Behavioral and Social Sciences Research (OBSSR). OBSSR coordinates and stimulates behavioral and social sciences research throughout the NIH and integrates it more fully into the NIH research enterprise. The Office provides leadership on matters relating to research on the roles of human behavior and the social environment in the development of health, prevention of disease, and therapeutic intervention, as well as in training, continuing education, and dissemination of research findings to the broader scientific community and the general public.
- Office of Research on Women's Health (ORWH). ORWH serves as the focal point for women's health research at NIH, and promotes, enhances, and expands efforts to improve the health of women through biomedical and behavioral research, including that on sex and gender factors. ORWH ensures compliance with policies on the inclusion of women and minorities in clinical research, and develops and implements NIH programs for the recruitment, retention, reentry, and advancement of women in biomedical careers.
- Office of AIDS Research (OAR). OAR is responsible for the scientific, budgetary, legislative, and policy elements of the NIH AIDS research program. Through its unique and comprehensive trans-NIH planning, budgeting, and portfolio assessment processes, OAR sets trans-NIH scientific priorities, enhances collaboration, and ensures that research dollars are invested in the highest priority areas of scientific opportunity that will lead to new tools in the global fight against AIDS. OAR also supports a number of initiatives to enhance dissemination of research findings to researchers, physicians, institutions, communities, constituency groups, and patients.

¹ With enactment of the Patient Protection and Affordable Care Act, on March 23, 2010, the National Center for Minority Health and Health Disparities became an institute—the National Institute for Minority Health and Health Disparities (NIMHD).

Appendix C: Common Fund Strategic Planning Report, 2009



Common Fund Strategic Planning Report, 2009

The National Institutes of Health Reform Act of 2006 requires the Secretary of Health and Human Services (HHS), acting through the Director of the National Institutes of Health (NIH), to submit a report to Congress containing a strategic plan for funding research that, "...represents important areas of emerging scientific opportunities, rising public health challenges, or knowledge gaps that deserve special emphasis and would benefit from conducting or supporting additional research that involves collaboration between 2 or more national research institutes or national centers, or would otherwise benefit from strategic coordination and planning" (42 U.S.C. §282(b)(7)(a)).

To date, the Common Fund has been used to support research initiatives under the NIH Roadmap for Medical Research. The NIH Roadmap is an innovative approach to accelerate fundamental discovery and translation of that knowledge into effective prevention strategies and new treatments. The strategic initiatives funded under the NIH Roadmap address critical roadblocks and knowledge gaps that currently constrain rapid progress in biomedical research. They synergize the work of many NIH Institutes and Centers (ICs), and collectively represent a unique effort that no single or group of ICs or other entity can do, but are the responsibility of the NIH as a whole.

Initiatives under the Roadmap programs are intended to be catalytic in nature and are not expected to receive long-term Common Fund support. The intent with Roadmap programs is to stimulate the development of tools or technologies, acquire fundamental knowledge and data sets, or build critical research resources. The continued use of the tools, data, and resources is to be funded through the ICs.

Although the Roadmap programs are currently the only programs funded by the Common Fund, this may not always be the case as new scientific opportunities emerge and the NIH determines how best to respond to new challenges. As the Common Fund grows, the NIH will maintain a continuous effort to be responsive to community needs while providing ongoing support for areas identified through strategic planning endeavors.

This report describes:

- The strategic planning processes undertaken to date to identify program areas currently supported by the Common Fund
- The current status of programs designed to meet the needs articulated through strategic planning
- The plans for future strategic planning efforts

I. Strategic Planning for the Common Fund, 2002-2008: the NIH Roadmap

As described in the Common Fund Strategic Planning Report of 2007, the NIH Roadmap is a series of cross-cutting programs designed to meet criteria established by the NIH Leadership before the Common Fund was established through the 2006

Appendix C: Common Fund Strategic Planning Report, 2009

Table 2: Common Fund/Roadmap Budget Data

Dollars in Millions	FY 2006 Actual B.A.	FY 2007 Actual B.A.	FY 2008 Actual B.A.	FY 2009 Enacted	2010 Request
Institute or Center Roadmap/ Common Fund Contribution	\$247.3	\$0.0	\$0.0	\$0.0	\$0.0
OD Roadmap/Common Fund Contribution	\$85.3	\$483.0	\$498.2	\$541.1	\$549.0
Roadmap/Common Fund	\$332.6	\$483.0	\$498.2	\$541.1	\$549.0
Roadmap/Common Fund Percent of NIH Labor/HHS Budget Authority ¹	1.2%	1.7%	1.7%	1.8%	1.8%

¹ Adjusted for Type I Diabetes, Global Fund for AIDS, Superfund, and Secretary's transfer authority for NLM.

The status of each of the programs is described in further detail below.

1. Roadblock: Clinical and translational research lags behind basic discoveries.

Programs designed to overcome this problem: Clinical and Translational Science Awards (CTSAs), Clinical Research Training Program (CRTP), Medical Scientist Training Program (MSTP), Rapid Access to Intervention Development (RAID), Patient-Reported Outcomes Measurement Information System (PROMIS), and Clinical Research Policy Analysis and Coordination (CRPAC).

A. Clinical and Translational Science Award Program (CTSAs)

Status: This program supports a national consortium that provides a foundation for clinical and translational science that will catalyze clinical and translational research and allow investigators to move more quickly toward improvements in health. The program is jointly supported by the Common Fund and the National Center for Research Resources. The CTSA program affords the provision of research services and facilities, development of information systems that link clinical research centers nationwide, expansion of the national clinical research enterprise to include community clinics, and training a new generation of clinical investigators. This program, begun in 2006, is transitioning out of the Roadmap to be supported solely by NCRR in 2015.

B. Clinical Research Training Program (CRTP)

Status: As part of the Roadmap's effort to bolster the pipeline of clinical investigators, NIH's CRTP immerses medical students in an intense 12-month research experience during which they acquire the skills necessary to become successful, independent investigators and clinicians. The training environment of

the NIH campus fosters multidisciplinary approaches and provides access to unique patient populations via the largest hospital dedicated to clinical research in the world. This program, begun in FY 2004, is transitioning to full support by the NIH Clinical Center in FY 2014.

C. Rapid Access to Intervention Development (RAID)/Translational Research Core Services

Status: This program makes available, on a competitive basis, certain critical resources that are needed 1) for the development of therapeutic agents and 2) to bridge the gap between discovery and clinical testing to enable more efficient translation of promising discoveries. The RAID program is designed to reduce some of the common barriers that block progress of therapeutic discoveries, especially in cases where efforts involve high risk ideas or therapies for uncommon disorders that cannot attract private sector investment. Where private sector capacity for drug development is limited or not available, the NIH provides the resources needed to facilitate development of promising new therapies for widespread clinical use. By providing investigators with access to drug development resources, as well as expertise in the planning and submission of documents to the Food and Drug Administration (FDA), the RAID Program plays an integral role in fostering the development of novel therapeutics. This program is expected to be continued by IC funds when it transitions out of the Common Fund in FY 2014.

D. Patient-Reported Outcomes Measurement Information System (PROMIS)

Status: PROMIS is a revolutionary effort to enhance the measurement of patient-reported symptoms and functions. In the first phase of the program (FY 2004-2008), PROMIS developed and tested a large survey for measuring patient-reported outcomes and created a computerized adaptive testing system that analyzes all the responses and cross checks them against each other to gain a better understanding of the patient's well being. By analyzing the answers to multiple questions, the computerized adaptive testing system arrives at a more robust, quantifiable measurement of the patient's condition. The PROMIS Program has also created a publicly available, continually updated, Web-based system that allows clinical researchers to access PROMIS-validated items, domains, computerized adaptive testing, and survey forms. Preliminary results demonstrate that brief, 4- to 10-question surveys of symptoms and functional states administered by the computerized adaptive testing outperforms today's commonly used, paper-based, self-reporting assessment tools in common health conditions. These results are indicative of the anticipated clinical research advantage of the PROMIS tool, which yields better answers with fewer patients. This program will be supported by the Common Fund through FY 2012, after which it is expected to be supported largely through public-private partnerships in support of clinical studies.

Appendix C: Common Fund Strategic Planning Report, 2009

E. Clinical Research Policy, Analysis, and Coordination (CRPAC)

Status: This program was established to help catalyze the harmonization of clinical research policies across U.S. Government agencies. CRPAC engages relevant Federal agencies as well as private sector stakeholders to coordinate, streamline, and optimize policies and requirements for the conduct and oversight of clinical research. The multiple and often inconsistent Federal requirements governing biomedical research present a considerable challenge to the biomedical research community. To address this problem, CRPAC has led a major effort to enhance the consistency of regulatory requirements, facilitate compliance, and optimize the analysis and use of adverse event data. CRPAC has developed a Basal Adverse Event Report (BAER) tool, a single baseline set of medical information for reporting adverse events and unanticipated problems in clinical research that is acceptable to multiple Federal agencies. The BAER includes both pre- and postmarket reporting and complies with national and international standards for data transmission and vocabularies. This program, established through the Office of Science Policy (OSP), NIH Office of the Director (OD), is transitioning out of the Roadmap to become a permanent activity within OSP in FY 2010.

2. Roadblock: Partnerships between NIH and private sector entities can be difficult to cultivate and maintain.

Program designed to overcome this problem: Public-Private Partnerships (PPP)

Status: This program was developed as part of NIH's efforts to facilitate new ways of conducting and supporting research, including the formation of collaborations with pharmaceutical and biotechnology industries, as well as other private entities. The program identifies appropriate partners inside and outside the NIH, as well as develops useful policies to oversee those partnerships. As part of this program, the NIH has established the Biomarkers Consortium, a complex group of related partnerships between the NIH, FDA, industry, and private entities that work to accelerate the development of new drugs by identifying, developing, and qualifying biomarkers, useful indicators of disease progression and effects of therapeutic interventions. This program, established through the OSP in the NIH OD, is transitioning out of the Roadmap to become a permanent activity within OSP in FY 2010.

3. Roadblock: Traditional R01 application and review processes can hamper innovation.

Programs designed to overcome this problem: High Risk High Reward Programs, including the NIH Director's Pioneer Program, NIH Director's New Innovator Program, and Transformative R01 Program.

Status: The High Risk High Reward component of the NIH Roadmap has been built with the intent of finding new ways to foster innovation by piloting new application and review processes. The Common Fund, through these programs, sets aside a small

percentage of the overall NIH budget for transformative research without designating specific funding levels for specific scientific areas. All areas compete, with the most innovative proposals receiving the funds.

A. NIH Director's Pioneer Awards

Status: This program seeks to identify individual investigators with a proven history of innovation and provide them with adequate funding to conduct pioneering research in a new area of investigation. It provides funding for scientists who propose innovative approaches that have the potential to produce an unusually high impact on a broad area of biomedical or behavioral research. The awardees propose to use pioneering and transformative approaches to address major scientific problems and challenge existing paradigms. Since 2004, the program has supported 63 individual investigators. Information about this program, as well as links to awardees by year, can be found at <http://nihroadmap.nih.gov/pioneer/>. This program has proven to be successful at the identification of outstanding scientists and innovative projects and receives funds from both the Common Fund and various ICs. The NIH Director therefore decided to continue Common Fund support for the program for the foreseeable future.

B. NIH Director's New Innovator Awards

Status: This program supports new investigators who propose research ideas that are unusually creative and highly innovative but lack the preliminary data required to apply for an RO1 grant. Since 2007, this program has supported 61 individual investigators. Information about this program, as well as links to awardees by year, can be found at <http://nihroadmap.nih.gov/newinnovator/>. Launched in response to Congressional language, this program, like the NIH Director's Pioneer Awards Program, is projected to continue with combined funding from the ICs and the Common Fund for the foreseeable future.

C. Transformative R01s

Status: A new program for 2009, this program is intended to allow investigators to articulate pressing needs or areas of opportunity and to fund the most transformative of these projects. Whereas the Pioneer Awards Program emphasizes the past history of the individual investigator, the Transformative R01 Program emphasizes the potential impact that each project may have. It encourages the formation of teams to accomplish the goals of the program and provides adequate funds to support complex projects. This program will pilot a new way of encouraging very high impact research by removing as many administrative barriers as possible. No budget cap is imposed, allowing maximum flexibility to investigators to develop complex approaches that may be beyond the budget of traditional R01s. Award decisions are made by the NIH Director based upon recommendations from a multidisciplinary group of outside experts. Areas of

Appendix C: Common Fund Strategic Planning Report, 2009

highlighted need have been identified through the Roadmap Strategic Planning Process, but these awards are open to all areas of investigation and no set-aside dollar figure has been established for any particular topic. If the areas of highlighted need are not adequately addressed through this program, future initiatives on these topics may be developed.

These areas include:

- a) Understanding and Facilitating Human Behavior Change
- b) Complex 3-Dimensional Tissue Models
- c) Formulation of Novel Protein Capture Reagents
- d) Providing an Evidence Base for Pharmacogenomics
- e) Functional Variation in Mitochondria in Human Disease
- f) Transitions from Acute to Chronic Pain

4. Roadblock: Interdisciplinary approaches to complex scientific problems can be difficult to develop.

Program designed to overcome this problem: Interdisciplinary Research (IR) Program

Status: This program overcomes barriers to interdisciplinary research by building research teams, training scientists in multiple disciplines, and changing academic research culture. The program includes initiatives to dissolve academic department boundaries within academic institutions and increase cooperation between institutions, train scientists to cultivate interdisciplinary efforts, and build bridges between the biological sciences and the behavioral and social sciences.

A total of nine IR consortia, managed by teams of NIH staff from multiple ICs, have been funded through this initiative, which represents a new funding mechanism for interdisciplinary research. Through this mechanism, the NIH is piloting a new way to fund projects that cross IC missions and require cooperation among NIH staff to manage the programs. These consortia address complex problems that require novel, interdisciplinary approaches, including aging, fertility in women who undergo cancer therapy, regenerative medicine, Fragile X Syndrome, neuropsychiatric disorders, obesity, genetic engineering strategies, stress and its effects on self control and addiction, and genomics-based drug discovery. Funded in FY 2007, these consortia will be funded by the Common Fund through FY 2011. If the new funding mechanism proves worthwhile, it may continue to be utilized through IC funds for either new projects or for continuation of the existing Common Fund-initiated projects.

As part of the IR Program's efforts, the Interdisciplinary Health Research Training Program enables institutions to develop postdoctoral training programs that provide formal coursework and research training in a new interdisciplinary field to individuals holding advanced degrees in different disciplines. Another IR program, entitled Training for a New Interdisciplinary Workforce, supports scientists at the undergraduate,

graduate, and postdoctoral levels by exposing them to both didactic and research experiences involving interdisciplinary and team approaches to address complex biomedical problems. These training programs, launched in FY 2004, will compete for IC funds with IC-specific training programs beginning in FY 2009.

In an effort to help bridge the gap between medical researchers and behavioral or social scientists, the IR Program also provides exploratory/developmental grants through the Methodological and Technological Innovation in the Behavioral and Social Sciences Program to help facilitate the introduction of new methodologies and technologies to the behavioral and social sciences. These projects, funded in FY 2007, followed workshops held to foster team building in FY 2004 and FY 2006.

Finally, the IR Program encourages changes to administrative practices at NIH in ways that encourage teamwork through recognition and support of team leadership. Working with the NIH Office of Extramural Research, members of the trans-NIH IR Working Group helped design and implement the policy through which NIH now recognizes multiple principal investigators on individual projects. The recognition of multiple principal investigators represents a transformative step through which NIH seeks to foster collaboration and teamwork.

5. Roadblock: Small molecular compounds are needed to explore functions of human genes and to serve as leads for therapeutic compounds that can modify activity.

Program designed to overcome this problem: Molecular Libraries and Imaging Program

Status: This program establishes a national network of centers and supporting technologies for the discovery and development of small molecule probes to interrogate and modify biological pathways. The program currently supports a network of research centers that have identified new “probes”—molecules that are useful for research purposes and could be adapted for therapeutic use. Experts at the centers optimize and perform assays designed by academic researchers and peer-reviewed by the NIH. The centers use advanced technology to screen thousands of small molecules for their ability to bind to or inhibit a protein or protein-mediated activity of interest. In collaboration with the academic scientists who designed the assays, the center validates the “hits” and chooses a subset to improve by chemical modification. To date, the program has assembled a variety of screening assays designed to test small molecules for their ability to target proteins in critical cellular processes such as cellular transport, enzymatic reactions, and protein-protein interactions that become anomalous in multiple diseases. The screening center program moved from its pilot phase to its production phase in FY 2008 and will be funded by the Common Fund through FY 2013, with cofunding from the ICs beginning in FY 2012. It is expected to transition exclusively to IC support beginning in FY 2014.

To support this large scale screening program, several support programs were developed as part of the pilot phase of the program and are continuing during the

Appendix C: Common Fund Strategic Planning Report, 2009

production phase. An assay development program, which funds investigators to develop high throughput screening assays for their biological area of interest, has been critical for enabling investigators to take advantage of the resources offered by the screening center. A technology development program enabled improvements to be made to the technical aspects of the high throughput screening process. In addition, an informatics component has been critical for the centralized collection of information about the molecules screened, their structures, and their activities in various assays; for allowing public access to this information; and for development of new informatics methodologies to mine the data. Finally, the library of compounds that the program has developed represents a truly unique and valuable component of the program as a whole. This collection is expected to grow from 300,000 to 500,000 compounds over the next 5 years. These components, which support the screening endeavor, are anticipated to transition to IC funding in FY 2014.

In addition to the small molecule screening effort, this program supports initiatives that are intended to develop novel imaging probes—in part, through adaptation of molecules that could be identified as probes through the screening centers. These initiatives have developed a database of imaging reagents and have supported the development of novel imaging reagents. Common Fund support for the database continues through FY 2013, while future funding for the imaging probe synthesis facility will be determined later this year.

6. Roadblock: A scientific gulf exists between basic nanotechnology research and clinical applications.

Program designed to overcome this problem: Nanomedicine

Status: This program establishes a network of Nanomedicine Centers to determine how cellular machines operate at the nanoscale level and use these design principles to develop and engineer new technologies and devices for repairing tissue, as well as preventing and curing diseases. Launched in FY 2005, the program's first five years were intended to address fundamental basic science questions as a prerequisite to the development of therapeutic strategies. To achieve the targeted goals of this program, the NIH uses flexible authority (Section 214 of the Appropriations Law) to oversee and manage the research. This authority facilitates the movement of funds to the most successful projects within the program. Approved for its second five-year funding period this past year, the program is now planned to continue with Common Fund support through FY 2014. This is a high risk program that expects the goals, if accomplishable, can be achieved within an overall 10-year timeframe of the program.

7. Roadblock: Limited technologies to analyze protein-protein interactions and cellular pathways hinder therapeutic applications.

Program designed to overcome this problem: Building Blocks, Biological Pathways, and Networks

Status: This program consists of two initiatives that are intended to catalyze basic studies of cellular functions by developing tools that will allow basic scientists to study protein-protein interactions and to analyze the consequences of cellular activities through examination of cellular metabolites.

The Technology Centers for Networks and Pathways develop and apply technologies to detect transient protein-protein interactions that control the cellular functions. Five centers were established in FY 2005 to develop innovative tools to enable researchers to determine, in real time, the amounts, locations, and interactions of large numbers of individual proteins within a single cell. These fundamental needs are still pressing and unsolved, so these centers will receive additional support through the Common Fund through FY 2013.

The Metabolomics initiative was established in FY 2004 to support the development of technologies that will allow investigators to monitor cellular processes more accurately through analysis of by-products (metabolites) generated by the processes. This program was developed as a 5-year program that has been jointly funded by the Common Fund and the ICs. FY 2008 was the last year of Common Fund support for this initiative, as IC-funded investigators can now use the technologies developed, and further technical advances are being funded through the ICs.

8. Roadblock: Limited technologies for structural analysis of membrane proteins can limit drug development.

Program designed to overcome this problem: Structural Biology of Membrane Proteins

Status: This program establishes centers for Innovation in Membrane Protein Production as well as individual research projects that aim 1) to formulate new methods for producing ample quantities of cellular membrane proteins that are of a quality suitable for structural and functional studies and 2) to develop and improve technologies and methods for structural analysis. The program develops novel approaches for the production and stabilization of membrane proteins to enable determination of their structures at high resolution. These approaches are paying off, as increasing numbers of membrane-associated protein structures are being determined and facilitating drug development. The success of the protein and continued need for technology development in this area prompted the decision to fund this program for an additional 5 years through the Common Fund; funding is now expected to continue through FY 2013. After that point, the community at large is expected to use the new technologies to analyze membrane proteins and use this knowledge to design novel therapies.

9. Roadblock: Computational tools that allow investigators to mine large datasets need to be developed and combined into an integrated network.

Program designed to overcome this problem: National Centers for Biomedical Computing (NCBCs)

Appendix C: Common Fund Strategic Planning Report, 2009

Status: This program was established in 2004 to develop computational tools intended to catalyze research in the basic and clinical sciences. The centers create innovative software programs and other tools that arm the biomedical community with the methods needed to integrate, analyze, model, simulate, and share data relevant to human health and disease. Each center also works with members of the research community to develop informatics needs targeted toward specific disease areas. These “driving biological problems” include Huntington’s Disease, Hypertension, Cardiovascular Disease, Alzheimer’s Disease, Diabetes, Schizophrenia and Bipolar Disorder, HIV, Prostate Cancer, and heritable disorders. The set of disease areas targeted by these efforts is dynamic and responsive to needs of the community. The need for informatics is so broad and cross-cutting that this program is continuing with Common Fund support through FY 2014.

10. Roadblock: Knowledge of the contribution of nonpathogenic microbes to human health is rudimentary but could potentially transform our understanding of health and disease.

Program designed to overcome this problem: Human Microbiome Project

Status: This program develops tools and generates resources to facilitate characterization of the human microbiome and analysis of its role in human health and disease. The program establishes links between the human microbiome and states of health and disease through several integrated initiatives.

The first was launched in FY 2007 to “jumpstart” the effort by sequencing a reference set of genomes from cultured microbes. These reference sequences will facilitate the analysis of complex mixtures of microbes to be obtained from human body sites. Beginning in FY 2009, samples from 5 body sites (skin, nose, mouth, gastrointestinal tract, and vagina) will begin to be collected from more than 100 individuals. By analyzing microbial populations at multiple body sites in normal, healthy individuals, the program builds the foundation for an advanced understanding of the degree of microbial diversity that may exist among individuals. A series of demonstration projects will build upon this foundation to analyze the microbiome in individuals with varying diseases or conditions to determine whether changes in our microbiome correlate with changes in health status.

In addition to the sequencing effort, this program supports the development of technological improvements that will enable the effort to proceed faster and with reduced costs. NIH is also working with researchers from several countries to establish the International Human Microbiome Consortium. This consortium will provide a forum for data sharing and information exchange relevant to the program. In addition, the vast amount of sequence data generated by this program will be deposited in a publicly accessible database and the sequences of the bacterial strains studied will be made available for future studies. Finally, the Ethical, Legal, and Social Implications (ELSI) of the microbiome project are being studied through a dedicated initiative.

The Human Microbiome Project will be funded by the Common Fund through FY 2012. During this timeframe, a foundation will be laid to allow the continued exploration of the human microbiome through investigator-initiated projects funded by the ICs.

11. Roadblock: Contributions of higher order DNA structure to human health and disease are poorly understood.

Program designed to overcome this problem: Epigenomics of Human Health and Disease

Status: This program seeks to help define the relationship between the modifications to DNA that alter its three-dimensional structure (the epigenome) and human health and disease. Like the Human Microbiome Project, a series of integrated initiatives has been established to achieve this goal.

Studies in experimental animal models has established that diet, environmental exposures, and aging can significantly alter genetic activity by producing chemical modifications to DNA that alter the coiled structure that DNA assumes in different cell types. However, very little information is available about the way that DNA coils in normal, healthy human cells, so it is difficult to know the extent to which human disease may result from changes to this structure. To clarify this, the Epigenomics Program is enabling the development of comprehensive reference maps of the human epigenome from many different cell types. It also fosters new technologies for epigenomic analysis, an integrated Data Coordinating Center, and novel regulators of epigenomic structure.

An understanding of the human epigenome has the potential to transform knowledge about disease onset and progression, as well as to lead to novel therapeutic approaches. Together with several international partners, the NIH is working to establish an International Consortium to foster collaboration and information exchange worldwide in this endeavor. The fundamental knowledge obtained through this program will catalyze research in all areas of medicine and increase our understanding of the genetic basis of health and disease. This program was launched with “jumpstart” funds in FY 2007 but major funding began in FY 2008. It is slated to receive Common Fund support through FY 2015.

12. Roadblock: Genome-Wide Association Studies reveal genetic variations that associate with disease, but the molecular effects of the variations is difficult to unravel.

Program designed to overcome this problem: Genotype/Tissue Expression (GTEx) Resource

Status: Genome-Wide Association Studies are revealing increasing numbers of genetic variations that result in susceptibility to disease. However, using this information to intercede before disease develops will require an understanding of the molecular consequences of the genetic variation. This is very difficult to unravel, since

Appendix C: Common Fund Strategic Planning Report, 2009

a change in DNA sequence may alter a part of the chromosome involved in regulating a gene (or genes) far removed from the sequence variant itself, and it could influence the regulation of genes in many tissues.

To overcome this problem, the GTEx program, to begin in FY 2010, will correlate genetic variability with variability in expression of many genes in many tissues. To do this, samples from 320 donors (either surgical donors or autopsy donors) will be acquired from several tissues, the genotypes determined for each, and then a gene expression profile obtained for each tissue. The genes expressed and the level at which they are expressed can then be correlated with genetic variations of the donors.

Common Fund support of this program will allow the feasibility of the approach to be determined through a two-year period of support. Analysis of the data from the initial two years will determine whether further investment to scale up the approach is warranted.

III. Looking to the Future: Strategic Planning for the Common Fund

The Common Fund was established by the 2006 Reform Act to encourage strategic planning for research that crosses IC borders and coordination in program management. These core principles for the Common Fund are sufficiently broad that they provide the NIH with flexibility to determine the most pressing needs and to respond corporately to these challenges.

Through the Roadmap Programs, the NIH addresses fundamental, cross-cutting challenges that influence virtually every disease area and have potential for exceptionally high impact. Future planning for Roadmap programs will continue to involve heavy input from the public to identify common bottlenecks and to articulate cross-cutting areas of exceptional opportunity. However, as the Common Fund grows, additional types of programs may be supported that serve the stated mission of the Common Fund to encourage multi-IC planning and coordination but do not address the criteria established for the Roadmap.

While growth and diversification of Common Fund programs will depend on growth of the Fund itself, the planning strategies for all types of Common Fund programs will share the requirement that multiple ICs and their respective communities are served by each program. This will require staff from multiple ICs to interact, share information, and bring their communities together to identify gaps in knowledge, brainstorm, and articulate programmatic needs.

Facilitated by the Office of Strategic Coordination within the Division of Program Coordination, Planning, and Strategic Initiatives, these planning activities will involve gathering input at multiple levels to establish priorities for Common Fund dollars. Data concerning the NIH research portfolio, research conducted elsewhere, and the research needs vocalized by the community will also be used to help establish these priorities.

Appendix 1: Criteria for NIH Roadmap Programs

The overarching goal of all Roadmap initiatives is to accelerate the discovery and translation of scientific knowledge into public health benefits. Roadmap is conceived of as a five- to ten-year "incubator space" for NIH initiatives that meet all of the following criteria:

Is the proposed initiative truly transforming—could it dramatically affect how biomedical and/or behavioral research is conducted over the next decade?

Will the outcomes from the proposed initiatives synergistically promote and advance the individual missions of the ICs to benefit health?

Does the proposed initiative require participation from NIH as a whole and/or does it address an area(s) of science that does not clearly fall within the mission of any one IC or OD program office?

Is the proposed initiative something that no other entity is likely or able to do, and is there a public health benefit to having the results of the research in the public domain?

Appendix D: Monitoring Adherence to the NIH Policy on the Inclusion of Women and Minorities as Subjects in Clinical Research (excerpt)

Link to on-line version of full report can be found at
<http://orwh.od.nih.gov/inclusion/2009AnnualTrackingInclusionComprehensiveRpt.pdf>

Department of Health and Human Services
National Institutes of Health

MONITORING ADHERENCE TO THE
NIH POLICY ON THE INCLUSION
OF WOMEN AND MINORITIES
AS SUBJECTS IN CLINICAL RESEARCH

Comprehensive Report: Tracking of Human Subjects Research
As Reported in Fiscal Year 2007 and Fiscal Year 2008

NIH Tracking/Inclusion Committee

Vivian W. Pinn, M.D., Co-Chair
Office of Research on Women's Health

Carl Roth, Ph.D., LL.M., Co-Chair
National Heart, Lung, and Blood Institute

Angela C. Bates, M.B.A.
Office of Research on Women's Health

Robin Wagner, Ph.D.
Liaison, Office of Extramural Research

Kim Jarema
Liaison, NIH Clinical Center

2009

Preface

To demonstrate effective implementation of Public Law 103-43 and implementation of NIH policies on the tracking and inclusion of women and minorities in clinical research, the Office of Research of Women's Health (ORWH), in collaboration with the Office of Extramural Research (OER) and the Office of Intramural Research (OIR), has led monitoring efforts for compliance including convening a trans-NIH Tracking and Inclusion Committee. Monitoring efforts have included the documentation of the numbers of males and females by race and ethnicity enrolled in clinical studies funded by NIH, as well as biennial statements from each Institute and Center (IC) Advisory Councils to confirm compliance with NIH policies. These and other efforts serve to ensure that NIH procedures comply with the NIH policy on the inclusion of women and minorities in clinical studies.

Data monitoring for the magnitude and diversity of clinical studies funded by NIH is not a simple task. There has been an extensive and dedicated effort to provide accurate and reproducible data. However, transitions in information system software at the NIH have introduced the need for modifications for monitoring inclusion and data collection.

The Acting Director of NIH has now established a task force to be co-chaired by the Director of ORWH, the Director of the National Center for Minority Health and Health Disparities (NCMHD), and an IC Director to examine the entire process for evaluating and monitoring the inclusion of women and minorities in clinical research funded by NIH; and the results of the deliberations of this task force should be reflected in the next biennial report. However, the FY2007 and FY2008 data in this document reflect the data reporting and current trends of the inclusion of participants in NIH clinical research.

This report would not be possible without the efforts of the members of the NIH Tracking and Inclusion Committee and the eRA Population Tracking User Group (ePTUG) who have each provided many hours addressing a multiplicity of issues related to data entry, reconciliation of grants, contracts and cooperative agreements, and other related issues or concerns.

Appendix D: Monitoring Adherence to the NIH Policy on the Inclusion of Women and Minorities as Subjects in Clinical Research (excerpt)

Monitoring Adherence to the NIH Policy on the Inclusion of Women and Minorities as Subjects in Clinical Research Summary Report of NIH Inclusion Data

NIH AGGREGATE POPULATION DATA REPORTED IN FY2007 and FY2008

Because new clinical research studies begin each year while other studies may be ending, the inclusion figures will vary from year to year due to the scientific topics under study and the prevalence of those conditions within each individual study. These data help to establish trends on the inclusion of women and minorities as subjects in clinical research. Data on inclusion are tabulated from human subject populations in NIH-defined Phase III clinical trials and other human subject research studies and are based on self identification by the participants. NIH clinical research studies are determined in accordance with the NIH definition of clinical research to include, for example, non-intervention clinical research, non Phase III clinical trials, epidemiological studies, behavioral studies, and database studies.

Analysis of aggregate NIH data on inclusion for FY2007 and FY2008 documents participants of all ages, that substantial numbers of women and men, non-minority men, and minorities of all ages have been included as research subjects in NIH clinical trials and other human subject research studies during these fiscal years. However, caution should be utilized to avoid over-interpreting the figures that are provided. The NIH Tracking and Inclusion Committee have provided for the reader's interest conclusions that can be reasonably drawn from the data.

Previous inclusion reports and aggregate enrollment figures for women, men and minority groups for FY1994 to the present can be found on the ORWH website at <http://orwh.od.nih.gov/inclusion.html>.

NIH CLINICAL RESEARCH: Fiscal Years 2007 and 2008

In FY2007 there were 15,567 extramural and intramural clinical research protocols, including Phase III and other clinical studies, of which 10,914 protocols reported human subject participation as noted in this report's trend summary tables (*Table 1A*). Of these, 95.9% were domestic protocols and 4.1% were foreign protocols. (*Table 1E*) Approximately 17.4 million participants were enrolled in extramural and intramural research protocols of which 92.7% were domestic participants and 7.3% were foreign participants. Of the 17.4 million participants, 58.2% were women, 39.5% were men and 2.3% did not provide sex identification. (*Table 1A*) Further, 29.9% of the total participants, and 26.5% of the Domestic-only participants, were reported as minorities following the current OMB categories for race and ethnicity. (*Table 1F and 2C*)

Correspondingly, in FY2008 there were 15,598 extramural and intramural clinical research protocols, including Phase III and other clinical studies, of which 11,045 protocols reported human subject participation as noted in this report's trend summary tables. (*Table 1A*) Of these, 95.5% were domestic protocols and 4.5% were foreign protocols. (*Table 1E*) Approximately 15.4 million participants were enrolled in extramural and intramural research protocols of which 91.7% were domestic participants and 8.3% were foreign participants. Of the 15.4 million participants, 60.0% were women, 38.9% were men and 1.1% did not provide sex identification. (*Table 1A*) Further 28.6% of the total participants, and 24.9% of the Domestic-protocol participants, were reported as minorities following the current OMB categories for race and ethnicity. (*Table 1F & Table 3C*)

While the number of participants in all extramural and intramural clinical research decreased (17.4M in FY2007 and 15.4M in FY2008), there was no significant change in the proportion of women and men (58.2%F and 39.5%M in FY2007; and 60.0%F and 38.9%M in FY2008). (Table 1A)

NIH Defined Phase III Clinical Research: FY2007 and FY2008

In FY2007 there were 749 extramural and intramural Phase III clinical research protocols, of which 653 protocols reported human subject participation as noted in this report's trend summary tables. (Tables 4A and 5A) Of these, 93.3% were domestic protocols and 6.7% were foreign protocols. Clinical studies not included in this analysis are those studies that have just begun and have not reported enrollment data or have not begun recruiting patients. (Table 4E) A total of 591,159 participants were enrolled in extramural and intramural Phase III research protocols of which 72.5% were domestic participants and 27.5% were foreign participants. Of the 591,159 participants, 54.9% were women, 42.2% were men and 2.8% did not provide sex identification. (Table 4A) Further, 41.4% of the total participants, and 20.6% of Domestic-protocol participants, in Phase III clinical research were reported as minorities following the current OMB categories for race and ethnicity. (Table 5C)

Of the 197 extramural and intramural Phase III research protocols that report following the former OMB standards in FY2007, minority representation was highest for Blacks (not Hispanic) at 10.3% and lowest for American Indian/Alaska Natives at 0.4%. Hispanics represented approximately 4.5%, Asian/Pacific Islanders were 1.9% and Whites (not Hispanic) 81.0% of the participants. The categories *Hawaiian/Pacific Islander* and *More Than One Race* were not designations with the former OMB standards. (Table 4B)

Moreover, in FY 2007, there were 424 extramural and intramural Phase III research protocols reporting data following the current OMB standards for reporting by both race and ethnicity. Accordingly, minority representation by race was highest for Blacks at 22.1% and lowest for Hawaiian/Pacific Islanders 0.1%. Asians represented 12.4%, American Indian/Alaska Natives 2.5% and Whites 34.9% of participants. Participants identifying as *More Than One Race* were 1.1% of the total number of participants. In addition, 26.9% did not identify a race category. (Table 4C) Of the 424 extramural and intramural Phase III research protocols designating an ethnicity in FY2007, 66.8 % of total participants identified as "Not Hispanic", 18.8 % of the total participants identified as "Hispanic or Latino", and 14.5% of the total participants did not identify an ethnicity category. The racial distribution of the "Hispanic or Latino" participants is also provided separately. (Table 4D)

Correspondingly, in FY2008 there were 726 extramural and intramural Phase III clinical research protocols, of which 639 protocols reported human subject participation as noted in this report's trend summary tables. (Tables 4A and 6A) Of these, 91.5% were domestic protocols and 8.5% were foreign protocols. Clinical studies not included in this analysis are those studies that have just begun and have not reported enrollment data or have not begun recruiting patients. A total of 792,578 participants were enrolled in extramural and intramural Phase III research protocols of which 74.6% were domestic participants and 25.4% were foreign participants. (Table 4E) Of the 792,578 participants, 57.5% were women, 40.3% were men and 2.2% did not provide sex identification. (Table 4A) Further, 38.9% of the total participants, and 20.2% of Domestic-only participants, in Phase III clinical research were reported as minorities following the current OMB categories for race and ethnicity. (Table 6C)

Of the 164 extramural and intramural Phase III research protocols that report following the former OMB standards in FY2008, minority representation was highest for Blacks (not Hispanic) at 9.7% and lowest for American Indian/Alaska Natives at 0.4%. Hispanics represented approximately 4.1%, Asian/Pacific Islanders were 2.0% and Whites (not Hispanic) 82.0% of the participants. The categories *Hawaiian/Pacific Islander* and *More Than One Race* were not designations with the former OMB standards. (Table 4B)

Appendix D: Monitoring Adherence to the NIH Policy on the Inclusion of Women and Minorities as Subjects in Clinical Research (excerpt)

Moreover, in FY 2008, there were 475 extramural and intramural Phase III research protocols reporting data following the current OMB standards for reporting by both race and ethnicity. Accordingly, minority representation by race was highest for Blacks at 18.4% and lowest for Hawaiian/Pacific Islanders 0.1%. Asians represented 17%, American Indian/Alaska Natives 2.7% and Whites 50.2% of participants. Participants identifying as *More Than One Race* were 2.2% of the total number of participants. In addition, 9.4% did not identify a race category. Of the 475 extramural and intramural Phase III research protocols designating an ethnicity in FY2008, 82.3 % of total participants identified as “Not Hispanic”, 11.5 % of the total participants identified as “Hispanic or Latino”, and 6.2% of the total participants did not identify an ethnicity category. The racial distribution of the “Hispanic or Latino” participants is also provided separately. (*Table 4C*)

While the number of participants in Phase III extramural and intramural clinical research increased (591,159 in FY2007 and 792,578 in FY2008), there was a slight change in the proportions of women and men (54.9%F and 42.2% in FY2007 and 57.5%F and 40.3%M in FY2008). (*Table 4A*)

The following sections provide data on extramural research and intramural research separately.

EXTRAMURAL CLINICAL RESEARCH: Fiscal Years 2007 and 2008

In FY2007, there were 13,719 extramural clinical research protocols, including Phase III and other clinical studies, of which 9,362 protocols reported human subject participation. Of these, 82.3% were domestic protocols and 3.5% were foreign protocols. (*Table 7A*) Approximately 13.9 million participants were enrolled in extramural research protocols of which 92.8% of the total enrollment is domestic participants and 7.2% of the total enrollment is foreign participants. (*Table 7B*) Of the 13.9 million participants, 61.80% were women, 35.54% were men and 2.62% did not provide sex identification. Further, 31.44% of the total participants were reported as minorities following the current OMB categories for race and ethnicity. (*Table 8A*)

Correspondingly, in FY2008, there were 11,045 extramural clinical research protocols, including Phase III and other clinical studies, of which 9,381 protocols reported human subject participation. Of these, 81.2% were domestic protocols and 3.7% were foreign protocols. (*Table 9A*) Approximately 12.6 million participants were enrolled in extramural research protocols of which 91.7% of the total enrollment is domestic participants and 8.3% of the total enrollment is foreign participants. (*Table 9B*) Of the 12.6 million participants, 63.84% were women, 35.04% were men and 1.12% did not provide sex identification. Further, 29.4% of the total participants were reported as minorities following the current OMB categories for race and ethnicity. (*Table 10A*)

While the number of participants in extramural clinical research protocols decreased (13.9 million in FY2007 and 12.6 million in FY2008), there was no significant change in the proportions of women and men (61.8%F and 35.5%M in FY2007 and 63.8%F and 35.0%M in FY2008). (*Table 8A and Table 10A*) However, when sex-specific studies were excluded, the proportions of women and men in all extramural clinical research reported in FY2008 were similar to the proportions in the general population reported in FY2009 (from 46.5% to 45.61% for females and 49.8% to 52.6% for males. (*Table 11A and Table 12A*)

NIH Defined Phase III Extramural Clinical Research: FY2007 and FY2008

In FY2007 there were 711 extramural Phase III clinical research protocols, of which 617 protocols reported human subject participation. (*Table 13A*) A total of 547,687 participants were enrolled in extramural Phase III research protocols of which 55.10% were women, 41.83% were men and 3.07% did not provide sex identification. (*Table 14A*)

In FY2007 there were 399 extramural Phase III research protocols reporting data following the current OMB standards for reporting race and ethnicity. Minority representation by race was highest for Blacks at 23.21% and lowest for Hawaiian/Pacific Islanders 0.13%. Asians represented 13.09%, American Indian/Alaska Natives 2.59% and Whites 34.29% of participants. Participants identifying as *More Than One Race* were 1.02% of the total number of participants. In addition, 25.7 % did not identify a race category. Of the 399 extramural Phase III research protocols designating an ethnicity in FY 2007, 67.77 % of total participants identified as “Not Hispanic”, 17.78% of the total participants identified as “Hispanic or Latino”, and 14.44 % of the total participants did not identify an ethnicity category. The racial distribution of the “Hispanic or Latino” participants is also provided separately. (Table 14B)

In FY2008 there were 696 extramural Phase III clinical research protocols, of which 602 protocols reported human subject participation. (Table 15A) A total of 776,034 participants were enrolled in extramural Phase III research protocols of which 57.22% were women, 40.58% were men and 2.2% did not provide sex identification. (Table 16A)

Correspondingly in FY2008, there were 452 extramural Phase III research protocols reporting data following the current OMB standards for reporting race and ethnicity. Minority representation by race was highest for Blacks at 18.68% and lowest for Hawaiian/Pacific Islanders 0.12%. Asians represented 17.41%, American Indian/Alaska Natives 2.74% and Whites 51.22% of participants. Participants identifying as *More Than One Race* were 2.22% of the total number of participants. In addition, 7.62 % did not identify a race category. Of the 452 extramural Phase III research protocols designating an ethnicity in FY 2008, 83.84 % of total participants identified as “Not Hispanic”, 10.38% of the total participants identified as “Hispanic or Latino”, and 5.78 % of the total participants did not identify an ethnicity category. The racial distribution of the “Hispanic or Latino” participants is also provided separately. (Table 16B)

While the number of extramural Phase III clinical research protocols decreased (711 in FY2007 and 696 in FY2008) (Table 13A and Table 15A), there was a slight increase in the proportion of women (55.1 %F and 41.8%M in FY2007 and 57.2%F and 40.6%M in FY2008). (Tables 14A and 16A)

INTRAMURAL CLINICAL RESEARCH: Fiscal Years 2007 and 2008

In FY2007 there were 1,848 intramural clinical research protocols, including Phase III and other clinical studies, of which 1,552 protocols reported human subject participation. (Table 7A) Approximately 3.5 million participants were enrolled in intramural research protocols of which 43.39% were women, 55.42% were men and 1.20% did not provide sex identification. (Table 16A)

In FY2007, approximately 3.5 million participants were reported in all intramural research including Phase III clinical trials, and other clinical studies. Of the 449 intramural research protocols that report data following the former OMB standards, minority representation was highest for Blacks (not-Hispanic) at 17.6% and lowest for American Indian/Alaska Natives at 0.2%. Asian/Pacific Islanders represented 3.65%, Hispanics 4.31%; and Whites (not Hispanic) 73.16% of the intramural research study population. The categories *Hawaiian/Pacific Islander* and *More Than One Race* were not designations with the former OMB standards. (Table 17C)

For the 1,103 intramural clinical research studies that reported data following the current OMB standards in FY 2007, the largest racial minority group was Blacks at 9.72 % and the smallest racial minority group was Hawaiian/Pacific Islanders at 0.16%. Asian represented 7.66%, American Indian/Alaska Natives 0.89% and Whites 69.85% of participants in all intramural clinical research. Approximately 0.56% of participants reported *More Than One Race* as their racial category. In addition, 11.16 % did not identify a

Appendix D: Monitoring Adherence to the NIH Policy on the Inclusion of Women and Minorities as Subjects in Clinical Research (excerpt)

race category. Of the 1,103 intramural research protocols following the current OMB standards designating an ethnicity in FY2007, 85.50 % of total participants identified as “Not Hispanic”, 4.19 % of the total participants identified as “Hispanic or Latino”, and 10.31 % of the total participants did not identify an ethnicity category. The racial distribution of the “Hispanic or Latino” participants is also provided separately. (*Table 17B*)

Correspondingly, in FY2008 there were 1,873 intramural clinical research protocols, including Phase III and other clinical studies, of which 1,664 protocols reported human subject participation. (*Table 9A*) Approximately 2.8 million participants were enrolled in intramural research protocols of which 42.82% were women, 55.93% were men and 1.25% did not provide sex identification. (*Table 18A*)

In FY 2008, approximately 2.8 million participants were reported in all intramural research including Phase III clinical trials, and other clinical studies. Of the 413 intramural research protocols that report data following the former OMB standards, minority representation was highest for Blacks (not-Hispanic) at 30.34% and lowest for American Indian/Alaska Natives at 0.15%. Asian/Pacific Islanders represented 3.38%, Hispanics 4.0%; and Whites (not Hispanic) 60.73% of the intramural research study population. The categories *Hawaiian/Pacific Islander* and *More Than One Race* were not designations with the former OMB standards. (*Table 18C*)

For the 1,251 intramural clinical research studies that reported data following the current OMB standards in FY 2008, the largest racial minority group was Asians at 9.8 % and the smallest racial minority group was Hawaiian/Pacific Islanders at 0.2%. Blacks represented 9.4%, American Indian/Alaska Natives 0.81% and Whites 67.92% of participants in all intramural clinical research. Approximately 0.61% of participants reported *More Than One Race* as their racial category. In addition, 11.30 % did not identify a race category. Of the 1,251 intramural research protocols following the current OMB standards designating an ethnicity in FY2008, 85.30 % of total participants identified as “Not Hispanic”, 4.07% of the total participants identified as “Hispanic or Latino”, and 10.62 % of the total participants did not identify an ethnicity category. The racial distribution of the “Hispanic or Latino” participants is also provided separately. (*Table 18B*)

While the number of participants specifically in Phase III intramural clinical research protocols significantly decreased (3.5M in FY2007 and 2.8M in FY2008), there was no substantive change in the proportions of women and men (43.4%F and 55.4% M in FY2007 and 42.8%F and 55.9%M in FY2008). (*Tables 17A and Table 18A*)

NIH Defined Phase III Intramural Clinical Research: FY2007 and FY2008

In FY2007 there were 38 intramural Phase III clinical research protocols, of which 36 protocols reported human subject participation. Of these, 88.8%, of the total number of protocols are domestic and 11.1% of the total number of protocols is foreign. (*Table 13A*) A total of 43,472 participants were enrolled in intramural Phase III research protocols of which 77.1 are domestic participants and 22.9% are foreign participants. (*Table 13B*) Of the 43,472 participants, 52.8% were women, 47.2% were men and 0% did not provide sex identification. (*Table 19A*) Further, 27.3% of total participants in Phase III intramural clinical research protocols were reported as minorities following the current OMB categories for race and ethnicity. (*Table 13C*)

Correspondingly, in FY2008 there were 39 intramural Phase III clinical research protocols, of which 37 protocols reported human subject participation. Of these, 89.1% of the total number of protocols is domestic and 10.8% of the total number of protocols is foreign. (*Table 15A*) A total of 16,544 participants were enrolled in intramural Phase III research protocols of which 36.7% of the total enrollment is

domestic participants and 63.2% are foreign participants. *(Table 15B)* Of the 16,544 participants, 69.71% were women, 28.92% were men and 1.37% did not provide sex identification. Further, 56.67% of total participants in Phase III clinical research protocols were reported as minorities following the current OMB categories for race and ethnicity. *(Table 20A)*

While the number of participants specifically in Phase III intramural clinical research protocols significantly decreased (43,472 in FY2007 and 16,544 in FY2008), there was a substantial increase in the proportions of women (52.8%F and 47.2% M in FY2007 and 69.7%F and 28.9%M in FY2008). *(Tables 19A and Table 20A)*

Appendix D: Monitoring Adherence to the NIH Policy on the Inclusion of Women and Minorities as Subjects in Clinical Research (excerpt)

TREND REPORT ON NIH AGGREGATE POPULATION DATA: FY1995 – FY2008

Trend data vary over time because the data for each year represent the net total of data resulting from: (1) studies continuing from the prior year; (2) the addition of new studies reported; and (3) the subtraction of studies that are no longer reported.

Table 21 is a fourteen year summary report showing a steady increase in the number of protocols and enrollment. The number of protocols with enrollment increased from 3,188 in FY1995 to 11,045 in FY2008 – a 3.5 fold increase. Reported enrollment increased from approximately 1.0 million (FY1995) to 15.4 million (FY2008) – a 15.1 fold increase; minority enrollment increased from approximately 0.4 million (FY1995) to 4.3 million (FY2008) – an 11.7 fold increase in minority representation in NIH clinical research. (*Table 21A*) The total number of protocols reported with enrollment data has increased such that, since FY2003 the number is in excess of 10,000 protocols per year. (*Table 21B*)

With the deployment of an updated population tracking system in 2002 and the OMB requirement to report data using the current format, NIH was able to report domestic and foreign data in a better way. Thus, trend data are available for domestic and foreign protocols and participation beginning in FY2002. Domestic enrollment increased from 10.2 million (FY2002) to 14.1 million (FY2008) – a 1.4 fold increase. Foreign enrollment increased from 0.9 million (FY2002) to 1.3 million (FY2008) – a 1.4 fold increase. (*Table 21A*) Overall, the total enrollment has increased with domestic participation ranging between 75.9-92.7% and foreign participation ranging between 7.3-24.1%. In FY2008, domestic and foreign enrollment was 91.7% and 8.3% respectively. (*Table 21C*)

Table 1 is a summary report of all extramural and intramural clinical research by sex/gender and minority representation following the old and new data formats for domestic and foreign studies. The report demonstrates that female participation in all extramural and intramural research generally ranged between 51.7% and 63.9%, male participation in all extramural and intramural research ranged between 34.0% and 45.0%. (*Table 1A*) Overall minority participation in all extramural and intramural clinical research ranged between 28.6% and 43.1%. (*Tables 1B-D*) *Table 1E* provides a comparison of domestic and foreign participation between FY2002 and FY2008. The vast majority of protocols are domestic (~94%-96%) of the total clinical research protocols. While the number of foreign protocols has increased, they incorporate only about 4%-6% of the total clinical research protocols with enrollment. *Table 1F* shows domestic and foreign enrollment for the seven-year period. Domestic minority enrollment varied between 24.1% and 28.9% of total domestic participation, while foreign minority enrollment varied between 67.7% and 90.9% of total foreign participation.

Table 4 is a summary of NIH-funded Phase III extramural and intramural clinical research by sex/gender and minority enrollment following the old and new data reporting formats for domestic and foreign studies. This table demonstrates that female participation in NIH funded Phase III extramural and intramural clinical research generally ranged between 54.1% and 74.8% and male participation in NIH-funded Phase III extramural and intramural clinical research ranged between 24.3% and 44.6%. (*Table 4A*) Overall minority participation in NIH-funded Phase III extramural and intramural clinical research ranged from 26.9% to 41.4%. (*Tables 4B-D*) *Table 4E* provides a comparison of domestic and foreign participation between FY2002 and FY2008. The vast majority of protocols are domestic, ranging from 75.5% and 95.8% of the total clinical research protocols. While the number of foreign protocols has decreased, they incorporate only about 4.2%-9.6% of the total clinical research protocols with enrollment in the last seven years. *Table 4F* shows domestic and foreign enrollment for the seven-year period. Domestic minority enrollment varied between 20.2% and 25.4% of total domestic participation, while foreign minority enrollment in NIH-funded Phase III clinical research varied between 48.4% and 96.2% of total foreign participation. In comparing both domestic and foreign Phase III enrollment over the seven

year period shows that the small percentage of foreign protocols in FY2008 account for a significant proportion of the total foreign enrollment.

Tables 22-25 summarize domestic and foreign participation for NIH funded clinical research and NIH-funded Phase III clinical research. For extramural and intramural clinical research, domestic participants enrolled in domestic protocols, female participation ranged between 58.1% and 67.3% while male participation ranged between 31.2 and 39.5%. (Table 22A) For NIH-funded Phase III extramural and intramural clinical research, domestic participants enrolled in domestic protocols, female participation ranged between 53.3 and 64.6% while male participation ranged between 34.4 and 44.8%. (Table 23A) For all extramural and intramural clinical research, foreign participants enrolled in foreign protocols, female participation varied from 39.2% to 59.5% while male participation varied from 39.3% to 60.4%. (Table 24A) For NIH-funded Phase III extramural and intramural clinical research, foreign participants enrolled in foreign protocols, female participation varied from 47.4% to 59.2% while male participation varied from 40.4% to 52.5%. (Table 25A)

Appendix E: Research Training and Graduate Medical Education Data

National Research Service Award (NRSA) and National Library of Medicine (NLM) Research Training Programs

Ph.D.s Awarded to NIH Trainees and Fellows		
Field of Study	FY 2007	FY 2008
Life Sciences	2,192	2,369
<i>Biological/Biomedical Sciences</i>	<i>1,943</i>	<i>2,120</i>
Biochemistry	188	218
Biomedical Sciences	68	72
Biophysics	64	49
Biotechnology	4	2
Bacteriology	8	4
Plant Genetics	5	7
Botany/Plant Biology	6	4
Anatomy	2	2
Bioinformatics	14	25
Biometrics & Biostatistics	25	19
Cell/Cellular Biology and Histology	131	133
Cancer Biology	43	121
Ecology	15	1
Developmental Biology/Embryology	77	69
Endocrinology	5	6
Entomology	2	2
Immunology	160	183
Molecular Biology	203	202
Microbiology	150	161

Neuroscience	327	359
Nutritional Sciences	24	19
Parasitology	6	9
Toxicology	41	46
Genetics, Human & Animal	137	147
Pathology, Human & Animal	21	37
Pharmacology, Human & Animal	96	100
Physiology, Human & Animal	64	59
Zoology, Other	1	3
Biology/Biological Sciences, General	37	28
Biology/Biomedical Sciences, Other	15	14
<i>Health Sciences</i>	<i>238</i>	<i>240</i>
Speech-Language Pathology & Audiology	9	12
Environmental Health	4	10
Environmental Toxicology	2	7
Health Systems/Service Administration	5	3
Public Health	39	35
Epidemiology	60	65
Kinesiology/Exercise Sciences	8	13
Nursing Science	56	60
Rehabilitation/Therapeutic Services	4	2
Veterinary Medicine	4	4
Health Sciences, General	4	3
Health Sciences, Other	22	11
<i>Agricultural Sciences/Natural Resources</i>	<i>11</i>	<i>9</i>
Agricultural Economics	1	1
Agricultural Science, Other	1	0
Plant Sciences, Other	0	2

Appendix E: Research Training and Graduate Medical Education Data

Environmental Science	0	3
Forest/Resources Management	1	
Social Sciences	300	288
<i>Psychology</i>	235	224
Clinical	81	96
Cognitive & Psycholinguistics	28	16
Counseling	2	6
Developmental & Child	24	26
Human Development & Family Studies	6	5
Experimental	14	10
Educational	2	
Industrial & Organizational	1	1
Personality	10	1
Physiological/Psychobiology	26	14
Psychometrics & Quantitative	7	0
School	1	2
Social	19	24
Psychology, General	9	12
Psychology, Other	7	10
<i>Social Sciences</i>	65	64
Anthropology	13	5
Demography/Population Studies	3	6
Economics	8	14
Public Policy Analysis	5	7
Sociology	23	20
Social Sciences, Other	5	0
Physical Sciences	115	139
<i>Chemistry</i>	67	85

Analytical	15	12
Inorganic	5	5
Organic	24	31
Medicinal/Pharmaceutical	1	0
Physical	6	10
Polymer	1	1
Theoretical	2	4
Chemistry, General	3	7
Chemistry, Other	10	15
<i>Computer Sciences</i>	11	11
Computer Science	10	8
Computer & Information Sciences, Other	1	2
<i>Geological & Earth Sciences</i>	1	
Geology	1	
<i>Mathematics</i>	12	12
Applied Mathematics	1	4
Geometry/Geometric Analysis	3	0
Statistics	5	6
Mathematics/Statistics, General	1	
Mathematics/Statistics, Other	0	1
<i>Ocean/Marine Sciences</i>	2	0
Marine Sciences	1	0
Oceanography, Chemical and Physical	1	0
<i>Physics</i>	23	31
Optics/Phototonics	1	1
Polymer Physics	1	0
Condensed Matter/Low Temperature	2	1
Physics, General	1	1

Appendix E: Research Training and Graduate Medical Education Data

Physics, Other	3	4
Engineering	143	174
Aerospace, Aeronautical & Astronautical	2	1
Bioengineering & Biomedical	99	130
Chemical	27	30
Computer	0	1
Electrical, Electronics and Communications	7	6
Environmental Health Engineering	3	1
Industrial & Manufacturing	1	0
Materials Science	1	
Mechanical	3	2
Education	18	13
Humanities	7	3
Other Fields	26	17
TOTAL	2,801	3,003
Note: Detailed field data are provided only for broad fields with ≥ 100 Ph.D. recipients		
Sources: NIH IMPAC II and the Doctorate Records File.		

Demographic Characteristics* of NRSA Participants		
Gender	FY 2007	FY 2008
Female	51.5%	51.5%
Male	45.8%	45.9%
Unreported	2.6%	2.6%
Race/Ethnicity		
White	67.2%	66.0%
Asian	15.0%	14.9%
Hispanic	6.7%	7.0%
African American	8.3%	7.6%
Native American	1.0%	1.0%
Pacific Islander	0.7%	0.7%
Unreported	5.9%	7.9%

Sources: NIH IMPAC II

*Reporting personal information such as sex, race, and ethnicity is voluntary.

Appendix E: Research Training and Graduate Medical Education Data

Graduate Medical Education: NIH-Sponsored, ACGME-Accredited, Residency and Subspecialty Training Programs

Successfully Completed Residency and Subspecialty Training By Academic Year		
NIH Clinical Center Program Specialty	Successfully Completed	
	2007/2008	2008/2009
Allergy and Immunology	4	3
Medical Genetics	4	1
Medical Biochemical Genetics	0	2
Critical Care Medicine	4	3
Endocrinology, Diabetes, and Metabolism	6	4
Hematology	3	4
Infectious Disease	3	4
Oncology	13	9
Rheumatology	2	4
Pathology-Anatomic and Clinical	4	3
Blood Banking/Transfusion Medicine	1	2
Cytopathology	1	1
Hematology (Pathology)	1	2
NICHD/Georgetown University Hospital Program / Pediatric Endocrinology*	2	3
Psychiatry	1	2
Total	49	47


*Cosponsored by NICHD and Georgetown University Hospital

Source: AAMC GME Track Database

Appendix F: Report of the Advisory Committee on Research on Women's Health, FYs 2007-2008 (excerpt)

Link to on-line version of full report can be found at http://orwh.od.nih.gov/pubs/07-08/IC/Report/Book_FINAL508.pdf

REPORT OF THE ADVISORY
COMMITTEE ON RESEARCH
ON WOMEN'S HEALTH



FISCAL YEARS
2007–2008

OFFICE OF
RESEARCH ON
WOMEN'S HEALTH
&
NIH SUPPORT
FOR RESEARCH ON
WOMEN'S HEALTH ISSUES

Preface

The Advisory Committee on Research on Women's Health (ACRWH), in concert with the Office of Research on Women's Health (ORWH) and the Coordinating Committee on Research on Women's Health (CCRWH), submits to the Director of the National Institutes of Health (NIH) this Biennial Report for fiscal years (FYs) 2007 and 2008. The report describes the comprehensive and coordinated efforts of the ORWH and the NIH Institutes, Centers (ICs), and Offices to address women's health issues through research and related activities in accordance with the NIH Revitalization Act of 1993. The information in this Biennial Report was prepared by the ORWH and by each of the NIH ICs and Offices to highlight significant research studies and other achievements and initiatives that have contributed to an increased knowledge of women's health. Using criteria supplied by the NIH Office of Financial Management (OFM) and the U.S. Department of Health and Human Services Office on Women's Health, and based on budget data provided by NIH ICs, this report also contains information on NIH budget allocations for women's health research during FY 2007 and FY 2008. In addition, the report contains information obtained from the NIH ICs and Offices documenting the inclusion of women and minorities in NIH-funded clinical research during the same time period.

The ACRWH has reviewed the information contained herein and believes that this Biennial Report accurately reflects the breadth and depth of research and related activities through which the NIH, in FY 2007 and FY 2008, has fulfilled its mandate from the U.S. Congress to address women's health issues and women's inclusion in research.

The ACRWH acknowledges the valuable contributions to this report of the CCRWH, which is made up of the directors of each of the ICs and Offices or their designated representatives. We are also grateful to the many NIH staff members who prepared and reviewed the reports of their ICs or Offices. We appreciate the work of the NIH Tracking and Inclusion Committee in preparing information on the inclusion of women and minorities in NIH-funded research and the work of the NIH OFM in collecting and tabulating the budgetary data published in this report.

Finally, the ACRWH wishes to acknowledge the work of ORWH staff. This Biennial Report reflects the achievements of the ORWH in fulfilling all aspects of its core mission in strengthening and enhancing research related to diseases and conditions that affect women; ensuring the appropriate representation of women in NIH research; supporting the advancement of women in biomedical careers; and building programs to ensure the development of a cadre of researchers, both women and men, in the field of interdisciplinary women's health research.

(For a full listing of ACRWH members for FY 2009, please see pages iv–vi.)

Appendix F: Report of the Advisory Committee on Research on Women's Health, FYs 2007-2008 (excerpt)

FISCAL YEARS 2007 & 2008

Introduction to the Biennial Report

As directed in the National Institutes of Health (NIH) Revitalization Act of 1993,¹ the Advisory Committee on Research on Women's Health (ACRWH) submits to the NIH Director a report describing the activities of the Committee and its findings related to the mandates and funding for women's health. This report includes coordinated efforts of the NIH Institutes, Centers (ICs), and Offices to address women's health issues through research and related activities. As the 20th anniversary of the establishment of the Office of Research on Women's Health (ORWH) approaches, this FY 2007–2008 Biennial Report bears witness to the phenomenal growth in women's health research and related programs that has occurred since the formation of the Office in 1990. This report reflects major FY 2007–2008 ORWH research programs, initiatives, and activities, as well as highlights that were reported through the Coordinating Committee on Research on Women's Health (CCRWH) from the NIH ICs and Offices. This report is not a comprehensive listing of all NIH research on women's health, which would necessarily be encyclopedic; however, the report does serve to summarize, under a single cover, examples of the wealth of NIH advances in women's health research. This Biennial Report also provides information on and analysis of support for women's health research and related activities. During FY 2007–2008, NIH spent approximately \$3.5 billion per year on research specifically related to women's health and approximately \$23 billion on research relevant to both women and men.

The Biennial Report is divided into two major parts. Part One is based on ORWH programs and describes ORWH scientific, interdisciplinary, research, career development, and research dissemination and outreach programs. Data are also reported on the inclusion of women and minorities in NIH-funded clinical research as provided from the Office of Extramural Research. Many ORWH programs reflect the Office's roles in coordinating trans-NIH activities. Most ORWH programs are conducted in collaboration with NIH ICs and Offices. Other ORWH activities are conducted in collaboration with Federal agencies and/or with public and private partners. Part Two of the Biennial Report provides the individual reports on women's health research from 20 NIH Institutes, 4 Centers, and 7 Offices, which include highlights of some of their most promising research programs.

Office of Research on Women's Health

Information about ORWH programs is organized into six sections covering the following areas: ORWH Research; ORWH Interdisciplinary Research and Career Development Programs; ORWH Biomedical Career Development Activities; ORWH Research Dissemination and Outreach; Monitoring Adherence to the NIH Policy on the Inclusion of Women and Minorities as Subjects in Clinical Research; and NIH Budget for Women's Health Research.

Section I describes FY 2007–2008 NIH women's health research priorities, developed in coordination with the CCRWH and reviewed by the ACRWH. It also provides a table of ORWH-funded projects grouped by diseases and conditions. It also provides examples of special ORWH research initiatives in FY 2007–2008 and highlights of ORWH-cofunded research projects and research workshops and conferences. A strategic planning effort, begun in 2008, is described in Section I. The effort, which will update the 1999 *Agenda for Research on Women's Health for the 21st Century*, is currently ongoing. It is anticipated that the updated research agenda will be completed in time for the 20th anniversary of the founding of ORWH in September 2010.

The *Agenda for Research on Women's Health for the 21st Century* recognized that women's health research is an inherently broad interdisciplinary field of endeavor, encompassing a full range of science. Since 1999, ORWH has been working to provide institutional support for interdisciplinary research and interdisciplinary research career development. Section II highlights major ORWH efforts to catalyze interdisciplinary women's health research and career development through two programs:

¹The NIH Revitalization Act of 1993, P.L. 103-43, 107, Stat. 22 [codified at 42 U.S.C. 289(a)(1)] [Sec. 486(287d)(d)].

Report of the Advisory Committee on Research on Women's Health

the Specialized Centers of Research (SCOR) on Sex and Gender Factors Affecting Women's Health, and the Building Interdisciplinary Research Careers in Women's Health (BIRCWH) Institutional Mentored Career Development Program. Section II also describes ORWH efforts to catalyze NIH interdisciplinary research and IC collaboration to advance understanding of a specific multifactorial condition predominantly affecting women, namely chronic fatigue syndrome.

Since its inception in 1990, the mandate of ORWH has included women's career development and the development of women's health researchers. The BIRCWH program is a major example of a highly successful mentored career development program that was developed and implemented by ORWH in 1999. Section III provides information on a number of other programs through which ORWH works to promote women's biomedical career development and the development of careers in research on women's health and sex/gender factors. Section III reports on the collaborative efforts of ORWH and the *Eunice Kennedy Shriver* National Institute of Child Health and Human Development (NICHD) in supporting the Women's Reproductive Health Research Career Development program, and on the ORWH-initiated trans-NIH Reentry into Biomedical and Behavioral Careers Research Supplement Program.

Section III describes the activities of the NIH Director's Working Group on Women in Biomedical Careers to provide an NIH response to the challenges to Federal agencies posed in the 2007 National Academy of Sciences report, *Beyond Bias and Barriers: Fulfilling the Potential of Women in Academic Science and Engineering*. Section III also highlights FY 2007–2008 ORWH/NIH Intramural Women's Health Research programs, ranging from a summer research program for high school students interested in science to negotiation skills for tenure-track women scientists. The section ends with a summary of a wide range of other ORWH activities to promote the career development of women, some of which involve partnering with professional societies.

Section IV on research dissemination and outreach provides information on new ORWH Internet-based health information initiatives, including a collaborative effort with the NIH National Library of Medicine to create an online resource for information on women's health research; a Web-based course cosponsored with the Food and Drug Administration (FDA) on *The Science of Sex and Gender in Human Health*; and a multimedia approach to communicate advances being made from past and current women's health research. ORWH strives to ensure that the information generated from the NIH investment in research on women's health informs future research efforts and improves women's health care. Thus, outreach to the largest possible population of clinicians and researchers, women, healthcare providers, and others interested in women's health is a very important part of its mandate. Section IV describes ORWH outreach activities, including the Women's Health Seminar series and the Vulvodynia Awareness campaign.

Section V details NIH efforts to monitor the inclusion of women and minorities in NIH-funded clinical research, including data by ICs as well as NIH aggregate figures. Section VI provides information on NIH expenditures on women's health research, including a breakdown of expenditures by disease category and other major categories of interest (e.g., aging research).

NIH IC Support for Research on Women's Health

Part Two of the Biennial Report is composed of individual reports from each of 20 NIH Institutes, 4 Centers, and 7 Offices located within the Office of the Director, NIH. These IC and Office reports summarize their major initiatives and activities and provide highlights of their funded research related to women's health and sex/gender research, consistent with their specific missions.

You are invited to read this in-depth report to become acquainted with the tremendous advances in women's health research that have taken place during this 2-year period and to appreciate the promise for even greater advances in the future, not just for women's health, but also for men's health and for careers in women's health research for both men and women.

Vivian W. Pinn, M.D.
Associate Director for Research on Women's Health
Director, Office of Research on Women's Health

Appendix F: Report of the Advisory Committee on Research on Women's Health, FYs 2007-2008 (excerpt)

Report of the Advisory Committee on Research on Women's Health

Office of Research on Women's Health (ORWH)

INTRODUCTION TO ORWH PROGRAMS

In 1983, the Assistant Secretary for Health, Dr. Edward N. Brandt, established the U.S. Public Health Service Task Force on Women's Health Issues, in recognition of the paucity of data related to women's health. The Task Force produced a 1985 report, *Women's Health: Report of the Public Health Service Task Force on Women's Health Issues, Volume I*.² The report delineated a series of criteria for differentiating a health problem, condition, or disease as a woman's issue. The criteria included the following:

- Diseases or conditions unique to women or some subgroup of women;
- Diseases or conditions more prevalent in women or some subgroup of women;
- Diseases or conditions more serious in women or some subgroup of women;
- Diseases or conditions for which risk factors are different for women or some subgroup of women; or
- Diseases or conditions for which interventions are different in women or some subgroup of women.

The report also recommended that "biomedical and behavioral research should be expanded to ensure emphasis on conditions and diseases unique to, or more prevalent in, women in all age groups."

Following the issuance of the Task Force report, the National Institutes of Health (NIH) established a policy for the inclusion of women in clinical research. This policy, which urged the inclusion of women, was first published in the *NIH Guide to Grants and Contracts* in 1987.³ Later that year, minority scientists and other researchers at NIH recognized the need to address the inclusion of minority populations. As a result, a subsequent version of the *NIH Guide* published for the first time a policy encouraging the inclusion of minorities in clinical studies.⁴

In 1990, the Congressional Caucus for Women's Issues requested that the General Accounting Office (GAO), now known as the Government Accountability Office, conduct an investigation into the implementation of the guidelines for the inclusion of women by NIH. This report, included in congressional testimony, indicated that the implementation of the policy for the inclusion of women was slow and not well communicated, that gender analysis was not being performed routinely, and that the impact of this policy could not be determined.⁵ The GAO testimony also indicated that there were differences in the implementation of the policy recommending the inclusion of minorities, and that not all Institutes and Centers (ICs) factored adherence to these policies into scientific merit review. GAO findings concerning the lack of consistent implementation of policies for inclusion of women in NIH clinical trials led NIH to establish the ORWH within the Office of the

²U.S. Public Health Service. *Women's health: Report of the Public Health Service Task Force on women's health issues. Public Health Reports* 100(1):74-106, 1985.

³Division of Research Grants. *Inclusion of women in study populations. NIH Guide to Grants and Contracts* 16(3):2, 1987.

⁴Division of Research Grants. *Inclusion of minorities in study populations. NIH Guide to Grants and Contracts* 16(32):3-4, 1987.

⁵*National Institutes of Health: Problems in Implementing Policy on Women Study Populations* (GAO/T-HRD-90-38, 1990). Washington, DC: U.S. Government Accountability Office.

NIH Director in September 1990. Since its establishment, ORWH has served as the focal point for women's health research at NIH. The responsibilities of the Director, ORWH, include the following:

- (1) Advises the NIH Director and staff on matters relating to research on women's health;
- (2) Strengthens and enhances research related to diseases, disorders, and conditions that affect women;
- (3) Ensures that research conducted and supported by NIH adequately addresses issues regarding women's health;
- (4) Ensures that women are appropriately represented in biomedical and biobehavioral research studies supported by NIH;
- (5) Develops opportunities for and supports recruitment, retention, reentry, and advancement of women in biomedical careers; and
- (6) Supports research on women's health issues. ORWH works in partnership with the NIH Institutes and Centers to ensure that women's health research is part of the scientific framework at NIH and throughout the scientific community.

ORWH was established in statute in the NIH Revitalization Act of 1993.⁶ An Advisory Committee on Research on Women's Health (ACRWH), composed of non-Federal members, was also statutorily mandated in the Revitalization Act as a mechanism for eliciting advice and recommendations on priority issues affecting women's health research. This Committee provides leadership to ORWH by advising the ORWH Director on appropriate research activities in women's health. ACRWH members are chosen from among health practitioners, advocates, research scientists, educators, and other professionals. Committee members are actively involved in reviewing and advising on matters related to research priorities, the women's health research portfolio for NIH, career development, inclusion of women and minorities in NIH-funded clinical research, and other ORWH or NIH programs related to women's health.

ORWH also benefits from the advice of a Coordinating Committee on Research on Women's Health (CCRWH). The CCRWH was also established in statute in the 1993 NIH Revitalization Act and is composed of Institute and Center Directors or their designees as a direct liaison for ORWH with NIH ICs. Both the ACRWH and the CCRWH provide valuable guidance, collaboration, and support for activities of ORWH in women's health research, career programs, and outreach efforts.

ORWH programs and efforts have expanded in breadth and depth over the years. The research funded or cofunded by ORWH is based on collaborative efforts with the ICs and supports peer-reviewed, science-driven initiatives. These collaborations are benefiting the health of all Americans across the lifespan, men as well as women, and all racial and ethnic groups.

⁶The NIH Revitalization Act of 1993, P.L. 103-43, 107, Stat. 22 [codified at 42 U.S.C. 289(a)(1)] [Sec. 486(287d)(d)].

Comprehensive Table of Contents

Volume I Contents

Preface

Chapter 1: About NIH

Statement of the Director.....	1-1
Overview of NIH Structure and Organization.....	1-7
Extramural and Intramural Research Programs.....	1-11
NIH Strategic Planning and the NIH Roadmap and Common Fund.....	1-17
NIH Implementation of the American Recovery and Reinvestment Act of 2009 (Recovery Act)	1-21
Providing the Platform for Discovery.....	1-27
Improving Research Management.....	1-33
Capitalizing on Discovery	1-39
Ensuring Responsible Research.....	1-43

Volume II Contents

Chapter 2: Summary of Research Activities by Disease Category

Cancer.....	2-1
Neuroscience and Disorders of the Nervous System.....	2-31
Infectious Diseases and Biodefense.....	2-71
Autoimmune Diseases	2-107
Chronic Diseases and Organ Systems	2-125
Life Stages, Human Development, and Rehabilitation.....	2-191
Minority Health and Health Disparities.....	2-231
Estimates of Funding for Various Research, Condition, and Disease Categories	2-273

Volume III Contents

Chapter 3: Summary of Research Activities by Key Approach and Resource

Fields and Approaches

Epidemiological and Longitudinal Studies	3-1
Genomics.....	3-27
Molecular Biology and Basic Sciences	3-55
Clinical and Translational Research.....	3-103

Tools and Training

Disease Registries, Databases, and Biomedical Information Systems	3-185
Technology Development.....	3-211
Research Training and Career Development.....	3-247

Health Information and Communication

Health Communication and Information Campaigns and Clearinghouses.....	3-271
--	-------

Volume IV Contents

Chapter 4: NIH Centers of Excellence

Introduction	4-1
Alzheimer’s Disease Centers.....	4-3
Claude D. Pepper Older Americans Independence Centers	4-13
Senator Paul D. Wellstone Muscular Dystrophy Cooperative Research Centers.....	4-19
National Center on Minority Health and Health Disparities Centers of Excellence Program.....	4-27
Rare Diseases Clinical Research Network	4-39
Autism Centers of Excellence	4-47

Volume V Contents

Chapter 5: Appendices

Appendix A: Legal Mandates for this Report.....	5-1
Appendix B: Priorities and Plans of the Institutes and Centers and the Program Offices in the Office of the Director.....	5-7
Appendix C: Common Fund Strategic Planning Report, 2009	5-13
Appendix D: Monitoring Adherence to the NIH Policy on the Inclusion of Women and Minorities as Subjects in Clinical Research (excerpt)	5-27
Appendix E: Research Training and Graduate Medical Education Data	5-37
Appendix F: Report of the Advisory Committee on Research on Women’s Health FYs 2007-2008 (excerpt).....	5-45
Comprehensive Table of Contents	5-51
Index	5-53

Index

A¹

- ACCORD (*see* Action to Control Cardiovascular Risk in Diabetes)
- Acetazolamide, **2:59, 3:140**
- ACF (*see* Administration for Children and Families)
- Acquired Immunodeficiency Syndrome (*see* HIV infection/AIDS; Office of AIDS Research)
- Action to Control Cardiovascular Risk in Diabetes, **2:136, 166, 3:160**
- Activation-induced deaminase, **2:111**
- Activities to Promote Research Collaborations in AIDS-Associated Malignancies, **2:23**
- Acupuncture, **2:66, 139, 179, 3:113, 166**
- Acute Liver Failure Study Groups, **2:136, 169, 3:149**
- Acute Renal Failure Trial Network, **2:137, 172**
- Acute Respiratory Distress Syndrome, **2:273**
- ADCS (*see* Alzheimer's Disease Cooperative Study)
- AddHealth (*see* National Longitudinal Study of Adolescent Health)
- Addiction (*see* Alcohol; Substance abuse and addiction; Tobacco)
- Adenine phosphoribosyl-transferase deficiency, **4:41**
- Adherence Research Network, **3:161**
- Adherence to treatment, **2:135, 3:161**
- Adjuvant Development Program, **2:74, 95, 3:80**
- Administration for Children and Families, **2:69, 228**
- ADNI (*see* Alzheimer's Disease Neuroimaging Initiative)
- Adolescent Medicine Trials Network for HIV/AIDS, **2:77, 88, 172, 201**
- Adolescents
- ADHD, **2:136, 160-161, 167-168, 213, 3:14-15, 139**
 - alcohol abuse and alcoholism, **2:34, 41-42, 44-45, 130, 146, 151, 156, 157, 218, 3:3, 36, 138-139, 288**
 - bariatric surgery for obesity, **2:137, 170-171, 3:18-19, 111, 150**
 - brain development, **2:35, 43-45, 217-218, 3:14, 92**
 - burden of illness, **2:126, 186, 234**
 - chronic diseases, **2:44, 126, 132, 133, 136, 137, 152, 156-157, 160-161, 167-168, 170-171, 215, 3:18-19, 138-139, 150**
 - clinical and translational research, **2:44, 77, 99, 156, 201, 215, 3:111, 138-139, 150, 152-153, 163**
 - communicating health information to, **2:44, 146, 156, 215, 3:138-139, 275, 281, 287, 288**
 - diabetes, **2:132, 152, 234**
 - epidemiological and longitudinal studies, **2:43-44, 137, 170-171, 217-218, 219, 238, 254, 3:2-3, 4, 8-9, 14-15, 18-19, 36, 111, 150, 192, 204**
 - eye diseases, **2:167, 215-216, 3:111, 152-153**
 - HIV/AIDS, **2:77, 85, 92, 99, 102, 201, 226, 234, 263, 3:114-115, 163, 287**
 - mental illness, **2:235, 238, 254, 3:9, 139, 281**
 - minority health and health disparities, **2:234, 235, 251, 254, 263, 3:9, 204**
 - obesity, **2:137, 170-171, 186, 195, 251, 3:18-19, 111, 150**
 - pregnancy, **2:289**
 - strategic plans, **2:226**
 - substance abuse and addiction, **2:32, 34, 35, 41-42, 43-45, 130, 133, 151, 156-157, 195, 215, 217-218, 254, 3:3, 8-9, 14-15, 92, 138-139, 163, 192, 204, 288**
 - suicide, **3:9**
- Advanced DNA Sequencing Technology program, **3:32**
- Advanced Platforms and Computational Sciences program, **2:8**
- Advancing Novel Science in Women's Health Research, **3:180**
- Advisory Committee on Research on Women's Health, report of, **5:45-50**
- Aequorea victoria*, **3:55**
- African Americans/blacks
- alcohol abuse, **3:16, 17**
 - Alzheimer's disease, **4:6**
 - arthritis, **2:125**
 - asthma, **2:234-235**
 - cancer, **2:20, 233, 235, 262, 266, 3:12-13, 16, 30, 51, 86-87, 97, 177-178, 179, 278, 4:29-30**
 - cardiovascular disease, **2:132, 149, 150-151, 159, 233-234, 251, 252-253, 262, 3:5, 16, 19, 24, 40, 45, 4:31**
 - communicating health information to, **2:65, 240, 249, 258-259, 261, 262, 3:114, 162, 276, 278, 281, 284-285, 286-287**
 - diabetes, **2:159, 234, 237, 3:103, 281**
 - digestive diseases, **2:259, 3:281**
 - genetic basis of disease, **2:159, 3:30, 37, 38, 40, 45, 51, 78, 118**
 - glaucoma, **2:55, 151, 235, 3:45**
 - health disparities research, **2:20, 220, 231, 233-236, 237, 238, 239, 240, 240, 249, 250, 266, 3:9, 12, 30, 37, 40, 78, 278, 4:28-31**
 - HIV/AIDS, **2:87, 234, 250, 256, 258-259, 261, 3:177**
 - hypertension, **2:135, 234**
 - infant mortality, **2:234**
 - kidney disease, **2:125, 132, 154, 237, 249, 259, 3:37, 114, 162, 276, 281**
 - lung diseases, **2:159, 3:38**
 - lupus, **2:117, 235-236, 237, 247-248, 3:43-44, 78, 118**
 - mental illness, **2:235, 238, 254, 3:9, 16**
 - obesity, **2:159, 170-171, 234, 251, 252, 3:18-19, 150, 4:30, 31**
 - oral health, **2:235, 3:30**
 - pregnancy, **2:285**
 - sexual maturation, **2:12-13, 208, 3:5, 12, 51, 86-87, 178**
 - sickle cell disease, **2:187**
 - statistics and burden of disease, **2:233-235, 4:29-30**
 - stroke, **2:65, 233-234, 238, 239, 253, 258-259, 3:16, 284-285, 4:29**
 - training and career development, **2:264, 3:250, 278**
 - women's health, **3:40, 45, 51, 78, 118**
- African sleeping sickness, **1:4**
- Age-Related Eye Disease Study, **2:137**
- Agency for Healthcare Research and Quality collaborations, **2:7, 8, 17, 154, 249-250, 261, 264, 3:34, 37, 147, 156-157, 163, 164, 165, 175, 182, 192, 203-204, 268, 290**
- Agency for Toxic Substances and Disease Registry, **3:161**
- Agent Orange and dioxin, **2:273**
- Aging (*see also* Alzheimer's disease; Claude D. Pepper Older Americans Independence Centers; National Institute on Aging; Older adults; Parkinson's disease)
- balance disorders, **4:15, 16**
 - behavioral and social sciences research, **2:38, 54-55, 3:91, 113, 164, 220-221, 246**
 - cancer, **2:2, 12, 23, 24-25, 194, 200, 205, 253, 3:13, 77, 172**
 - cardiovascular diseases, **2:23, 159, 194, 200-201, 220, 250, 3:42, 199**
 - clinical and translational research, **2:12, 54-55, 56-55, 76-77, 172, 207, 211, 265, 3:91, 113, 152, 164, 172, 220-221, 246, 4:15**
 - clinical practice, **3:91, 113, 164, 220-221, 246**

¹Bold numbers indicate volume, followed by Arabic page numbers in that volume

Aging (*continued*)

cognitive function, **2**:13, 32, 38, 53, 54-55, 77, 86, 132, 153, 194, 196, 200-201, 205, 206, 207, 211, 253, **3**:1, 9, 91, 113, 152, 164, 220-221, 246, **4**:5
 demographic and economic studies, **2**:211-212, **3**:9-10
 epidemiological and longitudinal studies, **2**:24-25, 76-77, 86, 159, 194, 200-201, 205, 211-212, 220, 250, **3**:1, 4, 9-10, 13, 211, **4**:4
 eye diseases, **2**:67, 125, 129, 131, 137, 140-141, 146, 173, 183, 187, 193, 196, 211, 227, **3**:77, 152
 funding for research, **2**:152, 156-157, 274
 genomics, **2**:23, 24, 25, 159, 194, 196, 198, 200, 208, 220, 250, 253, **3**:39, 42, 77, 199, **4**:15
 hearing loss (presbycusis), **2**:129, 196, 208
 infrastructure and resources for research, **2**:265, **4**:6
 interdisciplinary research, **3**:14
 lipid processing, **3**:15
 maintenance of function, **2**:54-55, 134, 158, 191
 minority health and health disparities, **2**:220, 250, 253, 265, **4**:6
 molecular biology and basic research, **2**:25, 194, 200, **3**:77, 91, 113, 164, 220-221, 246
 multidisciplinary studies, **2**:211, **3**:9, **4**:15
 neurodegenerative disorders, **2**:13, 32, 34, 38, 53, 54-55, 77, 86, 132, 153, 194, 196, 200-201, 203, 205, 206, 207, 208, 211, 253, **3**:152
 osteoporosis, **2**:13, 98, 128, 130, 132, 134, 143, 149, 153, 187, 205, 212, 217, 253, 262, 282, **3**:12, **4**:15
 prosthetics and orthotics, **2**:222
 sarcopenia (age-related muscle loss), **4**:14-15
 strategic plans, **2**:227
 technology development, **3**:91, 113, 164, 220-221, 246
 Werner Syndrome, **2**:25, 200, **3**:77
 women's health, **4**:15
 Aging, Demographics, and Memory Study, **4**:4
 Agricultural Health Study, **3**:148, **3**:6, 7, 20
 Agricultural Research Service, **3**:201
 AHRQ (*see* Agency for Healthcare Research and Quality)
 AHS (*see* Agricultural Health Study)
 AIDS (*see* HIV infection/AIDS; Office of AIDS Research)
 AIDS Clinical Trials Group, **3**:5
 AIDS International Training and Research Program, **2**:92-93, **3**:261-262
 AIDS-Science Track Award for Research Transition, **2**:91, **3**:170
 AIDSinfo service, **2**:258, **3**:290
 Alcohol Policy Information System, **3**:192, 204

Alcohol use and alcoholism (*see also* National Institute on Alcohol Abuse and Alcoholism; Substance abuse and addiction)
 adolescents, **2**:34, 41-42, 44-45, 130, 146, 151, 156, 157, 218, **3**:3, 36, 138-139, 288
 animal models, **2**:46-47, 141, **3**:92, 106, 130
 behavioral research, **2**:44-45, 156, 184, 215, 228, **3**:66, 174
 cancer role of, **2**:2, 7, 13, 28, 153, 205, 253, **3**:12
 cardiomyopathy, **2**:142
 children, **2**:44-45, **3**:138-139
 chronic diseases related to, **2**:125, 128, 142
 clinical and translational research, **2**:47, 48, 67, 97, 135, 137, 148, 156, 159, 160-161, 162, 215, 225, **3**:106, 121, 130, 139
 clinical practice, **3**:159
 clinician training, **2**:44-45, 146-147, 157, 218, **3**:288
 college students, **2**:133, 156-157
 communicating health information, **2**:146, **2**:278, 288
 developmental framework, **2**:44-45, 157, 193, 195, 213, 218
 environmental risk factors, **2**:34, 41, 44-45
 epidemiological and longitudinal studies, **2**:5, 13, 24-25, 34, 41-42, 66-67, 132, 151, 153, 157-158, 159, 160-161, 205, 213, 224, 238, 253, 255, 262, **3**:3, 10, 12, 16, 17, 21, 36, 159
 family studies, **2**:34, 41-42, 46-47, 132, 141, 151, **3**:36, 92
 fetal effects, **2**:67, 161, 184, 213, 228, 238, 255, 279, **3**:17, 139
 funding, **2**:274, 279
 genetics, **2**:34, 41-42, 44-45, 46-47, 132, 141, 151, 225, **3**:10, 36, 50, 92, 190, 200
 HIV-infected persons, **3**:159
 liver diseases, **2**:128, 129, 142, 186, **3**:159
 mental disorders comorbid with, **2**:41-42, 66-67, 129, 151, 157-158, 160-161, 224, **3**:16, 21, 36, 139, 177
 military members and families, **2**:133-134, 157-158, 224, **3**:21, 159
 minority health and health disparities, **2**:213, 238, 241, 255, 261, **3**:177
 molecular biology and basic research, **2**:46-47, 129-130, 141, 142, 184, **3**:66, 92
 multidisciplinary studies, **2**:41-42, 151, **3**:36
 neuroscience, **2**:34, 36, 41-42, 44-45, 46-47, 66-67, 68, 141, 148, 151, 156, 157, 160-161, 162, 170, 215, 218, 225, **3**:36, 92
 peer-facilitated interventions, **2**:133, 156-157
 pharmacological treatments, **2**:36, 46-47, 48, 68, 129, 135, 137, 141, 148, 162, 170, 184, 225, **3**:92, 106, 121

prevention, **2**:44, 48, 133-134, 148, 156-157, 215, 225, 261, **3**:138-139, 177, 278, 288
 protective effects of moderate consumption, **2**:129-130, 142
 Rapid Response Program, **2**:133, 156-157
 registries, databases, and information systems, **3**:10, 50, 190, 192, 200, 204
 relapse, **2**:36
 screening and counseling, **2**:44-45, 130, 133, 146-147, 157, **3**:218, 288
 sensitivity to alcohol, **2**:46-47, 129, 141, **3**:92
 smoking and, **2**:48, 148, 225
 statistics and burden of illness, **2**:33, 186, 188
 strategic plans, **2**:227-228
 stress response and, **2**:36, 47, 137, 170, 224
 underage drinking, **2**:44-45, 130, 157, 218
 young adults, **2**:133, 156-157, **3**:16
 Allergic disorders (*see* Food allergies; *specific disorders*)
 Allergic rhinitis (hay fever), **2**:274
 Alliance for Nanotechnology in Cancer, **2**:10, 14, **3**:134, 219, 241
 Alliance of Glycobiologists for Detection of Cancer and Cancer Risk, **3**:83, 129, 237
 Alopecia Areata Registry, **2**:109, **3**:191
 ALS (*see* Amyotrophic lateral sclerosis)
 Alum, **2**:74, 95, **3**:80
 Alzheimer, Alois, **4**:3
 Alzheimer's disease
 age-related cognitive decline
 distinguished from, **2**:194, 196, 200-201, **3**:1
 agitation and psychosis, **2**:196
 animal models, **3**:58
 ARRA funds, **4**:5, 6, 8
 assessment/diagnostic methods, **2**:38, 40, 58-59, 196, 207, **3**:107, 132, 151-152, **4**:7, 9
 beta amyloid and, **2**:38, 52, 206-207, **3**:74, 151-152, **4**:3, 7, 8-9
 biomarkers, **2**:40, 59, 207, **3**:107, 132, **4**:8-9
 clinical and translational research, **2**:37, 38, 52-53, 58-59, 196, 206-208, **3**:107, 108, 110, 118, 132, 151-152, 157, 284, **4**:5, 6, 7
 collaborative research, **2**:37, 52-53, 196, 206-207, **3**:110, 151-152, **4**:5, 6, 7
 description of, **4**:3-4
 early-onset, **4**:5
 epidemiological and longitudinal studies, **2**:196, 207, **3**:1, 10, 50, 190, 200, **4**:4
 funding, **1**:22, **2**:31, 274, **4**:6
 genomics, **1**:22, **2**:37, 58-59, 196, 207, **3**:10, 50, 61, 66, 107, 132, 190, 200, **4**:5-6, 7-8
 information resources, **3**:276, 278, 284, 290, **4**:6, 7, 8

- Alzheimer's disease (*continued*)
 infrastructure and research resources, **4:4-11**
 late-onset, **4:5-6**
 minority health and health disparities, **2:231, 4:6**
 molecular biology and basic research, **2:52, 3:58, 60, 61, 73-74**
 neuroimaging, **2:40, 58-59, 196, 207, 3:107, 132, 4:5, 6, 7-8**
 prevention research, **2:38, 52-53, 206-207, 3:118, 157, 4:7**
 registries, databases, and information systems, **2:196, 207, 3:10, 50, 66, 190, 200, 4:5, 6, 7, 8**
 risk factors, **4:4, 5**
 statistics and burden of disease, **2:33, 53, 206, 4:4**
 stem cell research, **3:60**
 tau proteins and, **2:52, 207-208, 3:152-153, 4:9**
 training and career development, **4:6**
 treatments, **2:37-38, 52-53, 196, 206-207, 3:73-74, 108, 118, 151-152, 4:7, 9**
- Alzheimer's Disease Centers of Excellence **4:3-12**
- Alzheimer's Disease Cooperative Study, **2:37, 52-53, 196, 206-207, 3:110, 151-152, 4:5, 6, 7**
- Alzheimer's Disease Education and Referral Center, **3:284, 4:6**
- Alzheimer's Disease Genetics Consortium, **4:5, 6**
- Alzheimer's Disease Genetics Initiative, **4:5**
- Alzheimer's Disease Neuroimaging Initiative, **2:40, 58-59, 196, 207, 3:107, 132, 4:5, 6, 7-8**
- Alzheimer's Project, **3:284**
- American Indian and Alaska Native Health Communications & Information Work Group, **3:276**
- American Indian Diabetes Beliefs and Practices, **4:32**
- American Indians and Native Alaskans, **2:117, 132, 213, 233-234, 235, 237, 238, 240, 244, 248, 255, 256, 259, 261, 274, 3:17, 43, 78, 118, 177, 250, 276, 285, 286-287, 4:6, 29-30, 31**
- American Recovery and Reinvestment Act
 communicating information on, **3:279, 280**
 economic/job impacts, **1:2, 21**
 extramural construction, **1:21, 22, 3:97-98, 167-168, 231**
 extramural research, **1:3, 21-22, 23**
 funding to NIH (*see also specific diseases and disorders*), **1:21, 63, 2:42, 195, 202-203, 274-290, 3:119, 4:5, 6, 8, 39**
 implementation and spending plans, **1:21-24**
 monitoring and reporting requirements, **1:23-24, 28**
 NIH buildings and facilities, **1:21, 23**
 oversight of programs, **1:23**
 performance measures, **1:23**
 response to FOAs, **1:21**
 Shared Instrumentation program, **1:21, 22-23**
- Amyotrophic lateral sclerosis, **2:32, 58, 63, 64, 3:10, 50, 71, 120-121, 122, 190, 200, 201**
- Analgesics, **2:37, 50, 139, 176, 178, 3:23, 70, 94**
- Analytical Methods and Reference Materials program, **3:217, 236**
- Andersen-Tawil syndrome, **4:42**
- Anencephaly, **2:34**
- Angelflight, **4:44**
- Angelman Syndrome, **4:42**
- Animal Care and Use Committee, **1:47**
- Animal models
 alcoholism, **2:46-47, 141, 3:92, 106, 130**
 Alzheimer's disease, **3:58**
 asthma, **3:38, 79**
 autoimmune diseases, **2:111, 115, 119, 246, 3:88, 181**
 cancer, **2:5, 8, 12-13, 18, 19-20, 21-22, 26, 208-209, 225-226, 3:4-5, 12-13, 51, 64-65, 69, 86-88, 177-178, 216, 233**
 chronic diseases, **2:46-47, 130, 133-134, 141, 142-143, 144-145, 3:74, 92**
 developmental processes and disorders, **3:57**
 diabetes, **3:77**
 food allergy, **3:58, 59**
 genome sequencing, **2:57, 82, 98, 3:28, 30, 35, 47-52, 58, 66, 95, 106**
 genetically engineered organisms, **2:18, 3:35, 50, 57, 58-59, 128**
 hearing and balance disorders, **3:67, 216, 234**
 Huntington's disease, **3:107**
 immunology and immunotherapy, **2:83-84, 3:233**
 infectious diseases, **2:75, 79, 83-84, 95, 97, 3:129-130, 155, 216, 233**
 informatics resources, **3:106, 126**
 modENCODE Project, **3:28, 35**
 Mouse Models of Human Cancer Consortium, **2:18**
 muscular dystrophies, **4:21, 22-23**
 National Primate Research Centers, **2:97, 3:106-107, 129-130, 171**
 neurological diseases and disorders, **2:37, 38, 46-47, 55, 97, 141, 208, 3:92, 108, 130, 216, 4:21, 22-23**
 physiologically based pharmacokinetic, **2:21-22, 225, 3:87-88, 177**
 pig model of cystic fibrosis, **2:144-145**
 plague, **2:95, 3:155**
 research resources, **1:28, 3:50, 66, 106, 128**
 retinitis pigmentosa, **3:118**
 training and career development, **3:171, 262**
 X-linked juvenile retinoschisis, **3:121**
- Animal Research Advisory Committee, **1:47**
- Animal welfare (*see* Laboratory animal welfare)
- Animals in Research website, **1:46**
- Ankylosing spondylitis, **2:109, 110, 117, 3:43, 200**
- Anorexia, **2:274**
- Anthrax, **2:71, 78, 79, 80, 82, 93, 95, 274, 3:47, 124, 155**
- Anti-inflammatory drugs, **2:52, 143, 207, 3:108, 118, 144-145**
- Antibiotics (*see also* Antimicrobial resistance; *specific drugs*), **2:74, 79, 81, 84, 95, 96, 101, 176, 3:23, 31, 39, 57, 64, 67, 94, 122, 155**
- Anticoagulants, **1:4, 3:34, 111-112, 137, 143, 156**
- Anticonvulsants, **2:38, 52, 63, 206, 3:122, 151-152**
- Antidepressants, **2:36, 45, 136, 160, 168, 176-177, 3:135, 136**
- Antiepileptic drugs, **2:61, 63, 3:122**
- Antihypertensives, **2:52, 207, 3:108, 118**
- Antimicrobial resistance, **2:73, 74, 75, 76, 81, 82, 84, 85, 86, 90, 93, 94, 95, 96, 102, 103, 274, 3:11, 31, 39, 57, 122-123, 125, 138, 155**
- Antioxidant supplements, **2:137**
- Antipsychotic drugs, **1:4, 2:177**
- Antiretroviral therapies, **1:1, 2:73, 75, 76-77, 84, 85, 86, 89, 90, 91, 92, 251, 263, 3:5, 15, 64, 94, 125, 138, 1599, 170, 245, 287**
- Anxiety (*see* Mental health)
- Aphasia, **2:274**
- APIS (*see* Alcohol Policy Information System)
- Apnea Positive Pressure Long-Term Efficacy Study, **2:136, 165-166, 3:136-137**
- Apoptosis, **2:196, 208**
- Appetite and feeding, **2:32, 49, 129, 141, 3:73**
- APPLES (*see* Apnea Positive Pressure Long-Term Efficacy Study)
- Arctic research, **2:274**
- AREDS (*see* Age-Related Eye Disease Study)
- Argonne National Laboratory, **3:96, 219, 243**
- Armed Forces Institute of Regenerative Medicine, **2:223, 3:75, 130-131, 238**
- ARRA (*see* American Recovery and Reinvestment Act)
- Arsenic, **3:23-24**
- ART Cohort Collaboration, **3:159**
- Arthritis (*see also* Osteoarthritis; Rheumatoid arthritis), **1:17, 2:125, 162, 246, 274, 3:110**
- Artificial pancreas, **2:113, 114, 120, 3:78, 144**
- ASD (*see* Autism and autism spectrum disorders)
- Ashkenazi Jews, **4:22**
- Asians/Pacific Islanders
 Alzheimer's disease, **4:6**
 cancer, **2:233, 4:29-30**
 cardiovascular disease, **2:132, 149-150, 159, 233-234, 252-253, 3:5, 19, 24, 40, 45**

- Asians/Pacific Islanders (*continued*)
communicating health information to, **2:256, 3:278, 286-287**
diabetes, **2:234, 3:103**
genetic basis of disease, **2:117**
HIV/AIDS, **2:234**
hypertension, **2:261, 3:177**
infant mortality, **2:234**
infrastructure and research resources, **244, 254**
lupus, **2:117, 236, 248, 3:43, 78, 118**
mental illness, **2:235, 238, 254, 3:9**
obesity, **2:261, 3:177, 4:30**
statistics and burden of disease, **2:231, 233-234, 235, 236, 4:29-30**
stroke, **4:29**
substance abuse, **2:254, 3:9, 204**
training and career development, **3:250, 252**
- Asperger's disorder, **4:48**
- Aspergillosis, **2:82, 3:47**
- Assistive technology, **2:274**
- Association for Assessment and Accreditation of Laboratory Animal Care International, **1:47**
- Asthma
adherence to treatment, **2:135**
adult-onset, **3:6**
animal models, **3:38, 79**
atopic dermatitis and, **2:143, 3:38, 79**
behavioral strategies, **2:180, 3:145**
biomarkers, **2:168-169, 238, 255**
childhood, **2:125, 127, 143, 168-169, 180, 220, 234-235, 238, 255, 3:17, 38, 79, 125, 150-151**
clinical and translational research, **2:71, 78, 115, 136, 138, 168-169, 174, 180, 238, 255, 3:38, 39, 130, 137, 145, 150-151**
communicating health information, **3:275**
environmental factors, **2:144, 3:4, 6, 7, 12, 28, 39, 130**
epidemiological and longitudinal studies, **2:13, 132, 149, 153, 159, 205, 220, 254, 256, 3:4, 6, 7, 12, 17, 19, 24, 45, 191**
exacerbations, **2:172, 3:79**
funding for research, **2:275**
genomics, **2:144, 159, 3:4, 24, 29, 30, 38, 39, 45, 79, 130**
H1N1 vaccines and, **2:71, 78**
immune tolerance approaches, **2:115, 174, 3:137-138**
immunology and immunotherapy, **2:115, 136, 168-169, 174, 238, 255, 3:60, 61, 137-138, 150-151**
Inner-City Asthma Consortium, **2:168-169, 238, 255, 3:150-151**
inter-agency collaborations, **3:7**
minority health and health disparities, **2:132, 136, 149, 168-169, 234-235, 238, 255-256, 3:6, 19, 30, 45, 150-151**
molecular biology and basic research, **2:172, 3:38, 60, 61, 79**
oxidative stress and, **2:130, 144, 3:39, 130**
quality-of-life improvements, **2:180, 3:145**
registries, databases, and information systems, **3:4, 191**
SHARe Asthma Resource Project, **2:159, 3:24, 45**
statistics and burden of illness, **2:185, 234-235**
- Ataxia-telangiectasia, **2:60, 69, 275, 3:142**
- Atherosclerosis, **2:114, 121, 132, 144, 149-150, 159, 252-253, 275, 3:5, 19, 24, 39, 40, 45, 61, 62, 119, 130**
- Atherosclerosis Prevention in Pediatric Lupus Erythematosus, **2:114, 121, 3:119**
- ATN (*see* Adolescent Medicine Trials Network for HIV/AIDS)
- Atopic dermatitis, **2:128, 130, 143, 187, 3:38, 79**
- Atrial fibrillation, **2:127, 185**
- Attention deficit hyperactivity disorder, **2:32, 33, 35, 43, 67, 136, 145, 160-161, 167-168, 195, 210, 213, 275, 3:14-15, 139, 281**
- Autism and autism spectrum disorders
ARRA funding, **2:42, 195, 202-203, 3:119, 4:49**
biomarkers, **2:35, 42, 203**
clinical and translational research, **2:42, 202-203, 3:119, 4:50**
description of disease, **4:48**
drug treatments, **4:50**
environmental factors, **2:42, 119, 195-196, 219, 220, 3:20-21, 88**
epidemiological and longitudinal studies, **2:35, 42, 176, 195-196, 218-219, 220, 3:16, 17, 20-21, 4:50**
familial risks, **2:35, 42, 195-196, 219, 3:20-21**
funding, **1:22, 2:35, 195-196, 275**
genomics/genetics, **2:34, 35, 42, 195-196, 219, 3:30, 72, 4:50**
heterogeneity in ASD, **2:35, 42, 195, 203-204**
infrastructure and research resources, **3:66, 189**
molecular biology and basic research, **3:66, 72, 88**
neurological research, **2:32, 34, 35, 39, 42, 57-58, 69, 195, 219, 3:20-21, 66, 72, 88, 4:50**
registries, databases, and information systems, **2:39, 57-58, 204-205, 3:189, 197, 4:49, 51**
statistics and burden of illness, **2:33, 4:48-49**
strategic plan, **2:35, 69, 228, 4:47-48**
tuberous sclerosis complex and, **2:64-65**
- Autism Centers of Excellence, **4:47-53**
- Autism Coordinating Committee, **4:47**
- Autoimmune diseases (*see also specific diseases*)
animal models, **2:111, 115, 119, 246, 3:88, 181**
ARRA funding, **2:81-82, 114, 274-290, 3:80**
bioengineering, **2:113, 116, 3:144, 202**
bioinformatics, **2:108, 114**
biomarkers, **2:56, 108, 111, 112, 113, 118, 119-120, 3:143**
clinical and translational research, **2:54, 107, 108, 110-111, 112-113, 115-116, 117-118, 119-121, 174, 246, 247-248, 3:43-44, 78, 118-119, 137-138, 143, 144, 171-172, 180-181, 236**
communicating health information, **2:108**
comorbidities, **2:111, 113-114, 119, 121, 3:88, 119**
defined, **2:107**
diagnosis and prognosis, **2:108, 110, 111, 112, 113, 118, 119-120, 3:44, 78, 118**
environmental factors, **2:107, 108, 110-111, 112, 119, 120, 3:65, 88, 144**
epidemiological and longitudinal studies, **2:5, 13, 24-25, 55, 107, 109, 112, 114, 120, 132, 148, 149, 152, 153, 159, 205, 253, 255-256, 262, 3:4, 6, 12, 19, 20, 24, 45, 144, 150**
funding, **2:81-82, 109, 114, 120, 274-290, 3:78, 80**
gene therapy, **2:113, 116, 3:144, 202**
genomics/genetics, **2:56, 107, 108, 109, 110, 111, 112, 115, 116, 117-120, 121, 246, 247-248, 3:43-45, 77, 78, 118-119, 143, 180, 181, 200, 202**
hormones and, **2:107**
immune tolerance strategies, **2:108, 112, 115, 138, 174, 3:137-138**
immunologic factors, **2:81-82, 107, 108, 111-112, 113, 114-115, 116, 118, 138, 174, 3:60, 79, 80, 137-138**
infrastructure and research resources, **2:109-110, 112, 113, 115-117, 120, 246, 3:61, 78, 171-172, 180-181, 217, 236**
international collaborations, **2:109, 110, 115, 117, 120-121, 174, 248, 3:43-44, 78, 118, 137-138, 144**
minority health and health disparities, **2:115-116, 117-118, 246, 247-248, 280, 3:43-44, 78, 118-119, 180-181, 4:28**
molecular biology and basic research, **2:81-82, 108, 111, 112, 113, 114-115, 117-119, 120, 246, 247-248, 3:43-44, 58, 60, 65, 77, 78, 79, 80, 118-119, 180-181**
multidisciplinary research, **2:108**
neurological diseases, **2:32, 34, 35, 39, 56, 63, 107, 109, 110, 113, 115, 119-120, 126, 138, 174, 281, 3:88, 119, 143**
pediatric, **2:110, 114, 120, 121, 3:119, 144**
photodynamic therapy, **2:113, 115, 3:181, 220, 245**
prevention and treatment, **2:56, 108, 112-113, 114, 119-121, 3:143**

- Autoimmune diseases (*continued*)
 rare and neglected diseases, **2**:109, 111, 118, 121, **3**:79, 119
 registries, databases, and information systems, **2**:109, 116, 117, **3**:43, 44-45, 191, 200, 202
 statistics and burden of illness, **2**:107, 108, 109
 stem cell research, **1**:1, **2**:113, 120, **3**:60, 78, 144
 strategic plans, **2**:121-122
 technology development, **2**:114, 116, **3**:171-172, 236
 training and career development, **2**:108, 110
 trans-NIH research, **1**:18, **2**:108, 122
 women's health, **2**:108, 110, 117, 235-236, 237, 248, **3**:43, 78, 118-119, 180
- Autoimmune Diseases Coordinating Committee, **2**:108
- Autonomic rare diseases, **4**:41
- Autosomal recessive primary microcephaly, **3**:165
- Ayurvedic medicines, **3**:24-25
- Azathioprine, **3**:136, 165
- Azithromycin, **2**:101
- B**
- β -catenin, **2**:26-27, **3**:68-69, 242-243
- B Cell Immunology for Protective HIV-1 Vaccine Program, **2**:76, 88, **3**:124
- BAC (*see* Brain Attack Coalition)
- BACH (*see* Boston Area Community Health)
- Baltimore Longitudinal Study of Aging, **2**:194, 200-201, **3**:1
- BARI 2D (*see* Bypass Angioplasty Revascularization Investigation 2 Diabetes)
- Bariatric surgery, **2**:137, 170-171, **3**:18-19, 111, 150
- Basal Adverse Event Report, **3**:117, 182, **5**:16
- Basic Behavioral and Social Science Opportunity Network, **3**:65, 89
- Basic HIV Vaccine Discovery Research Program, **2**:76, 88, **3**:124
- Batten disease, **2**:60, 63, 275, **3**:122, 142, **4**:41
- Bayh-Dole Act, **1**:39
- BCERCs (*see* Breast Cancer and the Environment Research Centers)
- BCSC (*see* Breast Cancer Surveillance Consortium)
- Becker muscular dystrophy, **2**:277, **3**:166, **4**:19
- Behavioral and social science research
 aging-related research, **2**:38, 54-55, **3**:91, 113, 164, 220-221, 246
 alcoholism, **2**:44-45, 156, 184, 215, 228, **3**:66, 174
 asthma, **2**:180, **3**:145
 basic research, **2**:20, 46-47, 48, 141, 155, 175-176, 246-247, 275, **3**:22-23, 36, 47, 55-56, 65-66, 89-94, 113, 128, 164, 209, 220-221, 227-228, 239, 246
 cancer, **2**:7, 12
 cardiovascular diseases, **2**:133, 157, 210, 237
 child health and development, **2**:175-176, **3**:22-23, 93-94
 chronic diseases, **2**:44, 125, 132-133, 136, 137, 155, 156, 167, 168, 172, 175-176, 180, 215, 249, **3**:22-23, 66, 90-91, 93-94, 111, 128, 136, 138-139, 145, 224-225
 clinical research and clinical trials, **2**:48, 66-67, 77, 86, 92, 99, 133, 135, 136, 137, 168, 170, 180, 195, 201, **3**:15-16, 22, 111, 136, 145, 146, 148, 150, 174
 clinical practice, **3**: 91, 111, 113, 157, 164, 166, 220-221, 246, 263
 cognitive-behavioral therapies, **2**:135, 137, 168, 172, 275, **3**:136, 224-225
 diabetes, **2**:120, 133, 136, 152, 167, 180, 195, 249, **3**:66, 103, 111, 145, 160, 247
 funding, **2**:275, **3**:90
 gene-environment interactions, **3**:22, 32-34, 47, 65, 91, 240, 263
 HIV/AIDS, **2**:77, 86, 92, 99, 172, 201, **3**:146, 224-225
 infectious diseases and biodefense, **2**:75, 86, **3**:66, 146
 interdisciplinary, **2**:133, 155, 210, **3**:89-91, 128, 239, 261
 lifestyle interventions, **2**:7, 133, 136, 154, 155, 167, 227, 248, 249, **3**:30, 103, 105, 111, 145, 160, **4**:32
 minority health and health disparities, **2**:237, 246-247, 251, **4**:32
 multidisciplinary, **3**:90
 obesity, **2**:136, 195, 251, **3**:65, **4**:31
 obstetrical care, **3**:166
 priority areas, **3**:65
 quality-of-life improvements, **2**:180, **3**:145
 self-management of health/illness, **2**:251, **3**:91, 152, 157, 163, 164, 246
 tobacco use, **2**:12
 strategic plans, **2**:226
 substance abuse prevention, **2**:44, 48, 92, 137, 156, 215, **3**:15-16, 138-139, 148
 systems science approaches, **3**:65-66, 169, 262
 technology development, **3**:89-90, 91, 113, 164, 220-221, 239, 246
 training and career development, **3**:174, 261, 262-263
 trans-NIH initiative, **3**:65, 89
 utilization of complementary and alternative medicine, **2**:175-176, **3**:22-23, 93-94
- Beltsville Human Nutrition Research Center, **3**:201
- Bench-to-Bedside Program (*see also* Clinical and translational research; Clinical research and clinical trials; Preclinical research), **3**:107, 134
- Benzene, **3**:2
- Beta amyloid, **2**:38, 52, 206-207, **3**:74, 151-152, **4**:3, 7, 8-9
- Beta cell, **2**:113, 120, 199, **3**:49, 78, 81, 99
- Beta Cell Biology Consortium, **2**:113, 120, **3**:66, 78
- Beta-defensin 3, **2**:143
- Beta-interferon, **2**:39, 56, 113, 119, **3**:143
- Betacyclodextrin, **2**:237, 245
- Bethesda Hospitals' Emergency Preparedness Partnership, **3**:195, 208, 279, 289
- BIG Health Consortium™, **2**:10, 11, **3**:194, 207, 225
- Biocontainment laboratories, **2**:80, 99, **3**:66
- Biodefense (*see* Infectious diseases and biodefense)
- Bioengineering, **2**:113, 116, 275, **3**:144, 202, 212, 240, 258
- Bioethics, **1**:27, 45, 46, 47, **3**:251, 255, 259
- Bioinformatics and computational biology, **2**:2, 4, 5, 9, 11, 18, 20, 22, 28, 73, 62, 73, 82, 84, 108, 114, 130, 144, 268, **3**:29, 33, 46-47, 61, 68, 80, 84-85, 170, 189, 194-195, 210, 212, 243-244, 251, 260, 261
- Biomarkers
 Alzheimer's disease, **2**:40, 59, 207, **3**:107, 132, **4**:8-9
 asthma, **2**:168-169, 238, 255
 autism spectrum disorders, **2**:35, 42, 203
 autoimmune diseases, **2**:56, 108, 111, 112, 113, 118, 119-120, **3**:143
 cancer, **2**:1, 6, 7, 12, 16, 19, 24-25, **3**:13, 107-108, 222
 kidney disease, **2**:154, 172-173, 237, 249-250
 lung diseases, **2**:165
 lupus, **2**:112
 multiple sclerosis, **2**:39, 56, 113
 muscular dystrophies, **2**:56
 osteoarthritis, **2**:153
 oxidative stress disease, **2**:144
 Parkinson's disease, **2**:38, 54
 protein, in infectious diseases, **2**:82
 public-private partnerships, **1**:29
 tobacco-related diseases, **2**:6, 12, 48, 148, 225
 traumatic brain injury, **2**:60, 222
- Biomarkers Consortium, **1**:29
- Biomaterials, **2**:26, 41-42, 151, **3**:232-233, 244
- Biomedical Advanced Research and Development Authority, **2**:79
- Biomedical Imaging in Oncology Forum, **3**:104
- Biomedical Informatics Research Network, **3**:66, 194, 207, 217, 225
- Biomedical information systems (*see* Disease registries and surveillance systems; Genomic information systems; Informatics infrastructure; Information resources and technology; National Library of Medicine; Registries, databases, and health information systems; Scientific databases)

- Biomedical Technology Research Centers, **3**:66, 83, 97, 128-129, 216, 217, 235, 237
- Biomedical Translational Research Information System, **3**:189, 198
- Biosafety and biosecurity, **1**:47-48, 49
- Biotechnology, funding, **2**:275
- Biotechnology Industry Organization, **1**:29
- Biowulf cluster, **3**:209, 214, 226
- Bipolar disorder, **2**:36, 45-46, 129, 161, 177, **3**:16, 28, 30, 35-36, 135, 281
- Bipolar Trials Network, **2**:45-46, 177, **3**:135
- BIRN (*see* Biomedical Informatics Research Network)
- BIRT (*see* Building Interdisciplinary Research Teams)
- Bisphenol A, **2**:12-13, 22, 193, 198, 208-209, 225-226, **3**:4-5, 12-13, 51, 62, 64-65, 85-87, 88-89, 131, 177-178
- Blacks (*see* African Americans/Blacks)
- Bladder diseases (*see also* Urology research), **2**:3, 5, 51, 128, 170, 182, 186, 221
- Blood diseases (*see also specific diseases*), **2**:128, 135, 187
- Blood storage for transfusions, **3**:76
- BLSA (*see* Baltimore Longitudinal Study of Aging)
- Body mass index, **2**:23, 127, 132, 148, 159
- Bone health (*see also* Musculoskeletal disorders; *specific diseases*)
 cancers, **2**:2
 density imaging, **2**:149, 212-213, 220, 250, **3**:10
 fracture healing, **2**:115, 246, **3**:180
 stem cell research, **2**:130, 142-143, 217, **3**:74
 vitamins C and D, **2**:132, 149, 212, **3**:10
- Bone marrow transplants, **2**: 173-174, **3**:81, **4**:40-41
- Bortezomib, **2**:14, **3**:134
- Boston Area Community Health Survey, **2**:170, **3**:22, 150
- Botulism, **2**:78, 79, 95, **3**:112, 155
- Brain (*see also* Neuroscience and neurological disorders; Stroke; Traumatic brain injury)
 adolescent development, **2**:35, 43-45, 217-218, **3**:14, 92
 anterior cingulate cortex activity, **2**:45, 176-177
 antibodies to brain antigens, **2**:119, 163
 appetite control, **2**:49, 129, 141, **3**:73
 beta amyloid deposits, **2**:38, 52-53, 206-207, **3**:74, 151-152, **4**:3, 7, 8-9
 cancer (*see also specific tumor types*), **1**:3, **2**:1, 4-5, 16, 17, 25, 28-29, 64-65, 69, 212, 275, **3**:30, 32, 47-48, 220, 245-246
 cannabinoid signaling system, **2**:37
 cognitive, emotional, and behavioral disorders (*see specific disorders*)
 computer interface systems, **2**:221-222
 deep brain stimulation, **2**:38, 51, 53, 63, 221, **3**:141, 220, 245
 degeneration, **2**:37-38, 39, 52-53, 54-55, 206, 207
 development, **2**:34, 35, 41, 43-44, 45, 119, 145, 157, 161, 194, 195, 200, 210, 217-218
 digestive system communication, **2**:168, 184
 epidemiological and longitudinal studies, **2**:43, 200
 epigenetic changes, **2**:36, 46
 epilepsy, **2**:31, 32, 40-41, 58, 61, 63, 64-65, 67, 126, 279, **3**:72, 122, 201
 funding for research, **2**:275, 280
 genomics, **2**:41, 46, 57, 161, 199
 HIV infection, **2**:45, 60, 176
 hypothalamus, **2**:49, 141
 imaging, **2**:25, 31, 35, 37, 38, 40, 43, 44, 45, 47, 49, 50, 55, 58-59, 62, 62, 133, 141, 156, 170, 176-177, 178, 196, 200, 207, 215, **3**:73, 107, 132, 135-136, 138-139, 220, 245-246, **4**:5, 6, 7-8
 inflammation, **2**:191
 light detection, **2**:128
 mapping connectivity of, **2**:31, 39, 57
 maturation trajectories, **2**:43-44, 145, 195, 210, 217-218, **3**:14, 92
 nicotine receptors, **2**:48, 148, 158, 225
 optogenetics, **2**:62-63
 pain perception and regulation, **2**:37, 50, 178
 photodynamic therapy, **2**:25, 113, 115, 246, **3**:181, 220, 244-245
 plasticity, **2**:36, 37, 45
 radiation countermeasures, **2**:96-97
 reward-related learning, **2**:36
 sleep deprivation effects, **2**:62, 157
 sound perception, **2**:55, 128, 208
 stem cell studies, **2**:37, 51
 stress-related systems, **2**:36, 47, 137, 170
 tau proteins, **2**:52, 207-208, **3**:152-153, **4**:9
 tissue repositories, **2**:60
 vascular malformations, **2**:40, 60, **3**:142, **4**:60
- Brain Attack Coalition, **2**:65, 239, 259, **3**:284-285
- Brain-derived neurotrophic factor, **2**:55
- Breast cancer, **1**:1, **2**:1, 2, 3, 5, 6, 12-13, 15, 18, 20, 22, 24-25, 132, 147, 153, 194, 205, 206, 208-209, 253, 254, 262, 276, **3**:3, 4-5, 8, 12-13, 21, 28, 30, 31, 46, 51, 64-65, 68, 84, 86-87, 90, 87, 114, 129, 133, 158, 163-164, 177-178, 186, 192, 208, 209, 215, 216, 228, 229, 235, 277, **4**:29
- Breast Cancer and the Environment Research Centers, **2**:5, 12-13, 194, 208-209, **3**:4-5, 12, 51, 64-65, 86-87, 177-178
- Breast Cancer Surveillance Consortium, **2**:22, **3**:21, 163-164, 208
- Breast reconstruction, **3**:180
- BRIC (*see* Building Research Infrastructure and Capacity)
- Brominated diphenyl ethers, **2**:42, 219, **3**:20-21
- Bronchopulmonary dysplasia, **2**:130, 144, **3**:39, 130
- Brown fat cells, **2**:130, 143, **3**:133-145
- BTRIS (*see* Biomedical Translational Research Information System)
- Building Blocks, Biological Pathways, and Networks, **5**:21-22
- Building Interdisciplinary Research Careers in Women's Health program, **3**:253, 268
- Building Interdisciplinary Research Teams Awards, **3**:99-100, 218, 237
- Building Research Infrastructure and Capacity program, **2**:243, 267
- Bupropion, **2**:48, 148, 225
- Buspirone, **4**:50
- Bypass Angioplasty Revascularization Investigation 2 Diabetes, **2**:138, 173, **3**:113, 159-160
- C**
- caBIG® (*see* Cancer Biomedical Informatics Grid®)
- Caenorhabditis elegans*, **3**:28, 35, 190
- Caenorhabditis* Genetics Center, **3**:58
- CAHDR (*see* Center for AIDS Health Disparities Research)
- caHUB (*see* Cancer Human Biobank)
- Calabresi Award in Clinical Oncology (K12) Program, **2**:20-21, **3**:260
- Calcium, **2**:161, **3**:147
- CALERIE (*see* Comprehensive Assessment of Long-Term Effects of Reducing Intake of Energy)
- Cancer (*see also* National Cancer Institute; *specific cancers, organs, and syndromes*)
 adjuvant therapy, **2**:27, 101
 aging-related processes and, **2**:2, 12, 24-25, 194, 200, 205, 253, **3**:13, 77, 172
 alcohol abuse and, **2**:2, 7, 13, 28, 153, 205, 253, **3**:12
 animal models, **2**:5, 8, 12-13, 18, 19-20, 21-22, 26, 208-209, 225-226, **3**:4-5, 12-13, 51, 64-65, 69, 86-88, 177-178, 216, 233
 ARRA grants, **2**:1-2, 10, 17-18, 28-29, 212, 276
 behavioral research, **2**:7, 12
 biomarkers, **2**:1, 6, 7, 12, 16, 19, 24-25, **3**:13, 107-108, 222
 causes and mechanisms, **2**:4-5, 17, 18, 20, 21-22, 266
 cell lines, **2**:20, 22
 Centers of Excellence, **2**:9, 247, **3**:100, 179
 chemotherapy resistance, **2**:17, 64, **3**:32
 clinical and translational research, **2**:1, 2, 4, 5, 6, 7, 8, 9, 10, 12-13, 14-15, 16, 17-18, 19, 21-22, 26, 27, 101, 201, 208-209, 212, 225, 247, 261, 266, **3**:4-5, 12-13, 51, 64-65, 86-88, 97, 100, 107-108, 110, 117, 132, 134-135, 153-154, 172, 177-179, 219, 241
 clinical practice, **2**:20, 22, **3**:21, 163-164, 208-209

- Cancer (*continued*)
- collaborative research, **2:1**, 2, 6, 7, 8-9, 10, 11, 12, 14, 17-18, 20, 22, 23, 24, 28, **3:6**, 8, 46, 97, 179, 192, 194, 203-204, 206-207, 214, 223-227
 - communicating health information, **1:27**, **2:5**, 9, 15-16, 19, 20, 27, 247, 266, **3:100**, 179283
 - community-based participatory research, **2:19**, 241, 247, **3:100**, 179, 278
 - comparative effectiveness research, **2:15**, 20, **3:90**, 209
 - computational and mathematical models, **2:5**, 22, 144, **3:84**
 - detection/diagnosis, **1:1**, **2:1**, 4-5, 7-8, 10, 14-15, 16-18, 19, 25, 28-29, 147, 212, 233, 241, 247, **3:83**, 87-88, 100, 129, 133-134, 153, 179, 219, 220, 222, 229, 237, 245-246, 241, 244-245
 - developmental processes and effects, **2:5**, 12-13, 21-22, 194, 208-209, 225-226, **3:4-5**, 12-13, 51, 64-65, 87-88, 177-178
 - drug discovery and development, **1:1**, **2:8**, 10, 15, 16, 21-22, 23, 26, 64, **3:60**, 108, 132
 - end-of-life palliative care, **2:27-28**
 - environmental factors, **2:4**, 5, 12, 13, 16-17, 21-22, 24-25, 132, 144, 153, 194, 205, 208, 225, 253, 254, 262, **3:2**, 4-5, 12-13, 39, 51, 62, 64-65, 86-88, 130, 177-178
 - epidemiological and longitudinal studies, **2:2**, 5, 12-13, 14, 18-19, 22, 23, 24-25, 45, 132, 153, 159, 194, 201-202, 205, 208-209, 253, 262, **3:1-3**, 4-5, 6, 8, 12-13, 21, 31, 42, 46, 51, 64-65, 86-87, 163-164, 177-178, 186, 192, 199, 203, 208-209
 - epigenomics, **2:11**, 25, 28
 - funding, **2:1-2**, 3-4, 10, 17-19, 20-21, 28-29, 212, 247, 274-290, **3:100**, 176-179, 260
 - genomics/genetics, **1:3**, 4, **2:1**, 2, 4-5, 7-8, 9, 10, 12-13, 14-15, 16, 17-19, 20, 22, 23, 24-25, 28-29, 46, 59-60, 64-65, 144, 154, 159, 194, 200, 208-209, 212, 214, 247-248, 249-250, 253, 262, 266, **3:2-3**, 4-5, 6, 8, 12-13, 28, 29, 30, 31-32, 42, 46-48, 51, 62, 64-65, 77, 84, 86-87, 97, 100, 134-135, 153, 177-178, 199, **4:31**
 - global health initiatives, **2:28**, 100-101, 181-182, **3:181**
 - glycomics and, **3:83**, 129, 237
 - health care delivery, **2:22**, **3:21**, 163-164, 298-209
 - high-throughput projects, **2:8**, 10
 - HIV/AIDS-related malignancies, **2:23**, 27, 74, 77
 - ICs that support cancer research, **2:2-3**, 7
 - imaging tools, resources, and applications, **2:2**, 4, 6, 7, 8, 9, 14, 15, 16, 22, 24, 25, 147, **3:153**, 220, 228, 229, 230, 245-246
 - immunology, **2:2**, 5, 16, 17, 21, 23, 26, 27, 64, 101, **3:153**, 232-233, 244
 - infectious diseases and, **2:6**, 14, 23, 27, 81, 101, 279
 - inflammation and, **2:5**, 27, 101, **3:61**
 - informatics, **2:1**, 2, 4, 5, 9, 10, 11, 12-13, 18, 22, 28, 208-209
 - infrastructure and research resources, **1:3**, **2:1**, 2, 4, 5, 7, 9-10, 11, 12-13, 14, 16, 19, 20, 23, 28-29, 208-209, 242, 247, 266, **3:33**, 46-47, 100, 110, 115, 153, 178-179, 194, 206-207, 214, 223-227
 - interdisciplinary research, **2:14-15**, **3:107-108**, 133-134
 - interagency partnerships, **2:17**, 20, **3:192**, 203
 - international collaborations, **2:2**, 9, 10, 17, 23, **3:192**, 203, 206, 225
 - metastases, **2:4**, 5, 7, 8, 16, 21, 22, 24-25, **3:13**, 222
 - minority health and health disparities, **2:1**, 2, 3, 4, 5, 6, 7, 8, 12, 13, 16, 19, 20-21, 22, 24-25, 132, 153, 154, 205, 233, 235, 239, 241, 242-243, 247, 248, 253, 261, 262, 266, **3:12**, 21, 97, 100, 153, 160, 163-164, 176-177, 178-179, 208-209, 260, 278, **4:28**, 29-30, 31
 - molecular biology and basic research, **2:4**, 5, 12-13, 14-15, 17, 18, 19-20, 21-22, 25, 26-27, 194, 200, 208-209, 225-226, 247, 266, **3:4-5**, 12-13, 51, 59, 60, 61, 62, 64-65, 68-70, 77, 83, 84, 86-88, 90, 97, 99, 129, 133-135, 177-178, 179, 209, 232-233, 237, 242-243, 244
 - multidisciplinary studies, **2:5**, 10, 18, 19, 23, 247, **3:100**, 178-179
 - nanotechnology, **2:7**, 10, 14, 25, **3:134**, 219, 220, 241, 245-246
 - neurogenetic disorders, **2:4-5**, 16, 17, 32, 63, 64-65, 68, 212, 286, **3:72**, 153
 - obesity and, **2:6**, 13, 18-19, 24-25, 127, 194, 205, 253
 - outcomes measurement, **2:8-9**
 - pediatric oncology, **2:4-5**, 16, 17-18, 212, **3:31**, 153
 - perinatal exposures to toxins and, **2:21-22**, 225-226
 - personalized medicine, **2:2**, 10-11, 14-15, 23, 25, **3:42**, 107-108, 199
 - photodynamic therapy, **2:25**, **3:220**, 244-245
 - prevention, **1:4**, **2:1**, 2, 4, 6-7, 16-17, 19, 24-25, 241, 247, 261, **3:13**, 100, 153, 177, 179, 278
 - prognosis and outcome prediction, **2:1**, 4-5, 14-15, 16, 18, 20, 25, 212, 266, **3:31**, 134, 153
 - proteomics, **2:5**, 7-8, 12-13, 22, 208-209, 214
 - public-private partnerships, **1:29-30**, **2:5**, 6, 7, 8, 9-10, 11, 20, 240, 258, 266, **3:97**, 179
 - quality-of-care research, **2:4**, 8-9, 22, **3:21**, 163-164, 208-209
 - quality-of-life research, **2:8**, 16, 22, **3:21**, 163-164, 208-209
 - rare cancers, **2:14**, **3:203**, **4:42**
 - registries, databases, and information systems, **1:2**, 3, 14, 23, **2:1**, 2, 4, 9-10, 11, 14, 17, 18, 20, 22, 23, 24, 28-29, 159, **3:21**, 31, 32, 42, 46-47, 90, 159, 163-164, 186, 189-190, 191, 192, 194, 197, 199, 203-204, 206-207, 208-209, 214, 225
 - relapse predictors, **2:4-5**, 14, 16, 18, 25, 212
 - reproductive tumors, **2:21-22**, 225-226, **3:30**, 87-88, 110, 177
 - statistics and burden of illness, **1:1**, **2:1**, 3, 7, 26, **3:69**, 233, **4:29-30**
 - strategic plans, **2:1**, 29, 227
 - stress and, **2:24-25**, **3:13**
 - surgery, **2:24**
 - surveillance, **2:2**, 14, 22, 262, **3:21**, 163-164, 208-209
 - survivors, **2:1**, 3, 9, 14, 233, 235, **3:203**
 - technology development, **1:3**, **2:2**, 4, 9, 10, 11, 14, 15, 18, 20, 24, 25, 26-27, 28, **3:68-69**, 83, 129, 134, 194, 206-207, 214, 219, 220, 222, 228, 232-233, 237, 241, 242-243, 244-245
 - therapies, **1:1**, 4-5, 8, 14-15, 17, 18, 25, 26-27, 64-65, 101, 212, **3:31**, 32, 68, 99, 108, 132, 133-134, 153, 211, 213, 220, 244-246
 - tobacco-related research, **2:2**, 6, 7, 10, 12, 13, 19, 23, 159, 247, **3:42**, 100, 178-179, 199
 - training and career development, **2:10**, 19, 20-21, 140, 241, 242, 247, 266, **3:97**, 100, 178-179, 260, 278
 - trans-NIH initiatives, **1:17**, 29-30
 - transdisciplinary research, **2:6**, 19, 247, **3:100**, 178-179
 - tumor stem cells, **2:5-6**, 21, **3:69-70**
 - vaccines, **2:6**, 17, 26, 27, 64, 81, 101, 281, **3:232-233**, 244
 - virology, **2:2**, 27, 101
 - women's health, **1:1**, **2:1**, 2, 3, 5, 6, 12, 13, 15, 18, 20, 22, 24, 132, 147, 153, 194, 205, 206, 208, 233, 253, 254, 262, **3:13**
 - Cancer and Inflammation Program, **2:5**
 - Cancer Biomedical Informatics Grid®, **2:9**, 10, 11, 18, 28, **3:194**, 206-207, 214, 225
 - Cancer Care Outcomes Research and Surveillance Consortium, **2:8-9**
 - Cancer Centers, **2:2**, 7, 9, 10, 11, 16, 20, 242, 266, **3:97**, 110, 153, 179, 206, 225
 - Cancer Control P.L.A.N.E.T., **2:9**, 17, **3:192**, 203-204
 - Cancer Diagnostics Using Nanotechnology Platforms, **2:14**
 - Cancer Education and Career Development Program, **2:20**, **3:260**
 - Cancer Genetic Markers of Susceptibility project, **2:5**, 24, **3:3**, 6, 8, 31, 46
 - Cancer Genome Anatomy Project, **2:7**, 28-29, **3:48**
 - Cancer Genomic Technology Initiative, **2:29**, **3:48**
 - Cancer Human Biobank, **2:9-10**

- Cancer Imaging Program, **2:8**, 15
- Cancer Immunology/Hematology Program, **2:21**, **3:69**
- Cancer Information Service, **2:15**, **3:283**
- Cancer Intervention and Surveillance Modeling Network, **2:20**, **3:90**, 209
- Cancer Nanotechnology Platform Partnerships, **2:10**
- Cancer Outcomes Measurement Working Group, **2:8-9**
- Cancer Research Network, **2:22**, **3:21**, 163, 208
- Cannabinoid signaling system, **2:37**
- Carcinogenic Potency Database, **3:197**
- CARDIA (*see* Coronary Artery Risk Development in Young Adults Study)
- Cardiovascular diseases and conditions (*see also* Stroke; *specific diseases*)
- aging-related changes, **2:23**, 159, 194, 200-201, 220, 250, **3:42**, 199
- alcohol consumption and, **2:142**
- aortic aneurysms, **3:191**
- autoimmune disease comorbidities, **2:111**, 119, 121, **3:88**, 119
- behavioral research, **2:133**, 157, 210, 237
- clinical and translational research, **2:54**, 121, 143, 144, 154, 164, 167, 206, 248, 249, 261, **3:113**, 120, 157, 177
- clinical practice, **2:136**, 138, 166, 173, **3:115**, 159-160, 164, 166, 167
- cognitive effects, **2:194**, 200-201
- comparative effectiveness research, **2:136**, 138, 149-150, 166, 173, **3:159-160**
- depression and, **3:134**, 160
- diabetes and, **2:114**, 125, 127, 133, 136, 138, 143, 154, 166, 167, 173, 192, 248, 249, **3:111**, 113, 144-145, 159-160
- environmental factors, **2:237**
- epidemiological and longitudinal studies, **2:13**, 23, 24-25, 86, 132, 149-150, 153, 159, 194, 201-202, 205, 220, 250, 252-253, 262, **3:1-2**, 3, 5, 12, 16, 19, 24, 40, 42, 45, 199
- families, **2:132**, 150, 252
- funding for research, **2:276**, 280
- genomics, **2:23**, 132, 149-150, 159, 237, 252-253, **3:4**, 19, 24, 30, 40, 42, 45, 191, 199
- ginkgo and, **2:53**, 206
- HIV/AIDS-related complications, **2:72**, 86, **3:15**
- imaging, **2:149-150**, 220, 250, 252, 262, **3:5**
- inflammation and, **2:143**, **3:61**
- infrastructure and research resources, **2:11**, 181, 251, **3:194**, 115, 206, 225
- international initiatives, **2:139-140**, 181
- lupus and, **2:114**, 121, **3:119**
- minority health and health disparities, **2:13**, 24-25, 65, 132, 149-150, 153, 154, 167, 205, 220, 231, 233-234, 237, 238, 248, 249, 250, 251, 252-253, 261, 262, **3:6**, 19, 40, 175-176, 177, **4:28**, 32
- obesity and, **2:132**, 143, 150, 192, 251, 252, **3:144-145**, **4:31**
- oxidative stress and, **2:130**, 144, **3:39**, 130
- pediatric, **2:121**
- periodontal disease, **2:128**
- prevention, **2:261**, **3:177**
- rheumatic diseases and, **2:121**
- registries, databases, and information systems, **2:11**, **3:191**
- smoking and, **2:139-140**
- statistics and burden of illness, **2:125**, 185, 192, 233-234
- technology development, **3:242**
- training and career development, **2:181**, 251
- types, **2:127**
- women's health, **2:13**, 132, 150, 151, 153, 159, 205, 252, 253, **3:12**, 180
- young adults, **2:132**, 251, 252
- CardioVascular Research Grid, **2:11**, **3:194**, 206, 214, 225
- Career development (*see* Training and career development)
- Career Enhancement Award for Stem Cell Research, **3:253-254**
- Career Symposium, **3:257-258**
- Career Transition Award, **3:263**, 267, 268
- Catalase, **3:118**
- Cataracts, **2:122**, 129, 131, 137, 146-147, **3:213**, 222
- Categorical Spending, **1:35**
- CATIE (*see* Clinical Antipsychotic Trials of Intervention Effectiveness)
- CATNAP study, **2:165-166**, **3:136-137**
- CCOP (*see* Community Clinical Oncology Program)
- CCR (*see* Center for Cancer Research)
- CDC (*see* Centers for Disease Control and Prevention)
- CEBS (see Chemical Effects in Biological Systems Knowledge Base)
- Celiac disease, **2:107**, 109, 110, 128, 259, **3:162**, 281
- Cell-based therapies, **2:113**, **3:60**, 78, 144
- Center for AIDS Health Disparities Research, **2:237**, 245
- Center for American Indian Diabetes Health Disparities, **4:32**
- Center for Cancer Research, **2:15**, 16, 29, **3:153-154**, 230
- Center for Cancer Training, **2:20**, **3:260**
- Center for Collaborative Genetic Studies, **3:48**
- Center for Genetic Dissection of Systemic Lupus Erythematosus, **2:111**, 115, 246, **3:115**, 181
- Center for Human Immunology, Autoimmunity, and Inflammation, **2:112**, 116, **3:61**, 171-172, 217, 236
- Center for Information Technology, **2:57-58**, 204-205, **3:96**, 197, 206, 209, 226, **5:10**
- Center for Interventional Oncology, **2:15**, **3:215**, 230
- Center for Lupus Research, **2:111**, 115, 246, **3:180**
- Center for Neuroscience and Regenerative Medicine, **2:40**, 60, 61, 197-198, 221, 222
- Center for Neurovisceral Sciences and Women's Health, **2:168**, **3:136**
- Center for New Approaches to Assess and Forestall Osteoarthritis in Injured Joints, **2:115**, 246, **3:115**, 181
- Center for Psoriasis Research Translation, **2:113**, 115, 246, **3:115**, 181
- Center for Research Translation in Scleroderma, **2:113**, 115, 246, **3:181**
- Center for Scientific Review, **1:12**, 14, 21, **2:69**, 122, 184, 185, 228, **5:10**
- Center for the Evaluation of Risks to Human Reproduction, **2:225-226**, **3:88-89**, 131
- Center for Translating Molecular Signal Pathways to Orthopaedic Trauma Care, **2:115**, 246, **3:180**
- Centers for Disease Control and Prevention collaborations
- addiction research, **2:7**, 48, 158, 188, **3:93**
- behavioral and social sciences research, **2:246**, **3:262**
- cancer research, **2:7**, 8, 17, 262, **3:203**
- cardiovascular diseases, **2:166**, **3:111**, 160
- child health and development, **2:152**, 205, 220, **3:16-17**, 143-144
- chronic diseases and organ systems, **2:48**, 152, 158, 166, 167, 175, 178-179, 205, 239, 248-249, **3:22-23**, 93-94, 112-113, 143-144, 145, 154, 160, 167, 284
- clinical and translational research, **2:88-89**, 152, 154, 167, 178-179, 205, 248-249, 259, 261-262, **3:111**, 112-113, 143-144, 145, 158, 162, 167, 176, 182, 281
- communicating health information, **2:65**, 85, 158, 239, 258-259, **3:162**, 277, 279, 281, 284-285, 287, 290, 291
- community-based participatory research, **2:261-262**, **3:175**, 176
- complementary and alternative medicine, **2:175**, **3:22-23**, 93-94
- diabetes, **2:152**, 154, 166, 167, 205, 248-249, 259, 263, **3:111**, 143-144, 145, 160, 162, 279, 281
- digestive diseases, **2:259**, **3:162**, 281
- epidemiological and longitudinal studies, **2:175**, 220, **3:16-17**, 18, 22-23, 93-94
- exercise and physical activity, **2:158**, **3:284**
- genomics initiatives, **3:33-34**, 164-165
- HIV/AIDS, **2:85**, 88-89, 258, **3:158**, 287, 290
- infectious diseases and biodefense, **2:78**, 79, 80, 85, 88-89, 94, 258, **3:66**, 95, 158, 190, 199, 277, 287, 290
- influenza, **2:78**, 79, 80, 94, **3:66**, 95, 190, 199, 277
- kidney diseases, **2:259**, 263, **3:162**, 281

Index

- Centers for Disease Control and Prevention collaborations (*continued*)
 minority health and health disparities, **2:154, 167, 239, 246, 248-249, 258-259, 261-262-263, 3:145, 162, 176, 281, 290**
 molecular biology and basic research, **2:48, 158, 175, 3:22-23, 93-94**
 neurological research, **2:61, 65, 69, 178-179, 221, 228, 239, 258-259, 3:112-113, 167, 284-285, 4:20**
 obesity, **2:192**
 pain research, **2:178-179, 3:112-113, 167**
 quality of care, **2:8, 263**
 registries, databases, and information systems, **2:78, 80, 94-95, 3:66, 95, 190, 199, 203**
 stroke, **2:65, 239, 258-259, 3:284-285**
 tobacco-related research, **2:7, 48, 158, 3:93**
 training and career development, **3:262, 267**
 traumatic brain injury, **2:61, 221**
- Centers for Medicare and Medicaid Services, **1:29, 2:8, 69, 165, 228, 263, 3:191, 284**
- Centers for Neurodegeneration Science, **2:38, 53-54, 3:85**
- Centers for Population Health and Health Disparities, **2:19, 247, 3:100, 179**
- Center for X-Linked Hypophosphatemic Rickets Research, **2:115, 246, 3:180**
- Centers in Self-Management or End-of-Life Research, **2:27-28, 196-197, 210, 3:157-158**
- Centers of Excellence, **4:1-52**
 aging, **4:13-18**
 Alzheimer's **4:3-12**
 autism, **2:35, 196, 214, 4:47-52**
 autoimmunity, **2:113**
 Biodefense and Emerging Infectious Diseases Research, **2:79, 80, 90, 93-94, 99, 3:124**
 cancer communication research, **2:19, 247, 3:100, 179**
 cancer nanotechnology, **2:10**
 chemical countermeasures, **2:66, 96**
 collaborating, **2:140, 181**
 community-based participatory research, **2:241**
 Department of Defense, **2:40, 66, 79, 96, 3:120**
 ethical, legal, and social implications, **3:51, 179-180**
 geriatrics research and training **4:13-18**
 influenza research and surveillance, **2:79, 93-94, 3:95-96, 125-126**
 international, **2:76, 81, 85, 140, 181, 3:123**
 malaria research, **2:76, 81, 85, 3:123**
 minority health, **2:251, 4:27-38**
 muscular dystrophy **4:19-26**
 Parkinson's disease, **2:38, 53, 3:141**
 rare diseases **4:39-46**
 Sub-Saharan Africa, **1:28**
- Centers of Research Translation (*see also specific centers*), **2:111, 115, 237, 246, 3:115, 180-181**
- Centers on the Demography and Economics of Aging, **2:211, 3:9**
- CER (*see Comparative effectiveness research*)
- Cerebral palsy, **2:32, 34, 63, 276, 3:141**
- Cerebrotendinous xanthomatosis, **4:42**
- Cerebrovascular disease (*see also Stroke*), **2:58, 140, 3:201**
- Cervical cancer, **2:6, 27, 101, 233, 262, 276, 281**
- Cesarean Registry, **2:201**
- CEWG (*see Community Epidemiology Work Group*)
- CGAP (*see Cancer Genome Anatomy Project*)
- CGEMS (*see Cancer Genetic Markers of Susceptibility*)
- Chagas' disease, **2:83, 3:124**
- Challenge Grants, **1:2, 21, 22, 47, 2:35, 266, 269**
- Channelopathies, **4:42**
- Charcot-Marie-Tooth disease, **2:64, 276, 3:71, 120, 4:41**
- Chemical Effects in Biological Systems Knowledge Base, **3:190, 214**
- Chemical Genomics Center, **2:97-98, 164, 3:132**
- Chemical threat countermeasures, **2:66, 71, 79-80, 96, 3:120**
- Child health and development (*see also Developmental processes and disorders; specific disorders*)
 abuse and neglect, **2:276, 3:104**
 ADHD, **2:32, 33, 35, 43, 67, 136, 145, 160-161, 167-168, 195, 210, 213, 3:14-15, 139**
 alcohol abuse, **2:44-45, 3:138-139**
 asthma, **2:125, 127, 143, 168-169, 180, 220, 234-235, 238, 255, 3:17, 38, 79, 125, 150-151**
 atopic dermatitis, **2:143, 3:38, 79**
 autoimmune diseases, **2:110, 114, 120, 121, 3:119, 144**
 behavioral and social science research, **2:175-176, 3:22-23, 93-94**
 brain development, **2:43, 200**
 bronchopulmonary dysplasia, **2:130, 144, 3:39, 130**
 burden of disease, **2:72-73, 126**
 cancer, **2:4-5, 16, 17-18, 212, 3:31, 153**
 cardiovascular disease, **2:121**
 chronic diseases, **2:44, 126, 133, 136, 137, 145, 152, 156, 160-161, 165, 167-169, 174-175, 180, 205, 210, 213, 215-216, 255, 3:14-15, 23-24, 93-94, 138-139, 143-144, 145-146, 148-149, 150-151, 152-153**
 clinical and translational research, **2:44, 71, 101, 110, 114, 120-121, 133, 138, 152, 156, 167, 168-169, 180, 195, 204, 205, 209-211, 215-216, 255, 3:109, 111, 119, 138-139, 140, 143-144, 148-149, 150-151, 152-153**
- communicating information on, **3:226, 226, 285, 289, 289**
 complementary and alternative medicine, **2:175-176, 3:22-23, 93-94**
 cystic fibrosis, **2:144-145**
 diabetes, **2:133, 152, 174, 192, 195, 205, 234, 3:143-144**
 enteric infections, **2:99-100, 217**
 environmental influences, **3:285**
 epidemiological and longitudinal studies, **2:43, 90, 99-100, 137, 167-168, 175-176, 200, 213, 214, 217, 219-220, 3:7-8, 11, 14-15, 16-17, 22-23, 93-94**
 eye diseases and disorders, **2:130, 144, 167, 195, 210-211, 215-216, 3:39, 111, 121, 130, 140, 152-153**
 family structure and, **2:219, 3:7-8**
 food allergies, **2:133, 155-156, 3:17-18, 126**
 funding for research, **2:276, 280, 282, 285**
 gene therapy, **2:195**
 hearing and vision screening, **2:219-220, 3:15**
 HIV/AIDS, **1:1, 2:77, 84, 90, 285, 3:11**
 infectious diseases, **2:74, 75, 81, 90, 99-100, 101-102, 217**
 injury, **2:282**
 intellectual and learning disabilities, **2:32, 34, 35, 39, 42, 57-58, 69, 191, 195, 202, 209-210, 214-215, 228, 260, 228, 239, 260, 277, 283, 3:91, 113, 148, 164, 220-221, 246, 288-289**
 language/speech impairment, **2:191, 202, 209-210, 3:148**
 learning math and science, **2:214-215**
 leukemia, **2:4-5, 17-18, 212**
 liver disease, **2:136, 138, 169, 3:148-149**
 lupus, **2:109, 114, 121, 3:119**
 malaria, **2:72, 90, 3:11**
 malnutrition, **2:74, 99-100, 217**
 mammary gland development, **2:12-13, 194, 208**
 meningitis, **1:2, 2:82, 191**
 minority health and health disparities, **2:168-168, 234-235, 238, 241, 255, 263-264, 3:150-151**
 molecular biology and basic research, **2:175-176, 3:22-23, 38, 79, 93-94**
 mood disorders, **3:281**
 muscular dystrophies, **2:56, 163, 278, 3:127, 166, 4:19, 21-22**
 neurological and mental disorders, **2: 32, 43-45, 61, 145, 200, 210**
 obesity, **2:19, 125, 127, 133, 150, 152, 186, 192-193, 194, 195, 205, 210, 220, 3:16-17, 143-144, 285**
 oral health care, **2:241**
 organ transplants, **2:138, 169, 3:148-149**
 palliative and end-of-life care, **2:180, 204, 3:145-146**
 prevention of chronic diseases in, **2:44, 133, 152, 156, 205, 215, 3:138-139, 143-144**

- Child health and development (*continued*)
 school experiences in early childhood, **2:219-220, 3:15**
 strategic plans, **2:226**
 substance abuse, **2:44-45, 156, 157, 215, 218, 3:138-139**
 trachoma, **2:81, 101**
 tuberculosis, **2:84, 90, 3:138**
 Werner Syndrome, **2:25, 200, 3:77**
- Childhood Cancer Survivors Study, **2:18-19, 212**
- Childhood Liver Disease Research and Education Network, **2:138, 169, 3:148-149**
- Children with HIV and Malaria Project, **2:90, 3:11**
- Children's Health Act of 2000, **4:47**
- Children's National Medical Center, **4:20, 23, 24, 45**
- Children's Oncology Group, **2:18, 212**
- Chinese Americans, **2:132, 149, 233, 252, 3:5, 19, 40**
- Chlamydia, **2:81, 82, 101, 3:47**
- Chloroquine, **2:73, 85, 3:106, 123**
- Cholera, **2:82, 3:47**
- Cholesterol, **2:237-238, 245-246**
- Chronic diseases and organ systems (*see also Aging; Alcohol; Substance abuse; specific diseases and organs*)
 adolescents, **2:44, 126, 132, 133, 136, 137, 152, 156-157, 160-161, 167-168, 170-171, 215, 3:18-19, 138-139, 150**
 alcoholism and, **2:125, 128, 142**
 animal models, **2:46-47, 130, 133-134, 141, 142-143, 144-145, 3:74, 92**
 ARRA funding, **2:177, 274-290, 3:134-135**
 behavioral and social research and interventions, **2:44, 125, 132-133, 136, 137, 155, 156, 167, 168, 172, 175-176, 180, 215, 249, 3:22-23, 66, 90-91, 93-94, 111, 128, 136, 138-139, 145, 224-225**
 children, **2:44, 126, 133, 136, 137, 145, 152, 156, 160-161, 165, 167-169, 174-175, 180, 205, 210, 213, 215-216, 255, 3:14-15, 23-24, 93-94, 138-139, 143-144, 145-146, 148-149, 150-151, 152-153**
 clinical and translational research, **2:44, 45-46, 47, 49, 54, 66-67, 115, 125, 130, 133-138, 143, 144-145, 147, 152, 153, 154, 155-156, 160-161, 162-177, 178-181, 204, 205, 211, 215-216, 248, 249, 255, 3:17-19, 22, 39, 81, 90-91, 103, 111, 112-113, 120, 121, 126, 127, 128, 130, 132-140, 141, 143-146, 148-149, 150-151, 152-153, 154, 155, 159-160, 161-162, 167, 172-173**
 clinician adherence to guidelines, **2:135**
 clinician prescribing practices, **2:176, 3:23, 94**
 collaborative studies, **2:48, 136, 148, 151, 159, 225, 3:24, 45**
 communicating health information, **2:131, 134, 146, 158, 3:284, 288**
 comorbidities, **2:66-67, 134-138, 143, 157-158, 160-161, 162-177, 224, 3:21, 139**
 comparative effectiveness research, **2:136, 137-138, 166-167, 173, 211, 3:141, 159-160, 152**
 complementary and alternative medicine, **2:126, 138-138, 142, 175, 179, 3:22-23, 70, 93-94**
 defined, **2:125**
 detection and diagnosis, **2:125, 130-131, 136, 145-148, 149-150, 168, 172-173, 176, 252-253, 3:19, 40, 136**
 developmental processes and disorders, **2:43, 145, 210**
 end-of-life care, **2:180, 204, 210, 3:145-146, 257-258**
 environmental factors, **2:48, 110, 120, 125, 132, 148, 150, 152, 160, 166, 194, 210, 225, 249, 3:4, 6, 7, 20, 35, 49, 81, 144, 155**
 epidemiological and longitudinal studies, **2:5, 13, 23, 24-25, 66-67, 132, 137, 148, 149-151, 152, 153, 155-156, 157-158, 159, 160-161, 167-168, 170-172, 175-176, 180-181, 205, 212-213, 218-219, 224, 252-253, 255-256, 262, 3:5, 6, 10, 14-15, 16, 17-18, 19, 20, 21, 22-23, 24, 38, 40, 42, 45, 93-94, 126, 139, 143-144, 150, 199**
 exercise-related injury, **2:163**
 funding, **2:126-127, 182, 274-290**
 gene therapies, **2:144-145, 163-164, 165, 167, 215-216, 3:152-153, 172-173**
 genomics/genetics, **2:23, 46-47, 48, 125, 132, 141-142, 143, 148, 152-153, 159, 132-133, 144-145, 147-148, 149-151, 152-153, 154, 159, 161, 163-164, 225, 237, 249-250, 252-253, 3:5, 19, 24, 35-36, 37, 38, 39, 40, 42, 45, 92, 130, 172-173, 199**
 global health initiatives, **2:28, 100-101, 139-140, 180-182**
 imaging tools, resources, and applications, **2:48, 49, 131, 136, 141, 146-147, 148, 149-150, 156, 170, 225, 252-253, 3:19, 40, 73, 222, 229**
 immunology and inflammation, **2:115, 143, 174, 3:137-138, 144-145**
 immunotherapies, **2:136**
 infectious diseases, **2:84, 144, 3:84-85, 243-244**
 infrastructure and research resources, **2:142, 147-148, 159, 160, 163-164, 165, 176, 177, 180-181, 3:24, 45, 155, 172-173**
 interdisciplinary research, **2:133, 144, 145, 155, 3:39, 90-91, 128, 130**
 international initiatives, **2:132, 139-140, 180-182**
 metabolic research, **2:159-160**
 military veterans, **2:157-158, 224, 3:21**
 minority health and health disparities, **2:132, 136, 149-150, 152-153, 154, 158, 167, 168-169, 210, 237, 248, 249-250, 252-253, 255-256, 3:6, 19, 35, 37, 40, 111, 145, 150-151, 160**
 molecular biology and basic research, **2:48, 49-50, 84, 126, 129-130, 140-145, 152, 155, 158, 163, 172-174, 175-176, 177-178, 217, 3:22-23, 70-71, 73, 74, 79, 81, 84-85, 90-91, 93-94, 127, 128, 139, 144-145, 179, 210, 243-244**
 multidisciplinary research, **2:48, 50, 130, 139, 144-145, 151, 158, 170, 178, 179-180, 3:22, 70-71, 93, 133, 152**
 neurological research, **2:43, 44, 46-48, 49-50, 137, 139, 141-142, 145, 148, 151, 156, 157, 158, 160-161, 162-163, 164, 170, 176-180, 210, 215, 225, 3:71, 73, 92, 93, 133, 138-139**
 nutrition and fitness, **2:132, 134, 136, 137, 149, 158, 159-160, 161, 167, 170, 195, 209, 212-213, 217, 249, 251, 259, 284, 3:10, 22, 111, 127, 145, 150, 162, 281, 284**
 older adults, **2:133, 158, 173-174, 3:147, 284**
 oxidative stress disease, **2:25, 54, 130, 144, 200, 3:39, 77, 130**
 pain and palliative care, **2:49-50, 125, 126, 139, 170, 177-180, 3:22, 70-71, 112-113, 150, 167**
 patient adherence to therapy, **2:135**
 placebo treatments, **2:176, 3:23, 94**
 prevention, **2:44, 131-134, 139-140, 148-161, 172, 205, 215, 248, 3:17-18, 126, 138-139, 143-144, 160, 169, 201, 224-225**
 quality-of-care research, **2:160**
 quality-of-life research, **2:125, 180-181, 3:145**
 rare and neglected diseases, **2:125, 131, 164-165, 3:132-133**
 registries, databases, and information systems, **2:23, 159, 160, 162, 176, 3:42, 155, 199**
 rehabilitation, **2:162, 177, 3:127, 134-135**
 risk factors, **2:125, 131-134, 148-161, 205, 255-256, 3:6, 19**
 self-management, **2:210, 3:157-158**
 statistics and burden of illness, **2:125, 126, 139, 185-188**
 stem cell research, **2:143-144, 217, 3:74**
 strategic plans, **2:182-185**
 technology development, **2:84, 125, 131, 144-145, 146-147, 162, 172, 3:84-85, 222, 224-225, 229, 243-244**
 tobacco-related mortality, **2:180-181**
 training and career development, **2:137, 140, 145, 169, 171, 181, 182, 3:161-162**
 trans-NIH research, **2:49, 126, 133, 141, 145, 147, 184-185, 3:73, 154**
 transdisciplinary research, **2:48, 148, 225**
 transplant research, **2:126, 138, 173-175, 3:81, 147**

- Chronic diseases and organ systems
(*continued*)
treatment interventions, **2**:47, 54, 125, 134-138, 153, 162-177, 201, **3**:120, 121, 136, 137, 214-215, 224
undiagnosed diseases, **1**:14-15, **2**:131, 147, **3**:154
women's health, **2**:132, 133, 136-137, 147, 149, 152, 153, 155, 158, 169-170, 201, 212-213, **3**:10
young adults, **2**:132, 150, 252
- Chronic fatigue syndrome, **2**:145, 276
- Chronic granulomatous disease, **2**:98
- Chronic inflammatory demyelinating polyneuropathy, **2**:64, **3**:120
- Chronic obstructive pulmonary disease, **2**:18, 48, 127, 132, 133, 136, 147, 149, 150-151, 158, 165, 182, 185, 255-256, 276, 278, **3**:5, 6, 19, 38, **4**:28
Learn More Breathe Better® Campaign, **3**:278
- Ciliary-derived neurotrophic factor, **2**:55
- CIP (*see* Cancer and Inflammation Program; Cancer Imaging Program)
- Circumcision, **2**:76
- CISNET (*see* Cancer Intervention and Surveillance Modeling Network)
- Cisplatin, **3**:110
- CIT (*see* Center for Information Technology)
- Citalopram, **4**:50
- Clarification of Optimal Anticoagulation through Genetics, **3**:30, 111-112, 143
- Claude D. Pepper Older Americans Independence Centers, **4**:13-18
- Clavulanate, **2**:75, 84, **3**:138
- Climate change research, **2**:276, 280
- Clinical and translational research (*see also* Clinical practice; Clinical research and clinical trials; Drug development; Preclinical translational research; *individual disease classes, diseases, and disorders*)
aging-related, **2**:12, 54-55, 56-55, 76-77, 172, 207, 211, 265, **3**:91, 113, 152, 164, 220-221, 246, **4**:15
alcohol abuse, **2**:47, 48, 67, 97, 135, 137, 148, 156, 159, 160-161, 162, 215, 225, **3**:106, 121, 130, 139
ARRA funding, **3**:97-98, 167-168, 215, 230-231
basic research (*see* Molecular biology and basic research; Preclinical research)
blood storage for transfusions, **3**:76
catalogs of activities, **3**:105-106
collaborative approaches, **2**:20, 24, 34, 39, 40, 47, 56, 59-60, 63, 93, 95, 136, **3**:124, 155, 172
defined, **3**:104, 160
dissemination of research findings, **2**:8, 16, 88-89, **3**:105, 153, 157-158, 290-291
economic benefits of, **2**:63
efficiency improvements, **2**:28, 88-89, 100-101, 181-182, **3**:116-117, 158, 181-182
ethical, legal, and social issues, **3**:51, 179-180
evaluation of programs, **3**:174-175
FDA regulations, **1**:46
funding, **2**:276-277, **3**:105
genomics, **3**:30, 32, 33-34, 50, 51, 111-112, 143, 156, 164-165, 179-180
global health initiatives, **2**:28, 100-101, 181-182, **3**:181
imaging tools, resources, and applications, **2**:8, 15, 25, 40, 45, 58-59, 176-177, **3**:135-136, 230
infrastructure and research resources, **1**:13, 14, 23, 28, **2**:1, 5, 9, 10, 11, 12-13, 16, 18, 19, 20, 21-22, 40, 45-46, 47, 57, 59, 88, 97-98, 93, 98, 116, 160, 164, 195, 208-209, 225, 247, 260-262, 266, 267-268, 269, **3**:4-5, 12-13, 50, 51, 64-65, 86-88, 97-98, 100, 105, 107-108, 110, 115, 124, 129-130, 142, 153-154, 155, 156, 165, 167-168, 169-170, 171-172, 175-176, 177-180, 215, 231-232, 236, 239-240, 257
interdisciplinary, **2**:14-15, 57, 98, **3**:107-108, 133-134, 154, 169, 173-174, 239-240, 257
international initiatives, **2**:23, 85
intramural program, **3**:105
policy and regulatory optimization, **2**:20
Public Trust Initiative, **3**:172
registries, databases, and information systems, **3**:104, 105, 109, 117, 147-148, 189, 193, 198
training and career development, **2**:20-21, 23, 44-45, 57, 59, 137, 146-147, 157, 171, 181, 218, 268, **3**:105, 116, 142, 158, 169, 171, 174, 177, 231-232, 254, 256, 257, 262, 288, **4**:44
transdisciplinary research, **2**:19
- Clinical and Translational Science Award program, **2**:243, 268, 269, **3**:105, 115, 116, 134, 168, 173, 174-175, 206, 231-232, 250, 253, 256, **5**:14
- Clinical Antipsychotic Trials of Intervention Effectiveness study, **1**:4
- Clinical Center (*see* NIH Clinical Center)
- Clinical Islet Transplantation Consortium, **2**:113, 120, **3**:144
- Clinical practice
adherence research, **2**:135, **3**:161
aging-related, **3**:91, 113, 164, 220-221, 246
alcohol abuse, **3**:159
bariatric surgery for obese adolescents, **2**:137, 170-171, **3**:18-19, 111, 150
behavioral and social sciences research, **3**: 91, 111, 113, 157, 164, 166, 220-221, 246, 263
cancer, **2**:20, 22, **3**:21, 163-164, 208-209
cardiovascular diseases, **2**:136, 138, 166, 173, **3**:115, 159-160, 164, 166, 167
communicating health information, **2**:182, 259, 264, **3**:114, 156-157, 162, 163, 277, 281, 287-288, 290-291
comparative effectiveness research, **2**:20, 39, 56, 66, 89-90, 91, 113, 119-120, 136, 137-138, 157, 165, 166-167, 170-171, 173, 179, 209-210, 224, 276, **3**:13-14, 18-19, 21, 104, 111, 112-113, 141, 143, 148, 149, 150, 156, 158, 159-160
complementary and alternative medicine, **2**:175-176, **3**:22-23, 93-94, 113, **3**:113, 166
consensus development program, **3**:156-157, 290-291
cost-effectiveness analysis, **3**:156
diabetes, **2**: 133, 138, 154, 173, 182, 248, 259, **3**:113, 114, 154, 159-160, 162, 281, 248, **4**:31
dissemination and implementation research, **3**:112, 114-115, 161
end-of-life care, **2**:27-28, 196-197, 203, 210, **3**:157-158
epidemiological and longitudinal studies, **2**: 133, 154, 175-176, 248, **3**: 21, 22-23, 93-94, 103, 113, 159, 160, 163-164, 166
genomic medicine, **3**:30, 32, 33-34, 38, 50, 51, 111-112, 114, 143, 156, 161, 164-165, 179-180
guidelines, **3**:114-115, 166
HIV/AIDS, **2**:88-89, 91, 92, 263, **3**:114-115, 158-159, 161, 162-163
infrastructure and research resources, **2**:20, 22, **3**:21, 115, 161-162, 163-164, 208-209
minority health and health disparities, **2**:92, 133, 154, 182, 248, 259, 263, **3**:103, 160, 162-163
nurses, **4**:31
obstetrical care, **3**:157, 166
oral health care, **2**:17, **3**:115, 161-162
placebo-prescribing practices, **2**:176, **3**:23, 94
prison inmates, **2**:92, **3**:162-163
quality of care, **2**:22, **3**:21, 163-164, 166, 208-209
rare diseases and disorders, **3**:165-166
self-management of chronic illness, **3**:157-158
substance abuse treatment, **2**:92, 263, **3**:162-163
training and career development, **2**:17, **3**:112, 116, 157-158, 161-162, 263, **4**:31
warfarin pharmacogenetics, **3**:114, 156
- Clinical Proteomic Technologies for Cancer, **2**:7-8, **3**:244
- Clinical Proteomic Technology Assessment for Cancer network, **2**:8
- Clinical Proteomics Centers for Infectious Diseases and Biodefense, **2**:82, **3**:48
- Clinical research and clinical trials (*see also* Epidemiological and longitudinal studies)
adolescents, **2**:44, 77, 99, 156, 201, 215, **3**:111, 138-139, 150, 152-153, 163
aging/cancer interface, **2**:12, **3**:172
adverse event reporting, **3**:117, 182, 198
ARRA funding, **3**:134-135
assessment of progress in, **2**:53, **3**:141

Clinical research and clinical trials

(continued)

behavioral research and interventions, **2:48**, 66-67, 77, 86, 92, 99, 133, 135, 136, 137, 168, 170, 180, 195, 201, **3:15-16**, 22, 111, 136, 145, 146, 148, 150, 174

biodefense, **2:95**, **3:112**, 155

children, **2:44**, 71, 101, 110, 114, 120-121, 133, 138, 152, 156, 167, 168-169, 180, 195, 205, 209-211, 215-216, 255, 263-264, **3:109**, 111, 119, 138-139, 140, 143-144, 148-149, 150-151, 152-153

community-based participatory research, **2:19**, 77, 99, 201, 240-241, 260-262, **3:176-177**

complementary and alternative medicine, **2:16**, 52-53, 66, 179, 206

conflicts of interest, **1:44**

consortia, cooperative study groups, and networks, **2:7**, 8, 12, 16, 19, 27-28, 36, 40, 45-46, 47, 59-60, 66, 76, 77, 79, 85-86, 88, 91, 93, 94, 96, 99, 111, 112, 113, 114, 120, 136, 157, 166-167, 169, 170, 171, 177, 201, 224, 247, **3:21**, 22, 100, 104, 109-110, 120, 124, 135-136, 140, 141, 142, 144, 148-149, 150, 153-154, 156, 158, 161-162, 179

defined, **3:104**, 112

dietary supplements, **3:147**

end-of-life care, **2:180**, 204, **3:145-146**

environmental effects on human health, **2:12-13**, 21-22, 110, 120, **3:111**, 144

gene therapy, **2:38**, 55-56, 63, 64-65, 113, 167, 215-216, 279, **3:111**, 152-153, **4:20**

health literacy promotion, **2:264**, **3:163**

health services research, **2:22**

human subjects protection, **1:7**, 12, 13, 29, 44, 45-46, 48, **2:171**, **3:109**

immunotherapies, **2:16**, 17, 27, 38, 48, 52-53, 56, 64, 115, 136, 168-169, 174, 215, **3:137-138**, 150-151

inclusion of women and minorities, **1:13**, **2:245**, **3:154-155**, **4:6**, **5:27-36**

inflammation, **2:143**, **3:144-145**

minority health and health disparities, **2:12**, 16, 19, 20, 22, 65, 136, 154, 236-238, 247-248, 249, 259-262, 263-264, 266, 267-269, **3:43-44**, 78, 97, 100, 104, 110, 111, 118-119, 145, 151, 154-155, 160, 168, 171, 175-177, 178-179, 231-232, 261

muscle recovery after injury, **2:163**, **3:127**

monoclonal antibodies, **2:16**, 17, 64

nanotechnology applications, **2:14**, 25, 45, **3:134**, 241

older adults, **2:54-55**, 134, 207, **3:152**, **4:15**

opportunities in, **1:3**

outcome studies and measures, **2:154**, 162, 173-174, 178-179, 248, **3:81**, 112-113, 160, 167, 224

phases of clinical trials, **3:109**

population health, **3:169**

prevention trials, **2:44**, 19, 76, 77, 85-86, 88, 91, 93-94, 99, 133, 152, 156, 195, 201, 205, 215, 261, **3:104**, 125-126, 138-139, 143-144, 146, 177

quality-of-life (supportive care) trials, **2:16**, 27-28, 180, **3:104**, 145

rare diseases, **2:40**, 59-60, 83, **3:104-105**, 111, 142, **4:43**

regenerative medicine, **2:60**, 130-131, 223, **3:75**, 130-131, 238

rehabilitation, **2:177**, 178-179, **3:112-113**, 134-135, 167

screening and diagnostic trials, **2:14-15**, 16-17, 21-22, 25, 38, 39, 40, 66, 89-90, 91, 93-94, 96, 157, 224, **3:21**, 104, 120, 125-126, 156, 230

technology assessment, **2:7-8**, 9, 13, 20, 25

technology development, **2:162**, **3:224**

tools and resources, **2:11**, 14, 15, 18, 29, 39, 57, 60, 110, 120, 162, **3:134**, 144, 224, 241

treatment trials, **2:4**, 19, 45-46, 47, 59-60, 66, 77, 92, 96, 99, 101, 152, 153, 165-166, 169, 176-177, 180, 201, 204, 205, 210-211, 261, **3:104**, 108, 110, 120, 135-137, 137, 140, 142, 143-144, 145-146, 148-149, 162-163

types and designs, **3:108-109**

website, **2:135**, **3:105**, 109, 147-148, 189, 193, 198

women's health, **2:59**, 98, 245, **3:154-155**, 156, 180

Clinical Research Education and Career Development awards, **2:268**, **3:116**, 171

Clinical Research Information System, **3:198**

Clinical Research Policy Analysis and Coordination Program, **1:46**, 48, **3:117**, 182, **5:15**, 17-18

Clinical Research Training Program, **3:254**, **5:15-16**

Clinical Research Training Scholars and Fellows program, **3:259**

Clinical Research Unit, **3:111**, 155

Clinical Trials in Organ Transplantation, **2:138**, 173-174, **3:81**

Clinical Trials Reporting Program, **2:16**, **3:117**, 153

ClinicalTrials.gov, **3:105**, 109, 147-148, 189, 193, 198

CMS (*see* Centers for Medicare and Medicaid Services)

CNRM (*see* Center for Neuroscience and Regenerative Medicine)

CO-MED (*see* Combining Medications to Enhance Depression Outcomes)

COAG (*see* Clarification of Optimal Anticoagulation through Genetics)

Coalition for Imaging and Bioengineering Research, **3:276**

Coalition of Patient Advocacy Groups, **4:43**

Cocaine, **2:36**, 46, 49, 163

Coenzyme Q10, **2:38**, 53, **3:141**

COGA (*see* Collaborative Study on the Genetics of Alcoholism)

Cognitive-behavioral therapies, **2:135**, 137, 168, 172, 275, **3:136**, 224-225

Cognitive impairment

aging-related, **2:13**, 32, 38, 53, 54-55, 77, 86, 132, 153, 194, 196, 200-201, 205, 206, 207, 211, 253, **3:1**, 9, 91, 113, 152, 164, 220-221, 246, **4:5**

cardiovascular disease and, **2:194**, 200-201

epigenomic projects, **3:62**

Ginkgo Evaluation of Memory Study, **2:53**, 208

Cohort Consortium, **2:24**, **3:6**, 8, 46

Cohorts for Heart and Aging Research in Genomic Epidemiology consortium, **2:23**, 159, **3:42**, 199

Collaboration, Education, and Genetic Test Translation Program for Rare Diseases, **3:165-166**

Collaborative Pediatric Critical Care Research Network, **3:110**

Collaborative Programs of Excellence in Autism, **4:47**

Collaborative Psychiatric Epidemiology Surveys, **2:238**, 254, **3:9**

Collaborative research (*see also* Public-private partnerships, Trans-NIH research)

Alzheimer's disease, **2:37**, 52-53, 196, 206-207, **3:110**, 151-152, **4:5**, 6, 7

Blueprint for Neuroscience Research, **2:31**, 39, 57-58, **3:169**, 194, 207, 225, 251, 257

cancer, **2:1**, 2, 6, 7, 8-9, 10, 11, 12, 14, 17-18, 20, 22, 23, 24, 28, **3:6**, 8, 46, 97, 179, 192, 194, 203-204, 206-207, 214, 223-227

chronic diseases, **2:48**, 136, 148, 151, 159, 225, **3:24**, 45

clinical and translational, **2:20**, 24, 34, 39, 40, 47, 56, 59-60, 63, 93, 95, 136, **3:124**, 155, 172

epidemiological and longitudinal studies, **2:22**, 42, 148, 157-158, 170, 175-176, 219, 224, **3:6-7**, 20-24, 94, 152, 163-164, 208-209

genomics, **2:151**, **3:45**, 48

interdisciplinary research consortia, **3:173-174**, 239-240, **5:19**

neurological, **2:31**, 32, 34, 35, 39-42, 47, 48, 56, 57-61, 63, 65, 132, 151, 162, 221, 222, **3:36**, 107, 121, 132, 140, 142, 169, 197, 201, 207, 225, 257, 284-285

pain, **2:39**, 57

registries, databases, and information systems, **2:9**, 10, 11, 18, 28, **3:194**, 206-207, 214, 225

technology development, **2:9**, 10, 11, 18, 28, **3:194**, 206-207, 214, 225

Collaborative Study of Suicidality and Mental Health in the U.S. Army, **3:7**

Collaborative Study on the Genetics of Alcoholism, **2:34**, 41-42, 132, 151, **3:36**

Index

- Collective Intelligence initiative, **3:96**, 193, 206
- College students, **2:133**, 156-157
- Colon cancer, **1:4**, **2:3**, 5, 18, 24, **3:3**, 8, 28, 46, 192, 216
- Colonography, **2:16**
- Colonoscopy, **1:4**, **3:209**, 226
- Colorectal cancer, **2:1**, 2, 3, 14, 16, 20, 137, 256, 261, 266, 277, **3:8**, 30, 31-32, 46, 90, 97, 157, 177, 179, 209, 277, 283, 290
- Combating Autism Act of 2006, **4:47**, 51
- Combining Medications to Enhance Depression Outcomes trial, **2:35**, 45-46, 177, **3:110**, 135
- CombiRx, **2:39**, 56, 113, 119-120, **3:143**
- Committee on the Science of Behavior Change, **2:133**, 155, **3:90-91**, 128
- Commission on Cancer, **2:17**, **3:203**
- Common Assay Reporting System, **3:96**, 206
- Common Fund (*see also* Roadmap for Medical Research), **1:5**, 18-19, **2:98**, 162, 199, 268-269, **3:34-35**, 41, 49, 50, 81, 82-83, 89-90, 94-95, 115, 121-122, 173, 174, 175, 182, 208, 224, 236, 239, 256, 257, **5:10**, 13-26
- Communicating health information (*see also specific campaigns*)
to adolescents, **2:44**, 146, 156, 215, **3:138-139**, 275, 281, 287, 288
Age Page fact sheets, **3:284**
alcoholism prevention, **2:146**, **2:278**, 288
Alzheimer's disease, **3:276**, 278, 284, 290, **4:6**, 7, 8
ARRA funding, **3:277**
asthma, **3:275**
autoimmune diseases, **2:108**, **3:278-279**
behavioral change initiatives, **3:273**
biosafety and biosecurity, **1:49**
brain imaging applications, **2:133**
campaigns and clearinghouses, **2:146**, 216, 259, 260, **3:134**, 226, 271-272, 277-278, 281-282, 287-289
cancer, **1:27**, **2:5**, 9, 15-16, 19, 20, 27, 247, 266, **3:100**, 179, 275, 276, 278, 283
cardiovascular disease, **3:271**
catalog of activities, **3:273**
child health and development, **3:226**, 226, 285, 287, 289, 289
chronic diseases, **2:131**, 134, 146, 158, **3:278**, 284, 288
Clear Communication website, **3:272-273**
clinical practice, **2:182**, 259, 264, **3:114**, 156-157, 162, 163, 277, 281, 287-288, 290-291
clinical research, **2:264**, **3:163**, 226, 273, 285, 289
commemorative days, **3:275**
community-based collaborations, **3:278-279**
conferences and health fairs, **3:279-280**
diabetes, **2:143**, 183, 239, 257, 259, **3:114**, 162, 275, 276, 279, 281, 286, 296
disaster response, **3:279**
disseminating information and research findings, **2:8**, 15, 16, 88-89, 240, 256, 258, 259, **3:105**, 112, 114-115, 153, 157-158, 161, 162, 273, 276, 279, 281-283, 289-291
documentaries, **3:278**, 284
education and outreach, **2:15-16**, 134, 158, 239-240, 256, 257, 259, **3:272**, 275-276, 278, 283-287
end-of-life issues, **3:278**
environmental risk factors, **2:256**, 258, **3:286-287**, 289-290
exhibitions, **3:282-283**
eye health issues, **3:279**
families/caregivers, **2:216**, 260, **3:288**
genetic diseases and testing, **3:169**, 188, 282
grant funding linked to research, **3:283**
health literacy promotion, **2:264**, **3:163**, 277-278
hearing campaigns, **3:281**, 287
HIV/AIDS, **2:77**, 78, 88, 172, 239, 240-241, 258, **3:188-189**, 275, 287, 290
IC-specific programs, **3:278-279**, 280
i on NIH video, **3:274**
infectious diseases, **2:85**, **3:277**, 287
international initiatives, **3:280**
journalist training, **3:272**, 274, 285
kidney disease, **2:259**, **3:114**, 162, 275, 276, 281
lecture series, **3:275**
maternal and child health, **3:285**
mental health information, **3:278**, 281
minority and health disparity initiatives, **2:19**, 20, 216, 231, 239-240, 256-259, 260, 264, 266, **3:162**, 163, 276, 278-280, 281, 282, 283, 286-288, 289-290, **4:28**, 31
neurological diseases and disorders, **1:27**, **2:40-41**, 65, 239, 258-259, **3:284-285**
newsletters, **3:273**, 280
NIH health information portal, **2:272**, 273
NIH Research Matters column, **3:273**
obesity, **2:239-240**, 257, 259, **3:114**, 143-144, 162, 261, 281, 286
to older adults, **2:65**, 158, 239, **3:284-285**
oral health care, **3:277**, 279, 287-288
pain management, **3:276**
Picture and Video Galleries, **3:275**
public information officers, **3:274**
public participation, **3:274**, 275, 284
public-private partnerships, **2:15**, 240, 258, **3:208**, 272, 289-290, 291
public service announcements, **3:279**
radio, **3:274-275**
rare diseases, **3:282**
Research Results for the Public site, **3:273**
to scientific and research communities, **3:156-157**, 279-280, 290-291
social media venues, **3:272**, 274, 275-276
substance abuse and addiction, **2:44**, 146, 156, 215, **3:138-139**, 278
Talking to Your Doctor site, **3:274**
time-sensitive issues, **3:276-277**, 287
trans-NIH initiative, **3:276**
Web materials, **3:272-273**, 274, 282, 284
Wikipedia®. collaboration, **3:274**
women's health, **3:271**, 274, 276
Community-Based Participatory Research Program, **2:19**, 77, 99, 201, 220, 240-241, 247, 250, 260-262, **3:100**, 175-177, 179, 278
Community Cancer Centers Program, **2:9**, 11, 16, **3:110**, 153, 225
Community Clinical Oncology Program, **2:7**, 16, 19, 247, **3:100**, 153, 179
Community Epidemiology Work Group, **2:254**, **3:8-9**, 192, 204
Community Networks Program to Reduce Cancer Health Disparities Through Education, Research and Training, **2:19**, 241, 247, **3:100**, 179, 278
Community Participation in Research, **2:261**, **3:176**
Community Participation Research Targeting the Medically Underserved, **2:261**, **3:176**
Comparative effectiveness research
ARRA funding, **3:112**, 165
BARI 2D, **2:138**, 173, **3:113**, 159-160
cancer, **2:15**, 20, **3:90**, 209
cardiovascular disease, **2:136**, 138, 149-150, 166, 173, **3:159-160**
chronic diseases, **2:136**, 137-138, 166-167, 173, 211, **3:141**, 159-160, 152
clinical practice, **2:20**, 39, 56, 66, 89-90, 91, 113, 119-120, 136, 137-138, 157, 165, 166-167, 170-171, 173, 179, 209-210, 224, 276, **3:13-14**, 18-19, 21, 104, 111, 112-113, 141, 143, 148, 149, 150, 156, 158, 159-160
defined, **3:112**
diabetes prevention program, **1:4**, **2:136**, 166-167, 173, **3:113**, 141, 159-160
diagnostic methods, **2:136**
eye diseases, **2:173**, 210-211, **3:140**, 152
funding, **1:21**, **2:277**, **3:112**, 165
imaging technologies, **2:15**, 149-150
infrastructure and capacity building, **3:165**
minority health and health disparities, **2:266**, 268, **3:175**
SPORT, **2:139**, 177-178, **3:112-113**, 167
tools and resources, **2:20**, **3:90**, 209
Comparative Molecular Pathology Unit, **2:21**, **3:260**
Comparative Oncology Program, **2:8**, 18
Comparison of AMD Treatments Trials:
Lucentis-Avastin Trial, **2:137**, 173, 211, **3:152**
Complementary and alternative medicine
acupuncture, **2:66**, 139, 179, **3:113**, 166
children, **2:175-176**, **3:22-23**, 93-94
chronic diseases, **2:126**, 138-138, 142, 175, 179, **3:22-23**, 70, 93-94
clinical practice, **2:175-176**, **3:22-23**, 93-94, 113, **3:113**, 166

- Complementary and alternative medicine
(*continued*)
clinical research, **2**:16, 52-53, 66, 179, 206
epidemiological and longitudinal studies, **2**:175-176, **3**:22-23, 93-94, 166
funding, **2**:277
Ginkgo Evaluation of Memory Study, **2**:53, 206
glucosamine/chondroitin sulfate, **2**:138, 175, **3**:70, 113, 166
grape seed polyphenol extract, **2**:38, 52, **3**:73-74
liver disease from, **2**:142
massage therapy, **2**:27-28, 66, 138, 175, **3**:23, 94
neurological diseases and disorders, **2**:52, 53, 57, 58, 66, 68, 139, 179, 206, **3**:73-74
utilization, **2**:175-176, **3**:22-23, 93-94
- Comprehensive Assessment of Long-Term Effects of Reducing Intake of Energy, **2**:159, 195, 209
- Comprehensive Cancer Centers, **2**:2, 7
- Comprehensive Sickle Cell Centers, **2**:231
- Computational biology, **1**:3, 27, 28, **2**:22, 57, 152, 210, **3**:84, 169, 257
- Computed tomography, **2**:15, 149-150, 252, **3**:5, 19, 40, 153, 215, 230, 242
- Computer Retrieval of Information on Scientific Projects system, **1**:36
- Conference on the Prevention of Preterm Birth, **2**:202
- Conflicts of interest
clinical research, **1**:44
financial, **1**:13, 43, 45
- Congestive heart failure, **2**:54, 135, 164, **3**:120, 247
- Consortium for Radiologic Imaging Studies of PKD, **2**:154, 249
- Consortium of Food Allergy Research, **2**:155-156, **3**:17-18, 126
- Consortium for Functional Glycomics, **3**:64, 83, 129, 237
- Consortium to Establish a Registry for Alzheimer's Disease, **4**:5
- Consumer Health Resource Information Service, **2**:240
- Continuing Umbrella of Research Experiences Program, **2**:242-243
- Continuous positive airway pressure therapy, **2**:165-166, **3**:136-137
- Convergence Insufficiency Treatment Trial, **2**:210-211, **3**:140
- Cooley's anemia, **2**:128, 277
- Cooperative International Neuromuscular Research Group, **4**:21
- Cooperative Lifestyle Intervention Program, **4**:15
- Cooperative Program in Translational Research, **2**:56, 63, **3**:122
- Cooperative Study Group for Autoimmune Disease Prevention, **2**:111, 118, **3**:77
- COP (*see* Comparative Oncology Program)
- COPD (*see* Chronic obstructive pulmonary disease)
- Core Facility Renovation, Repair, and Improvement activity awards, **2**:22
- Cornea Donor Study, **2**:138, 174-175, **3**:147
- Coronary artery disease, **2**:132, 138, 150, 173, 237, 252, **3**:30, 159
- Coronary Artery Risk Development in Young Adults Study, **2**:132, 150, 252
- Coronary heart disease, **1**:2, **2**:127, 129, 135, 185, 233-234, 280, **3**:5, 30
- Corticosteroids, **2**:136, 165, 166
- Cost-effectiveness research, **2**:277, **3**:156
- Council of Councils, **1**:18
- Council of Public Representatives, **3**:272
- CounterACT Research Network, **2**:66, 79, 80, 96, **3**:120
- CPAP (*see* Continuous positive airway pressure)
- CPES (*see* Collaborative Psychiatric Epidemiology Surveys)
- CPTAC (*see* Clinical Proteomic Technology Assessment for Cancer)
- CPTC (*see* Clinical Proteomic Technologies for Cancer)
- Cranial sensory ganglia, **2**:42-43, 214, **3**:72
- Creatine, **2**:38, 53, 163, **3**:127, 141
- Criminal Justice-Drug Abuse Treatment Studies, **2**:92, **3**:162-163
- CRIS (*see* Clinical Research Information System)
- CRISP (*see* Computer Retrieval of Information on Scientific Projects; Consortium for Radiologic Imaging Studies of PKD)
- Crohn's disease, **1**:3, **2**:119, 128, 277, **3**:30, 44, 108, 122
- CRpac (*see* Clinical Research Policy Analysis and Coordination)
- CRTP (*see* Clinical Research Training Program)
- CSR (*see* Center for Scientific Review)
- CTOT (*see* Clinical Trials in Organ Transplantation)
- CTSA (*see* Clinical and Translational Science Award)
- Cuban Americans, **2**:149, 234, 255
- Cultural issues (*see* Minority health and health disparities; *individual minorities*)
- CURE (*see* Continuing Umbrella of Research Experiences Program)
- Cystic fibrosis, **2**:125, 127, 130, 134, 135, 144-145, 163-164, 185, 277, **3**:27, 172-173, **4**:40
- Cystic Fibrosis Research and Translation Core Center, **2**:163-164, **3**:172-173
- Cystinuria, **4**:41
- Cytomegalovirus, **4**:41
- D**
- Data and Technology Coordinating Center, **4**:44
- Data sharing, **1**:13, **2**:39, 57-58, 204
- Data standards, **1**:40, **2**:17, 57-58, **3**:96, 185-186, 187, 193, 204-206, 223-224
- Databases (*see* Disease registries and surveillance systems; Genomic information systems; Informatics infrastructure; Information resources and technology; Registries, databases, and information systems; Scientific databases; *specific systems, diseases, and conditions*)
- dbGaP, **1**:29, **2**:151, 159, **3**:3, 10, 22, 24, 42, 45, 50, 186, 190, 200
- Deafness (*see* Hearing)
- Delaware Work Release study, **2**:92, **3**:162-163
- Demographic and economic studies, **2**:211-212, **3**:9-10
- Demonstration Projects in High Risk/High Reward Research, **1**:8
- Dengue fever, **2**:74, 80, 83, 93, **3**:124, 125
- Dental and craniofacial disorders (*see also* Oral; *specific diseases*), **2**:129, 132, 137, 149, 171, 188, 216-217, 227, 235, 239, 255, 260, 263, 277, **3**:67-68, 161-162, 234-235
- Department of Defense, **2**:40, 51, 60, 61, 66, 79, 96, 157, 197, 221, 222, 223, 224, **3**:21, 75, 120, 130, 182, 220, 238, 245
- Department of Education, **2**:69, 215, 219, 228, **3**:15
- Department of Health and Human Services
ethical conduct standards, **1**:43
policy coordination with NIH, **2**:100
Office for Human Research Protections, **1**:44, 45, 46, **3**:182
Office of Public Health Preparedness, **3**:208, 289
Office of Research Integrity, **1**:44, 45
Office of the General Counsel, **1**:43
Office of the National Coordinator for Health Information Technology, **3**:193, 204-205, 224
Office on Disability, **2**:69, 228
Panel on Pediatric Antiretroviral Therapy and Management Guidelines, **1**:1
Strategic Plan, **1**:17, 35
Trans-Federal Task Force on Optimizing Biosafety and Biocontainment Oversight, **1**:49-50
- Department of State, **3**:280
- Department of Veterans Affairs, **2**:8, 38, 40, 51, 53, 61, 63, 157, 221, 224, **3**:7, 21, 141, 159, 182, 220, 245
- Depression, **2**:34, 35, 36, 38, 41, 45, 46, 53, 67, 98, 127, 128-129, 134, 151, 160, 161, 176, 177, 188, 192, 206, 235, 277, **3**:16, 36, 94, 110, 135, 136, 139, 141, 154, 245
- Depression Trials Network, **2**:46, 177, **3**:110, 135
- Developmental processes and disorders (*see also* Autism)
ADHD, **2**:32, 33, 35, 43, 67, 136, 145, 160-161, 167-168, 195, 210, 213, 275, **3**:14-15, 139

Index

Developmental processes and disorders

(continued)

alcoholism/addiction, **2**:44-45, 157, 193, 195, 213, 218
 animal models, **3**:57
 brain development, **2**:34, 35, 41, 43-44, 45, 119, 145, 157, 161, 194, 195, 200, 210, 217-218
 cancer, **2**:5, 12-13, 21-22, 194, 208-209, 225-226, **3**:4-5, 12-13, 51, 64-65, 87-88, 177-178
 cerebral palsy, **2**:32, 34, 63, 276, **3**:141
 chronic diseases, **2**:43, 145, 210
 cranial sensory ganglia, **2**:42-43, 214, **3**:72
 drug abuse vulnerability, **2**:43-45
 environmental factors, **2**:119, 193-194, 198-199, 225-226, **3**:64-65, 85-86, 88-89, 131
 epidemiological and longitudinal studies, **2**:43, 200, 220, **3**:15-16
 epigenetics, **2**:193-194, 198-199, **3**:85-86
 eye diseases, **3**:121
 funding, **2**:281
 genomics, **2**:34, 35, 41, 42, 195-196, 199, 208
 intellectual and learning disabilities, **2**:32, 34, 35, 39, 42, 57-58, 69, 195, 214, 228, 277
 international initiatives, **2**:41, 199, **3**:34
 molecular biology and basic research, **2**:192, 198-199, **3**:57, 59-60, 64-65, 85-86
 neurological, **2**:32, 33, 34-35, 41-45, 57, 63, 69, 145, 151, 156, 157, 191, 192, 195, 199, 200, 202-203, 210, 214, 215, 217-218, 219, 228, 275, 277, 284, **3**:14, 20-21, 34, 36, 72, 88, 92, 119, 138-139
 sexual maturation, **2**:12-13, 194, 208, **3**:5, 12, 51, 86-87, 178

DHA, **2**:38, 52, 127, 206

Diabetes
 adolescents, **2**:132, 152, 234
 animal models, **3**:77
 bariatric surgery and, **2**:137, 170-171, **3**:18-19, 111, 150
 behavioral and social science research, **2**:120, 133, 136, 152, 167, 180, 195, 249, **3**:66, 103, 111, 145, 160, 247
 cardiovascular complications, **2**:114, 125, 127, 133, 136, 138, 143, 154, 166, 167, 173, 192, 234, 248, 249, **3**:111, 113, 144-145, 159-160
 cell-based therapies, **2**:113, **3**:60, 78, 144
 children, **2**:133, 152, 174, 192, 195, 205, 234, **3**:143-144
 clinical and translational research, **2**:64, 75, 98, 107, 111, 112-113, 114, 120-121, 136, 143, 152, 155, 166-167, 205, 249, 251, 261, **3**:71, 77, 103, 104, 111, 115, 120-121, 137-138, 141, 143-144, 145, 150, 173, 176-177

clinical practice, **2**: 133, 138, 154, 173, 182, 248, 259, **3**:113, 114, 154, 159-160, 162, 248, 281, **4**:31
 communicating health information, **2**:143, 183, 239, 257, 259, **3**:114, 162, 275, 276, 279, 281, 286, 296
 community-based participatory research, **2**:241, 261, **3**:176-177
 comparative effectiveness research, **1**:4, **2**:136, 166-167, 173, **3**:113, 141, 159-160
 cystic fibrosis-related, **2**:134
 depressive disorders with, **2**:134, 160
 environmental factors, **2**:110, 120, 132, 148, 152, 166, 194, 249, **3**:4, 6, 7, 20, 35, 49, 81, 144
 epidemiological and longitudinal studies, **2**:55, 107, 114, 115, 120, 148, 149, 152, 159, 205, 255-256, **3**:4, 6, 19, 20, 24, 45, 143-144, 150
 epigenetics, **2**:194, 199, **3**:49, 81
 families, **2**:132
 funding, **2**:237, 278, **3**:78, 98, 99, 115, 173, 176-177
 genomics/genetics, **2**:110, 111, 112-113, 117, 118-119, 132, 152-153, 159, 194, 199, 237, 249, **3**:4, 10, 24, 29, 30, 35, 43, 45, 49, 50, 77, 81, 190, 191, 200
 gestational, **2**:122, 127, 155, 192, 194, 199, **3**:49-50, 81
 global health research, **1**:4-5
 health outcomes, **1**:1-2
 immune tolerances approaches, **2**:112, 113, 115, 120, 174, **3**:60, 137-138
 infectious diseases comorbid with, **2**:75
 infrastructure and research resources, **3**:66, 77, 78, 141, 144, 173, 240, 279
 international initiatives, **2**:115, 118, 120, 132
 lifestyle interventions, **2**:136, 167, 249, **3**:111, 145
 kidney disease, **2**:107, 114, 120, 125, 126, 127, 132, 154, 237, 249, 259, 263, **3**:37, 103, 114, 144, 162, 275, 276, 281
 macular edema, **2**:166-167, **3**:141
 minority health and health disparities, **2**:132, 133, 136, 149, 152-153, 154, 167, 234, 237, 248, 249, 251, 255-256, 259, 261, 263, **3**:6, 19, 35, 103, 111, 143-144, 145, 160, 162, 176-177, 276, 281, 296, **4**:28, 32, 33
 molecular biology and basic research, **2**:64, 112-113, 118-119, 120, 140-141, 194, 199, **3**:49, 58, 60, 66, 68, 76, 77, 78, 81, 98, 99, 120-121
 neuropathies, **2**:38, 55, 64, 114, 125, 127, **3**:71, 120-121
 obesity and, **2**:127, 133, 136, 143, 154, 167, 170, 192, 195, 205, 234, **3**:19, 111, 114, 144-145, 154, 160, 162
 obstructive sleep apnea and **2**:166, **3**:137
 pancreatic islet transplantation, **2**:112, 113, 115, 120, 174, **3**:137
 pathogenesis, **2**:127, 234

periodontal disease and, **2**:128
 protein folding and, **3**:98, 99
 prevention, **1**:4, **2**:98, 115, 118, 132, 133, 154, 155, 248, 251, 259, 261, **3**:77, 103, 104, 143-144, 145, 160, 177, 281
 quality-of-care research, **2**:263
 quality-of-life improvements, **2**:180, **3**:145
 registries, databases, and information systems, **2**:117, **3**:4, 10, 43, 50, 185, 190, 191, 200
 retinopathy, **2**:107, 114, 125, 127, 129, 136, 140-141, 187, **3**:77, 141
 sickle cell trait comorbid with, **2**:259, **3**:162, 281
 statistics and burden of illness, **2**:107, 109, 125, 185, 187, 192, **3**:103
 stem cell research, **1**:1, **2**:113, 120, **3**:60, 78, 144
 strategic plans, **2**:183, 228, 270
 stroke, **2**:107, 127, 164, 167, 173, 234, 249, **3**:111
 taste receptors and, **3**:73, 222
 technology development, **3**:213, 222, 240
 training and career development, **3**:247
 trans-NIH research, **1**:18, **2**:69, 122
 treatment/management, **2**:113, 133, 143, **3**:144, 159-160, 247
 type 1, **1**:1-2, **2**:75, 98, 107, 109, 110, 111, 112-113, 114, 115, 118, 120-121, 127, 132, 138, 143, 152-153, 174, 237, 149, **3**:35, 58, 60, 66, 77, 78, 137-138, 144, 200
 type 2, **1**:4, **2**:98, 125, 127, 132, 133, 136, 138, 152-153, 154, 167, 192, 194, 205, 234, 237, 248, 149, **3**:30, 35, 66, 103, 111, 114, 143-144, 145, 154, 160, 279, 281
 women's health, **2**:98, 127, 155, **3**:154

Diabetes Control and Complications Trial, **1**:1-2, **2**:107, 114, 120, **3**:144

Diabetes Genetics Replication and Meta-analysis Consortium, **2**:132

Diabetes Prevention Program, **1**:4, **2**:132, 133, 154, 155, 248, **3**:103, 160

Diabetes Prevention Program Outcomes Study, **2**:133, 154, 248, **3**:103, 160

Diabetic Retinopathy Clinical Research Network, **2**:166-167, **3**:141

Diagnosis/detection of diseases (*see also* Imaging; Screening)
 aging-related changes, **3**:91, 113, 164, 220-221, 246
 Alzheimer's disease, **2**:38, 40, 58-59, 196, 207, **3**:107, 132, 151-152, **4**:7, 9
 autoimmune diseases, **2**:108, 110, 111, 112, 113, 118, 119-120, **3**:44, 78, 118
 cancer, **1**:1, **2**:1, 4-5, 7-8, 10, 14-15, 16-18, 19, 25, 28-29, 147, 212, 233, 241, 247, **3**:83, 87-88, 100, 129, 133-134, 153, 179, 219, 220, 222, 229, 237, 245-246, 241, 244-245

- Diagnosis/detection of diseases (*continued*)
 chronic diseases, **2**:125, 130-131, 136, 145-148, 149-150, 168, 172-173, 176, 252-253, **3**:19, 40, 136
 clinical trials, **2**:14-15, 16-17, 21-22, 25, 38, 39, 40, 66, 89-90, 91, 93-94, 96, 157, 224, **3**:21, 104, 120, 125-126, 156, 230
 comparative effectiveness research, **2**:136
 funding for, **2**:278
 infectious disease tools and platforms, **2**:78, 91, 93-94, 98, **3**:125-126, 158
 home-based assessment methods, **3**:91, 113, 164, 220-221, 246, **4**:7
 minority disparities, **2**:233
 preterm delivery, **2**:203, **3**:239
 technology development, **2**:196, 202, 203, **3**:221-223, 239, 245-246
 tuberculosis, **2**:84, 98
 Dialysis Access Consortium, **2**:137, 172, **3**:18
 Dietary Supplement Ingredient Database, **3**:201
 Dietary Supplement Labels Database, **3**:201-202, 217
 Dietary supplements, **1**:8, **2**:16, 23-24, 138, 149, 175, 198, 228, 255-256, **3**:147, 201-202, 217, 236
 Diethylenetriaminepentaacetic acid, **2**:80, 97, **3**:123
 Diethylstilbestrol, **2**:278
 Digestive diseases (*see also specific diseases and organs*), **1**:18, **2**:74, 122, 128, 185, 186, 239, 259, 278, **3**:162, 281
 Dioxin, **2**:5, 12-13, 208-209, 273, **3**:4-5, 12-13, 51, 64-65, 86-87, 177-178
 DIRA (deficiency of the interleukin-1 receptor antagonist), **2**:121, **3**:119
 Director of NIH (*see also Office of the Director*)
 policy advisors, **1**:8
 statement of, **1**:1-6
 Director's Working Group on Women in Biomedical Careers, **3**:248
 Disaster Information Management Research Center, **3**:194, 195, 208, 289
 Disaster preparedness and response, **2**:66, 79, 80, 96, 257, **3**:120, 189, 194, 195, 208, 212, 213, 221, 279, 286, 289
 Discovery Initiative, **3**:193, 196, 205
 Disease registries and surveillance systems
 Alopecia Areata Registry, **2**:109, **3**:191
 Alzheimer's disease, **2**:196, 207, **3**:10, 50, 66, 190, 200, **4**:5, 6, 7, 8
 APIS, **3**:192, 204
 California Parkinson's Disease Registry, **3**:191
 Cancer Control P.L.A.N.E.T., **2**:9, 17, **3**:192, 203-204
 CWEG survey, **2**:254, **3**:8-9, 192, 204
 diabetes, **2**:117, **3**:4, 10, 43, 50, 185, 190, 191, 200
 EPR, **2**:160, **3**:4, 11, 155, 191, 202-203
 focus of, **3**:186
 GenTAC, **3**:191
 HIV/AIDS, **2**:60, 98-99, **3**:191, 197, 202
 IeDEA, **2**:98-99, **3**:191, 202
 INTERMACS, **3**:191-192
 Latin American Epidemiology Network, **2**:254, **3**:8-9, 204
 MTF survey, **2**:254, **3**:8-9, 192, 204
 NCRAD, **4**:5, 6
 NNTC, **2**:60, **3**:197
 muscular dystrophies, **4**:22
 Parkinson's disease, **2**:58
 rare diseases, **4**:44
 rheumatoid arthritis, **2**:109
 SEER, **2**:2, 14, **3**:186, 192, 203
 Sjogren's Syndrome, **3**:191
 uses, **3**:191-192
 Disparities Research and Education:
 Advancing our Mission Program, **2**:268
 Dissemination and Implementation Research in Health program, **3**:161
 Dissertation Research Award, **2**:266
 Diversity Short-Term Trainee Program, **3**:195, 210, 261
 DNA (*see also Gene; Genetic; Genomic*)
 conserved sequences, **3**:28
 damage and repair, **2**:25
 diagnostics techniques, **2**:14
 insulators and their proteins, **3**:37, 82
 "junk," **3**:27
 methylation, **2**:193-194, 198, **3**:37, 82, 85
 sequencing (*see also Genomics; Human Genome Project*), **1**:3, **2**:117, **3**:27, 32
 structure, **3**:27, 29-30, 41
 DNMT2 centronuclear myopathy, **3**:165
 DOCK8 immunodeficiency syndrome, **2**:74, 147-148
 Docosahexaenoic acid, **4**:7
 Dopamine, **4**:16
 Down Syndrome, **2**:32, 69, 195, 214, 228, 278, **3**:91, 99, 164, 246
 DPP (*see Diabetes Prevention Program*)
 DPPOS (*see Diabetes Prevention Program Outcomes Study*)
 DREAM (*see Disparities Research and Education Advancing our Mission*)
Drosophila melanogaster, **3**:28, 35
Drosophila Stock Center, **3**:58
 Drug abuse (*see Substance abuse and addiction*)
 Drug development (*see also individual drugs and drug classes*)
 addiction treatments, **2**:49, 162-163, **3**:39-40, 94, 106, 245
 adjuvant therapy, **2**:27, 74, 95, **3**:80
 aging-related macular degeneration, **2**:173, 211, **3**:152
 alcoholism treatments, **2**:36, 46-47, 48, 68, 129, 135, 137, 141, 148, 162, 170, 184, 225, **3**:92, 106, 121
 Alzheimer's disease, **2**:37-38, 52, 53, 196, 206-207
 animal models of physiologically based pharmacokinetics, **2**:21-22, 225, **3**:87-88, 177
 biodefense, **2**:66, 96, **3**:120
 cancer therapies, **1**:1, **2**:8, 10, 15, 16, 21-22, 23, 26, 64, **3**:110, 132
 cerebral palsy prevention, **2**:34
 comparative effectiveness research, **1**:4, **2**:173, 211, **3**:152
 funding, **2**:282
 HIV/AIDS, **2**:45, 176, **3**:135-136
 idiopathic intracranial hypertension, **2**:58
 kappa opioid binders, **3**:94-95, 245
 liver disease, **2**:54
 mental health disorders, **2**:4, 36, 45-46, 160, 176-177, **3**:135-136
 molecular biology and basic research, **3**:56, 57, 59, 60, 62, 64, 68, 94-95, 245
 multiple sclerosis, **2**:56
 nanotechnology-related delivery systems, **2**:45, 176, **3**:135-136
 muscular dystrophies, **2**:56, **3**:106
 new indications for established agents, **2**:36, 54, 64, 74, 135, 164, **3**:120
 Parkinson's disease, **2**:54
 perinatal dosing, **2**:21-22, 34
 pharmacogenomics, **1**:4, **2**:47, 97-98, 162, 164, **3**:23, 29, 30, 38, 59, 62, 111-112, 114, 121, 143, 156
 rare and neglected diseases, **1**:3, **2**:97-98, 135, 164-165, 284, **3**:132-133
 resources, **3**:108
 small molecule, **1**:3, **2**:36, 52, 56, 85, 97-98, 142, 164-165, 207, 212, **3**:68, 108, 118, 127, 128, 132, 157, 158-159, 185, 188, 197
 tobacco addiction, **2**:48, 148, 225
 topical microbicides, **2**:76, 85-86, 88, 97, 237, 245-246, 273, 289, **3**:130, 158-159
 tuberculosis, **2**:75, 84, **3**:138
 "virtual pharma" strategy, **2**:63, **3**:108, 122
 Drug-Induced Liver Injury Network, **2**:142, 169
 DSID (*see Dietary Supplement Ingredient Database*)
 DSLD (*see Dietary Supplement Labels Database*)
 DTPA (*see Diethylenetriaminepentaacetic acid*)
 Dual-use technologies, **1**:47-48, 49-50
 Duchenne muscular dystrophy, **2**:56, 163, 278, **3**:127, 166, **4**:19, 20, 21-23
 Ductal carcinoma in situ, **3**:114
 Dynamic light scattering technology, **2**:131, 146-147
 Dyspepsia, **2**:136, 168, **3**:136
 Dystonias, **2**:40, 60, 278, **3**:142, 165-166, **4**:40
 Dystrophin protein, **4**:19, 23
- ## E
- e-Reporter, **3**:280
 EARLI (*see Early Autism Risk Longitudinal Investigation*)
 Early Autism Risk Longitudinal Investigation, **2**:35, 42, 195-196, 219, **3**:20-21, **4**:50

- Early Childhood Longitudinal Study, **2**:219-220, **3**:15
- Early Detection Research Network, **2**:7, 16
- Early Markers of Pre-eclampsia in American Indians with Type 2 Diabetes, **4**:32
- Eating disorders, **2**:32, 278
- Ebola virus, **1**:4, **2**:71, 72, 79, 95, **3**:64, 112, 155
- ECLS (*see* Early Childhood Longitudinal Study)
- Eczema, **3**:35, 38, 79, 82
- EDIC (*see* Epidemiology of Diabetes Intervention and Complications)
- EDRN (*see* Early Detection Research Network)
- Education and outreach (*see* Communicating health information; Science education and literacy; Training and career development)
- Edward R. Roybal Centers for Translation Research (*see* Roybal Centers for Translation Research)
- EEMS (*see* Etiology and Early Marker Studies)
- EGFR (*see* Epidermal growth factor receptor)
- Electronic health records, **2**:22, **3**:185, 187, 192, 193, 204-205, 223-224
- Electronic Research Administration system, **1**:1, **2**:250, 265
- Electronic Scientific Portfolio Assistant, **3**:232
- Emphysema, **2**:278
- ENCODE (*see* ENCyclopedia Of DNA Elements)
- ENCyclopedia Of DNA Elements, **3**:28, 35
- End of life care, **2**:15, 27-28, 139, 180, 192, 196-197, 203, 204, 210, **3**:145-146, 157-158, 257-258, 277
- End-stage renal disease, **2**:137, 171-172, 186, **3**:18
- Endocannabinoid pathway, **2**:129, 142
- Endometrial cancer, **2**:18
- Endometriosis, **2**:13, 132, 153, 205, 253, 279, **3**:12
- Enviro-Health Links, **2**:94-95, **3**:95, 199
- Environmental Autoimmunity Group, **2**:112
- Environmental factors
 alcohol abuse, **2**:34, 41, 44-45
 arsenic, **3**:23-24
 asthma, **2**:144, **3**:4, 6, 7, 12, 28, 39, 130
 autism, **2**:42, 119, 195-196, 219, 220, **3**:20-21, 88
 autoimmune diseases, **2**:107, 108, 110-111, 112, 119, 120, **3**:65, 88, 144
 Ayurvedic medicine contaminants, **3**:24-25
 BDEs, **2**:42, 219, **3**:20-21
 bisphenol A, **2**:12-13, 22, 193-194, 198, 208-209, 225-226, **3**:1, 4-5, 12-13, 51, 62, 64-65, 86-87, 88-89, 131, 177-178
 cancer, **2**:4, 5, 12, 13, 16-17, 21-22, 24-25, 132, 144, 153, 194, 205, 208, 225, 253, 254, 262, **3**:2, 4-5, 12-13, 39, 51, 62, 64-65, 86-88, 130, 177-178
 cardiovascular diseases, **2**:237
 child health and development, **3**:285
 chronic diseases, **2**:48, 110, 120, 125, 132, 148, 150, 152, 160, 166, 194, 210, 225, 249, **3**:4, 6, 7, 20, 35, 49, 81, 144, 155
 clinical research, **2**:12-13, 21-22, 110, 120, **3**:111, 144
 communicating health information on, **2**:256, 258, **3**:285, 286-287, 289-290
 developmental disabilities, **2**:119, 193-194, 198-199, 225-226, **3**:64-65, 85-86, 88-89, 131
 diabetes, **2**:110, 120, 132, 148, 152, 166, 194, 249, **3**:4, 6, 7, 20, 35, 49, 81, 144
 epidemiological and longitudinal studies, **2**:5, 13, 24-25, 132, 153, 160, 205, 253, 262, **3**:1, 4, 11, 12, 13, 22, 23-23, 155, 191, 202-203
 fetal/perinatal exposures, **2**:21-22, 42, 119, 193-194, 198-199, 219, 225, **3**:20-21, 85-86, 87-88, 177
 genetic interactions, **2**:5, 12-13, 194, 208-209, **3**:2-3, 12, 22, 28, 41, 42-43, 48, 51, 64-65, 86-87, 177-178
 infectious diseases, **2**:74, 93
 lead poisoning, **2**:282, **3**:23-24
 manganese poisoning, **3**:98-99
 mercury, **2**:111, 119, **3**:23-24, 65, 88
 minority health and health disparities, **2**:240, 258, **3**:289-290
 molecular biology and basic research, **2**:5, 12-13, 21-22, 44, 53-54, 93, 98, 119, 198-199, 208-209, 225-226, **3**:4-5, 12-13, 51, 64-65, 85-89, 131, 177-178
 neurological diseases and disorders, **2**:34, 42, 44, 53-54, 119, 144, 217-218, 219, **3**:14, 20-21, 39, 85, 88, 92, 130
 PCBs, **2**:42, 219, **3**:20-21
 persistent organic pollutants, **2**:42, 219, **3**:20-21
 pesticides, **2**:38, 54, 98, 132, 148, 263, **3**:6, 7, 20, 85, 151
 toxicant screening, **2**:98, **3**:87
- Environmental Health Information Partnership, **2**:256, **3**:286
- Environmental Influences on Epigenetic Regulation, **2**:198-199, **3**:85-86
- Environmental Polymorphism Registry, **2**:160, **3**:4, 11, 155, 191, 202-203
- EPA (*see* U.S. Environmental Protection Agency)
- Epidemiological and longitudinal studies (*see also specific diseases and disease classes*)
 AddHealth, **2**:219, **3**:2-3, 7-8
 adolescents, **2**:43-44, 137, 170-171, 217-218, 219, 238, 254, **3**:2-3, 4, 8-9, 14-15, 18-19, 36, 111, 150, 192, 204
 aging-related, **2**:24-25, 76-77, 86, 159, 194, 200-201, 205, 211-212, 220, 250, **3**:1, 4, 9-10, 13, 211, **4**:4
 AHS, **2**:148, **3**:6, 7, 20
 alcohol use and alcoholism, **2**:5, 13, 24-25, 34, 41-42, 66-67, 132, 151, 153, 157-158, 159, 160-161, 205, 213, 224, 238, 253, 255, 262, **3**:3, 10, 12, 16, 17, 21, 36, 159
 Ayurvedic medicines with toxic metals, **3**:24-25
 BACH Survey, **2**:170, **3**:22, 150
 BCERC, **2**:5, 12-13, 208-209, **3**:4-5, 12-13, 51, 64-65, 86-87, 177-178
 BLSA, **2**:194, 200-201, **3**:1
 CARDIA, **2**:132, 150, 252
 catalog of research activities, **3**:2
 CEWG, **2**:254, **3**:8-9, 204
 CGEMS, **2**:5, 24, **3**:3, 6, 8, 31, 46
 child health and development, **2**:43, 90, 99-100, 137, 167-168, 175-176, 200, 213, 214, 217, 219-220, **3**:7-8, 11, 14-15, 16-17, 22-23, 93-94
 clinical practice, **2**: 133, 154, 175-176, 248, **3**: 21, 22-23, 93-94, 103, 113, 159, 160, 163-164, 166
 cooperative/collaborative, **2**:22, 42, 148, 157-158, 170, 175-176, 219, 224, **3**:6-7, 20-24, 94, 152, 163-164, 208-209
 Collaborative Study of Suicidality and Mental Health in the U.S. Army, **3**:7
 complementary and alternative medicine, **2**:175-176, **3**:22-23, 93-94, 166
 COPDGene, **2**:150-151, **3**:5, 38
 CPES, **2**:238, 254, **3**:9
 dbGaP, **1**:29, **2**:151, 159, **3**:3, 10, 22, 24, 42, 45, 50, 186, 190, 200
 developmental processes and disorders, **2**:43, 200, 220, **3**:15-16
 EARLI, **2**:34, 35, 41-42, 132, 151, 195-196, 219, **3**:20-21, **4**:50
 ECLS, **2**:219-220, **3**:15
 EDIC, **2**:107, 114, 120, **3**:144
 environmental factors, **2**:5, 13, 24-25, 132, 153, 160, 205, 253, 262, **3**:1, 4, 11, 12, 13, 22, 23-23, 155, 191, 202-203
 EPR, **2**:160, **3**:4, 11, 155, 191, 202-203
 Fragile Families and Child Well-Being Study, **2**:219, **3**:7-8
 Framingham Heart Study, **3**:1-2, 3
 Framingham Osteoporosis Study, **2**:132, 149, 212, **3**:10
 genetic basis of disease, **2**:5, 18-29, 23, 24, 41-42, 109, 132, 149-151, 159, 160, 214, 237, 252-253, **3**:3, 4, 5, 6, 8, 10, 11, 19, 22, 24, 31, 36, 38, 40, 42, 43-44, 45, 46, 50, 191, 199, 200, 202-203
 HANDLS, **2**:220, 250
 Hispanic Community Health Study, **2**:132, 149, 255-256, **3**:6, 19
 HRS, **2**:211, **3**:4, 9, **4**:4
 infants, **2**:214
 LABS, **2**:137, 170-171, **3**:18-19, 111, 150
 long-term studies, **2**:124, 77, 86, 92, 149, 176, 194, 200-201, 211-213, 218-219, 254, **3**:1, 2-4, 7-10, 15-16, 46, 50, 148, 200, 204

Epidemiological and longitudinal studies
(continued)

Longitudinal Mental Health Tracking System, **2:176**, 196, 218-219, **3:16**
 MACS, **2:77**, 86, 92, **3:15-16**, 148
 MESA, **2:132**, 149-150, 159, 252-253, **3:5**, 19, 24, 40, 45
 military personnel and veterans, **3:20**, 159, 246-247
 minority health and health disparities, **2:5**, 12-13, 24-25, 65, 77, 86, 92, 132, 149-150, 153, 159, 205, 208-209, 213, 216, 235, 238, 252-256, 262, **3:4-5**, 6, 7-8, 9, 12-13, 15-16, 17, 19, 24, 40, 45, 51, 64-65, 86-87, 148, 177-178
 MISMS, **2:78**, 100
 Mr. OS, **2:149**, 212-213, **3:10**
 MRI Study of Normal Brain Development, **2:43**, 200
 MTA, **2:136**, 167-168, 213, **3:14-15**
 MTF, **2:254**, **3:3**, 4, 8-9, 192, 204
 multidisciplinary, **3:2**, 4, 5, 9, 14, 17, 22
 multidisease studies, **2:132**, 149, 255-256, **3:6**, 19
 National Comorbidity Survey, **2:66-67**, 160-161, 238, **3:139**
 National Latino and Asian American Study, **2:238**, 254, **3:9**
 NCS, **2:220**, **3:16-17**
 NESARC, **2:66-67**, 160-161, **3:16**, 139
 New Immigrant Survey, **2:219**, **3:7-8**
 NHANES, **2:38**, 55, 148, 161, 235, **3:18**, 20
 NHIS, **2:138**, 175, 234, **3:22-23**, 93-94
 NSAL, **2:238**, 254, **3:9**
 OHARA, **2:89-90**, **3:5**, 13-14, 149
 older adults, **2:211**, **3:4**, 9
 PASS, **2:213**, 238, 255, **3:17**
 placebo-prescribing practices, **2:176**, **3:23**, 94
 population-based studies, **2:132**, 170, 218, **3:1-2**, 3-4, 7-8, 22, 42-43, 150
 public-private partnerships, **3:22**, 42-43
 quality of care, **2:22**
 REGARDS, **2:65**, 238, 253
 registries, databases, and information systems, **2:43**, 98-99, 109, 200, 254, **3:9**, 191, 202
 SHARe, **2:149-150**, 159, 252-263, **3:3**, 5, 19, 24, 40, 45
 Sister Study, **2:5**, 13, 24-25, 132, 153, 205, 253, 262, **3:12**, 13
 SOF, **2:149**, 212-213, **3:10**
 Strong Heart Study, **2:132**, 150, 252
 substance abuse, **2:43-44**, 66-67, 92, 157-158, 160-161, 217-218, 224, 254, **3:3**, 4, 8-9, 14, 15-16, 92, 139, 148, 192, 204
 Teen-LABS, **2:137**, 170-171, **3:18-19**, 111, 150
 tobacco-related mortality, **2:180-181**

treatment and prevention (clinical practice), **2:5**, 12-13, 24-25, 77, 86, 89-90, 92, 132, 137, 149-150, 153, 155-156, 159, 167-168, 170-171, 176, 205, 208-209, 213, 218-220, 252-253, 255, 262, **3:4-5**, 11-20, 24, 40, 45, 51, 64-65, 86-87, 128, 148, 149, 150, 177-178
 trans-NIH research, **3:6**
 United States Renal Data System, **2:171**, **3:18**
 VACS, **3:159**
 WIHS, **2:77**, 86, **3:15**
 young adults, **2:254**, **3:3**, 4, 8-9, 192, 204
 Epidemiology of Diabetes Intervention and Complications, **2:107**, 114, 120, **3:144**
 Epigenetics, **2:25**, 28-29, 36, 44, 46, 193-194, 198-199, 200, 218, **3:36**, 41, 47-48, 49-50, 62, 77, 81, 85-86, 92-93, 227-228
 Epigenome Data Analysis and Coordinating Center, **3:48**
 Epigenomics, **2:11**, 25, 28, 194, 199, **3:41**, 48, 49-50, 62, 81, **5:24**
 Epigenomics of Human Health and Disease, **5:24**
 Epidermal growth factor receptor, **2:14-15**, 46, 129, 141, **3:92**
 Epilepsy, **2:31**, 32, 40-41, 58, 61, 63, 64-65, 67, 126, 279, **3:72**, 122, 201
 Episodic ataxias, **4:42**
 Epstein-Barr virus, **4:41**
 eRA (see Electronic Research Administration)
 Erbitux, **2:10**
 Erythropoietin, **2:54**, 164
Escherichia coli, **3:55**
 ESRD (see End-stage renal disease)
 Estrogen, **2:5**, 12, 13, 24-25, 132, 153, 194, 205, 206, 208, 253, 262, 279, **3:12**, 154, 180
 Estrogen receptor alpha signaling process, **2:98**
 Ethical conduct, issues, and research
 Center of Excellence in Ethical, Legal, and Social Implications, **3:51**, 179-180
 clinical and translational research, **3:51**, 179-180
 financial conflicts of interest, **1:13**, 43, 44, 45
 genomics, **3:47**, 51, 179-180
 guidelines, **1:44**, 45
 NIH employees, **1:43**
 training, **1:43**, 44, 45, 46, 47, **3:251**, 259
 Ethics in Government Act, **1:43**
 Ethics Office, **1:8**, 43, 49
 Etiology and Early Marker Studies, **2:16-17**
 Eunice Kennedy Shriver National Institute of Child Health and Human Development (see also National Center for Medical Rehabilitation Research)
 adolescent health and development, **2:43-44**, 99, 201, 217-218, 219, 226, **3:8**, 92
 ankylosing spondylitis, **2:117**
 anthrax, **2:82**
 asthma, **2:220**, **3:17**
 ataxia-telangiectasia, **2:69**

autism, **2:42**, 57-58, 69, 203-205, 214, 220, 228, **3:17**, 119, 197, **4:49**
 autoimmune diseases, **2:116**, 117, 120-121, 122, **3:43**, 78, 144, 171-172, 200, 236
 behavioral and social science research, **2:72**, 155, 219, 246-247, **3:8**, 47, 89, 90-91, 128, 174
 cancer, **2:2**, 28, **3:72**, 180
 cerebral palsy, **2:63**, **3:141-142**
 chemical threat countermeasures, **2:66**, 93
 child health and development, **2:41**, 43-44, 57, 192, 199, 200, 208-210, 214, 215-216, 217-218, 219-220, 226, **3:8**, 16-17, 148, 153, 226, 285, 289
 chronic diseases and organ systems, **2:28**, 100-101, 147, 152-153, 154, 155, 163, 169, 170, 181-182, 184, 185, 201, 210, 248, 249, **3:22**, 90-91, 127, 128, 148-149, 150, 154, 160
 clinical and translational research, **2:28**, 42, 56, 57, 59-60, 63, 66, 85-86, 88-89, 93, 98, 100-101, 116, 120-121, 147, 154, 155, 163, 169, 170, 181-182, 202, 203-204, 224, 248, 261-262, 264, **3:22**, 90-91, 119, 120, 127, 128, 141-142, 144, 148-149, 150, 153, 154, 158-159, 160, 163, 169, 171-172, 174, 176, 180, 226, 236, 257, 259, 289
 communicating health information, **2:216**, 259, 260, 264, **3:163**, 226, 285-286, 287-288, 289
 community-based participatory research, **2:261-262**, **3:172**, 176
 developmental processes and disorders, **2:41**, 43-44, 57, 192, 199, 200, 214, 217-218, 220, 227, **3:14**, 16-17, 34, 92, 148, 180
 diabetes, **2:69**, 98, 117, 120-121, 122, 152-153, 154, 228, 248, 249, **3:35**, 78, 144, 160
 digestive diseases, **2:122**, 185
 Down Syndrome, **2:69**, 214, 228
 drug abuse vulnerability, **2:43-44**, 217-218, **3:14**, 92
 environmental factors, **2:220**, **3:16-17**
 epidemiological and longitudinal research, **2:43-44**, 86, 98-99, 170, 213, 219, 220, 255, **3:7-8**, 14, 15, 16-17, 92, 150, 203
 fetal alcohol effects, **2:213**, 255, **3:17**
 fragile X Syndrome and associated disorders, **2:69**, 214, 228
 genomics/genetics, **2:41**, 43-44, 57-58, 63, 117, 152-153, 199, 204-205, 214, 217-218, 249, **3:34**, 35, 43, 47, 72, 91, 142, 180, 200
 global health, **2:28**, 100-101, 181-182, **3:181**, 259-260
 HIV/AIDS, **2:71-72**, 77, 85-86, 88-89, 92-93, 98-99, 102, 201, **3:15**, 158-159, 203, 261-262

- Eunice Kennedy Shriver National Institute of Child Health and Human Development (*continued*)
 imaging tools, resources, and applications, **2**:43, 57-58, 63, 200, 204-205, 217-218, **220**, **3**:169, 207, 225, 257
 infectious diseases and biodefense, **2**:28, 66, 71-72, 77, 82-83, 85-86, 88-89, 92-93, 98-99, 100-101, 102, 181-182, 201, **3**:15, 120, 158, 203
 infrastructure and research resources, **3**:171-172, 207, 225
 intellectual and developmental disabilities, **2**:214, 228, **3**:17
 interagency research, **2**:69
 interdisciplinary research, **2**:57, 98, 155, **3**:90-91, 154, 169, 257, 268
 international initiatives, **2**:77, 92-93, **3**:259-260, 261-262
 language impairment, **2**:209-210, **3**:148
 learning math and science, **2**:215-216
 liver disease, **2**:169, 185, **3**:148-149
 lupus, **2**:117, **3**:180
 malaria, **2**:82
 menopause, **2**:98, 196, 206
 minority health and health disparities, **2**:63, 152-153, 154, 213, 216, 219, 220, 246-247, 255, 259, 260, 261-262, 264, 267-268, **3**:8, 17, 35, 160, 163, 171, 176, 285-286, 287-288
 mission, **5**:8
 molecular biology and basic research, **2**:43-44, 64-65, 120, 155, **3**:14, 47, 78, 89, 90-91, 100-101, 238-239
 multidisciplinary research, **2**:43-44, 92-93, 170, 213, 217-218, 255, **3**:14, 259-260
 muscle biology and diseases, **2**:163, **3**:127, 180
 muscular dystrophies, **2**:56, 68-69, 163, **3**:127, **4**:19
 nanotechnology, **3**:241-242
 neurofibromatosis, **2**:64-65, **3**:72
 neurological research, **2**:32, 41, 42, 43-44, 51, 56, 57-58, 59-60, 61, 63, 64-65, 66, 68-69, 93, 199, 200, 203-205, 217-218, 221-222, 221, **3**:14, 34, 72, 92, 119, 120, 127, 141-142, 169, 197, 207, 225, 245, 257
 newborn screening, **2**:202
 obesity, **2**:98, 152, 184, 210, 220, **3**:17
 oligosaccharides, **2**:82-83
 oral health, **2**:216, 260, **3**:287-288
 Parkinson's disease, **2**:63, 221-222, **3**:141-142
 pelvic floor disorders, **2**:169, 201, **3**:153
 perinatology, **2**:201-202, 227, **3**:153
 population health, **2**:219, **3**:7-8, 169
 prosthetics, **2**:51, 221-222, **3**:245
 proteomics, **2**:214
 psoriasis, **2**:117
 rare diseases, **2**:59-60, 214, **3**:142, **4**:39
 registries, databases, and information systems, **2**:57-58, 98-99, 117, 204-205, **3**:43, 197, 200, 203, 207, 225
 rehabilitation research, **2**:192, 221-222, **3**:245
 reproductive health, **2**:192, 201-202, 226, 227, **3**:180
 rheumatoid arthritis, **2**:117
 SIDS, **2**:259, **3**:285-286
 space-based research, **3**:100-101, 238-239
 strategic plans, **2**:68, 102, 122, 184, 185, 226, 228
 technology development, **2**:51, 58, 116, 202, 221-222, **3**:100-101, 207, 225, 236, 238-239, 241-242, 245, 289
 training and career development, **2**:57, 92-93, 182, 267-268, **3**:169, 174, 257, 258, 259-260, 261-262, 265, 268
 traumatic brain injury, **2**:61, 63, 221
 tuberous sclerosis complex, **2**:64-65, 68, **3**:72
 undiagnosed diseases, **2**:147, **3**:154
 urology research, **2**:170, **3**:22, 150
 vaccine research, **2**:82
 women's health, **2**:98, 169, 170, 192, 196, 201-202, 206, 226, 227, **3**:22, 150, 153, 158-159, 180, 268, 285
 European Union, partnerships with, **1**:29
 Evidence-Based Practice Centers Program, **3**:147
 Evolution of Infectious Diseases Program, **2**:93
 Experimental Therapeutics Program, **2**:8, 15, **3**:108, 132
 Exposure Biology Program, **3**:65, 240
 Exendin-4, **2**:54, 164, **3**:120
 Exercise and physical activity (*see also* Lifestyle interventions; Nutrition and fitness), **2**:134, 158, 163, 191, **3**:91, 113, 164, 220-221, 246, 284
 Exploratory/Developmental Projects for Translational Research in Neuromuscular Disease, **2**:56, **3**:127
 Exploratory Investigations in Food Allergy, **2**:155-156, **3**:17-18, 126
 Exploratory Studies in the Neurobiology of Pain in Sickle Cell Disease, **2**:139, 179-180, **3**:133
 Extramural Clinical Research Loan Repayment Program for Individuals from Disadvantaged Backgrounds, **2**:243, 265
 Extramural research
 ARRA funding, **1**:3, 21-22, 23
 community, **1**:11
 conflicts of interest, **1**:43-44
 construction awards, **1**:21, 22, 23, **3**:97-98, 167-168, 216, 231
 eRA system, **1**:11, **2**:250, 265
 faculty development, **1**:22
 funding decisions, **1**:13-14
 grants and awards overview, **1**:11-12
 integrity, **1**:44
 leadership, policy guidance, and oversight, **1**: 7, 9, 11, 24, 35, 39, 44, 45, 46, **2**:245
 peer review process, **1**:12-13
 post-award administration, **1**:13
 revision applications/administrative supplements, **1**:21
 signature initiatives, **1**:22, **2**:2, 24, 63, **3**:8, 46, 122, 259-230
 technology transfer policy, **1**:39
 training and career development, **1**:7, 11, 21, 22, 45, **2**:20-21, 242, 249-254, 267-268, **3**:105, 255-265, 266-268
 Extramural Research Facilities Improvement Program, **1**:22, **3**:216
 Eye diseases and vision disorders
 adolescents, **2**:167, 215-216, **3**:111, 152-153
 aging-related, **2**:67, 125, 129, 131, 137, 140-141, 146, 173, 183, 187, 193, 196, 211, 227, **3**:77, 152
 animal models, **3**:118
 cancers, **2**:23
 cataract, **2**:122, 129, 131, 137, 146-147, **3**:213, 222
 children, **2**:130, 144, 167, 195, 210-211, 215-216, **3**:39, 111, 121, 130, 140, 152-153
 communicating health information, **3**:279
 comparative effectiveness research, **2**:173, 210-211, **3**:140, 152
 convergency insufficiency, **2**:210-211, **3**:140
 corneal transplants, **2**:138, 174-175, **3**:147
 developmental, **3**:121
 diabetic retinopathy and macular edema, **2**:107, 114, 125, 127, 129, 136, 140-141, 166-167, 187, **3**:77, 141
 epidemiological and longitudinal studies, **3**:18
 funding, **2**:279
 gene therapy, **2**:167, 215-216, **3**:111, 121, 152-153
 glaucoma, **2**:39, 55-56, 129, 132, 151, 235, **3**:45
 Graves' disease, **2**:40, 59, **3**:140
 idiopathic intracranial hypertension, **2**:40, 59, **3**:140
 imaging tools, resources, and applications, **2**:131, 136, 146-147, **3**:222
 infectious diseases, **2**:81, 101
 laser treatment, **2**:166-167, **3**:141
 Leber congenital amaurosis, **2**:167, 195, 215-216, **3**:111, 121, 152-153
 macular degeneration, **2**:67, 128, 129, 137, 140-141, 173, 183, 187, 193, 196, 211, 227, 283, **3**:77, 152
 minority health and health disparities, **2**:231, 235
 neurological diseases and disorders, **2**:39, 40, 55-56, 59, 128, 151, 235, **3**:45, 140
 NORDIC, **2**:40, 59, **3**:140
 refractive errors, **3**:18

Eye diseases and vision disorders (*continued*)
 retinitis pigmentosa, **2**:129, **3**:117-118
 retinopathy of prematurity, **2**:130, 144,
3:39, 130
 screening children for, **2**:219-220, **3**:15
 statistics and burden of disease, **2**:187,
3:18
 strategic plans, **2**:227
 therapeutic targets, **2**:129, 140-141, **3**:77
 visual impairment, **1**:17, **2**:38-39, 174
 X-linked juvenile retinoschisis, **3**:121
 eyeGENE (*see* National Ophthalmic Disease
 Genotyping and Phenotyping Network)

F

Fabry disease, **4**:41
 Facioscapulohumeral muscular dystrophy,
2:56, 279, **3**:127, **4**:19-20, 21, 22
 Familial amyloidotic polyneuropathy, **2**:64,
3:71, 120
 Families
 alcoholism, **2**:34, 41-42, 46-47, 132, 141,
 151, **3**:36, 92
 autism risk study, **2**:35, 42, 195-196, 219,
3:20-21
 cardiovascular disease, **2**:132, 150, 252
 communicating health information to
 caregivers, **2**:216, 260, **3**:288
 diabetes, **2**:132
 epidemiological and longitudinal studies,
2:219, **3**:7-8
 fragile X syndrome, **2**:214
 mental health disorders, **2**:133-134, 157-
 158, 224, **3**:21
 military, **2**:133-134, 157-158, 224, **3**:21
 oral health care, **2**:263-264, **3**:151
 satisfaction with end-of-life care, **2**:203,
3:157
 structural effects on child welfare, **2**:219,
3:7-8
 substance abuse, **2**:48, 133-134, 148, 157-
 158, 224, 225, **3**:21
 Family History Initiative, **3**:33-34, 164
 Fast ForWord Language, **2**:208, **3**:148
 Fatty liver disease, **2**:128, 129, 130, 142
 FDA (*see* U.S. Food and Drug
 Administration)
 Federal Adverse Event Task Force, **3**:182
 Federated Authentication Identity Service
 (iTrust), **1**:28, **3**:206
 Federal Technology Transfer Act, **1**:39
 Feedback Loop, **3**:280
 Fellows Committee, **3**:257
 Fellowships (*see* Grants and fellowships)
 Fenoterol, **2**:54, 135, 164, **3**:120
 Fetal
 alcohol effects, **2**:67, 161, 184, 213, 228,
 238, 255, 279, **3**:17, 139
 environmental exposures, **2**:21-22, 42,
 119, 193-194, 198-199, 219, 225, **3**:20-
 21, 85-86, 87-88, 177
 funding for research, **2**:277, 279, 281
 Fibromyalgia, **2**:279
 FIC (*see* Fogarty International Center)

Fidelity Charitable Gift Fund, **3**:284
 Filariasis, **2**:83, **3**:124-125
 Finland-US Investigation of NIDDM
 Genetics, **2**:132
 Fludarabine phosphate, **3**:110
 FNIH (*see* Foundation for the NIH)
 Fogarty International Center
 autoimmune diseases, **2**:122
 behavioral and social science research,
3:89, 90-91, 128, 166
 bioethics, **3**:259
 cancer, **2**:2, 7, 23, 28, 29
 child health and development, **2**:217
 chronic diseases and organ systems,
2:155, 180-182, 184, 185, **3**:128
 clinical and translational research, **2**:28,
 100-101, 181-182, 224, **3**:128, 153, 161,
 166, 169, 172, 180, 181, 259
 community-based research, **3**:172
 global health, **2**:28, 100-101, 181-182,
3:181, 226, 251, 259-260, 263-264
 HIV/AIDS, **3**:261-262
 infectious diseases and biodefense, **2**:71-
 72, 92-93, 99-101, 103, **3**:261-262
 informatics, **3**:226, 263-264
 intramural research, **1**:14
 mission, **5**:10
 molecular biology and basic research,
3:89, 90-91, 128
 neuroscience and neurological disorders,
2:33, 68
 obstetrical care, **3**:166
 population health, **3**:169
 technology development, **3**:241-242
 training and career development, **2**:92-93,
3:226, 251, 259-260, 261-262, 263-264,
 266-267
 women's health, **3**:166, 180
 Fogarty International Clinical Research
 Scholars Program, **2**:23
 Fogerty International Research Collaboration
 Award, **3**:267
 Folic acid/folate, **2**:34, 41, 192, 194, 199,
3:34, 85, **4**:4, 32
 Food allergies, **2**:115, 133, 155-156, 174, 183,
3:17-18, 58, 59, 126, 138
 Food and Drug Administration Act of 2007,
1:iii, v, **3**:189, **5**:4
 Food safety, **2**:279
 Foundation for the NIH, **1**:29-30, **2**:38, 54,
 99-100, 207, 217, **3**:22, 42, 116, 152, 264
 Fragile Families and Child Well-Being Study,
2:219, **3**:7-8
 Fragile X syndrome, **2**:69, 195, 214, 228, 273,
 279
 Fragile X Syndrome Research Centers, **2**:214
 Framingham Heart Study, **3**:1-2, 3
 Framingham Osteoporosis Study, **2**:132, 149,
 212, **3**:10
 Framingham SHARe, **2**:159, **3**:24, 45
 Framework Programs for Global Health,
3:259-260
 Frontotemporal dementia, **2**:32, 279, **3**:166,
4:5

Functional Dyspepsia Treatment Trial, **2**:136,
 168, **3**:136
 Funding (*see also* Grants and awards; *specific
 diseases and disorders*)
 aging-related research, **2**:152, 156-157,
 274
 alcohol-related research, **2**:274, 279
 ARRA initiatives, **1**:21-24, **2**:273-290
 categorical spending reports, **1**:35-36,
2:3, 33, 73, 109, 126, 193, 236, 273-290
 Common Fund/Roadmap budget data,
5:15
 decision process for extramural research,
1:13
 expansion of payline, **1**:13, 21
 information resources on, **3**:283
 infrastructure and personnel, **1**:21
 multidisciplinary research, **1**:22, 29
 partnerships, **1**:8
 paylines, **1**:13
 revision applications/administrative
 supplements, **1**:21
 transparency and accountability, **1**:36,
3:283

G

GAIN (*see* Genetic Association Information
 Network)
 Gallbladder diseases, **2**:127, 128, 186, 278
 GARD (*see* Genetic and Rare Diseases
 Information Center)
 Gardasil®, **2**:6
 Gastrointestinal disorders (*see also* Digestive;
specific disorders and organs)
 acute radiation syndrome, **2**:80, 97, **3**:123
 functional, **2**:136, 168, **3**:136
 infectious, **2**:74, 82-83, 99-100, 217
 Gastroparesis Clinical Research Consortium,
2:168, **3**:136
 Gastroparesis Registry, **2**:168, **3**:136
 Gates Foundation, **2**:99-100, 217
 GEI (*see* Genes, Environment, and Health
 Initiative)
 GeMCRIS (*see* Genetic Modification Clinical
 Research Information System)
 Gene Therapy and Cystic Fibrosis Centers
 Program, **2**:163-164, **3**:172-173
 Gene therapy/transfer, **1**:47, 49, **2**:10, 38, 53,
 55-56, 59-60, 63, 64-65, 113, 116, 144-
 145, 163-164, 165, 167, 195, 215-216,
 279, **3**:42, 111, 121, 122, 127, 141, 142,
 144, 152-153, 172-173, 202, **4**:20, 21, 22,
 23
 GENE-TOX, **3**:197
 Genes, Environment, and Health Initiative,
3:22, 32-34, 65, 240
 Genetic and Rare Diseases Information
 Center, **3**:282
 Genetic Association Information Network,
1:29, **3**:22, 42-43
 Genetic engineering, **2**:18, 62-63, 144-145,
3:35, 42, 50, 57, 58-59, 128
 Genetic Epidemiology of COPD study, **2**:132,
 150-151, **3**:38

Index

- Genetic Investigation of Anthropometric Traits consortium, **2:23**, 159, **3:42**, 199
- Genetic Modification Clinical Research Information System, **1:49**
- Genetic testing, **1:49**, **2:280**, **3:30**, 33-34, 161, 165-166, 169, 188, 282, **4:22**
- Genetics Home Reference, **3:169**, 188, 282
- Genetics Initiative, **4:6**
- Genetics of Coronary Artery Disease in Alaska Natives Study, **2:132**, 150, 237, 252
- Genome Sequencing Centers of Infectious Diseases, **2:82**, **3:47**
- Genome-wide association studies
 autoimmune diseases, **2:108**, 109, 110, 114, 116, 117, 119-120, **3:43-45**, 118-119, 143, 200, 202
 cancer, **2:5**, 23, 24, 159, **3:3**, 8, 10, 28, 31, 42, 46, 50, 199, 200
 cardiovascular diseases, **2:132**, 149-150, 159, 237, 252-253, **3:19**, 24, 40, 35
 chronic diseases, **2:23**, 149-150, 151, 159, 161, 252-253, **3:10**, 19, 24, 29, 35-36, 40, 42, 45, 50, 190, 199, 200
 glaucoma, **2:151**, **3:45**
 GTEx Resource, **5:34-25**
 HIV/AIDS susceptibility, **3:29**
 mental illness, **2:161**, **3:35-36**
 minority health and health disparities, **2:132**, 149-150, 151, 159, 236, 237, 252-253, **3:19**, 24, 40, 43-44, 45, 118-119
 neurological diseases and disorders, **2:39**, 56, 59, 119-120, 196, 207, **3:10**, 50, 107, 132, 143, 190, 200, **4:7-8**
 policy, **3:190**
 population research, **3:22**, 42-43
 registries, databases, and information systems, **1:29**, **2:151**, 159, **3:3**, 10, 22, 24, 42-43, 44-45, 50, 107, 128, 132, 186, 190, 191, 200, 202
 technology development for, **3:209**, 214, 226
- Genomic information systems
 autoimmune diseases, **2:116**, 117, **3:43**, 44-45, 200, 202
 cancer, **1:3**, **2:1**, 2, 4, 9, 10, 23, 28, 159, **3:31**, 42, 46-47, 199
 CEBS Knowledge Base, **3:190**, 214
 chronic diseases, **2:23**, 159, **3:42**, 199
 dbGaP, **1:29**, **2:151**, 159, **3:3**, 10, 22, 24, 42, 45, 50, 186, 190, 200
 DSID, **3:201**
 DSLD, **3:201-202**, 217
 EPR, **2:160**, **3:4**, 11, 155, 191, 202-203
 eyeGene, **3:190**, 200-201
 GeMCRIS, **1:49**
 GenBank, **3:66**, 186, 189, 190
 focus of, **3:186**
 HapMap, **3:29**
 Influenza Virus Resource, **2:78**, 80, 94-95, **3:66**, 95, 190, 199
 KOMP, **3:50**
 NIA Genetics of Alzheimer's Disease Data Storage Site, **3:190**
 NIMH Genetics Repository, **3:190**
 NINDS Human Genetics Repository, **2:58**, **3:190**, 201
 PharmGKB, **3:38**, 114, 156
 Rat Genome Database, **3:190**
 REMBRANDT, **2:29**, **3:48**
 siRNA library of cancer genes, **2:22**
 SRA, **3:32**, 189-190
 TCGA, **1:3**, **2:1**, 2, 4, 9, 10, 28-29, **3:31**, 46-47
 UniProt Knowledgebase, **3:190**
 WormBase, **3:190**
- Genomics (*see also* Genome-wide association studies; *specific diseases, disease classes, and disorders*)
 1,000 Genomes Project, **3:29**
 3-D analysis, **3:41**, 214
 addiction, **2:6**, 23, 34, 36, 41-42, 44-45, 46-47, 48, 90, 97, 132, 141, 148, 151, 158, 159, 225, **3:36**, 92-93, 130, 227-228
 aging-related, **2:23**, 24, 25, 159, 194, 196, 198, 200, 208, 220, 250, 253, **3:39**, 42, 77, 199, **4:15**
 antimicrobial resistance, **2:74**, 93, 96, **3:39**, 122
 ARRA funding, **2:28-29**, **3:47-48**
 behavioral and social sciences research, **3:22**, 32-34, 47, 62, 65, 91, 240, 263
 brain, **2:41**, 46, 57, 161, 199
 chemical, **2:97-98**, 164, **3:37**, 82
 clinical, **3:30**, 32, 33-34, 38, 50, 51, 111-112, 114, 143, 156, 161, 164-165, 179-180
 collaborative studies, **2:151**, **3:45**, 48
 comparative, **3:35**, 39, 48
 costs of sequencing, **3:32**, 40
 defined, **3:27**
 developmental, **2:34**, 35, 41, 42, 195-196, 199, 208
 disease (functional), **2:14-15**, 16, 17, 18, 41-42, 46, 64, 74, 78, 96, 112, 117, 118, 119, 130, 132, 144, 147-148, 149-150, 151, 152-153, 154, 163-164, 167, 199, 208, 212, 215, 237, 248, 249-250, **3:5**, 19, 27-28, 30, 32-40, 92-93, 122-123, 130, 227-228
 ENCODE, **3:28**, 35
 educational resources, **1:27**, **3:28**
 environmental factors, **2:5**, 12-13, 38, 42, 53-54, 194, 208-209, **3:2-3**, 12, 22, 28, 41, 42-43, 48, 51, 64-65, 86-87, 177-178
 epidemiology, **2:5**, 18-19, 23, 24, 41-42, 109, 132, 149-151, 159, 214, 237, 252-253, **3:3**, 4, 5, 6, 8, 10, 11, 19, 22, 24, 31, 36, 38, 40, 42, 43-44, 45, 46, 50, 191, 199, 200, 202-203
 epigenomic initiatives, **2:28**, 199, **3:41**, 49-50, 62, 81
 ethical, legal, and social issues, **3:47**, 51, 179-180
 funding, **2:274-290**, **3:40**, 277
 infrastructure and capacity building, **2:41-42**, 82, 97-98, 109, 149-150, 151, 164, 195, 199, 252-253, **3:10**, 19, 33-34, 36, 40, 48-52, 66, 81, 164, 200
 international collaborations, **3:29**, 30-31, 34, 35, 38, 63, 82, 156
 metagenomics, **3:31**
 microbiomics, **1:3**, 47, **2:74**, 84, 90-91, 144, 251, **3:31**, 32, 34-35, 62-63, 82-83, 85, 244
 minority health and health disparities, **2:117-118**, 132, 149-150, 152-153, 154, 231, 236-237, 247-248, 249-250, 252-253, **3:19**, 30, 35, 37, 40, 43-44, 78, 118-119
 molecular biology and basic research, **2:12**, 14-15, 22, 46, 97, 108, 117-119, 247-248, **3:43-44**, 47, 56, 61, 62, 64-65, 77, 78, 82, 83, 91, 118-119, 123, 134
 multidisciplinary studies, **2:41-42**, 130, 151
 Multiplex Initiative, **3:30**, 33, 164
 nonhuman genomes, **2:57**, 82, 98, **3:28**, 30, 35, 47-52, 58, 66, 95, 106
 opportunities for research, **1:2-3**
 oversight, **1:49**, **3:161**
 personalized medicine, **1:4**, **2:47**, 97-98, 162, 167, **3:23**, 29, 30, 33, 38, 59, 111-112, 114, 121, 143, 156
 pharmacogenetics, **1:4**, **2:47**, 97-98, 162, 167, **3:23**, 29, 30, 38, 59, 62, 111-112, 114, 121, 143, 156
 population genomics, **3:22**, 42-43
 proteomics, **1:4**, 30, 98, **2:2**, 7-8, 9, 11, 12, 22, 73, 82, 98, 195, 208, 214, **3:41**, 82, 243
 rare diseases and disorders, **3:33**, 227, **4:40**
 registries, databases, and information systems, **2:22**, 116, 160, **3:4**, 10, 11, 44-45, 48, 50, 66, 155, 200, 202-203
 regulation of gene expression, **2:4**, 91, **3:37**, 82, 170
 sequencing, **1:3**, 49, **2:4**, 27-28, 32, 236
 structural analysis of DNA, **3:29-30**, 41
 TARGET, **2:4-5**, 18, 212, **3:31**
 technology development, **2:36**, 46, 62-63, 216, **3:32-33**, 36, 40-42, 82, 92-93, 211, 214-215, 227-228, 240, 243
 tools and resources for scientists, **2:5**, 7, 12-13, 28-29, 98, 208-209, **3:4-5**, 12-13, 33-34, 47-48, 51, 64-65, 86-87, 161, 164, 177-178
 training and career development, **3:263**
 trans-NIH research, **3:34-35**, 50, 82-83
- Genotype/Tissue Expression Resource, **5:34-25**
- GenTAC (*see* National Registry of Genetically Triggered Thoracic Aortic Aneurysms and Cardiovascular Conditions)
- Geoffrey Beene Gives Back Alzheimer's Initiative, **3:284**

- Geographic Management Program, **2:19, 247, 3:100, 178-179**
- Geriatric Research and Training Centers, **4:13**
- Giardia lamblia*, **3:30**
- Ginkgo Evaluation of Memory Study, **2:53, 206**
- Glatiramer acetate, **2:39, 56, 113, 119-120, 3:143**
- Glaucoma, **2:39, 55-56, 129, 132, 151, 235, 3:45**
- Glaucoma Human Genetics Collaboration, **2:132**
- Gleevec®, **2:10, 64, 3:72**
- Glioblastoma, **2:1, 17, 28, 64, 3:32, 47-48**
- Global Fund to Fight AIDS, Tuberculosis, and Malaria, **2:80**
- Global health initiatives (*see also* International programs and activities)
- cancer, **2:28, 100-101, 181-182, 3:181**
 - cardiovascular and lung diseases, **2:181**
 - chronic diseases, **2:28, 100-101, 139-140, 180-182**
 - clinical and translational research, **2:28, 100-101, 181-182, 3:181**
 - diabetes, **1:4-5**
 - exhibitions, **3:282**
 - infectious diseases, **2:80, 10**
 - informatics training, **3:195, 226, 251, 263-264**
 - research recommendations from IOM, **2:4-5, 28, 100-101, 139-140, 181-182**
 - smoking and death in India, **2:180-181**
 - strategic plan, **2:29, 68, 103, 164**
- Global Network for Women's and Children's Health Research, **2:224, 3:110, 153**
- Glucocorticoids, **2:251**
- Glucosamine/Chondroitin Arthritis Intervention Trial, **2:138, 175, 3:70, 113, 166**
- Glycans, **3:63-64, 83, 129, 237**
- Glycomics, **3:63-64, 83, 129, 237**
- Glycoproteinoses, **4:41**
- Gonorrhea, **2:82, 3:47**
- Government Performance and Results Act goals
- alcoholism, **2:47, 151, 162, 3:36, 121**
 - Alzheimer's disease, **2:52-53, 206-208, 3:118, 151-152**
 - antimicrobial resistance, **2:96, 3:39-40, 122-123**
 - asthma, **2:172, 3:79**
 - behavioral strategies for chronic diseases, **2:180, 3:145**
 - biodefense, **2:66, 96, 3:120**
 - cancer, **2:12-13, 15, 16, 24, 208-209, 3:5, 12-13, 51-52, 86-87, 153-154, 177-178, 230**
 - COPD, **2:165**
 - depression, **2:160**
 - developmental processes and disorders, **2:42, 43-44, 200, 217-218, 3:5, 12-13, 14, 92**
 - diabetes, **2:167, 249, 3:145**
 - eye diseases, **2:151, 3:18, 45**
 - genomics, **2:41-42, 46, 97-98, 151, 3:36-37, 38, 45, 51-52, 86-87, 92-93, 142-143, 156, 177-178, 227-228**
 - HIV/AIDS, **2:88, 92, 263, 3:124, 162-163**
 - imaging technologies, **3:228, 230**
 - infectious diseases, **2:88, 92, 96, 97-98, 263, 3:39-40, 122-123, 124, 162-163**
 - infrastructure and capacity building, **2:268, 3:153-154, 170-171**
 - liver disease, **2:169, 3:148-149**
 - minority health and health disparities, **2:65, 167, 249, 253, 268, 3:145, 170-171**
 - muscular dystrophies, **2:56, 3:127**
 - neuroscience and neurological disorders, **2:41-42, 43-44, 46, 47, 48, 49, 52-53, 56, 62, 65, 66, 151, 158, 162-163, 200, 206-208, 217-218, 253, 3:14, 36, 92-93, 118, 121, 127, 139-140, 151-152, 227-228**
 - osteoarthritis, **2:153, 3:137**
 - pharmaceutical research, **3:38, 68, 94-95, 121, 139-140, 142-143, 156, 245**
 - planning and reporting requirements, **1:8**
 - registries, databases, and information systems, **3:196**
 - stroke, **2:65, 253**
 - substance abuse/addiction, **2:43-44, 46, 49, 92, 162-163, 217-218, 263, 3:14, 36-37, 92-93, 139-140, 162-163, 227-228**
 - technology development, **3:92-93, 94-95, 228, 245**
 - tobacco addiction, **2:48, 158, 3:93**
 - toxicology, **3:87**
 - training and career development, **3:252-253, 265, 266**
 - warfarin therapy, **3:38, 142-143, 156**
- GPRA (*see* Government Performance and Results Act)
- Graduate & Professional School Fair, **3:258**
- Graduate Partnerships Program, **3:254, 263**
- Graduate Student Council, **3:257**
- Grand Challenges, **1:30, 2:39, 57**
- Grand Opportunity Grants, **1:2, 21, 22, 2:35, 265**
- Grants and awards (*see also* Funding; Training and career development; *specific types of grants*)
- A-START Award, **2:91**
 - AIDS-Science Track Award for Research Transition, **2:91, 3:170**
 - application changes, **1:34**
 - Avant-Garde Award series, **2:91**
 - Beeson Awards, **3:265**
 - BIRT Awards, **3:99-100, 218, 237**
 - Calabresi Award in Clinical Oncology (K12), **2:20-21, 3:260**
 - Career Development Awards, **3:253, 263, 265, 267**
 - Career Transition Award, **3:263, 267, 268**
 - Clinical Research Education and Career Development awards, **2:268, 3:116, 171**
 - Core Facility Renovation, Repair, and Improvement awards, **2:22**
 - CTSA program, **2:243, 268, 269, 3:105, 115, 116, 134, 168, 173, 174-175, 206, 231-232, 250, 253, 256, 5:14**
 - early career investigators, **2:20, 91**
 - electronic document/content management system, **1:11**
 - Fogerty International Research Collaboration Award, **3:267**
 - High-End Instrumentation program, **1:23, 3:66, 98, 168, 215, 230-231**
 - IDeA program, **1:28, 2:244, 260, 268, 3:170, 175**
 - institutional research training grants, **3:247, 248, 249, 255, 261, 265**
 - International Bioethics Education and Career Development Award, **3:259**
 - International Clinical, Operational, and Health Services Research Training Award, **3:166, 266-267**
 - Mentored Clinical Scientist Research Career Development Award, **3:253, 267**
 - Mentored Patient-Oriented Research Career Development Award, **3:253, 267**
 - Mentored Quantitative Research Career Development Award, **3:253-254**
 - Near-Term Development for Genome Sequencing Grants, **3:40, 227**
 - New Innovator Award Program, **3:98-99, 5:19**
 - NIH Guide for Grants and Contracts*, **1:11, 24, 28**
 - NRSA, **3:247, 249, 250-251, 252, 255-256, 258, 265, 266, 267, 5:37-42**
 - overview for extramural research, **1:11-12**
 - Pathway to Independence Awards, **2:21, 3:254, 267**
 - Pioneer Awards, **2:91, 3:99-100, 5:17, 18**
 - Presidential Early Career Award for Scientists and Engineers, **3:247**
 - REAP, **3:180**
 - Research Scientist Development Award, **3:267**
 - Revolutionary Genome Sequencing Technologies Grants, **3:40, 227**
 - Shared Instrumentation program, **1:23, 3:66, 98, 168, 215, 230-231**
 - Specialized Centers Cooperative Agreement award, **4:19**
 - tutorial on applying for, **3:280**
 - types and activity codes, **1:11-12**
- Granulibacter bethesdensis*, **2:98**
- Grape seed polyphenol extract, **2:38, 52, 3:73-74**
- Green fluorescent protein, **3:55**
- Griffithsin protein, **3:64**
- GSPE (*see* Grape seed polyphenol extract)
- Graves' disease, **2:40, 59, 3:140**
- GTEX (*see* Genotype/Tissue Expression Resource)
- GWAS (*see* Genome-wide association studies)

H

- Haemophilus influenzae* type b, **1:2, 2:82, 191**
HANDLS (*see* Healthy Aging in Neighborhoods of Diversity Across the Life Span)
Haplotype Map (HapMap), **3:29**
Head and neck cancers, **2:3, 14, 26-27, 3:59, 68-69, 242-243**
Health and longevity gains, **1:1-2**
Health and Retirement Study, **2:211, 3:9, 4:4**
Health behavior (*see also* Behavioral and social science research)
 personalized disease risk information and, **1:4**
 self-regulation, **2:251**
Health care delivery, **2:80-81, 88, 92, 135, 172**
Health care reform, **1:4**
Health communication (*see* Communicating health information; Science education and literacy)
Health disparities (*see* Minority health and health disparities; *specific minorities*)
Health Education Program Partnership, **3:279**
Health Insurance Portability and Accountability Act, **3:213**
Health Literacy Workgroup, **3:104**
Health Partnership Program, **3:278-279**
Health Resources and Services Administration, **2:8, 60, 228, 258, 261, 3:34, 164, 193, 205, 224**
Health services research, **2:22, 280**
Health Services Research and Development Service, **3:159**
Healthy Aging in Neighborhoods of Diversity Across the Life Span, **2:220, 250**
Healthy Lifestyles program, **4:32**
Healthy Living Program, **2:86, 3:146**
Healthy People 1979, **2:231**
Healthy People 2010, **1:4, 17, 3:277, 291**
HEALTHY study, **2:133, 152, 205, 3:143-144**
Hearing and balance disorders, **2:3, 38, 51, 55, 128, 129, 132, 149, 187, 191, 196, 197, 208, 219-220, 227, 255, 3:15, 19, 67, 216, 220, 234, 245, 281-282, 287**
Heart failure, **2:54, 127, 135, 164, 185**
Heart Truth® campaign, **3:271**
Heidelberg Award for Significant Contributions to the Field of Gerontology, **2:211, 3:9**
Hematology, **2:280**
Hematopoietic acute radiation syndrome, **2:80, 97, 3:123**
Hemochromatosis, **2:128**
Hemophilia, **2: 125, 127, 128**
Hepatic fibrosis, **3:108, 122**
Hepatitis, **2:126, 128, 136, 147, 169, 186, 280, 3:114, 229**
Hepatitis B Clinical Research Network, **2:169, 3:110, 148-149**
Herceptin®, **2:10**
HHS (*see* Department of Health and Human Services)
High-throughput projects, **1:4, 2:8, 10**
High Risk High Reward Programs, **5:17-18**
Hispanic Community Health Study, **2:132, 149, 255-256, 3:6, 19**
Hispanics/Latinos (*see also* Minority health and health disparities)
 adolescents, **2:28, 254, 3:9**
 alcohol abuse, **3:16**
 Alzheimer's disease, **4:6**
 asthma, **2:234**
 cancer, **2:235, 3:16, 4:29-30, 32**
 cardiovascular disease, **2:132, 149-150, 159, 252-253, 255-256, 3:5, 6, 16, 19, 24, 40, 45**
 child health and development, **2:263-264, 3:151**
 collaborative research, **2:244**
 communicating health information to, **2:65, 216, 239, 240, 256, 260, 3:284-285, 286-287, 288-289**
 diabetes, **2:234**
 epidemiological and longitudinal studies, **2:132, 149-150, 159, 238, 252-253, 255-256, 3:5, 6, 9, 16, 19, 24, 40, 45**
 HIV/AIDS, **2:77, 87, 234, 258, 3:290, 4:32**
 infant mortality, **2:234**
 InfoSIDA, **2:258, 3:290**
 lupus, **2:117, 247-248, 3:43, 78, 118**
 mental health, **2:238, 254, 3:9, 16**
 obesity, **4:30**
 oral health, **2:216, 235, 241, 260, 263-264, 3:151, 289**
 risk factors for chronic diseases, **2:149, 255-256, 3:6, 19**
 Spanish-Language Oral Health Website, **2:216, 260, 3:289**
 statistics and burden of disease, **4:29-30**
 stroke, **2:65, 149, 234, 239, 255-256, 3:6, 16, 19, 284-285, 4:29**
 substance abuse, **2:254, 3:9, 16, 204**
 suicide, **2:28, 254, 285, 3:9**
 training and career development for, **2:240, 264**
Historically Black Colleges and Universities ACCESS Project, **2:240, 256, 3:286**
HIV Cohorts Analyzed Using Structural Approaches to Longitudinal Data, **3:159**
HIV infection/AIDS
 adherence research, **3:161**
 adolescents, **2:77, 85, 92, 99, 102, 201, 226, 234, 263, 3:114-115, 163, 287**
 alcohol abusers, **3:159**
 antiretroviral therapies, **1:1, 2:73, 75, 76-77, 84, 85, 86, 89, 90, 91, 92, 251, 263, 3:5, 15, 64, 94, 125, 159, 170, 245, 287**
 behavioral and social sciences research, **2:77, 86, 92, 99, 172, 201, 3:146, 224-225**
 brain, **2:45, 60, 176**
 cardiovascular complications, **2:72, 86, 3:15**
 cholesterol and, **2:237-238, 245-246**
 circumcision and, **2:76**
 clinical and translational research, **2:23, 35, 45, 64, 71, 75, 77, 78, 81, 84, 85-86, 89-91, 97, 99, 176-177, 201, 237-238, 245-246, 261, 3:13-14, 15-16, 110, 120-121, 125, 130, 135-136, 146, 148, 149, 169-170**
 clinical practice, **2:88-89, 91, 92, 263, 3:114-115, 158-159, 161, 162-163**
 co-infections, **2:75, 76, 81, 82, 84, 85, 90-91, 3:11, 138, 287**
 communicating information on, **2:77, 78, 88, 172, 239, 240-241, 258, 3:188-189, 287, 290**
 cure, **2:77, 89**
 drug abusers, **2:76, 77, 86, 91, 92, 172, 3:15-16, 146, 148, 158, 162-163, 170, 224-225**
 epidemiological and longitudinal studies, **2:77, 86, 89-90, 92, 98-99, 3:5, 11, 13-14, 15-16, 148, 149, 159, 191, 202**
 funding for research, **1:22, 2:72, 91, 92, 273, 281, 285, 3:170**
 genomics, **2:88, 91, 245-246, 3:30, 170**
 guidelines for medical management, **2:85, 3:287**
 health care delivery, **2:80-81, 88, 92, 172, 3:169-170**
 homeless adults, **2:77, 86, 3:146**
 homosexual or bisexual men, **2:77, 86, 87, 89, 92, 234, 3:15-16, 125, 148**
 heterosexuals, **2:80, 85-86**
 immunology, **2:76, 87-88, 91, 3:170**
 influenza and, **2:76, 85, 3:287**
 infrastructure and research resources, **2:97, 3:169-170**
 interagency research, **2:103**
 international collaborations, **1:4, 2:23, 77, 80-81, 92-93, 98-99, 3:5, 191, 202, 261-262**
 kidney disease, **2:154, 237, 249**
 malignancies, **2:23, 27, 74, 77**
 mathematical modeling, **2:89, 91, 3:125, 170**
 mental disorders, **2:35, 45, 46, 77, 86, 176, 3:15, 135-136**
 microbicides (topical), **2:76, 85-86, 88, 97, 237, 245-246, 273, 289, 3:130, 158-159**
 microbiome of lung and respiratory tract, **2:74, 90-91, 251**
 military veterans, **3:159**
 minority health and health disparities, **1:47, 2:77, 87, 90-91, 92, 154, 231, 234, 237-238, 239, 241-242, 245-246, 250, 258, 261, 263, 269, 3:15-16, 148, 170, 177, 290, 4:28, 32**
 molecular biology and basic research, **2:64, 74, 88, 90-91, 237-238, 245-246, 3:60, 64, 120-121**
 neurological disorders, **2:35, 45, 46, 60, 64, 68, 92, 176, 3:120-121, 135, 197**
 older adults, **2:76-77, 86, 3:15**
 oral complications, **2:89-90, 3:5, 13-14, 149**

- HIV infection/AIDS (*continued*)
 pediatric, **1:1**, **2:77**, 84, 90, 285, **3:11**
 portfolio and budget management, **2:86-88**, 250
 pre-exposure prophylaxis, **2:76**, 89, **3:125**
 prevention strategies, **2:76**, 85-86, 88-89, 91, 172, 261, **3:125**, 146, 158, 170, 224-225
 prison inmates, **2:77**, 91, 92, 241-242, 263, **3:158**, 162-163
 registries, databases, and information systems, **2:60**, 98-99, **3:191**, 197, 202
 respiratory infections, **2:90-91**, 251
 sleep disorders, **2:86**, **3:15**
 statistics and burden of illness, **2:33**, 72, 73, 89, 139, 234
 strategic plans, **2:68**, 102, 103, 184, 269
 technology development, **2:172**, **3:224-225**
 testing, counseling, and treatment, **2:76**, 77, 89, 91, **3:125**, 158
 training and career development, **2:92-93**, **3:261-262**
 transformative research, **2:91**, **3:170**
 transmission, **2:71**, 75
 vaccines, **1:22**, **2:76**, 88, 91, 97, **3:124**, 130, 169-170
 Web-based interventions, **2:172**, **3:214**, 224-225
 women, **2:76**, 77, 78, 80, 85-86, 88, 97, 234, 237, 245-246, 273, **3:15**, 130, 158-159, 180, **4:32**
- HIV Prevention Trials Network, **2:85**, **3:159**
 HIV Rapid Testing and Counseling in Drug Abuse Treatment Programs, **2:77**
 HIV Vaccine Trials Network, **2:76**, 88, **3:124**
 Hodgkin's disease, **2:281**
 Homeless adults, **2:77**, 86, **3:146**
 Homosexual or bisexual men, **2:77**, 86, 87, 89, 92, 234, **3:15-16**, 125, 148
 Hookworm, **1:4**
 Howard Temin Pathway to Independence Award in Cancer Research, **2:21**, **3:260**
 HPV (*see* Human papillomavirus)
 HRS (*see* Health and Retirement Study)
 HRSA (*see* Health Resources and Services Administration)
 Human Connectome Project, **2:31**
 Human development (*see* Aging; Child health and development; Developmental processes and disorders; Molecular biology and basic research; Regeneration; Rehabilitation)
 Human Genome Project, **1:1**, 47, **2:7**, 279, **3:4**, 10, 27, 32, 33, 40, 50, 62, 66, 164, 200, 214, 219, 227
 Human Microbiome Project, **1:3**, 47, **3:31**, 34, 63, 82, **5:23-24**
 Human papillomavirus, **2:6**, 14, 23, 27, 81, 101, 281
 Human Salivary Proteome Annotation System, **3:96**, 206
 Human subjects protection, **1:7**, 12, 13, 29, 44, 45-46, 47, 48, **2:171**, **3:109**
- Human Subjects Research Advisory Committee, **1:45**
 Huntington's disease, **2:63**, 97, 281, **3:58**, 107, 122, 130
 Hydrocephalus, **2:32**
 Hydroxyurea treatment, **3:114**
 Hyperbaric oxygen therapy, **2:281**
 Hyperimmunoglobulinemia D with periodic fever syndrome, **4:42**
 Hypertension/high blood pressure, **2:40**, 59, 90, 127, 134, 136, 165, 166, 194, 234, 237, 241, 251, 261, 281, **3:30**
 Hypothermia therapy, **2:61**, 221
- I**
- IACUCs (*see* Institutional Animal Care and Use Committees)
 ICBP (*see* Integrative Cancer Biology Program)
 IDEA (*see* Institutional Development Award)
 IDEAL (*see* Insight into the Determinants of Exceptional Aging and Longevity)
 IDeANet, **2:268**, **3:170**
 Idebenone, **2:56**, 120, **3:143**
 Idiopathic inflammatory myopathies, **2:112**
 Idiopathic intracranial hypertension, **2:40**, 59, **3:140**
 Idiopathic pulmonary fibrosis, **2:127**, 136, 165
 Idiopathic Pulmonary Fibrosis Clinical Research Network, **2:136**, 165
 IeDEA (*see* International Epidemiologic Databases to Evaluate AIDS)
 iEdison system, **1:39**
 IHS (*see* Indian Health Service)
 Imaging (*see also* National Institute of Biomedical Imaging and Bioengineering)
 bone density, **2:149**, 212-213, 220, 250, **3:10**
 brain, **2:25**, 31, 35, 37, 38, 40, 43, 44, 45, 47, 49, 50, 55, 58-59, 62, 62, 133, 141, 156, 170, 176-177, 178, 196, 200, 207, 215, **3:73**, 107, 132, 135-136, 138-139, 220, 245-246, **4:5**, 6, 7-8
 cancer detection and treatment, **2:2**, 4, 6, 7, 8, 9, 14, 15, 16, 22, 24, 25, 147, **3:153**, 220, 228, 229, 230, 245-246
 cardiovascular, **2:149-150**, 220, 250, 252, 262, **3:5**
 chest/lung, **2:15**, 149, 252
 chronic diseases, **2:48**, 49, 131, 136, 141, 146-147, 148, 149-150, 156, 170, 225, 252-253, **3:19**, 40, 73, 222, 229
 clinical and translational research, **2:8**, 15, 25, 40, 45, 58-59, 176-177, **3:135-136**, 230
 comparative effectiveness research, **2:15**, 149-150
 computed tomography, **2:15**, 149-150, 252, **3:5**, 19, 40, 153, 215, 230, 242
 dynamic light scattering, **2:131**, 146-147
 eye diseases and disorders, **2:131**, 136, 146-147, **3:222**
 funding, **2:277**
- Human Connectome Project, **2:31**
 informatics tools and resources, **2:39-40**, 58, **3:207**, 225
 infrastructure, **1:28**, **2:9**, 15, 39, 62
 interventions guided by, **2:24**, 25, 31, **3:97**, 128-129, 216, 228, 236, 245-246
 kidney, **2:154**, 249, **3:37**
 magnetic resonance imaging, **2:24**, 35, 40, 43, 58-59, 62, 131, 147, 149-150, 154, 200, 207, 249, 252, **3:5**, 19, 37, 40, 107, 132, 215, 218, 228, 229, 242, **4:7**, 8
 magentoencephalography, **2:45**, 176-177, **3:135**
 medical GPS, **3:211**, 215, 228-229
 mobile medical research vehicles, **2:220**, 250
 molecular, **1:3**, **2:4**, 15, 22, 25, 60, 62, **3:96**, 97, 128-129, 216-217, 219, 235, 243
 nanoparticle-based agents, **2:14**, 25, **3:134**, 241
 neuroimaging, **2:31**, 35, 37, 38, 39-40, 43, 44, 45, 47, 48, 49, 50, 55, 57-59, 60-61, 62, 63, 133, 136, 141, 156, 170, 176-177, 178, 194, 196, 200, 204, 207, 215, 218, 222, 225, **3:73**, 107, 132, 135-136, 169, 207, 225, 229, 257, **4:5**, 6, 7-8
 NIH Image Processing Facility, **1:28**
 optical coherence tomography, **2:24**, 67, 183, 227, **3:218**, 228
 Pittsburgh compound B, **2:59**, 207, **3:107**, 132, **4:7-8**
 positron emission tomography, **2:40**, 58-59, 207, **4:7-8**
 public-private partnerships, **1:29-30**
 registries, databases, and information systems, **2:43**, 59, 153, 194, 200
 small animal program, **2:1**, 15, **3:230**
 spiral computed tomography, **2:15**, **3:230**
 stem cell mobility, **3:242**
 strategic plans, **2:67**, 183
 technology development, **2:2**, 9, 15, 24, 25, 31, 58, 62, 131, 145-147, **3:15**, 41, 96, 215, 218, 219, 222, 229-230, 236, 242, 245-246
 training and career development, **2:57**, 78-79, **3:169**, 257
 trans-NIH research, **1:29-30**, **2:141**
 ultrasound, **2:131**, 147, 149-150, 252, **3:5**, 19, 40, 213, 215, 218, 229, 239
 X-ray, **2:15**, 278, **3:230**
- Immune Tolerance Network, **2:112**, 115, 138, 174, **3:137-138**
- Immunodeficiency (*see also* HIV infection/AIDS)
 primary immune deficiency diseases, **2:74**, 147-148, **3:58**, 60, **4:41**
 Immunoglobulin, **2:28**, 52, 208, **3:151**, **4:7**
 Immunology and immunotherapy (*see also* Vaccines)
 adjuvant therapy, **2:74**, 95-96, **3:80**
 animal models, **2:83-84**, **3:233**
 ARRA funding, **2:81-82**, 114, **3:80**

Index

- Immunology and immunotherapy (*continued*)
 asthma, **2**:115, 136, 168-169, 174, 238, 255, **3**:60-61, 137-138, 150-151
 autoimmune diseases, **2**:81-82, 107, 108, 111-112, 113, 114-115, 116, 118, 138, 174, **3**:60, 137-138
 B cell, **2**:76, 88, 111
 B cell and T cell interaction, **2**:81
 cancer, **2**:2, 5, 16, 17, 21, 23, 26, 27, 64, 101, **3**:153, 232-233, 244
 chronic diseases, **2**:115, 136, 143, 174, **3**:137-138, 144-145
 clinical and translational research, **2**:16, 17, 27, 38, 48, 52-53, 56, 64, 115, 136, 168-169, 174, 215, 255, **3**:137-138, 150-151
 diabetes, **2**:112, 113, 115, 120, 174, **3**:60, 137-138
 HIV/AIDS research, **2**:76, 87-88, 91, **3**:170
 infectious diseases, **2**:81-82, 83-84, 91, 114, 143, **3**:80, 233
 infrastructure and research resources, **2**:112, 116, **3**:61, 171-172, 217, 236
 lipid rafts, **2**:111
 molecular biology and basic research, **2**:26, 81-82, 93, 94, 95, 114, 118, 143, **3**:58, 60-61, 64, 79, 80, 94-96, 144-145
 morphine and, **2**:91, **3**:170
 neurological disorders, **2**:36, 38, 45, 48, 52-53, 56, 64, 111, 120, 158, 174, 206-207
 nutrition and, **2**:74
 oligosaccharides and, **2**:74, 82-83
 organ transplants, **3**:60
 profiling human immune responses, **2**:74, 81-82, 92-93, 114, **3**:80
 somatic hypermutation, **2**:111
 T helper cells, **2**:111, 118, **3**:79
 TB, **2**:75, 84
 technology development, **2**:83-84, **3**:233
 tobacco addiction, **2**:48, 158, **3**:93
 trans-NIH research, **3**:61
- Immunosuppression (*see also* HIV infection/AIDS; other specific disorders)
 vaccination, **2**:102
- Impact of CPAP on Functional Outcomes in Milder Obstructive Sleep Apnea study, **2**:136
- Inclusion body myopathy, **3**:166
- Indian Health Service, **2**:8, 154, 248, 259, 261, **3**:160, 276
- Infants
 cesarean section complications, **2**:201
 congenital conditions, 202
 epidemiological and longitudinal studies, **2**:214
 fetal alcohol syndrome, **2**:67, 161, 184, 213, 228, 238, 255, 279, **3**:17, 139
 funding for research, **2**:281, 285-286
 inhaled nitric oxide therapy, **3**:157, 290
 low birth weight, **2**:234, 279, **3**:285
 mortality, **1**:1, **2**:234, 281, **3**:285
 newborn screening, **2**:195, 202, **3**:193, 205, 224
 perinatal exposures to toxins, **2**:21-22, 225-226
 preterm, **2**:34, 130, 144, 202, 203, 220, 226, 234, 285, **3**:157, 285, 290
 respiratory distress syndrome, **2**:285
 retinopathy of prematurity, **2**:130, 144, **3**:39, 130
 SIDS, **2**:202, 213, 238, 239, 255, 259, 285, **3**:17, 285-286
- Infectious diseases and biodefense (*see also specific diseases*)
 adjuvant therapies, **2**:74, 95-96, **3**:80
 animals models, **2**:75, 79, 83-84, 95, 97, **3**:129-130, 155, 216, 233
 antimicrobial resistance, **2**:73, 74, 75, 76, 81, 84, 90, 93, 94, 85, 86, 96, 102, 103, 274, **3**:11, 31, 39-40, 57, 122-123, 125, 138, 155
 ARRA funding, **2**:81-82, 93, 96-97, 114, 278, 281, **3**:80, 123
 behavioral and social sciences research, **2**:75, 86, **3**:66, 146
 biomarkers, **2**:82
 cancer-related, **2**:6, 14, 23, 27, 81, 101, 279
 biodefense, **2**:66, 71-72, 78-80, 90, 93-94, 95, 96, 99, 102, 103, 275, **3**:112, 120, 124, 155, 221
 bioinformatics, **2**:73, 82, 84, 144, **3**:84-85, 243-244
 children, **2**:74, 75, 81, 90, 99-100, 101-102, 217
 chronic, **2**:84, 144, **3**:84-85, 243-244
 clinical and translational research, **2**:71, 72, 75-76, 77, 78, 81, 83, 84, 85-86, 88-89-90, 91, 92, 93-94, 96, 98, 99, 101-102, 201, **3**:15-16, 39-40, 122-123, 124-126, 146, 148, 149, 154, 158-159, 162-163, 169-170
 clinical practice, **2**:95, **3**:112, 155
 communicating information on, **2**:85, **3**:287
 diabetics, **2**:75
 diagnostic tools and platforms, **2**:78, 91, 93-94, 98, **3**:125-126, 158
 emerging and re-emerging threats, **2**:71-72, 78-80, 93-97, 278, **3**:124
 environmental factors, **2**:74, 93
 epidemiological and longitudinal studies, **2**:77, 79, 86, 89-90, 92, 98-100, 217, **3**:11, 15-16, 148, 149, 191, 202
 funding, **2**:73, 91, 92, 93, 273-290, **3**:15-16, 124, 148, 170
 gastrointestinal diseases, **2**:74, 82-83, 99-100, 217
 genomics, **2**:74, 78, 80, 82, 83, 93, 94-95, 96, 97-98, **3**:39-40, 47-48, 66, 95, 122-123, 190, 199
 global health initiatives, **2**:28, 100-101, 181-182
 goals of NIH research, **2**:71
 health care services, **2**:80-81
 ICs involved in research, **2**:71-72, 102-103, 191
 immune response, **2**:81-82, 83-84, 91, 114, 143, **3**:80, 233
 infrastructure and research resources, **2**:71, 72, 74, 79, 80, 82, 90, 93-94, 97-99, **3**:47, 95-96, 124
 interagency research, **2**:103
 interdisciplinary research, **2**:74, 98, **3**:154
 international collaboration, **2**:72, 75-76, 80-81, 83, 85, 92-93, 98-102, **3**:191, 202, 261-262
 major infectious diseases, **2**:75-78, 84-93
 microbiomics, **2**:74, 84, 90-91, 144, 251
 minority health and health disparities, **1**:47, **2**:72, 75, 77, 87, 90-91, 92, 154, 231, 234, 237-238, 239, 241-242, 245, 250, 251, 258, 263, 269, 280, **3**:15-16, 148
 molecular biology and basic research, **2**:72, 73-75, 81-84, 94-95, 114, 130, 143, 144, **3**:57, 76, 80, 84-85, 95-96, 199, 233, 243-244
 multidisciplinary research, **2**:23, 76, 85, 92, 99, **3**:123
 nuclear/radiological countermeasures, **2**:66, 79, 80, 96-87, 103, **3**:120, 123
 oligosaccharides and, **2**:74, 82-83
 pathogens and transmission routes, **2**:71-72, 98
 proteomics, **2**:82, 98
 prevention, **2**:85-86, 88-89, **3**:125, 146, 158-159
 primary immune deficiency diseases, **2**:74, 147-148
 public-private partnerships, **2**:83, 95, 99-100, 217, **3**:155
 rare and neglected diseases, **2**:81, 83, 97-98, **3**:124-125
 registries, databases, and information systems, **2**:78, 80, 82, 94-95, 98-99, **3**:66, 95, 190, 191, 199, 202
 respiratory infections, **2**:74
 statistics and burden of illness, **2**:72-73, 100, 101
 stem cell research, **2**:75, 83-84, **3**:76, 233
 strategic plans, **2**:85, 102-103
 technology development, **2**:83-84, 98, 144, **3**:84-85, 220, 233, 243-244
 training and career development, **2**:72, 73, 78-79, 92-93, 99, **3**:261-262
 trans-NIH research, **2**:87, 103, 250
 transformative research, **2**:91, **3**:170
 urinary tract, **2**:98, 128, 186, **3**:154
 vaccines, **2**:27, 71, 72, 74, 75-76, 78, 81, 82, 85, 88, 91, 93-94, 95, 101, **3**:80, 123, 124, 125-126, 155, 169-170
 vector-borne, **2**:83, 290
 women's health, **2**:85-86, 87, 98, 102, **3**:154, 158-159
- Infertility, **2**:281
- Inflammation (*see also* Immunology)
 brain, **2**:191
 cancer, **2**:5, 27, 101, **3**:61

- Inflammation (*continued*)
- cardiovascular disease, **2**:143, **3**:61
 - chronic diseases, **2**:115, 143, 174, **3**:137-138, 144-145
 - clinical research, **2**:143, **3**:144-145
 - neurological diseases, **3**:61
 - obesity and fat cell biology, **2**:143, **3**:144-145
 - oxidative stress disease, **2**:25, 54, 130, 144, 200, **3**:39, 77, 130
- Inflammatory bowel disease, **2**:107, 109, 110, 126, 281, **3**:60
- Inflammatory demyelinating polyneuropathy, **2**:64, **3**:71, 120
- Inflammatory neuropathies, **2**:64, **3**:71, 120
- Inflammasomes, **2**:74, 95, **3**:80
- Influenza
- adjuvant therapy, **2**:74, 95
 - antiviral drugs, **2**:78, 94
 - and asthma, **2**:71, 78
 - biodefense research, **2**:78, 93-94
 - biosafety and biosecurity, **1**:50
 - CEIRS, **2**:79, 93-94, **3**:95-96, 125-126
 - clinical and translational research, **2**:78, 79, 93, 94-95, **3**:112, 124-125
 - diagnostics, **2**:78, 94, **3**:124-125
 - environmental changes and, **2**:74
 - epidemiological and longitudinal studies, **2**:79, 100
 - funding, **2**:282, 286
 - genomics, **2**:78, 80, 82, 94-95, **3**:28, 30, 47, 58, 66, 95, 190, 199
 - H1N1, **2**:71, 78-79, 82, 85, 93-95, **3**:28, 95-96, 124, 125-126, 188, 199, 277, 287
 - H5N1 (avian), **2**:71, 72, 94, **3**:96, 112
 - health care worker training, **2**:78-79
 - HIV-infected individuals, **2**:76, 85, **3**:287
 - information resources, **2**:78, 80, 94-95, 100, **3**:188, 190, 277, 287
 - molecular biology and basic research, **2**:78, 80, 94-95, **3**:66, 95, 190, 199
 - neuraminidase inhibitor, **2**:94
 - registries, databases, and information systems, **2**:78, 80, 94-95, **3**:66, 95, 188, 190, 199
 - SEACRN, **2**:79
 - seasonal, **2**:79
 - statistic and burden of illness, **2**:73, 78, 79, 100
 - strategic plans, **2**:102
 - surveillance, **2**:79, 94, 100, **3**:95-96
 - transmission, **2**:71
 - vaccines, **2**:78, 93, 94
- Influenza Genome Sequencing Project, **2**:94, **3**:95, 190, 199
- Influenza Virus Resource, **2**:78, 80, 94-95, **3**:66, 95, 190, 199
- Informatics infrastructure (*see also* Bioinformatics)
- BCSC, **2**:22, **3**:21, 163-164, 208
 - BIG Health, **2**:10, 11, **3**:194, 207, 225
 - Bioinformatics and Computational Biology initiatives, **3**:194-195
 - biomedical informatics research and training, **3**:187, 195-196, 209-210, 251
 - Biositemaps, **3**:195
 - BIRN, **3**:66, 194, 207, 217, 225
 - caBIG@, **2**:9, 10, 11, 18, 28, **3**:47-48, 194, 206-207, 214, 225
 - CISNET, **2**:20, **3**:90, 209
 - CVRG, **2**:11, **3**:194, 206, 214, 225
 - Disaster Information Management Research Center, **3**:194, 195, 208, 289
 - funding, **2**:281
 - imaging tools and resources, **2**:39-40, 58, **3**:207, 225
 - international collaborations, **3**:194
 - large-scale, **2**:9, 10, 11, 18, 20, 22, 28, 39-40, 58, **3**:21, 90, 163-164, 187, 194-195, 206-209, 214, 225
 - national biomedical data and information management system, **3**:194-195
 - NCBC, **3**:95, 195, 208, 236
 - NIF, **3**:194
 - NITRC, **2**:39-40, 58, **3**:194, 207, 214, 225
 - training and career development, **3**:187, 195-196, 209-210, 226, 251, 261, 263-264
- Informatics Training for Global Health Program, **3**:195, 226, 251, 263-264
- Information campaigns and clearinghouses (*see* Communicating health information)
- Information resources and technology (*see also* Disease registries and surveillance systems; Communicating health information; Genomic information systems; Informatics infrastructure; Registries, databases, and health information systems; Scientific databases)
- animal models, **3**:106, 126
 - Biowulf cluster supercomputer, **3**:209, 214, 226
 - Business Intelligence Services (nVision), **1**:28
 - Collective Intelligence initiative, **3**:96, 193, 206
 - contact information for NIH constituency organizations, **3**:280
 - Discovery Initiative, **3**:193, 196, 205
 - electronic health records, **2**:22, **3**:185, 187, 192, 193, 204-205, 223-224
 - Federated Authentication Identity Service (iTrust), **1**:28, **3**:206
 - grant application tutorial, **3**:280
 - health data standards, **1**:40, **3**:192-193, 223-224
 - Image Processing Facility, **1**:28
 - ITAS Time and Attendance, **3**:206
 - leadership, administration, and oversight, **1**:27-28
 - LOINC nomenclature, **3**:193, 205, 224
 - NeuroLex, **3**:194
 - Newborn Screening Codes and Terminology Guide, **3**:193, 205, 224
 - Pipeline to Partnerships, **1**:39-40, **3**:280
 - Radiation Event Medical Management, **3**:208, 289
 - rare diseases, **3**:282
 - RePORT Expenditures and Results, **1**:35, 36
 - RxNorm, **3**:193, 205, 224
 - Scientific Information System, **3**:206
 - SharePoint for Genome Research, **3**:206
 - SNOMED CT, **3**:193, 205, 224
 - tools and resources, **1**:28, 35, **3**:194
 - Unified Medical Language System, **3**:192-193, 205, 223-224
 - xTrain, **3**:252-253, 265-266
- Infrastructure and research resources (*see also* Grants; Informatics infrastructure; Repositories, databases, and information systems; Training and career development; *specific centers*)
- Alzheimer's disease, **4**:4-11
 - aging-related research, **2**:265, **4**:6
 - animal model development, **1**:28, **2**:97, **3**:50, 66, 106-107, 128, 129-130, 171
 - ARRA funding, **3**:167-168
 - autism, **3**:66, 189
 - autoimmune diseases, **2**:109-110, 112, 113, 115-117, 120, 246, **3**:61, 78, 171-172, 180-181, 217, 236
 - biocontainment laboratories, **2**:80, 99, **3**:66
 - cancer, **1**:3, **2**:1, 2, 4, 5, 7, 9-10, 11, 12-13, 14, 16, 19, 20, 23, 28-29, 208-209, 242, 247, 266, **3**:33, 46-47, 100, 110, 115, 153, 178-179, 194, 206-207, 214, 223-227
 - cardiovascular disease, **2**:11, 181, 251, **3**:194, 115, 206, 225
 - chronic diseases, **2**:142, 147-148, 159, 160, 163-164, 165, 176, 177, 180-181, **3**:24, 45, 155, 172-173
 - clinical and translational research, **1**:13, 14, 23, 28, **2**:1, 5, 9, 10, 11, 12-13, 16, 18, 19, 21-22, 40, 45-46, 47, 57, 59, 88, 97-98, 93, 98, 116, 160, 164, 195, 208-209, 225, 247, 260-262, 266, 267-268, 269, **3**:4-5, 12-13, 50, 51, 64-65, 86-88, 97-98, 100, 105, 107-108, 110, 124, 129-130, 142, 153-154, 155, 156, 165, 167-168, 169-170, 171-172, 175-176, 177-180, 215, 231-232, 236, 239-240, 257
 - clinical practice, **2**:20, 22, **3**:21, 115, 161-162, 163-164, 208-209
 - comparative effectiveness research, **3**:165
 - core facilities management and utilization, **1**:29
 - CORT program, **2**:111, 115, 237, 246, **3**:115, 180-181
 - CTSA program, **2**:243, 268, 269, **3**:105, 115, 116, 134, 168, 173, 174-175, 206, 231-232, 250, 253, 256
 - cyberinfrastructure, **1**:28, **2**:244, 260, 268, **3**:48, 170
 - diabetes research, **3**:66, 77, 78, 141, 144, 173, 240, 279

- Infrastructure and research resources
(*continued*)
extramural construction and improvements, **1**:21, 22, **3**:97-98, 167-168, 216, 231
genomics, **2**:41-42, 82, 97-98, 109, 149-150, 151, 164, 195, 199, 252-253, **3**:10, 19, 33-34, 36, 40, 48-52, 66, 81, 164, 200
High-End Instrumentation program, **1**:23, **3**:66, 98, 168, 215, 230-231
imaging, **1**:28, **2**:9, 15, 39, 62
immunology, **2**:112, 116, **3**:61, 171-172, 217, 236
infectious diseases and biodefense, **2**:71, 72, 74, 79, 80, 82, 90, 93-94, 97-99, **3**:47, 95-96, 124
instrumentation, **1**:28, **2**:21, 22-23, 28, **3**:10
international collaboration, **1**:10, 28, **2**:10, 23, 139-140, 181
intramural, **1**:13, 23, **2**:160, **3**:105
minority health and health disparities, **1**:28, **2**:19, 20, 115, 232, 233, 243-246, 260, 262-263, 265, 266-269, **3**: 116, 168, 171, 175-176, 180-181, 231-232, **4**:6, 32-33
molecular biology and basic research, **2**:9, 10, 11, 18, 19, 20, 28, 78, 80, 94-95, 247, 266, **3**:49, 66, 75, 94-98, 100, 167-168, 178-179, 190, 193, 194, 195, 199, 206-207, 208, 214, 215, 225, 230-231, 236
mobile clinics, **3**:169-170
multidisciplinary studies, **2**:99, 244, 268
neuroscience and neurological diseases and disorders, **2**:31, 39-40, 41-42, 45-46, 47, 56, 57-58, 59, 66, 93, 151, 204-205, **3**:36, 92-93, 115, 127, 142, 194, 197, 207, 214, 225, 227-228
NIH buildings and facilities, **1**:13, 23
Public Trust Initiative, **3**:172
Shared Instrumentation program, **1**:23, **3**:66, 98, 168, 215, 230-231
- Injury, accidents, **2**:282
- Innate Immune Receptors and Adjuvant Discovery Program, **2**:74, 95, **3**:80
- Inner-City Asthma Consortium, **2**:136, 168, 238, 255, **3**:150-151
- Innovative Approaches to Personalizing the Treatment of Depression, **2**:36, 45, 176
- Innovative Technologies for Molecular Analysis of Cancer, **2**:10
- Insight into the Determinants of Exceptional Aging and Longevity, **3**:1
- Insmmed, **4**:21
- Institute of Education Sciences, **2**:219, **3**:15
- Institute of Medicine recommendations, **2**:28, 100-101, 140, 161, 181-182, 193, 202, **3**:158, 165
- Institute on Systems Science and Health, **3**:263
- Institutes and Centers (*see also* individual institutes and centers)
list of, **1**:8-9
- National Advisory Councils/Boards, **1**:12, 13, 34, **2**:68, 85, 87, 102, 184, 228, 245, 258
strategic planning, **1**:17
- Institutional Animal Care and Use Committees, **1**:46
- Institutional Development Award program, **1**:28, **2**:244, 260, 268, **3**:170, 175
- Institutional Review Boards, **1**:45, 46, **3**:189, 198
- Insulin, **2**:13, 19, 107, 113, 138, 120, 143, 153, 170-171, 173, 205, 251, 253, **3**:12, 19, 73, 78, 99, 113, 144, 150, 159, 180
- Insulin Resistance and Glucocorticoids program, **2**:251, **4**:32
- Insurance coverage, **2**:211, 233, 241, 263, **3**:4, 9, 51, 151, 161, 180, 195, 213
- Integrated Preclinical/Clinical Program, **2**:45, **3**:135
- Integrative Cancer Biology Program, **2**:5, 22, 144, **3**:64, 84
- Integrative Neural Immune Interest Group, **3**:255
- Intellectual and learning disabilities, **2**:32, 34, 35, 39, 42, 57-58, 69, 82, 191, 195, 202, 209-210, 214, 228, 260, 228, 239, 260, 277, 283, **3**:91, 113, 148, 164, 220-221, 246, 277, 288-289
- Intellectual and Learning Disability Research Centers, **2**:214
- Intellectual property, **1**:29, 39
- Interagency Autism Coordinating Committee, **2**:35, 42, 203, **3**:119, **4**:47
- Interagency Oncology Task Force, **2**:20, **3**:244, 260
- Interagency Registry for Mechanically Assisted Circulatory Support, **3**:191-192
- Interdisciplinary Health Research Training Program, **3**:257, **5**:19
- Interdisciplinary research (*see also* Collaborative research, Multidisciplinary research, Trans-NIH research, Transdisciplinary research)
aging-related, **3**:14
behavior and social sciences, **2**:133, 155, 210, **3**:89-91, 128, 239
cancer, **2**:14-15, **3**:107-108, 133-134
chronic diseases, **2**:133, 144, 145, 155, **3**:39, 90-91, 128, 130
clinical and translational, **2**:14-15, 57, 98, **3**:107-108, 133-134, 154, 169, 173-174, 239-240, 257
consortia, **3**:173-174, 239-240, **5**:19
end-of-life and palliative care, **2**:197, 210
funding, **1**:22, 269
infectious diseases and biodefense, **2**:74, 98, **3**:154
molecular biology and basic research, **3**:56-57, 64, 84, 89-91, 99-100, 237, 239
neuroscience and neurological disorders, **2**:40, 57, 60, 222, **3**:169, 257
oxidative stress-induced disease, **2**:144
peer review challenges, **1**:5, 33
rehabilitation, **2**:222
- sex and gender factors, **2**:98
training and career development, **2**:21, 57, 210, **3**:169, 257, 261, 264, 268, **5**:19-20
- Interdisciplinary Research Program, **5**:19-20
- Interleukin-15, **2**:27, 101
- Interleukin-17, **2**:111, 118, **3**:79
- INTERMACS (*see* Interagency Registry for Mechanically Assisted Circulatory Support)
- International Bioethics Education and Career Development Award program, **3**:259
- International Centers of Excellence, **2**:76, 81, 85, 140, 181, **3**:123
- International Clinical, Operational, and Health Services Research Training Award, **3**:166, 266-267
- International collaboration
autoimmune diseases, **2**:109, 110, 115, 117, 120-121, 174, 248, **3**:43-44, 78, 118, 137-138, 144
Biomarkers Consortium, **1**:29
cancer, **2**:2, 9, 10, 17, 23, **3**:192, 203, 206, 225
cardiovascular disease, **2**:139-140, 181
chronic diseases, **2**:132, 139-140, 180-182
clinical and translational research, **2**:23, 85
communicating health information, **3**:280
developmental processes and disorders, **2**:41, 199, **3**:34
diabetes, **2**:115, 118, 120, 132
genomics, **3**:29, 30-31, 34, 35, 38, 63, 82, 156
HIV/AIDS, **1**:4, **2**:23, 77, 80-81, 92-93, 98-99, **3**:5, 191, 202, 261-262
infectious diseases and biodefense, **2**:72, 75-76, 80-81, 83, 85, 92-93, 98-102, **3**:191, 202, 261-262
informatics, **3**:194
infrastructure and research resources, **1**:10, 28, **2**:10, 23, 139-140, 181
lung diseases, **2**:140, 181
minority health and health disparities, **2**:242, 247-248, 264, 265, **3**:43-44, 78, 118
National Academies Government-University-Industry Roundtable
International Agreements, **1**:29
neuroscience, **2**:34, 37, 41, 52-53, 196, 199, 206-207, **3**:34
obesity, **2**:140
tobacco-related research, **2**:10, 139-140, 181
- International Council on Active Aging, **2**:158, **3**:284
- International Epidemiologic Databases to Evaluate AIDS, **2**:98-99, **3**:191, 202
- International Health Terminology Standards Development Organisation, **3**:193, 205, 224
- International Opportunities Expo, **3**:258

International Severe Irinotecan Neutropenia Consortium, **3:38**, 114, 156

International Site Development Initiative Perinatal and Pediatric cohorts, **2:77**

International Tamoxifen Pharmacogenetics Consortium, **3:38**, 114, 156

International Tobacco and Health Research and Research Resources Program, **2:10**, 139-140, 181

International Warfarin Pharmacogenetics Consortium, **3:38**, 156

Interstitial cystitis/painful bladder syndrome, **2:128**, 170, 186, 259, 282, **3:22**, 150

Interventions for a Focused Diabetes and Chronic Kidney Disease Disparities Project, **2:263**

Intramural Clinical Research Steering Committee, **1:45-46**

Intramural research

- Board of Scientific Counselors, **1:14**
- Clinical Center, **1:14-15**, 46
- ethical conduct, **1:43**
- guidelines, **1:14**, 44, 45
- extramural/intramural collaboration, **2:24**, 116, 119-120, 135, 197-198
- human subjects protection, **1:44**, 45-46
- infrastructure, **1:13**, 23, **2:160**, **3:105**
- integrity, **1:44**, 45
- laboratory animal welfare, **1:46-47**
- leadership, administration, and oversight, **1:7**, 8, 9, 13-14, 45-47, **2:245**
- program directions and research priorities, **1:14**
- Scientific Directors, **1:14**
- standards of research integrity, **1:44**, 45
- technology transfer, **1:39-40**
- tools and resources, **1:28**
- training and career development programs, **1:7**, 11, 13, 14, 46, **2:20-21**, 242, **3:254-255**, 257-258, 263, 266

Inventions, reporting, **1:39**

IOM (*see* Institute of Medicine)

IPCP (*see* Integrated Preclinical/Clinical Program)

iPREX study, **2:69**

IRBs (*see* Institutional Review Boards)

Irinotecan, **3:38**, 114, 156

Irritable bowel syndrome, **2:127**, 136, 168, 180

Isocitrate dehydrogenase, **2:19**

ITAS Time and Attendance, **3:206**

It's a Noisy Planet. Protect Their Hearing campaign, **3:281**, 287

Ixodes scapularis, **3:30**

J

Jackson Heart Study, **2:262**

Janus kinases, **2:4-5**

Japanese Americans, **2:233**

Job's syndrome, **2:111**, 118, **3:79**

John E. Fogarty International Center (*see* Fogarty International Center)

John Edward Porter Neuroscience Research Center (*see* Porter Neuroscience Research Center)

Joint Working Group on Telehealth, **3:104**

Jointly Sponsored Predoctoral Training Program in the Neuroscience, **3:251**

Juvenile Diabetes Research Foundation International, **2:115**, 118, 174, **3:77**, 137-138

K

K-12 programs (*see* Science education and literacy)

Kaposi sarcoma, **2:23**

Ketamine, **2:36**, 45, 176-177

Kidney diseases

- acute injury, **2:172-173**
- biomarkers, **2:154**, 172-173, 237, 249-250
- cancer, **2:3**, 64, **3:72**, 215, 233
- chronic, **2:125**, 127-128, 154, 186, 231, 237, 263, **3:37**, 276
- communicating health information, **2:259**, **3:114**, 162, 275, 276, 281
- diabetes-related, **2:107**, 114, 120, 125, 126, 127, 132, 154, 237, 249, 259, 263, **3:37**, 103, 114, 144, 162, 275, 276, 281
- ESRD, **2:137**, 171-172, 186, **3:18**
- funding, **2:282**, 286
- genetic factors, **2:132**, 154, 237, 249-250, **3:37**, 276
- hemodialysis, **2:137**, **3:18**
- hereditary nephrolithiasis and kidney failure, **4:41**
- HIV/AIDS-associated, **2:154**, 237, 249
- imaging, **2:154**, 249, **3:37**
- kidney stones, **2:186**
- lupus-induced, **2:111**, 112, 117, 235-236, 248, **3:44**, 78, 118-119
- nephrotic syndromes and nephrosis, **4:41**
- minority health and health disparities, **2:125**, 132, 149, 154, 231, 235-236, 237, 249-250, 255-256, 259, 263, 280, **3:6**, 19, 37, 114, 162, 276, 281, **4:28**
- polycystic, **2:127**, 154, 182, 249, 286, **3:37**
- quality-of-care research, **2:263**
- radiation-induced injury, **2:97**, **3:119**
- rare, **4:41**
- statistics and burden of illness, **2:107**, 186
- strategic plans, **2:182-183**, 270
- transplant and immunosuppressive therapy, **2:115**, 138, 173-174, **3:81**, 138

Knockout Mouse Project, **3:50**

Know Stroke in the Community program, **2:65**, 239, 258-259, **3:284-285**

KRAS gene, **2:14-15**

L

Laboratory animal welfare, **1:7**, 12, 13, 46-47

LABS (*see* Longitudinal Assessment of Bariatric Surgery)

Lactose intolerance, **3:157**, 290

Language/speech impairment, **2:191**, 202, 209-210, **3:148**, 281-282

Large B-cell lymphoma, **2:14**

Lariat Networking Project, **2:244**, 268, **3:170**

Laser treatment, **2:166-167**, **3:141**

Late infantile neuronal ceroid lipofuscinosis, **4:41**

Late Onset Alzheimer's Disease Genetics Initiative, **4:5-6**

Lead poisoning, **2:282**, **3:23-24**

Leap into the Community, **2:261-262**, **3:177**

Learn More Breathe Better® Campaign, **3:278**

Learning (*see also* Intellectual and learning disabilities)

- math and science, **2:214-215**
- reward-related, **2:36**

Leber congenital amaurosis, **2:167**, 195, 215-216, **3:111**, 121, 152-153

Legal mandates for Biennial Report, **1:iii**, v-vi, **5:1-5**

Leishmaniasis, **2:83**, **3:124**

Leukemia

- acute lymphoblastic, **2:4-5**, 17-18, 212, **3:30**, 31
- acute myelogenous, **2:5**
- funding, **2:276**
- genomics, **1:3**, **2:14**, 16, 17-18, 212
- molecular profiling, **2:14**
- relapse, **2:16**, 17-18, 212, **3:153**

Levetiracetam, **2:47**, 137, 162, **3:121**

Lewy body dementia, **4:5**

Life expectancy gains, **1:1**, 2

Life stages research (*see also* Adolescents; Aging; Child health and development; Developmental processes and disorders; End of life; Epidemiological and longitudinal studies; Older adults; Pregnancy; Young adults)

- defined, **2:194**

Lifestyle interventions, **2:7**, 133, 136, 154, 155, 167, 227, 248, 249, **3:30**, 103, 105, 111, 145, 160, **4:32**

LifeWorks®, **1:27**

Limb-girdle muscular dystrophies, **4:20**, 22

Linking Animal Models to Human Disease Initiative, **3:106**, 126

Lithium Use for Bipolar Disorder trial, **2:36**, 45-46, 177, **3:135**

LiTMUS (*see* Lithium Use for Bipolar Disorder)

Liver

- cancer, **2:2**, 3, 5, 23, 233, 282
- disease, **1:18**, **2:3**, 127, 128, 129, 138, 132, 136, 138, 142, 144, 147, 149, 169, 186, 192, 255-256, 276, 282, **3:6**, 19, 108, 122, 148-149, 159, 229, **4:28**
- transplant, **2:115**, 138, 169, 174

LOAD (*see* Late Onset Alzheimer's Disease Genetics Initiative)

Loan Repayment Program for Health Disparities Research, **2:243**, 265, 266

Logical Observation Identifiers Names and Codes nomenclature, **3:193**, 205, 224

- LOINC (*see* Logical Observation Identifiers Names and Codes)
- Long QT syndrome, **2**:127
- Long-Term Oxygen Treatment Trial, **2**:136, 165
- Longevity, **3**:1, 39
- Longevity Assurance Gene Initiative, **3**:39
- Longitudinal Assessment of Bariatric Surgery consortium, **2**:137, 170-171, **3**:18-19, 111, 150
- Longitudinal Mental Health Tracking System, **2**:176, 196, 218-219, **3**:16
- Look AHEAD (Action for Health in Diabetes) trial, **2**:136, 167, 249, **3**:111, 145
- Low back pain, **2**:129, 139, 178, 179
- Louisiana Optical Network Initiative, **2**:268, **3**:170
- Lung (*see also* National Heart, Lung, and Blood Institute; *specific diseases*)
biomarkers, **2**:165
cancer, **2**:3, 5, 6, 7, 15, 16, 18, 20, 23, 24, 48, 158, 159, 282, **3**:1, 8, 10, 16, 30, 32, 42, 46, 50, 90, 93, 110, 190, 199, 200, 209, 216, 230
chronic diseases, **2**:127, 135, 140, 144-145, 149, 150-151, 159, 165, 181, 182, 185, 210, 252, 282, **3**:5, 19, 24, 38, 40, 45, 79, 136, 157, 242
clinical and translational research, **2**:136, 165, **3**:136, 157
epidemiological and longitudinal studies, **2**:150-151, **3**:5, 38
funding for research, **2**:278, 282
genomics, **2**:150-151, 159, **3**:5, 24, 45, 38
H1N1 replication in, **2**:78, 94, **3**:125
imaging, **2**:15, 149, 252, **3**:230
international initiatives, **2**:140, 181
microbiome of HIV infected people, **2**:74, 90-91, 251
oxygen therapy, **2**:136, 165
radiation-induced injuries, **2**:80, 97, **3**:123
technology development, **3**:242
training and career development, **2**:210, 140
- Lupus (*see* Systemic lupus erythematosus)
- Lutein/zeaxanthin, **2**:137
- Lyme disease, **2**:72, 283, **3**:30
- Lymphoma, **2**:14, 281, **3**:110, 134
- Lymphoma/Leukemia Molecular Profiling Project, **2**:14, **3**:134
- Lymphoproliferative disorders, **2**:81, 112, **3**:60
- Lysosomal storage disorders, **2**:32, 40, 60, 163, **3**:142, **4**:41
- M**
- MACS (*see* Multicenter AIDS Cohort Study)
- Macular degeneration, **2**:67, 128, 129, 137, 140-141, 173, 183, 187, 193, 196, 211, 227, 283, **3**:77, 152
- Macular edema, **2**:166-167, **3**:141
- Magnesium sulfate, **2**:34
- Magnetic resonance imaging, **2**:24, 35, 40, 43, 58-59, 62, 131, 147, 149-150, 154, 200, 207, 249, 252, **3**:5, 19, 37, 40, 107, 132, 215, 218, 228, 229, 242, **4**:7, 8
- Magnetic Resonance Imaging Study of Normal Brain Development, **2**:35, 43, 200
- Magnetoencephalography, **2**:45, 176-177, **3**:135
- Magnuson Clinical Center, **1**:14
- Malaria, **1**:4, **2**:71, 72, 73, 74, 75-76, 80, 81, 82, 85, 90, 93, 96, 102, 141, 283, **3**:11, 30, 39, 106, 110, 122, 123, 213, 251
- Malignant gliomas, **2**:17, 19, 64
- Malnutrition, **2**:74, 99-100, 217
- Management of research (*see also* Peer review)
improving, **1**:33-38
- Manganese poisoning, **3**:98-99
- Marburg virus, **2**:79, 95, **3**:112, 155
- Marfan syndrome, **2**:127
- Mark O. Hatfield Clinical Research Center, **1**:14
- Massage therapy, **2**:27-28, 66, 138, 175, **3**:23, 94
- Maternal and Fetal Medicine Network, **2**:201, 224, **3**:110, 153
- Mathematical modeling of disease, **2**:89, 91, **3**:125, 170
- Mathematics and Science Cognition and Learning program, **2**:214-215
- Matrix metalloproteases, **2**:50, 139, 178, **3**:71
- Medical cost savings, **1**:2
- Medical Countermeasures Against Radiological and Nuclear Threats, **2**:66, 96-97, 103, **3**:120
- Medical GPS, **3**:211, 215, 228-229
- Medical Research Council UK, **3**:159
- Medical Scientist Training Program, **3**:251, 256, **5**:15
- Medulloblastoma, **2**:17, 24
- Melanoma, **2**:18, 23, **3**:30, 32, 46
- Meningitis, **1**:2, **2**:82, 191
- Meningococemia, **3**:185
- Menopausal Symptoms**1**: Finding Lasting Answers for Sweats and Hot Flashes (MS FLASH), **2**:206
- Mental health (*see also* Alzheimer's disease; Substance abuse and addiction)
adolescents, **2**:235, 238, 254, **3**:9, 139, 281
AIDS-associated, **2**:35, 45, 46, 77, 86, 176, **3**:15, 135-136
alcoholism comorbid with, **2**:41-42, 66-67, 129, 151, 157-158, 160-161, 224, **3**:16, 21, 36, 139, 177
bipolar disorder, **2**:36, 45-46, 129, 161, 177, **3**:16, 35-36, 135, 281
cardiovascular disease and, **3**:134, 160
children, **3**:281
clinical and translational research, **2**:45-46, 66-67, 176-177, 203, **3**:20, 110, 135-136, 139, 146-147
communicating information on, **3**:278, 281
comorbid conditions, **2**:66-67, 129, 134, 157-158, 160-161, 224, **3**:15, 16, 139
dementias, **2**:33
depression, anxiety, and other mood disorders, **2**:27-28, 32, 34, 35, 36, 38, 41, 45-46, 53, 60, 67, 98, 127, 128-129, 134, 151, 160-161, 176-177, 188, 192, 206, 222, 235, 254, 277, **3**:16, 36, 94, 110, 135, 135-136, 139, 141, 154, 245, 281
drug development, **2**:4, 36, 45-46, 160, 176-177, **3**:135-136
epidemiological and longitudinal studies, **2**:176, 196, 218-219, 238, 254, **3**:7, 9, 16, 20, 146-147
families, **2**:133-134, 157-158, 224, **3**:21
funding, **2**:283, 287, 289
genomics, **2**:161, **3**:35-36, 49
military personnel and veterans, **2**:157-157, 224, **3**:7, 15, 20, 146-147
minority health and health disparities, **2**:235, 238, 241, 251, 254, 261, **3**:9, 177, **4**:28
older adults, **2**:203
post-traumatic stress disorder, **2**:32, 40, 60, 133-134, 157, 222, 224, 256, **3**:15, 281
quality of care, **2**:160
schizophrenia and psychoses, **2**:31, 32, 119, 128, 161, 177, 192, 287, **3**:28, 30, 35-36, 88, 134-135
social phobia, **3**:16
statistics and burden of illness, **2**:33, 188
strategic plans, **2**:226
suicide, **2**:28, 235, 238, 254, 261, 289, **3**:7, 9, 20, 62, 99, 146, 177
- Mentored Clinical Scientist Research Career Development Award, **3**:253, 267
- Mentored Patient-Oriented Research Career Development Award, **3**:253, 267
- Mentored Quantitative Research Career Development Award, **3**:253-254
- Mercury, **2**:111, 119, **3**:23-24, 65, 88
- Mercury Induced Autoimmunity Project, **2**:119, **3**:88
- Merkel cell carcinoma, **2**:23
- Meropenem, **2**:75, 84, **3**:138
- MESA (*see* Multi-Ethnic Study of Atherosclerosis)
- Metabolic modeling, **2**:84, 144
- Metabolic research, **2**:159-160
- Metabolic syndrome, **2**:192, **4**:32
- Metabolomics, **1**:4, **2**:19, 80, 97, **5**:22
- Metformin, **2**:133, 136, 154, 155, 169, 248, **3**:103, 148, 160
- Methamphetamine, **2**:254, 283, **3**:8-9, 204
- Methicillin-resistant *Staphylococcus aureus* (MRSA) infection, **2**:73, 74, 96, **3**:31, 39, 122
- Methodological and Technological Innovation in the Behavioral and Social Sciences Program, **5**:20

- Mexican Americans, **2**:149, 234, 235, 255, 263, **4**:32
- MHIRT (*see* Minority Health and Health Disparities International Research Training)
- MI/CCP (*see* Minority Institution/Cancer Center Partnership)
- Microarray technology, **1**:3
- Microbial Sequencing Centers, **2**:96, **3**:39, 122
- Microbicide Innovation Program, **2**:85, **3**:159
- Microbicide Trials Network, **2**:85, **3**:159
- Microbiomics, **1**:3, 47, **2**:74, 84, 90-91, 144, 251, **3**:31, 32, 34-35, 62-63, 82-83, 85, 244
- Mid-Atlantic HERC, **3**:258
- Midazolam, **2**:66, 96, **3**:120
- Military personnel, veterans, and families, **2**:33, 40, 60, 61, 133-134, 157-158, 221-222, 224, **3**:7, 20, 21, 146-147, 159, 237-238, 246-247
- Millennium Promise Awards**1**:
Noncommunicable Chronic Diseases Research Training Program, **2**:140, 182
- Mind and body research, **2**:283
- Minority health and health disparities (*see also* National Center on Minority Health and Health Disparities; NCMHD Centers of Excellence; *specific minorities*)
adolescents, **2**:234, 235, 251, 254, 263, **3**:9, 204
aging-related research, **2**:220, 250, 253, 265, **4**:6
alcohol use and alcoholism, **2**:213, 238, 241, 255, 261, **3**:17, 177
Alzheimer's disease, **2**:231, **4**:6
ARRA appropriations, **2**:236, 265, 274-290, **3**:168, 231-232, **4**:6
asthma, **2**:132, 136, 149, 168-169, 234-235, 238, 255-256, **3**:6, 19, 30, 45, 150-151
autoimmune diseases, **2**:115-116, 117-118, 246, 247-248, 280, **3**:43-44, 78, 118-119, 180-181, **4**:28
behavioral and social sciences research, **2**:237, 246-247, 251, **4**:32
bioinformatics tools and training, **2**:268
bone health, 262
cancer, **2**:1, 2, 3, 4, 5, 6, 7, 8, 12, 13, 16, 19, 20-21, 22, 24-25, 132, 153, 154, 205, 233, 235, 239, 241, 242-243, 247, 248, 253, 261, 262, 266, 280, **3**:12, 21, 97, 100, 153, 160, 163-164, 176-177, 178-179, 208-209, 260, 278, **4**:28, 29-30, 31
cardiovascular disease, **2**:13, 24-25, 65, 132, 149-150, 153, 154, 167, 205, 220, 231, 233-234, 237, 238, 248, 249, 250, 251, 252-253, 261, 262, **3**:6, 19, 40, 175-176, 177, **4**:28, 32
child health and development, **2**:168-168, 234-235, 238, 241, 255, 263-264, **3**:150-151
chronic diseases, **2**:132, 136, 149-150, 152-153, 154, 158, 167, 168-169, 210, 237, 248, 249-250, 252-253, 255-256, **3**:6, 19, 35, 37, 40, 111, 145, 150-151, 160
clinical and translational research, **1**:13, **2**:12, 16, 19, 20, 22, 65, 115, 117-118, 136, 154, 167, 236-238, 245-246, 247-248, 249, 259-262, 263-264, 266, 267-269, **3**:43-44, 78, 97, 100, 104, 110, 111, 118-119, 145, 151, 154-155, 168, 171, 175-177, 178-179, 231-232, 281
clinical practice, **2**:92, 133, 154, 182, 248, 259, 263, **3**:103, 160, 162-163
communicating health information to, **2**:19, 20, 216, 231, 239-240, 256-259, 260, 264, 266, **3**:162, 163, 276, 278-279, 281, 283, 286-287, 289-290, **4**:28, 31
community-based participatory research, **2**:19, 220, 240-241, 250, 260-262, **3**:175-177, 278-279
comparativeness effectiveness research, **2**:266, 268, **3**:175
contributing factors, **2**:231
COPD, **2**:149, 255-256, **3**:6, 19, **4**:28
defined, **4**:27
dental caries and periodontal diseases, **2**:149, 235, 239, 241, 255-256, 260, 263-264, 270, **3**:6, 19
diabetes, **2**:132, 133, 136, 149, 152-153, 154, 167, 234, 237, 248, 249, 251, 255-256, 259, 261, 263, **3**:6, 19, 35, 103, 111, 143-144, 145, 160, 162, 176-177, 276, 281, 296, **4**:28, 32, 33
diagnosis/screening, **2**:233
digestive diseases, **2**:259, **3**:162, 281
environmental health issues, **2**:240, 258, **3**:289-290
epidemiological and longitudinal research, **2**:5, 12-13, 24-25, 65, 77, 86, 92, 132, 149-150, 153, 159, 205, 208-209, 213, 216, 235, 238, 252-256, 262, **3**:4-5, 6, 7-8, 9, 12-13, 15-16, 17, 19, 24, 40, 45, 51, 64-65, 86-87, 148, 177-178
eye diseases, **2**:231, 235
fetal alcohol syndrome, **2**:213, 238, 255, **3**:17
framework for addressing, **2**:232
funding for research, **2**:236, 238, 242-243, 265, 274-290, **3**:168, 231-232
genetic vulnerabilities, **2**:117-118, 132, 149-150, 152-153, 154, 231, 236-237, 247-248, 249-250, 252-253, **3**:19, 30, 35, 37, 40, 43-44, 78, 118-119, **4**:31
HIV/AIDS, **1**:47, **2**:77, 87, 90-91, 92, 154, 231, 234, 237-238, 239, 241-242, 245-246, 250, 258, 261, 263, 269, **3**:15-16, 148, 170, 177, 290, **4**:28, 32
inclusion of minorities in research, **1**:13, **2**:245, **3**:154-155, **4**:6, **5**:27-36
infant mortality, **2**:231, 234, **4**:28
infectious diseases and biodefense, **1**:47, **2**:72, 75, 77, 87, 90-91, 92, 154, 231, 234, 237-238, 239, 241-242, 245, 250, 251, 258, 263, 269, 280, **3**:15-16, 148
infrastructure and research resources, **1**:28, **2**:19, 20, 115, 232, 233, 243-246, 260, 262-263, 265, 266-269, **3**: 116, 168, 171, 175-176, 180-181, 231-232, **4**:6, 32-33
international programs, **2**:242, 247-248, 264, 265, **3**:43-44, 78, 118
kidney disease, **2**:125, 132, 149, 154, 231, 235-236, 237, 249-250, 255-256, 259, 263, 280, **3**:6, 19, 37, 114, 162, 276, 281, **4**:28
liver disease, **2**:149, 255-256, **3**:6, 19, **4**:28
loan repayment programs, **2**:243, 265
lupus, **2**:115, 117, 231, 235-236, 237, 246, 247-248, **3**:43-44, 78, 118-119, 180
mental illness, **2**:235, 238, 241, 251, 254, 261, **3**:9, 177, **4**:28
mobile medical research vehicles, **2**:220, 250
molecular biology and basic research, **2**:19, 20, 117-118, 236, 246-248, 266, **3**:43-44, 78, 97, 100, 118-119, 178-179
multidisciplinary collaborations, **2**:19, 231, 232, 236, 244, 247, 255, 268
neurological disease, **2**:33, 63, 65, 239, 258-259, 280, **3**:141-142, 253, 284-285
NIH Science of Eliminating Health Disparities Summit, **2**:232-233
nurses/nursing, **2**:260
obesity, **2**:132, 150, 234, 251, 252, 259, 261, **3**:114, 162, 177, 281, **4**:28, 30, 31
opportunities for research, **1**:4, 22
oral health care, **2**:216, 235, 239, 241, 260, 263-264, **3**:151, 289
osteoarthritis, **2**:115, 246, **3**:181
outreach, **2**:216, 231, 239-240, 256-257, 260, **3**:289
population distribution of minorities, **2**:231
pregnancy outcomes, **2**:213, 238, 255, **3**:17, **4**:32
psoriasis, **2**:115, 246, **3**:181, **4**:28
public-private partnerships, **2**:239-240, 258, **3**:280-290
quality of care for Medicare recipients, **2**:263
research plus outreach, **2**:240-242, 258, 260-264
rheumatic diseases, **3**:278-279
scleroderma, **2**:237, **4**:28
screening and diagnosis, **2**:233
sickle cell disease, **2**:125, 128, 139, 179-180, 187, 231, 259, 284, **3**:27, 108, 114, 122, 133, 162, 281
SIDS, **2**:238, 239, 259, **3**:285-286
sleep disorders, **3**:149, 255-256, **3**:6, 19
statistics and burden of illness, **2**:231, 233-236, **4**:28-30

- Minority health and health disparities
(*continued*)
strategic plan and budget, **1**:17, 18,
2:232, 233, 269-270, **4**:30
stress, **2**:231, 251
stroke, **2**:65, 132, 149, 167, 231, 233-234,
238, 239, 249, 253, 255-256, 258-259,
3:6, 19, 284-285, **4**:28, 29
substance abuse treatment interventions,
2:92, 241-242, 254, 261, 263, **3**:8-9, 162-
163, 175-176, 177
suicide, **2**:235, 238, 261, **3**:177
summit, **2**:232
technology development, **2**:247, 269,
3:168, 231-232, 246, **4**:31, 33
tobacco-related, **2**:12, 19, 247
training and career development, **2**:19,
20-21, 216, 232, 233, 239-240, 241-244,
247, 251, 256, 257-258, 260, 262, 264-
265, 266-267, 268, **3**:97, 100, 179, 195,
210, 260, 261, 278, 288-289, **4**:28
trans-NIH research, **2**:232
transdisciplinary research, **2**:19
women's health, **2**:233, 234, 235-236,
237, 241, 244, 245, 270, **3**:154-155, **4**:32
- Minority Health and Health Disparities
International Research Training Program,
2:242, 264, 265
- Minority Health and Health Disparities
Research and Education Act of 2000,
4:27
- Minority Institution/Cancer Center
Partnership, **2**:20, 242, 266, **3**:97, 179
- MISMS (*see* Multinational Influenza Seasonal
Mortality Study)
- Miyoshi myopathy, **4**:20
- Mobile medical research vehicles, **2**:220, 250
- Modafinil, **2**:135
- Modeling and simulation
cancer, **2**:20, **3**:84
flux-balance analysis (network map),
2:73, 82, 84, 130, 144, **3**:84-85, 243-244
HIV infection/AIDS, **2**:89, 91
systems science approaches, **3**:65-66,
169, 262
tools and resources, **2**:20, **3**:90, 209
virtual experiments, **3**:64
- Model ENCODE project, **3**:28, 35
- Models of Infectious Disease Agent Study,
3:66
- Moffitt Transdisciplinary Center, **4**:28
- Molecular biology and basic research (*see*
*also specific classes of diseases, diseases,
disorders, and organs*)
aging-related research, **2**:25, 194, 200,
3:77, 91, 113, 164, 220-221, 246
ARRA funding, **2**:81-82, 114, **3**:80, 90,
97-98, 167-168, 215, 230-231
behavioral and social science research,
2:20, 46-47, 48, 141, 155, 175-176, 246-
247, 275, **3**:22-23, 36, 47, 55-56, 65-66,
89-94, 113, 128, 164, 209, 220-221, 227-
228, 239, 246
bioinformatics and computational
biology, **2**:73, 82, 84, 130, 144, 152, 210,
3:56, 61, 65-66, 68, 84-85, 243-244
biomaterials, **3**:76, 246
blood storage for transfusions, **3**:76
cell and molecular biology, **1**:27, **2**:21,
25, 26, 49-50, 51, 56, 57, 64, 81-82, 83-
84, 93, 95-96, 97, 111, 113, 114, 117-119,
120, 129, 140-141, 142-143, 172, 173-
174, 194, 200, 208, 217, 223, 237, 247-
248, **3**:38, 43-48, 55, 56, 59-61, 74-81,
118-119, 123, 130-131, 144-145, 232-
233, 238, 244, **4**:20
child health and development, **2**:175-176,
3:22-23, 38, 79, 93-94
chronic diseases, **2**:48, 49-50, 84, 126,
129-130, 140-145, 152, 155, 158, 163,
172-174, 175-176, 177-178, 217, **3**:22-23,
70-71, 73, 74, 79, 81, 84-85, 90-91, 93-
94, 127, 128, 139, 144-145, 179, 210,
243-244
clinical and translational research, **3**:57,
83, 87-88, 91, 97, 98, 113, 128-129, 164,
168, 215, 216-217, 220-221, 230-231,
235, 237, 246
dental and orofacial disorders, **2**:216-217,
3:67-68, 234-235
developmental processes and disorders,
2:192, 198-199, **3**:57, 59-60, 64-65, 85-
86
diabetes, **2**:64, 112-113, 118-119, 120,
140-141, 194, 199, **3**:49, 58, 60, 66, 68,
76, 77, 78, 81, 98, 99, 120-121
drug development, **3**:56, 57, 59, 60, 62,
64, 68, 94-95, 245
environmental factors, **2**:5, 12-13, 21-22,
44, 53-54, 93, 98, 119, 198-199, 208-209,
225-226, **3**:4-5, 12-13, 51, 64-65, 85-89,
131, 177-178
epigenetics, **2**:25, 28-29, 36, 44, 46, 193,
194, 198-199, 200, 218, **3**:36, 47-48, 49-
50, 56, 62, 77, 81, 83, 85-86, 92-93, 227-
228
funding, **2**:98-101, 275, **3**:75, 98-101
genomics, **2**:12, 14-15, 22, 46, 97, 108,
117-119, 247-248, **3**:43-44, 47, 56, 61,
62, 64-65, 77, 78, 82, 83, 91, 118-119,
123, 134
glycomics, **3**:63-64, 83, 129, 237
imaging tools, resources, and
applications, **1**:3, **2**:4, 15, 22, 25, 60, 62,
3:96, 97, 128-129, 216-217, 219, 235,
243
immunobiology and inflammation, **2**:26,
81-82, 93, 94, 95, 114, 118, 143, **3**:58,
60-61, 64, 79, 80, 94-96, 144-145
infrastructure and resources, **2**:9, 10, 11,
18, 19, 20, 28, 78, 80, 94-95, 247, 266,
3:49, 66, 75, 94-98, 100, 167-168, 178-
179, 190, 193, 194, 195, 199, 206-207,
208, 214, 215, 225, 230-231, 236
interdisciplinary research, **3**:56-57, 64,
84, 89-91, 99-100, 237, 239
metabolomics, **2**:84, **3**:56, 63
microbiomes, **1**:3, 47, **2**:74, 84, 90-91,
144, 251, **3**:31, 32, 34-35, 62-63, 82-83,
85, 244
minority health and health disparities,
2:19, 20, 117-118, 236, 246-248, 266, **3**:
43-44, 78, 97, 100, 118-119, 178-179
model organisms and systems, **2**:21-22,
46-47, 84, 144, 208, 216-217, 224-225,
3:43-44, 56, 57, 58-59, 67-68, 78, 84-85,
87-88, 118-119, 234-235, 243-244
molecular mechanisms, pathways, and
networks, **2**:22, 26-27, 42-43, 46-47, 49-
50, 52, 64-65, 175, 177-178, 214, **3**:55,
56, 59, 68-74, 120-121, 233, 242-243
multidisciplinary collaborations, **3**:90
neuroscience, **2**:31, 32, 36, 40, 42-44, 46-
47, 48, 49-50, 51-52, 53-54, 61, 62, 64-
65, 129, 141, 159, 177-178, 214, 217-218,
3:14, 36, 59, 61, 70-71, 72, 73-74, 85, 92-
93, 99, 120-121, 227-228, **4**:20
pain, **2**:45, 49-50, 139, 177-178, 179-180,
3:59, 70-71, 133
phosphorylation modeling, **3**:84
proteins and proteomics, **1**:4, 30, **2**:2, 7-8,
9, 11, 12, 22, 73, 82, 97, 108, 143, 195,
208, 214, **3**:37, 41, 55, 56, 57, 59, 61, 62,
63, 64-65, 68, 82, 99, 123, 243, 244
registries, databases, and information
systems, **3**:61-62, 75, 95, 96, 193, 195,
206, 208, 236
reproductive health, **3**:87-88
stem cells, **2**:21, 51, 83-84, 130, 142-143,
200, 217, 223, **3**:37, 60, 74, 75, 76, 82,
130-131, 233, 238
space-related research, **3**:100-101, 238-
239
structural biology, **3**:63, 96, 219, 243
substance abuse and addiction, **2**:43-44,
46, 48, 49, 90, 129, 142, 158, 217-218,
3:14, 36, 92-93, 227-228
systems biology, **2**:5, 22, 73, 82, 84, 144,
3:20, 56, 57, 64, 84-85, 96, 97, 100, 128,
195, 206, 235, 237, 243-244, 251
taste receptors, **3**:73
technology development, **2**:26-27, 46, 83,
223, **3**:36, 41, 55, 61, 66, 68, 69, 75, 76,
82, 83, 87, 89-90, 91, 92-93, 94-100, 113,
128-129, 164, 130-131, 167-168, 195,
208, 215, 216-217, 219, 220-221, 227-
228, 230-231, 233, 235, 236, 237, 238,
239, 243, 245, 246
toxicology testing, **3**:87
trans-NIH research, **3**:34-35, 82-83, 89
transcriptomics, **3**:56, 61, 63
- Molecular Imaging Program, **2**:15, **3**:230,
5:20-21
- Molecular Libraries Initiatives, **3**:188, 193,
197, 209, 212, 214, 226, **5**:20-21
- Molecular Therapy Centers for Cystic Fibrosis
and Other Genetic Metabolic Diseases,
2:135, 163-164, **3**:172-173
- Monitoring the Future Survey, **2**:254, **3**:8-9,
192, 204
- Monoclonal antibodies, **2**:16, 17, 57, 64

- Mood (*see* Mental health)
- Morphine, **2:91, 3:170**
- Morris K. Udall Centers for Excellence in Parkinson's Disease (*see* Udall Centers for Excellence in Parkinson's Disease)
- Mouse Models of Human Cancer Consortium, **2:18**
- Mr. OS, **2:149, 212-213, 3:10**
- MRSA (*see* Methicillin-resistant *Staphylococcus aureus*)
- MS (*see* Multiple sclerosis)
- MSTP (*see* Medical Scientist Training Program)
- MTF (*see* Monitoring the Future)
- Mucociliary clearance disorders, **4:40**
- Mucopolidosis type IV, **4:41**
- Mucopolysaccharidosis, **2:163-164, 283, 3:172-173, 4:41**
- Multi-Ethnic Study of Atherosclerosis, **2:132, 149-150, 159, 252-253, 3:5, 19, 24, 40, 45**
- Multicenter AIDS Cohort Study, **2:77, 86, 92, 2:15-16, 148**
- Multidisciplinary Approach to the Study of Chronic Pelvic Pain Research Network, **2:170, 3:22, 110, 150**
- Multidisciplinary research (*see also* Collaborative research, Interdisciplinary research, Trans-NIH research, Transdisciplinary research)
- aging-related, **2:211, 3:9, 4:15**
 - alcoholism, **2:41-42, 151, 3:36**
 - autoimmune diseases, **2:108**
 - behavioral and social sciences, **3:90**
 - cancer, **2:5, 10, 18, 19, 23, 247, 3:100, 178-179**
 - chronic diseases, **2:48, 50, 130, 139, 144-145, 151, 158, 170, 178, 179-180, 3:22, 70-71, 93, 133, 152**
 - cystic fibrosis, **2:130, 145**
 - epidemiological and longitudinal studies, **3:2, 4, 5, 9, 14, 17, 22**
 - fetal alcohol effects, **2:213, 255**
 - funding, **1:12, 22, 29**
 - genetic, **2:41-42, 130, 151**
 - ICBP, **2:5**
 - infectious diseases and biodefense, **2:23, 76, 85, 92, 99, 3:123**
 - infrastructure and research resources for, **2:99, 244, 268**
 - minority health and health disparities, **2:19, 231, 232, 236, 244, 247, 255, 268**
 - molecular biology and basic research, **3:90**
 - neuroscience and neurological disorders, **2:31, 32, 41-42, 44, 48, 50, 54, 151, 158, 178, 179-180, 217-218, 3:14, 36, 70-71, 85, 92, 93, 133**
 - oxidative stress-induced diseases, **2:130**
 - pain, **2:50, 139, 170, 178, 179, 3:133**
 - rehabilitation, **2:221-222**
 - substance dependence/addiction, **2:41-42, 43-44, 48, 151, 158, 217-218, 3:14, 92**
 - training programs for researchers, **2:92, 3:256, 259-260**
 - TREK initiative, **2:18-19**
 - urology research, **2:170**
- Multimodal Treatment Study of Children with ADHD, **2:136, 167-168, 213, 3:14-15**
- Multinational Influenza Seasonal Mortality Study, **2:78, 100**
- Multiparameter intelligent monitoring in intensive care system, **211, 223**
- Multiple myeloma, **2:6**
- Multiple sclerosis, **2:32, 34, 35, 39, 56, 63, 107, 109, 110, 113, 115, 119-120, 126, 138, 174, 283, 3:60, 137, 141-142, 143**
- Multiplex Initiative, **3:30, 33, 164**
- Muscle recovery after injury, **2:163, 3:127**
- Muscular dystrophies (*see also* Wellstone Muscular Dystrophy Cooperative Research Centers), **1:18, 2:32, 39, 56, 63, 64, 68, 69, 163, 223, 278, 279, 284, 3:71, 75, 120-121, 122, 127, 130, 166, 191, 238, 4:19-23**
- Muscular Dystrophy Community Assistance, Research, and Education Amendments of 2001, **4:19**
- Musculoskeletal disorders (*see also specific disorders*), **2:116, 128, 162, 187, 192, 3:127**
- Mutant Mouse Regional Resource Centers, **3:50, 66, 128**
- Myasthenia gravis, **2:284, 3:50**
- Myc-induced tumorigenesis, **2:18**
- Myotonic dystrophy, **2:284, 4:19, 20, 22**
- ## N
- N-acetylcysteine, **2:136, 165, 169, 3:148**
- Nanomedicine, **3:212, 5:21**
- Nanotechnology, **1:3, 22, 47, 48, 2:4, 7, 8, 9, 10, 14, 25, 37, 45, 50-51, 176, 223-224, 284, 3:134, 135, 211, 216, 218-219, 220, 234, 241-242, 245-246**
- Nanotechnology Characterization Laboratory, **2:10**
- Nanotechnology Task Force, **3:241**
- National Academies, **1:29, 35, 3:248, 252, 280**
- National Advisory Council for Biomedical Imaging and Bioengineering, **3:230**
- National Advisory Mental Health Council Workgroup on Research Training, **3:266**
- National Aeronautics and Space Administration, **3:100-101, 213, 218, 238-239**
- National Alzheimer's Coordinating Center, **4:5, 6, 7**
- National Assessment of Adult Literacy, **3:277**
- National Cancer Institute (*see also* Cancer; *specific cancers, organs, and programs*)
- animal models, **2:18**
 - ataxia-telangiectasia, **2:29, 3:142**
 - autoimmune diseases, **2:116, 117-118, 120-121, 122, 247-248, 3:42-43, 78, 118-119, 144, 171-172, 236**
 - behavioral and social sciences research, **2:152, 155, 180, 246-247, 3:47, 89, 90-91, 128, 145, 174, 261**
 - biostatistics, **3:260**
 - Cancer Centers, **2:2, 9, 10, 11, 16, 266, 3:97, 110, 153, 179, 206, 225**
 - Center for Applied Preclinical Research, **2:18**
 - chronic diseases and organ systems, **2:23, 46, 48, 147, 148, 152, 154, 155, 157-158, 159, 169, 180-181, 182, 184, 204, 210, 249-250, 3:20, 21, 37, 42, 90-91, 93, 128, 145-146**
 - clinical and translational research, **2:8, 10, 14, 16, 18, 29, 117-118, 120-121, 147, 155, 169, 180, 204, 208-209, 224, 247-248, 261-262, 3:12-13, 21, 56-57, 78, 83, 86-87, 90-91, 97, 100, 108, 110, 117, 118-119, 128-129, 132, 133-134, 142, 144, 145-145, 148-149, 153-154, 156, 161, 163-164, 165, 169, 171-172, 174, 176, 177-179, 180, 181, 208-209, 236, 237, 241, 259**
 - communicating information, **2:15-16, 19, 247, 264, 3:100, 161, 163, 172, 179, 283**
 - community-based participatory research, **2:261-262, 3:172, 176, 179**
 - Community Cancer Centers Program, **2:9, 11, 16, 3:110, 206, 225**
 - comparative effectiveness research, **2:20, 3:90, 148-149, 165, 209**
 - Cooperative Group Program, **2:16, 3:153**
 - cost-effectiveness analysis, **3:156**
 - developmental processes and disorders, **2:12-13, 214, 3:12-13, 56-57, 86-87, 177-178**
 - diabetes research, **2:69, 120-121, 148, 228, 3:20, 144**
 - diagnostics/screening, **2:14, 15, 16-17, 24-25, 3:21, 46, 83, 128-129, 133-134, 230, 241**
 - digestive diseases, **2:18-19, 122, 185**
 - Down Syndrome, **2:69, 214, 228**
 - drug development, **2:8, 15, 3:108, 132, 133-134**
 - end-of-life care, **2:180, 204, 3:145-146**
 - environmental exposures and risk factors, **2:12-13, 24, 148, 208-209, 3:12-13, 20, 36-37, 56-57, 86-87, 92-93, 144, 177-178, 227-228**
 - epidemiological and longitudinal studies, **2:2, 14, 18-19, 24-25, 86, 98-99, 148, 157-158, 208-209, 219, 3:7-8, 12-13, 15, 20, 21, 46, 56-57, 177-178, 202, 203, 208-209**
 - Experimental Therapeutics Program (NExT), **2:8, 15**
 - extramural research, **2:2, 11, 12, 14, 15-21, 23, 23-25**
 - Fragile X Syndrome and associated disorders, **2:69, 214, 228**
 - Frederick Small Animal Imaging Program, **2:15**

- National Cancer Institute (*continued*)
 genomics/genetics, **2**:12-13, 17-19, 22, 23, 24-25, 28-29, 46, 59-60, 64-65, 154, 159, 208-209, 214, 247-248, 249-250, 266, **3**:8, 12-13, 28, 34-35, 36-37, 42, 43-44, 46-47, 56-57, 78, 82-83, 84, 86-87, 91, 92-93, 96, 118-119, 142, 177-178, 199, 206, 227-228
 global health, **2**:28, 100-101, 181-182, **3**:181, 259-260
 glycomics, **3**:83, 128-129, 237
 HIV/AIDS, **2**:23, 72, 86, 92-93, 98-99, **3**:15, 202, 261-262
 imaging tools, resources, and applications, **2**:15, 22, **3**:96, 228-229, 230, 243
 immunologic and antiviral approaches, **2**:27, 101, 116
 infectious diseases and biodefense, **2**:23, 27, 72, 86, 92-93, 98-99, 101, 103, **3**:15
 infrastructure and research resources, **2**:2, 9, 11, 12-13, 16, 19, 224, 247, **3**:46-47, 75, 90, 96, 100, 153, 178-179, 194, 203-204, 206-207, 209, 236
 intellectual and developmental disabilities, **2**:214
 interdisciplinary research, **2**:155, **3**:261
 international initiatives, **2**:11, 16, 23, 92-93, 98-99, 180-181, 182, **3**:42-43, 202, 259-260, 261-262
 intramural research, **2**:2, 8, 11, 14, 15, 16-17, 18-19, 20-21, 22, 23-25, 37
 investments in research, **2**:7, 10
 kidney diseases, **2**:154, 249-250, **3**:37
 liver diseases, **2**:169, 185, **3**:148-149
 lupus, **2**:117-118, 247-248, **3**:42-43, 78, 118-119
 metabolic research, **2**:18-19
 microbiomics, **3**:34-35, 82-83
 minority health and health disparities, **2**:12-13, 16, 19, 20, 219, 242-243, 246-250, 261-262, 264, 266, **3**:12-13, 37, 78, 86-87, 97, 100, 118-119, 163, 176, 177-179
 mission, **5**:7
 molecular biology and basic research, **2**:20, 21, 22, 46, 64-65, 155, 208-209, 247-248, **3**:12-13, 34-35, 36-37, 46-47, 56-57, 69-70, 72, 75, 78, 82-83, 84, 86-87, 89, 90-91, 92-93, 96, 97, 100-101, 118-119, 128-129, 133-134, 177-179, 209, 227-228, 237, 238-239, 243, 244-245
 multidisciplinary initiatives, **2**:10, 18-19, 23, 48, 92-93, 158, 247, **3**:93, 100
 nanotechnology, **2**:14, **3**:123, 241-242
 neurological research, **2**:16, 17, 28-29, 46, 48, 59-60, 64-65, 68, **3**:72, 92-93, 142, 153-154, 227-228
 obesity, **2**:18-19, 23, 152, 159, 182, 184, 210, **3**:12-13
 pediatric oncology, **2**:16, 17, 169, 212, **3**:153-154
 population health, **2**:219, **3**:7-8, 100, 169, 179
 prevention trials, **2**:16-17
 proteomics, **2**:12-13, 22, 208-209, 214, **3**:96, 206, 244-245
 quality-of-care research, **2**:9, 22, **3**:21, 163-164, 208-209
 quality-of-life research, **2**:180, **3**:145
 rare disorders, **2**:59-60, **3**:142
 registries, databases, and information systems, **2**:2, 11, 14, 17, 20, 22, 23, 28-29, 98-99, 159, **3**:21, 42, 46-47, 90, 96, 117, 163-164, 194, 199, 202, 203-204, 206-207, 208-209, 225
 reproductive system cancers, **2**:16-17, 20, 24, 27
 space-based research, **3**:100-101, 238-239
 stem cell research, **2**:21, **3**:69-70, 75
 strategic plans, **2**:29, 182, 227
 stress response, **3**:12-13, 21
 structural biology, **3**:96, 243
 substance abuse/addiction, **3**:21, 36-37, 92-93, 227-228
 systems biology, **3**:84, 96, 206
 technology development, **2**:2, 11, 14, 15, 18, 28-29, 46, **3**:83, 92-93, 96, 100-101, 128-129, 134, 171-172, 206-207, 211, 225, 227-229, 230, 236, 237, 238-239, 241-242, 243, 244-245
 tobacco-related research, **2**:12, 19, 48, 148, 157-158, 180-181, 224, 225, 247, **3**:93, 100, 179
 training and career development, **2**:10, 19, 20-21, 23, 92-93, 169, 182, 242-243, 266, **3**:97, 100, 174, 179, 258, 259-262, 268
 transplantation research, **2**:122, 169, 185, 228
 undiagnosed diseases, **2**:147, **3**:154
 women's health, **3**:180, 268
 National Cancer Program, **5**:7
 National Cell Repository for Alzheimer's Disease, **4**:5, 6
 National Center for Biotechnology Information, **3**:61-62, 165, 196, 206
 National Center for Canine Models of Duchenne Muscular Dystrophy, **4**:21, 23
 National Center for Complementary and Alternative Medicine
 aging-related conditions, **2**:53
 autoimmune diseases, **2**:122, **3**:144
 Ayurvedic medicine toxicity, **3**:23-24
 behavioral and social sciences research, **2**:155, **3**:89, 90-91, 128, 174
 bioethics, **3**:259
 cancer research, **2**:2, 27-28, 29
 chronic diseases and organ systems, **2**:145, **3**:93-94, 128, 136
 clinical and translational research, **2**:28, 52, 100-101, 120-121, 153, 155, 158, 181-182, 206, 224, **3**:128, 136, 137, 144, 153, 165, 166, 169, 174, 180, 181
 comparative effectiveness research, **3**:165
 diabetes, **2**:69, 120-121, 122, 228, **3**:144
 digestive diseases, **2**:122, 168, 185, **3**:136
 epidemiological and longitudinal studies, **2**:175, 176, **3**:22-24, 93-94, 166
 genomics, **3**:47, 91
 global health initiatives, **2**:28, 100-101, 181-182, **3**:181
 imaging tools, resources, and applications, **3**:169, 207, 225, 257
 interdisciplinary research, **3**:257
 international initiatives, **3**:267-268
 liver disease, **2**:185
 menopausal symptom relief, **2**:206
 mission, **5**:9
 molecular biology and basic research, **2**:52, 155, 175, 176, **3**:47, 70, 73-74, 89, 90-91, 93-94
 neurological research, **2**:52, 53, 57, 58, 66, 68, 74, 179, 206, **3**:169, 207, 225, 257
 osteoarthritis, **2**:153, 175, **3**:70, 137, 166
 pain management, **2**:66, 179
 placebo treatments, **2**:176, **3**:23, 94
 population health, **3**:169
 registries, databases, and information systems, **2**:58, **3**:207, 225
 strategic plans, **2**:29, 68, 103, 122, 184
 technology development, **3**:207, 225
 training and career development, **3**:169, 174, 257, 259, 266-267
 women's health, **3**:180
 National Center for Education Statistics, **2**:219, **3**:15
 National Center for Health Statistics, **2**:175, **3**:22-23, 93-94
 National Center for Medical Rehabilitation Research, **2**:32, 68, 226
 National Center for Research Resources
 age-related diseases, **2**:212-213, 228
 animal model resources, **3**:50, 126, 128, 129-130
 ARRA funding, **1**:21, **2**:269, **3**:97-98, 167-168, 230-232
 autoimmune diseases, **2**:117-118, 122, 247-248, **3**:43-44, 78, 79, 118-119, 200
 behavioral and social sciences research, **3**:89
 BIRN, **3**:207, 235
 BTRCs, **3**:97, 128-129, 235
 cancer, **2**:28, **3**:83, 87, 129, 235, 237
 child health and development, **3**:226, 289
 chronic diseases and organ systems, **2**:149, 154, 163, 182, 184, 185, **3**:10, 37, 127
 clinical and translational research, **2**:117-118, 163, 247-248, 267-268, **3**:38, 43-44, 50, 78, 83, 97, 98, 118-119, 126, 127, 128-130, 134, 156, 165, 167-168, 169, 170, 171, 172, 173, 174-176, 181, 226, 230-232, 235, 237, 262, 289
 collaborative research, **2**:260-261, **3**:134, 170, 174-176, 235, 280
 communicating health information, **2**:257, **3**:226, 280, 286, 289
 community-based research, **2**:260-261, **3**:172, 175-176

National Center for Research Resources
(continued)
comparative effectiveness research, **3:165**
CTSA program, **5:15**
epidemiological and longitudinal studies, **2:149, 3:10, 15**
evaluation of programs, **3:174-175**
Extramural Construction program, **1:21, 3:97-98, 167-168, 231**
genomics/genetics, **2:117, 247-248, 3:37, 38, 43-44, 50, 78, 118-119, 128, 156, 200**
global health, **2:28, 100-101, 181-182, 3:181**
glycomics, **3:83, 129, 237**
HIV/AIDS, **2:71-72, 3:15, 130**
imaging tools, resources, and applications, **3:97, 128-129, 169, 207, 225, 257**
infectious diseases and biodefense, **2:72, 86, 97, 101, 3:15, 130**
instrumentation programs, **3:98, 168, 230-231**
interdisciplinary research, **3:169, 211, 257**
intramural research, **1:14**
kidney disease, **3:37**
lupus, **3:43-44, 78, 118-119**
minority health and health disparities, **2:117-118, 245-246, 247-248, 249-250, 257, 260-261, 267-268, 3:37, 43-44, 78, 170, 171, 175-176, 231-232, 246, 286**
mission, **5:9**
molecular biology and basic research, **2:117-118, 3:43-44, 75, 78, 79, 83, 89, 97-98, 100-101, 118-119, 128-129, 167-168, 230-232, 235, 237, 238-239, 257**
nanotechnology, **3:241-242**
neurological research, **2:57, 58, 69, 3:127, 130, 169, 207, 225, 257**
osteoporosis, **3:10**
public-private partnerships, **3:171, 174-175**
rare diseases, **4:39**
registries, databases, and information systems, **2:58, 117, 3:43, 126, 200, 206, 207, 225, 235**
Scientific Information System, **3:206**
space-related health research, **3:100-101, 238-239**
stem cell research, **3:50, 75**
technology development, **3:83, 97, 98, 100-101, 129, 167-168, 207, 211, 225, 226, 230-232, 235, 237, 238-239, 241-242, 246, 289**
training and career development, **3:169, 171, 173, 174, 256, 257, 258, 262**
veterinary medicine, **3:171, 262**
warfarin therapy, **3:38, 156**
women's health, **3:10**

National Center for Toxicological Research, **2:226, 3:88-89, 131**

National Center on Minority Health and Health Disparities (see also NCMHD Centers of Excellence)
adolescent health, **2:219, 3:8**
alcohol abuse, **3:177**
ARRA funding, **2:266**
behavioral and social science research, **3:89**
cancer, **2:2, 13, 205, 253-253, 262, 3:12, 153, 177**
cardiovascular disease, **2:161, 3:177**
chronic diseases, **2:149, 205, 255-256, 3:6, 19, 137, 145**
clinical and translational research, **2:167, 249, 253-254, 261, 3:134, 137, 145, 165, 171, 176-177**
collaborative research, **2:262-263**
community-based participatory research, **2:241, 255-256, 261, 3:176-177**
comparative effectiveness research, **3:165**
diabetes, **2:69, 122, 167, 228, 249, 263, 3:145, 177**
digestive diseases, **2:122, 185**
epidemiological and longitudinal studies, **2:149, 205, 219, 255-256, 262, 3:6, 7-8, 12, 19**
family and child well-being, **2:219, 3:8**
health services, **2:262**
HIV/AIDS, **3:177**
immigrants, **2:219**
infrastructure and research resources, **2:267-268, 3:171**
international programs, **2:264**
Intramural Research Program, **2:266**
kidney disease, **2:263**
mission, **5:9-10**
molecular biology and basic research, **3:89**
obesity, **2:184, 3:177**
osteoarthritis, **2:153, 3:137**
osteoporosis, **2:262**
population research, **2:219, 3:7-8**
Research Endowment Program, **2:244, 266-267**
strategic plan, **2:269**
suicide prevention, **3:177**
technology development, **2:247, 3:241-242, 246**
training and career development, **2:243, 244, 264-265, 266-267, 3:259, 268**
women's health, **3:12**

National Centers for Biomedical Computing, **3:95, 195, 208, 230, 236, 5:22-23**

National Centers for Systems Biology, **3:64, 84**

National Children's Study, **2:220, 3:16-17**

National Commission on Libraries and Information Science, **2:257**

National Commission on Orphan Diseases, **4:39**

National Community Health Representative Program, **3:276**

National Comorbidity Survey, **2:66-67, 160-161, 238, 3:139**

National Comorbidity Survey—Replication, **2:254, 3:9**

National Database for Autism Research, **2:39, 57-58, 204-205, 3:189, 197, 4:49, 51**

National Diabetes Education Program, **2:182, 259, 3:114, 162, 279, 281**

National Drug Abuse Treatment Clinical Trials Network, **2:91, 157, 224, 3:21, 158**

National Epidemiologic Survey on Alcohol and Related Conditions, **2:66-67, 160-161, 3:16, 139**

National Eye Institute
ataxia-telangiectasia, **2:69**
autoimmune diseases, **2:122**
behavioral and social sciences research, **3:47, 89, 91**
cancer research, **2:2, 23, 28, 100-101, 181-182, 3:181**
cardiovascular diseases, **2:149-150, 154, 166, 252-253, 3:19, 40, 160**
cataracts, **2:146-147, 3:222**
chemical threat countermeasures, **2:66, 96, 103, 3:120**
childhood eye diseases, **2:167, 210-211, 215-216, 219-220, 3:15, 122, 140, 152-153**
chronic diseases and organ systems, **2:146-147, 3:19, 45, 77, 147, 152-153, 160, 222**
clinical and translational research, **2:28, 40, 57, 59, 66, 96, 100-101, 154, 166-167, 173, 174-175, 181-182, 210-211, 215-216, 248, 3:117-118, 120, 122, 140, 141, 147, 152-153, 160, 169, 180, 181**
communicating health information, **3:279, 280**
comparative effectiveness research, **3:140, 141, 152**
convergence insufficiency, **2:210-211**
corneal transplants, **2:174-175, 3:147**
diabetes, **2:69, 122, 140-141, 154, 166-167, 228, 248, 3:77, 141, 160**
epidemiological and longitudinal studies, **2:67, 149-150, 183, 219-220, 227, 3:15, 18, 19, 40**
gene therapy, **3:152-153**
genomics, **2:55-56, 132, 149-150, 151, 167, 252-253, 3:19, 40, 45, 47, 91, 117-118, 122, 190, 200-201**
glaucoma, **2:55-56, 132, 151, 3:45**
global health, **2:28, 100-101, 181-182, 3:181**
Graves' disease, **2:59**
idiopathic intracranial hypertension, **2:40, 3:140**
imaging tools, resources, and applications, **2:57, 58, 67, 146-147, 183, 227, 3:169, 222, 257**
infectious diseases and biodefense, **2:66, 96, 103, 101-102, 3:120, 181**
infrastructure and research resources, **2:40, 59, 3:140, 207, 225**
interdisciplinary research, **2:57, 3:169, 257**

Index

- National Eye Institute (*continued*)
 Leber congenital amaurosis, **2**:167, 215-216, **3**:152-153
 macular degeneration, **2**:67, 140-141, 173, 183, 211, 227, **3**:77, 152
 macular edema, **3**:141
 minority health and health disparities, **2**:149-150, 154, 252-253, **3**:19, 40, 160
 mission, **5**:8
 molecular biology and basic research, **2**:140-141, 183, 227, **3**:47, 77, 89, 91
 nanotechnology, **3**:241-242
 neurological research, **2**:32, 40, 51, 55-56, 57, 58, 59, 66, 67, 96, 220-221, **3**:120, 140, 169, 207, 225, 245, 257
 NORDIC network, **2**:40, 59, **3**:140
 rare disorders, **2**:59, **3**:122
 refractive vision errors, **3**:18
 registries, databases, and information systems, **2**:58, **3**:190, 200-201, 207, 227
 rehabilitation, **2**:51, 220-221, **3**:245
 retinitis pigmentosa, **3**:117-118
 strategic plans, **2**:67, 183, 227
 technology development, **2**:51, 58, 146-147, 220-221, **3**:207, 222, 225, 241-242, 245
 trachoma, **2**:101-102
 training and career development, **2**:57, **3**:169, 257, 258
 women's health, **3**:180
 X-linked juvenile retinoschisis, **3**:122
- National Graduate Student Research Festival, **3**:258
- National Health and Nutrition Examination Survey, **2**:38, 55, 148, 161, 235, **3**:18,20
- National Health Interview Survey, **2**:138, 175, 234, **3**:22-23, 93-94
- National Heart, Lung, and Blood Institute
 aging- related research, **2**:53, 208
 anticoagulant pharmacogenomics, **3**:28, 38, 143, 156
 asthma, **2**:172, **3**:45, 79
 ataxia-telangiectasia, **2**:69
 autoimmune diseases, **2**:116, 117-118, 122, 247-248, **3**:43-44, 78, 118-119, 171-172, 200, 236
 behavioral and social science research, **2**:155, **3**:89, 90-91, 128, 174, 261
 blood storage for transfusion, **3**:76
 cancer, **2**:2, 7, 23, 28, 68, 262, **3**:42, 199, 228-229
 cardiovascular diseases, **2**:23, 149-150, 154, 159, 166, 167, 173, 208, 248, 249, 252-253, 255-256, 262, **3**:19, 28, 38, 40, 159-160, 242
 chemical threat countermeasures, **2**:103
 child health and development, **2**:151, 210, 214, **3**:226, 289
 chronic diseases and organ systems, **2**:144-145, 147, 149-151, 152, 154, 155, 159, 165-166, 167, 172, 173-174, 179-180, 181-182, 184-185, 210, 212-213, 248, 249-250, 252-253, 255-256
 chronic fatigue syndrome, **2**:145
 clinical and translational research, **2**:28, 53, 56, 59-60, 100-101, 116, 117-118, 144-145, 147, 154, 155, 159, 165-166, 167, 172, 173-174, 179-180, 208, 247-248, 249, 261-262, 264, 267-268, **3**:28, 83, 90-91, 118-119, 127, 128, 129, 133, 136-137, 142, 143, 145, 154, 156, 159-160, 161, 163, 165, 169, 171-172, 174, 176, 180, 181, 226, 236, 237, 289
 communicating health and research information, **2**:262-253, 264, **3**:161, 163, 226
 community-based participatory research, **2**:261-262, **3**:6, 19, 176
 comparative effectiveness research, **2**:173, **3**:159-160, 165
 cystic fibrosis, **2**:144-145
 dementias and Alzheimer's disease, **2**:53, 208
 diabetes, **2**:69, 117, 122, 154, 159, 166, 167, 173, 228, 248, 249, **3**:145, 159-160
 Down Syndrome, **2**:69, 214, 228
 epidemiological and longitudinal studies, **2**:23, 149-151, 159, 212-213, 252, 255-256, 261-263, **3**:6, 10, 19, 24, 38, 45
 Fragile X Syndrome, **2**:214
 genomics/genetics, **2**:23, 60, 117-118, 149-151, 154, 159, 210, 247-248, 249-250, 252, **3**:24, 28, 37, 38, 40, 42, 43-44, 45, 78, 143, 156, 199, 200
 global health, **2**:28, 100-101, 181-182, **3**:181
 HIV/AIDS, **2**:72, 90-91, 92-93, 251, **3**:260-261
 imaging tools, resources, and applications, **2**:154, 249-250, 252-253, **3**:228-229
 infectious diseases and biodefense, **2**:72, 90-91, 92-93, 103, 251
 infrastructure and research resources, **2**:92-93, 181, 262-263, **3**:165, 171-172
 intellectual and developmental disabilities, **2**:214
 interdisciplinary research, **2**:145, 155
 international initiatives, **2**:92-93, 181, **3**:100-101, 238-239, 259, 260-261
 kidney disease, **2**:154, 249-250, **3**:37
 liver disease, **2**:185, 255-256
 lung diseases, **2**: 144-145, 150-151, 159, 165, 172, 251, 255-256, **3**:38, 42, 136
 lupus, **2**:117-118, 247-248, **3**:43-44, 78, 118-119, 176
 microbiomics, **2**:90-91, 251
 minority health and health disparities, **2**:90-91, 117-118, 149-151, 152, 154, 159, 167, 247-248, 249-250, 251, 252-253, 255-256, 261-263, 264, 267-268, **3**:6, 19, 24, 37, 40, 45, 145, 160, 163, 171, 176
 mission, **5**:7
 molecular biology and basic research, **2**:90-91, 117-118, 155, 172, 173-174, 210, 247-248, **3**:75, 76, 78, 79, 81, 83, 89, 90-91, 100-101, 128, 129, 237
 multidisciplinary research, **2**:144-145, 179-180
 muscular dystrophies, **2**:56, **3**:127
 nanotechnology, **3**:241-242
 neurological research, **2**:32, 53, 56, 59-60, 68, 69, 103, 179-180, 208, **3**:127, 133, 142
 obesity, **2**:23, 32, 150, 152, 154, 159, 184, 210, 248, 252, **3**:42
 osteoporosis, **2**:149, 212-213, 262, **3**:10
 pain, **2**:179-180, **3**:133
 population health, **3**:169
 pregnancy and perinatology, **2**:202
 radiological threat countermeasures, **2**:103
 rare diseases, **2**:59-60, 214, **3**:142, **4**:39
 registries, databases, and information systems, **2**:23, 117, 159, **3**:24, 45, 199, 200
 sickle cell disease, **2**:179-180, **3**:133
 sleep disorders, **2**:32, 149, 165-166, 255-256, **3**:136-137
 space-related health research, **3**:100-101, 238-239
 stem cell research, **3**:75, 242
 strategic plans, **2**:69, 182
 stroke, **3**:32
 technology development, **2**:116, **3**:83, 129, 226, 228-229, 236, 237, 238-239, 241-242, 289
 training and career development, **2**:92-93, 181, 262-263, 267-268, **3**:174, 256, 258, 259, 260, 261-262, 289
 transplant research, **2**:122, 173-174, 185, 228, **3**:81
 undiagnosed diseases, **2**:147, **3**:154
 women's health, **2**:2, 149, 152, 159, 202, 210, 212-213, **3**:10, 43-44, 45, 78, 118-119, 180
- National Human Genome Research Institute
 animal models, **3**:50, 128
 autoimmune diseases, **2**:117, 122, **3**:43, 200
 behavioral and social sciences research, **2**:155, **3**:47, 89, 90-91, 128, 179-180, 261
 bioethics, **3**:51, 179-180, 259
 biostatistics, **3**:260
 cancer, **2**:2, 23, 28-29, 159, **3**:42, 46-47, 199
 Centers of Excellence in Ethical, Legal, and Social Issues, **3**:51, 179-180
 chemical genomics, **2**:97-98
 chronic diseases and organ systems, **2**:23, 147, 152-153, 155, 159, 164-165, 181-182, 184, 185, 249, **3**:35, 42, 90-91, 128, 132-133, 154, 199
 clinical and translational research, **2**:59-60, 147, 155, 164-165, 181-182, **3**:33-34, 50, 51, 90-91, 128, 132-133, 142, 154, 164-165, 179-180
 collective intelligence initiative, **3**:96, 206
 communicating health information, **3**:282
 developmental genomics, **2**:41, 199, **3**:34

National Human Genome Research Institute
(continued)

- diabetes, **2:69**, 122, 152-153, 228, 249, **3:35**
- diagnostic microbiology, **2:98**
- epidemiological and longitudinal studies, **2:2**, 23, 28-29, **3:22**, 42-43, 199
- functional genomics of disease, **2:41**, 199, **3:33-35**, 82-83, 164-165, 227
- global health, **2:28**, 100-101, 181-182, **3:181**, 226, 263-264
- GWAS, **3:42-43**, 199, 200
- immunology, **3:80**
- infectious diseases and biodefense, **2:81**, 97-98, 100-101, 181-182, **3:80**
- infrastructure and research resources, **3:33-34**, 46-47, 50, 96, 128, 164-165, 179-180, 200, 206, 227
- interdisciplinary research, **2:155**
- international collaborations, **3:35**
- liver disease, **2:185**
- microbiomics, **3:34-35**, 82-83
- minority health and health disparities, **2:152-153**, 249, **3:35**
- mission, **5:9**
- molecular biology and basic research, **2:81**, 155, **3:34-35**, 47, 80, 82-83, 89, 90-91, 128, 206
- nanotechnology, **3:241-242**
- neurological research, **2:41**, 59-60, 69, 199, **3:34**, 142
- nonhuman genomics, **3:35**, 48
- obesity, **2:184**
- population research, **3:22**, 42-43
- rare and neglected diseases, **2:59-60**, 97-98, 164-165, **3:33**, 132-133, 142, 227, 282
- registries, databases, and information systems, **2:23**, 117, 159, **3:42**, 43, 46-47, 96, 199, 200, 206, 263-264, 282
- structural genomics, **3:41**
- technology development, **2:98**, **3:33**, 40, 41, 226, 227, 241-242
- training and career development, **3:226**, 258, 259, 260, 261, 263-264
- undiagnosed diseases, **2:147**, **3:154**
- National Institute for Occupational Safety and Health, **3:167**, 176, 287
- National Institute of Allergy and Infectious Diseases
- adolescent health, **3:7-8**
- antimicrobial resistance, **2:96**, 101, **3:39-40**, 122-123
- asthma, **2:168-169**, 174, 255, **3:150-151**
- autoimmune diseases, **2:28**, 116, 117-119, 120-121, 122, 174, 183, 247-248, **3:43-44**, 77, 78, 80, 118-119, 137-138, 144, 171-172, 200, 236
- behavioral and social science research, **2:155**, **3:15-16**, 89, 90-91, 128
- bioethics, **3:259**
- biostatistics, **3:260**
- cancer, **2:2**, 27, 28, 101, **3:181**
- child health and development, **3:7-8**, 150-151
- chronic diseases and organ systems, **2:28**, 100-101, 145-146, 147, 152-153, 155-156, 168-169, 174, 181-182, 185, **3:17-18**, 81, 90-91, 126, 128, 137-138, 150-151, 154, 181
- chronic fatigue syndrome, **2:146**
- clinical and translational research, **2:97-98**, 147, 155-156, 168-169, 174, 223, 228, 247-248, **3:15-16**, 17-18, 39-40, 43-44, 75, 90-91, 118-119, 120, 122-123, 124-126, 128, 130-131, 137-138, 142, 144, 148, 149, 150-151, 154, 155, 158-159, 169-170, 171-172, 180, 181, 236, 238, 259
- communicating health information, **3:172**
- community-based participatory research, **3:172**
- cystic fibrosis, **2:145-146**
- diabetes, **2:28**, 120-121, 122, 152-153, 174, 228, 249, **3:35**, 137-138, 144
- diagnostic microbiology, **2:98**
- digestive diseases, **2:122**, 185
- emerging disease threats, **2:93**, **3:124**
- epidemiological and longitudinal studies, **2:86**, 98-99, 155-156, 219, **3:7-8**, 11, 13-14, 15-16, 17-18, 126, 148, 149, 202
- food allergies, **2:155-156**, 183, **3:17-18**, 126
- genetics/genomics, **2:82**, 97-98, 117, 152-153, 247-248, 249, **3:28**, 35, 39-40, 43-44, 47-48, 78, 118-119, 122-123, 200
- global health, **2:28**, 100-101, 181-182, **3:181**
- HIV/AIDS, **2:71-72**, 85-86, 87, 88-90, 92-93, 98-99, 101, 250, **3:11**, 13-14, 15-16, 124, 125, 148, 149, 158-159, 169-170, 202, 261-262
- immunology research, **2:81-82**, 101, 114-115, 116, 118, 147-148, 173-174, **3:80**, 137-138, 171-172, 236
- infectious diseases and biodefense, **2:28**, 66, 71-72, 85-86, 87, 88-90, 92-93, 95, 96-97, 98-99, 100-101, 181-182, 250, **3:11**, 13-14, 28, 39-40, 47-48, 80, 95-96, 120, 122-123, 124-126, 138, 148, 149, 155, 158-159, 169-170, 171-172, 181, 202, 261-262
- influenza, **2:93-94**, 101, **3:95-96**, 125-126
- infrastructure and research resources, **1:23**, 99, **3:47-48**, 124, 198, 236, 280
- intellectual and developmental disabilities, **2:214**, 228
- interdisciplinary research, **2:146**, 155
- international programs, **2:92-93**, 98-99, 174, **3:259**, 261-262
- liver disease, **2:185**
- malaria, **2:85**, 96, 101, **3:11**, 123
- medical countermeasures against attacks, **2:96-97**, 103
- menopause-related research, **2:98**
- minority health and health disparities, **2:152-153**, 168-169, 247-248, **3:7-8**, 35, 43-44, 78, 118-119, 150-151, 169-170
- mission, **5:8**
- molecular biology and basic research, **2:117-118**, 223, 247-248, **3:43-44**, 47-48, 75, 77, 78, 80, 81, 89, 95-96, 118-119, 128, 130-131, 238
- multidisciplinary research, **2:146**
- nanotechnology, **3:241-242**
- neurological research, **2:60**, 66, 69, 96, **3:120**, 142
- population research, **2:219**, **3:7-8**
- primary immune deficiency diseases, **2:147-148**
- proteomics, **2:98**, **3:47-48**
- rare and neglected diseases, **2:83**, 97-98, **3:124-125**, 142, **4:39**
- regenerative medicine, **2:223**, **3:75**, 130-131, 238
- registries, databases, and information systems, **2:98-99**, 117, **3:43**, 198, 200, 202, 232
- stem cell research, **2:223**, **3:75**, 130-131, 238
- strategic plans, **2:102**, 103
- technology development, **2:3**, 116, 223, **3:75**, 130-131, 232, 236, 238, 241-242
- topical microbiocides, **2:85-86**, **3:158-159**
- training and career development, **2:92-93**, **3:248**, 259, 260, 261-262
- transplantation research, **2:122**, 173-174, 183, 185, **3:81**, 137-138
- tuberculosis, **2:84**, 96, **3:11**, 138
- undiagnosed diseases, **2:147**, **3:154**
- vaccine research, **2:23**, 85, 88, 93-94, 95-96, 101, **3:80**, 123, 124, 155, 169-170
- women's health, **2:122**, 270, **3:78**, 118-119, 158-159, 180
- National Institute of Arthritis and Musculoskeletal and Skin Diseases
- atopic dermatitis, **2:143**
- autoimmune diseases, **2:115-116**, 117-118, 119, 121, 122, 246, 247-248, **3:43-44**, 78, 79, 118-119, 121, 171-172, 180-181, 200, 236
- behavioral and social sciences research, **3:47**, 89, 91, 174
- bone health, **2:115**, 149, 246, 262, **3:180**
- cancer, **2:2**, 28, 100-101, 181-182, 262, **3:181**
- cardiovascular disease, **2:262**
- Centers of Research Translation, **2:115-116**, **3:180-181**
- chemical threat countermeasures, **2:66**, 103, **3:120**
- chronic diseases and organ systems, **2:28**, 100-101, 143, 145, 147, 149, 153, 162, 163, 175, 177-178, 181-182, 183, 185, **3:70**, 127, 137, 154, 167, 181, 224
- chronic fatigue syndrome, **2:145**

- National Institute of Arthritis and Musculoskeletal and Skin Diseases (*continued*)
 clinical and translational research, **2**:28, 56, 59-60, 66, 96, 98, 100-101, 115-116, 117-118, 121, 147, 153, 163, 177-178, 181-182, 223, 246, 247-248, 261-262, 267-267, **3**:43-44, 70, 75, 78, 118-119, 120, 127, 130-131, 137, 142, 154, 167, 171-172, 174, 176, 180-181, 238
 communicating health information, **2**:261-262, **3**:275, 278-279
 community-based participatory studies, **2**:261-262, **3**:176, 278-279
 Crohn's disease, **2**:119
 diabetes and chronic kidney disease, **2**:263
 epidemiological and longitudinal studies, **2**:149, 212-213, **3**:10
 genomics/genetics, **2**:96, 115, 117-118, 119, 246, 247-248, **3**:43-44, 47, 78, 91, 118-119, 127, 200
 global health research, **2**:28, 100-101, 181-182, **3**:181
 immunology and inflammation, **3**:78, 171-172, 236
 infectious diseases and biodefense, **2**:28, 66, 96, 98, 100-101, 103, 181-182, **3**:120, 154, 181
 infrastructure and research resources, **2**:115, 267-268, **3**:171-172, 180-181, 236
 interdisciplinary research, **2**:98, 145, **3**:99-100, 154, 237, 268
 international initiatives, **3**:100-101, 181, 238-239
 lupus, **2**:115, 119, 121, 246, 247-248, **3**:43-44, 78, 118-119, 180
 minority health and health disparities, **2**:115-116, 117-118, 246, 247-248, 261-263, 267-268, **3**:43-44, 78, 118-119, 171, 176, 180-181, 278-279
 mission, **5**:8
 molecular biology and basic research, **2**:117-118, 175, 223, 247-248, **3**:43-44, 47, 70, 75, 78, 79, 89, 91, 99-101, 118-119, 130-131, 180, 237, 238-239
 multidisciplinary studies, **2**:145
 muscle recovery after injury, **2**:163, **3**:127
 muscular dystrophies, **2**:56, 68, 69, 163, 223, **3**:127, **4**:19, 24
 nanotechnology, **3**:241-242
 neurological research, **2**:56, 59-60, 66, 103, **3**:120, 127, 142, 167
 obesity, **2**:184
 osteoarthritis, **2**:115, 153, 175, 246, **3**:70, 137, 181
 osteoporosis, **2**:149, 212-213, 262, **3**:10
 pain, **2**:177-178, **3**:167
 pediatric diseases, **2**:121, **3**:119
 psoriasis, **2**:115, 118, 119, 246, **3**:44, 181
 rare disorders, **2**:59-60, **3**:142, **4**:39
 regenerative medicine, **2**:223-224, **3**:75, 130-131, 238
 registries, databases, and information systems, **2**:117, 162, **3**:43, 200, 224
 rheumatic diseases, **2**:119, 121, **3**:119
 rickets, **2**:115, 246, **3**:180
 scleroderma, **2**:115, **3**:181
 space-related health research, **3**:100-101, 238-239
 stem cell research, **2**:223, **3**:75, 130-131, 238
 strategic plans, **2**:68-69, 103, 121, 183, 184, 228
 technology development, **2**:116, 162, 223-224, **3**:75, 99-101, 130-131, 171-172, 224, 236, 237, 238-239, 241-242
 training and career development, **2**:267-268, **3**:174, 253, 258, 266, 268
 transplantation research, **2**:122, 185, 228
 tuberous sclerosis, **2**:68
 undiagnosed diseases, **2**:147, **3**:154
 women's health, **2**:98, 149, 212-213, 262, **3**:10, 43-44, 78, 118-119, 154, 180, 268
- National Institute of Biomedical Imaging and Bioengineering
 Alzheimer's disease, **2**:58-59, 207, **3**:132
 autoimmune diseases, **2**:120, 122, **3**:78
 behavioral and social sciences research, **3**:89
 biomimetic materials, **3**:76, 246
 cancer research, **2**:2, 24, 25, **3**:222, 228, 245-246
 chronic diseases and organ systems, **2**:69, 120, 122, 147, 153, 184, 228, **3**:137, 229
 clinical and translational research, **2**:57, 58-59, 153, 207, 223, 264, **3**:75, 130-131, 132, 137, 163, 165, 169, 180, 238, 257
 communicating health information, **2**:264, **3**:163
 comparative effectiveness research, **3**:165
 diabetes, **2**:69, 120, 122, 228, **3**:78
 diagnostics and point-of-care technologies, **3**:221-222, 245-246
 digestive diseases, **2**:122, 185
 global health, **3**:259-260, 263-264
 imaging tools, resources, and applications, **2**:2, 24, 57, 58-59, 147, 207, **3**:132, 169, 207, 225, 228-229, 230, 257
 information technology, **3**:205, 223, 226, 263-264
 infrastructure and research resources, **3**:207, 225
 interdisciplinary research, **2**:57, **3**:169, 257, 264
 liver disease, **2**:185, **3**:229
 minority health and health disparities, **2**:247, 264, **3**:163, 246
 mission, **5**:9
 molecular biology and basic research, **2**:120, 223, **3**:75, 76, 78, 89, 100-101, 130-131, 230, 238-239, 245-246
 multidisciplinary studies, **2**:221-222
 nanotechnology, **2**:50-51, 223-224, **3**:234, 241-242
 neurological research, **2**:50-51, 57, 58-59, 69, 207, 223, **3**:132, 169, 207, 223, 225, 234, 245, 257
 obesity, **2**:184
 osteoarthritis, **2**:153, **3**:137
 prosthetics, **2**:51, 221-222, **3**:234, 237-238, 245
 regenerative medicine, **2**:50-51, 223, **3**:75, 130-131, 238
 registries, databases, and information systems, **2**:58, **3**:205, 207, 225
 rehabilitation research, **2**:192, **3**:237-238, 245
 space-related research, **3**:100-101, 238-239
 stem cell research, **2**:120, 223, **3**:75, 130-131, 238
 strategic plans, **2**:69, 122, 184-185, 228
 technology development, **2**:2, 24, 25, 50-51, 58, 147, 221-222, 223, 247, **3**:75, 76, 100-101, 130-131, 205, 207, 211, 221-222, 225, 225, 228-229, 230, 234, 237-239, 241-242, 245, 246
 training and career development, **2**:57, **3**:169, 226, 257, 258, 259-260, 263-264
 transplant research, **2**:122, 185, 228
 women's health, **3**:180
- National Institute of Dental and Craniofacial Research
 autoimmune diseases, **2**:116, 117-118, 121, 122, 247-248, **3**:43-45, 78, 118-119, 200, 202
 behavioral and social sciences research, **2**:155, **3**:47, 89, 90-91, 128, 261
 bioethics, **3**:259
 biostatistics, **3**:260
 bone therapies, **2**:217
 cancer, **2**:3, 26-27, 29, **3**:68-69, 173-174, 232-233, 239-240, 242-243, 244
 child health and development, **2**:263-264, **3**:151, 153
 chronic diseases and organ systems, **2**:28, 49-50, 100-101, 142-143, 144, 145, 147, 149, 153, 155, 171, 177-178, 181-182, 183, 184-185, 217, 255-256, **3**:19, 71, 74, 84-85, 128, 137, 154, 161-162, 243-244
 chronic fatigue syndrome, **2**:145
 clinical and translational research, **2**:28, 59-60, 89-90, 100-101, 117-118, 147, 153, 155, 181-182, 224, 247-248, 261-262, 263-264, **3**:13-14, 43-44, 78, 118-119, 128, 137, 142, 149, 151, 153, 154, 161-162, 163, 169, 172, 173-174, 176, 180, 181, 239-240, 257
 collaborative research, **2**:57, 224, **3**:153, 173-174, 241-242
 communicating health information, **2**:216, 260, 264, **3**:161, 163, 279, 288
 community-based participatory research, **2**:261-262, **3**:172, 176
 developmental processes and disorders, **2**:41, 42-43, 199, 214, 216, **3**:34, 67-68, 72-73, 74, 234-235, 239-240

National Institute of Dental and Craniofacial Research (*continued*)

diabetes, **2:69**, 122, 228, **3:43**, 173-174, 200, 239-240
 Down Syndrome, **2:69**, 214, 228
 epidemiological and longitudinal studies, **2:89-90**, 149, 255-256, **3:6**, 13-14, 19, 149
 Fragile X Syndrome, **2:214**
 funding, **3:180**, 266-267
 genetics/genomics, **2:41**, 59-60, 116, 117-118, 199, 214, 216, 247-248, **3:34**, 41-42, 43-45, 47, 67-69, 78, 82, 91, 118-119, 200, 243
 global health, **2:28**, 100-101, 181-182, **3:181**
 HIV/AIDS, **2:89-90**, **3:13-14**, 149, 180
 imaging tools, resources, and applications, **2:57**, 58, 59-60, **3:169**, 207, 225, 257
 infectious diseases and biodefense, **2:28**, 83-84, 89-90, 100-101, 102, 144, 181-182, **3:13-14**, 76, 84-85, 149, 233, 243-244
 infrastructure and research resources, **2:49-50**, **3:153**, 169, 207, 225, 239-240
 intellectual and developmental disabilities, **2:214**
 interdisciplinary research, **2:145**, **3:90-91**, 173-174, 239-240, 257
 international initiatives, **3:259**, 266-267
 liver disease, **2:185**
 lupus, **2:117-118**, 247-248, **3:43-44**, 78, 118-119, 180, 200
 metabolic modeling, **2:84**, 144
 minority health and health disparities, **2:117-118**, 149, 216, 247-248, 255-256, 260, 261-262, 263-264, 270, **3:19**, 43-44, 78, 118-119, 151, 163, 176, 288
 mission, **5:7**
 molecular biology and basic research, **2:26-27**, 42-43, 49-50, 84, 117-118, 144, 155, 177-178, 214, 216, 217, 247-248, **3:41-42**, 43-44, 47, 67-69, 71, 72-73, 74, 75, 76, 78, 82, 84-85, 89, 90-91, 96, 128, 206, 233, 234-235, 242-243, 244
 multidisciplinary research, **2:145**
 nanotechnology, **3:241-242**
 neurological research, **2:32**, 41, 42-43, 49-50, 57, 58, 59-60, 69, 177-178, 199, 214, **3:34**, 71, 72-73, 142, 169, 207, 225, 257
 obesity, **2:182**, **3:173-174**, 180, 239-240
 oral health, **2:84**, 144, 171, 216, 260, 263-264, **3:41-42**, 67-68, 69, 82, 84-85, 151, 161-162, 173-174, 233, 234-235, 243-244, 288
 osteoarthritis, **2:153**, **3:137**
 pain research, **2:32**, 49-50, 57, 177-178, **3:71**
 Patient Advocates Forum, **3:279**
 population health, **3:169**
 rare disorders, **2:59-60**, **3:142**, **4:39**

registries, databases, and information systems, **2:58**, 116, 117, **3:43**, 44-45, 75, 96, 200, 202, 206, 207, 225
 rehabilitation research, **2:192**, **3:67-68**
 reproductive health, **3:180**, 239-240
 salivary gland disorders, **2:116**, **3:41-42**, 44-45, 82, 202, 243
 stem cell research, **2:59-60**, 83-84, 142-143, 217, **3:74**, 75, 233
 strategic plans, **2:29**, 69, 102, 121, 182, 227, 270
 technology development, **2:26-27**, 83-84, 144, 216, **3:41-42**, 67-69, 76, 82, 84-85, 173-174, 207, 225, 232-233, 234-235, 239-240, 241-244
 tooth development, **2:216**, **3:67-68**, 234-235
 training and career development, **2:57**, 171, **3:161-162**, 169, 256, 257, 258, 259, 260, 261, 266-267
 trans-NIH research, **2:122**, 145, 147, 182-183, 228, **3:6**, 89
 transplantation research, **2:122**, 185, 228
 undiagnosed diseases, **2:147**, **3:154**
 women's health, **3:43-44**, 78, 118-119, 153, 180

National Institute of Diabetes and Digestive and Kidney Diseases
 adolescent health, **2:152**, 170-171, 205, **3:18-19**, 143-144, 150
 appetite control, **2:32**, 49, 141, **3:83**
 autoimmune diseases, **2:115**, 116, 117, 118-119, 120-121, 122, 174, **3:43**, 77, 78, 137-138, 144, 171-172, 200, 236
 bariatric surgery, **2:170-171**, **3:18-19**, 150
 behavioral and social sciences research, **2:155**, 246-247, **3:47**, 89, 90-91, 128
 cancer, **2:3**, 23, **3:42**, 199
 cardiovascular disease, **2:166**, 173, 249, **3:159-160**
 chronic diseases and organ systems, **2:23**, 115, 141, 142, 143, 144-145, 149, 152-153, 154, 155, 159, 163-164, 166, 167, 168, 169, 169, 170-174, 182-183, 201, 205, 248, 249-250, 255-256, **3:18-19**, 22, 35, 37, 42, 81, 128, 136, 137-138, 143-145, 148-149, 150, 159-160, 172-173, 199
 clinical and translational research, **2:59-60**, 64, 98, 115, 116, 120-121, 143, 152, 154, 155, 163-164, 166, 167, 168, 169, 170-171, 173, 174, 183, 205, 248, 249, 259, 267-268, **3:18-19**, 22, 71, 120-121, 128, 136, 137-138, 142, 143-145, 148-149, 150, 150, 154, 159-160, 162, 165, 171-173, 236, 281
 communicating health information, **2:258**, 259, **3:162**, 279, 281
 comparative effectiveness research, **2:173**, **3:18-19**, 150, 165
 cystic fibrosis, **2:144-145**, 163-164, **3:172-173**

diabetes, **2:55**, 64, 69, 98, 115, 117, 118-119, 120-121, 122, 152-153, 154, 155, 166, 167, 173, 174, 182, 199, 205, 228, 248, 249, 259, **3:35**, 49-50, 71, 77, 78, 81, 120-121, 137-138, 143-145, 159-160, 162, 279, 281
 digestive diseases, **2:3**, 122, 168, 184, 259, **3:136**, 162, 281
 environmental exposures, **3:240**
 epidemiological and longitudinal studies, **2:149**, 170-172, 255-256, **3:6**, 18-19, 22, 42, 150, 150
 Fragile X Syndrome and associated disorders, **2:69**, 228
 genomics/genetics, **2:23**, 59-60, 64, 117, 118-119, 141, 152-153, 154, 159, 163-164, 199, 249-250, **3:35**, 37, 42, 43, 47, 49-50, 81, 82, 91, 172-173, 199, 200, 240
 hearing impairment, **2:55**
 HIV/AIDS, **2:64**
 imaging tools, resources, and applications, **2:49**, 59-60, 141, 154, 249-250
 infectious diseases and biodefense, **2:82**, 98, **3:154**
 inflammation, **2:116**, 143
 infrastructure and research resources, **2:116**, 267-268, **3:165**, 171-172, 236
 interdisciplinary research, **2:98**, 155, **3:90-91**, 154
 international research, **2:115**, 174
 kidney disease/injury, **2:3**, 154, 171-173, 182-183, 249-250, 259, **3:18**, 37, 162, 281
 liver disease, **2:3**, 142, 169, 184, **3:148-149**
 malaria, **2:82**
 minority health and health disparities, **2:149**, 152-153, 154, 167, 246-247, 248, 249-250, 255-256, 259, 267-268, 270, **3:19**, 35, 37, 145, 160, 171, 281
 mission, **5:7**
 molecular biology and basic research, **2:64**, 118-119, 120, 141, 143, 155, 174-175, 199, **3:18**, 37, 47, 49-50, 71, 73, 75, 77, 78, 81, 82, 89, 90-91, 120-121, 128, 144-145, 240
 multidisciplinary research, **2:144-145**, 170, **3:150**
 nanotechnology, **2:241-242**
 neurological research, **2:32**, 49, 55, 59-60, 64, 68, 69, 141, **3:71**, 73, 120-121, 142
 obesity, **2:23**, 49, 98, 141, 143, 152, 154, 159, 170-171, 183, 205, **3:18-19**, 73, 144-145, 150, 199
 pain, **3:33**, 150
 pelvic floor disorders, **2:169**, 201
 peripheral neuropathies, **2:64**, **3:71**, 120-121
 population studies, **3:240**
 pregnancy and perinatology, **2:155**, 202, **3:49-50**
 prostate research, **2:3**, 183

- National Institute of Diabetes and Digestive and Kidney Diseases (*continued*)
 rare disorders, **2:59-60, 3:142, 4:39**
 registries, databases, and information systems, **2:23, 117, 159, 3:42, 199, 200**
 rehabilitation, **2:169**
 stem cell research, **2:59-60, 120, 3:75**
 strategic plans, **2:182-183, 228, 270**
 stress response, **2:32**
 technology development, **2:116, 3:171-172, 236, 240, 241-242**
 training and career development, **2:267-268, 3:253, 256, 267**
 trans-NIH research, **2:68, 69, 122, 183-184, 3:89**
 transplantation research, **2:122, 173-174, 184, 228, 3:81**
 tuberous sclerosis, **2:68**
 urology research, **2:3, 170, 182, 183, 3:22, 150**
 vaccine research, **2:82**
 women's health, **2:98, 155, 169, 170, 199, 201, 202, 3:154**
- National Institute of Environmental Health Sciences
 autism, **2:42, 57-58, 69, 119, 203-205, 219, 220, 228, 3:20-21, 119, 197**
 autoimmune diseases, **2:119, 122, 3:88**
 behavioral and social sciences research, **3:89**
 bioethics, **3:259**
 bisphenol A exposure, **2:21-22, 225-226, 3:85-86, 88-89, 130, 178**
 cancer, **2:3, 5, 12-13, 21-22, 153, 205, 208-209, 225, 253-254, 262, 3:12-13, 51-52, 86-88, 177-178**
 chemical threat countermeasures, **2:66, 96, 103, 3:120**
 child health and development, **2:220, 3:12-13, 16-17, 20-21, 51-52, 86-87**
 chronic diseases and organ systems, **2:13, 28, 100-101, 130, 144, 145, 148, 153, 160, 181-182, 184, 205, 253-254, 3:12, 39, 130, 155**
 chronic fatigue syndrome, **2:145**
 clinical and translational research, **2:12-13, 21-22, 28, 42, 57, 59-60, 66, 96, 100-101, 144, 160, 181-182, 203-204, 208-209, 225-226, 261-262, 3:12-13, 39, 51-52, 86-89, 119, 120, 130, 142, 130, 155, 163, 169, 176, 177-178, 180, 181, 256, 257**
 Clinical Research Unit, **2:160, 3:155**
 communicating health information, **2:5, 258, 264, 3:163, 279, 289-290**
 community-based participatory research, **2:261-262, 3:176**
 developmental processes and disorders, **2:12-13, 42, 119, 198-199, 208-209, 219, 220, 225-226, 3:12-13, 51-52, 85-86, 87-89, 130, 177-178**
 diabetes, **2:69, 122, 148, 3:20**
 digestive diseases, **2:122, 185**
 Director's Challenge Program, **2:130**
 epidemiological and longitudinal studies, **2:12-13, 42, 148, 153, 205, 208-209, 219, 220, 253-254, 262, 3:11, 12-13, 16-17, 20-21, 22, 42-43, 51-52, 86-87, 202-203**
 exposure assessment methods, **3:240**
 extramural research, **2:12-13**
 genomics/genetics, **2:12-13, 42, 59-60, 97-98, 160, 198-199, 208-209, 253-254, 262, 3:11, 22, 39, 42-43, 49, 51-52, 83, 85-87, 130, 202-203, 240**
 global health, **2:28, 100-101, 181-182, 3:181**
 imaging tools, resources, and applications, **2:57, 58, 59-60, 3:169, 207, 225, 257**
 infectious diseases and biodefense, **2:28, 66, 71, 96, 97-98, 100-101, 103, 181-182, 3:120**
 infrastructure and research resources, **2:57, 3:49, 83, 86-87, 177-178, 207, 225**
 interdisciplinary research, **2:57, 145, 3:169, 257, 268**
 international initiatives, **3:259**
 liver disease, **2:185**
 mercury exposure, **2:119, 3:88**
 minority health and health disparities, **2:12-13, 153, 205, 208-209, 253-254, 258, 261-262, 264, 270, 3:12, 163, 289-290**
 mission, **5:8**
 molecular biology and basic research, **2:12-13, 21-22, 53-54, 119, 198-199, 208-209, 225-226, 3:12-13, 49, 51-52, 83, 85-89, 130, 177**
 multidisciplinary research, **2:53-54, 130, 145**
 nanotechnology, **3:241-242**
 neurological research, **2:33, 42, 53-54, 57-58, 59-60, 66, 69, 119, 203-204, 3:85, 88, 119, 120, 142, 169, 197, 207, 225, 257**
 obesity, **2:220**
 organic pollutant exposure, **2:219, 3:20-21**
 oxidative stress-induced diseases, **2:130, 144, 3:39, 130**
 Parkinson's disease, **2:53-54, 119, 205, 3:85**
 pesticide exposure, **2:53-54, 148, 3:20, 85**
 population health, **3:22, 42-43, 169, 240**
 public-private partnerships, **2:258, 3:279, 289-290**
 radiological countermeasures, **2:103**
 rare diseases, **2:59-60, 97-98, 3:142**
 registries, databases, and information systems, **2:57-58, 204-205, 3:11, 22, 49, 53, 190, 197, 202-203, 207, 225**
 reproductive health, **3:87-89, 177**
 stem cell research, **2:59-60**
 strategic plan, **2:103**
 technology development, **2:58, 3:87, 207, 211, 225, 240, 241-242**
 toxicology research, **3:87-88, 130, 177**
 training and career development, **2:57, 182, 270, 3:169, 256, 257, 259, 268**
 women's health, **2:12-13, 21-22, 219, 262, 3:12-13, 180, 268**
- National Institute of General Medical Sciences
 asthma, **3:38, 79**
 ataxia-telangiectasia, **2:69**
 autoimmune diseases, **2:122, 230, 3:38, 79**
 behavioral and social sciences research, **2:155, 3:89, 90-91, 128, 261**
 bioethics, **3:259**
 biostatistics, **3:260**
 cancer, **2:3, 3:83, 129, 237**
 cardiovascular disease, **3:28, 38**
 chemical threat countermeasures, **2:66, 96, 103, 3:120**
 child health and development, **2:228, 230, 3:38, 79, 83, 129, 237**
 chronic diseases and organ systems, **2:155, 185, 3:90-91, 128**
 clinical and translational research, **2:57, 96, 155, 3:28, 38, 90-91, 120, 128, 156, 169, 172, 180, 256, 257**
 communicating health and research information, **3:280, 283**
 diabetes, **2:69, 122, 228, 3:99**
 digestive diseases, **2:122, 185**
 Fragile X Syndrome and associated disorders, **2:69, 228**
 genetic engineering research methods, **3:42**
 genomics, **3:28, 38, 42, 79, 49, 156**
 glycomics, **3:83, 129, 237**
 imaging tools, resources, and applications, **2:57, 58, 3:96, 207, 225, 257**
 infectious diseases and biodefense, **2:66, 93, 96, 103, 3:120**
 infrastructure and research resources, **2:57, 3:49, 75, 94-95, 207, 208, 225**
 interdisciplinary research, **3:84, 90-91, 169, 257**
 intramural research, **1:14**
 liver disease, **2:185**
 minority health and health disparities, **2:260**
 mission, **5:8**
 molecular biology and basic research, **2:155, 200, 3:38, 68, 74, 75, 79, 83, 84, 89, 90-91, 94-95, 96, 98-99, 128, 129, 208, 236, 237, 242, 243, 245**
 multidisciplinary collaborations, **3:90**
 musculoskeletal simulations, **3:230**
 nanotechnology, **3:241-242**
 neurological research, **2:57, 58, 66, 69, 96, 3:98, 120, 207, 225, 257**
 Parkinson's disease, **3:98-99**
 pharmaceutical research, **3:28, 38, 68, 94-95, 156, 245**
 public-private partnerships, **3:172**

- National Institute of General Medical Sciences (*continued*)
 registries, databases, and information systems, **2:58, 3:95, 207, 208, 225, 236, 245**
 rehabilitation research, **2:200**
 skin diseases, **3:38, 79**
 stem cell research, **2:200, 3:74, 75**
 structural biology, **3:96, 242, 243**
 systems biology, **3:84**
 technology development, **2:58, 3:83, 94-95, 96, 129, 207, 225, 230, 236, 237, 241-242, 243**
 training and career development, **2:57, 260, 3:169, 250, 256, 257, 258, 259, 260, 261**
 women's health, **3:180**
- National Institute of Mental Health
 addiction, **2:32, 46, 66-67, 98, 157-158, 160-161, 224, 3:36-37, 92-93, 139, 227-228**
 adolescent health, **2:99, 201, 3:9**
 aging-related mental disorders, **2:204**
 attention deficit hyperactivity disorder, **2:32, 43, 66-67, 145, 160-161, 167-168, 210, 213, 3:14-15, 139**
 autism, **2:32, 42, 57-58, 64-65, 69, 203-205, 214, 3:72, 119, 197, 4:49**
 autoimmune diseases, **2:122**
 behavioral and social science research, **2:86, 92, 155, 3:15-16, 47, 89, 90-92, 128, 146, 161, 169**
 cancer, **2:3, 23, 64-65, 3:42, 199**
 Center for Collaborative Genetic Studies, **3:48**
 child health and development, **2:43, 145, 167-168, 200, 210, 213, 3:14-15**
 chronic diseases and organ systems, **2:23, 28, 43, 45-46, 66-67, 100-101, 145, 147, 155, 157-158, 159, 160-161, 167-168, 176-177, 181-182, 183, 184, 210, 213, 218-219, 224, 3:14-15, 16, 42, 90-91, 128, 134-135, 154, 199**
 chronic fatigue syndrome, **2:145**
 clinical and translational research, **2:28, 42, 45-46, 66-67, 85-86, 88-89, 97-98, 147, 100-101, 160-161, 176-177, 181-182, 203-204, 261-262, 267-268, 3:15-16, 90-91, 128, 134-136, 139, 146-147, 148, 154, 158-159, 161, 163, 165, 169, 171, 176, 180, 181, 256, 257**
 communicating health information, **2:86, 264, 3:163, 278, 281**
 community-based participatory research, **2:261-262, 3:176**
 comparative effectiveness research, **3:163**
 comorbid mental disorders, **2:66-67, 157-158, 160-161, 224, 3:21, 139, 146-147**
 developmental processes and disorders, **2:32, 43, 145, 200, 210**
 diabetes, **2:69, 98, 122, 228**
 Down Syndrome, **2:69, 214, 228**
 epilepsy, **2:64-65, 3:72**
 epidemiological and longitudinal studies, **2:43, 66-67, 92, 157-158, 160-161, 167-168, 213, 214, 218-219, 224, 254, 3:9, 14-16, 20, 21, 148**
 Fragile X Syndrome and associated disorders, **2:69, 214, 228**
 genomics/genetics, **2:23, 46, 62-63, 64-65, 97-98, 159, 161, 3:28, 35-37, 42, 47, 48, 72, 91-93, 190, 199, 227-228**
 global health, **2:28, 100-101, 181-182, 3:181**
 HIV/AIDS, **2:45, 60, 72, 85-86, 88-89, 92-93, 99, 176-177, 201, 3:15-16, 135-136, 146, 148, 158-159, 161, 197, 261-262**
 imaging tools, resources, and applications, **2:43, 45, 57, 58, 62, 200, 222, 3:135-136, 169, 207, 225, 229, 257**
 infectious diseases and biodefense, **2:28, 45, 60, 72, 85-86, 88-89, 92-93, 97-98, 99, 100-101, 176-177, 181-182, 201, 3:15-16, 146, 148, 164**
 infrastructure and research resources, **3:48, 57, 171, 207**
 intellectual and developmental disabilities, **2:214**
 interdisciplinary research, **2:57, 60, 98, 145, 155, 222, 3:128, 169, 257, 261-262, 268**
 international initiatives, **3:261-262, 266-267**
 military veterans and families, **2:60, 157-158, 224, 3:20, 21, 146-147**
 minority health and health disparities, **2:92, 214, 247, 254, 261-262, 264, 267-268, 3:9, 163, 171, 176, 246**
 mission, **5:8**
 molecular biology and basic research, **2:46, 64-65, 3:36-37, 47, 72, 89, 90-92, 93, 119, 169, 206, 227-228**
 mood and anxiety disorders, **2:32, 45-46, 98, 160-161, 176-177, 254, 3:28, 35-36, 135-136**
 multidisciplinary research, **2:92-93, 145**
 nanotechnology, **3:241-242**
 neurofibromatosis, **2:64-65**
 neurological research, **2:32, 42, 43, 45-46, 57-58, 60, 61, 62-63, 64-65, 66-67, 68, 145, 160-161, 176-177, 200, 203-205, 210, 221, 222, 3:36-37, 72, 92-93, 119, 135-136, 169, 197, 207, 225, 227-228, 229, 257**
 obesity, **2:23, 98, 159, 184**
 Parkinson's disease, **2:160**
 post-traumatic stress disorder, **2:32, 60, 222**
 population health, **3:169**
 rare and neglected diseases, **2:97-98, 214**
 registries, databases, and information systems, **2:23, 57-58, 60, 159, 176, 204-205, 3:16, 42, 93, 190, 197, 199, 206, 207, 225**
 rehabilitation research, **2:60, 177, 221, 222**
 schizophrenia and psychoses, **2:32, 161, 177, 3:28, 35-36, 134-135**
 strategic plans, **2:68, 69, 183**
 substance abuse, **2:157-158, 224, 3:15-16, 21, 92-93**
 suicidality, **3:20, 146-147**
 technology development, **2:45, 46, 58, 62-63, 97-98, 159, 176-177, 247, 3:36-37, 92-93, 207, 225, 227-228, 241-242, 246**
 training and career development, **3:57, 92-93, 169, 253, 256, 257, 261-262, 266-268**
 transplantation research, **2:122, 185, 228**
 traumatic brain injury, **2:60, 61, 221, 222**
 tuberous sclerosis complex, **2:64-65, 68**
 undiagnosed diseases, **2:147, 3:154**
 women's health, **2:85-86, 98, 158-159, 164, 180, 3:268**
- National Institute of Neurological Disorders and Stroke
 addiction, **2:97**
 Alzheimer's disease, **2:53, 206**
 amyotrophic lateral sclerosis, **2:58, 63, 64, 3:122, 201**
 ataxia-telangiectasia, **2:69**
 autism, **2:42, 57-58, 64-65, 69, 203-205, 214, 228, 3:119, 197, 4:49**
 autoimmune diseases, **2:56, 116, 117-118, 119-120, 122, 3:43-44, 78, 118-119, 143, 171-172, 236**
 Batten disease, **2:63, 3:122**
 behavioral and social sciences research, **2:155, 3:47, 89, 90-91, 128, 261**
 biodefense, **2:65, 96, 103, 3:120**
 biostatistics, **3:260**
 brain development, **2:43, 200, 3:229**
 cancer, **2:3, 17, 23, 28-29, 64, 69, 159, 182, 253-254, 3:42, 46-47, 129, 180, 199, 237**
 cerebral palsy, **3:141**
 child health and development, **2:43**
 chronic diseases and organ systems, **2:23, 28, 100-101, 145, 147, 149, 155, 159, 163, 178, 179-180, 181-182, 184-185, 3:6, 19, 42, 70-71, 78, 90-91, 127, 128, 133, 154, 199**
 chronic fatigue syndrome, **2:145**
 clinical and translational research, **2:28, 42, 53, 56, 57, 59-60, 61, 63, 64-65, 96, 97, 100-101, 116, 119-120, 147, 163, 179-180, 181-182, 203-204, 247-248, 3:38, 43-44, 50, 71, 78, 83, 90-91, 118-119, 120-121, 122, 127, 128, 129-130, 133, 141, 142, 143, 154, 156, 165, 169, 171-172, 180, 236, 237, 256, 257**
 communicating health information, **2:65, 258-259, 3:284-285**
 comparative effectiveness research, **2:56, 119-120, 3:165**
 Crohn's disease, **3:122**
 developmental processes and disorders, **2:43, 200, 214**
 diabetes, **2:64, 69, 122, 228**
 Down Syndrome, **2:69, 214, 228**

- National Institute of Neurological Disorders and Stroke (*continued*)
- epilepsy, **2:62**, 63, 64-65, **3:122**, 201
 - epidemiological and longitudinal studies, **2:149**, 253-254, 255-256, **3:6**, 19, 43-44
 - Fragile X Syndrome and associated disorders, **2:69**, 214, 228
 - genomics/genetics, **2:23**, 28-29, 53, 56, 58, 59-60, 63, 64-65, 117-118, 159, 204-205, 214, 247-248, **3:38**, 42, 43-44, 46-47, 50, 72, 78, 91, 118-119, 122, 128, 142, 156, 190, 199, 201
 - global health, **2:28**, 100-101, 181-182, **3:180**, 259-260
 - HIV/AIDS, **2:60**, 64, 71-72, 97, **3:129**-130, 180, 197
 - Huntington's disease, **2:63**, 97, **3:122**, 130
 - imaging tools, resources, and applications, **2:43**, 50, 57, 58, 59-60, 62, 63, 178, 200, 204-205, 222, **3:169**, 207, 225, 229, 257
 - infectious diseases, **2:28**, 60, 64, 65, 71-72, 96, 97, 100-101, 103, 181-182, **3:129**-130
 - infrastructure and research resources, **2:57**, 61, 214, **3:46**-47, 50, 128, 129, 207, 225, 237
 - intellectual and developmental disabilities, **2:214**
 - interdisciplinary research, **2:60**, 145, 155, 178, 222, **3:169**, 257
 - international research, **2:182**, **3:100**-101, 238-239
 - Laboratory of Functional and Molecular Imaging, **2:61**, **3:229**
 - liver disease, **2:185**, **3:122**
 - lupus, **2:117**-118, 247-248, **3:43**-44, 78, 118-119, 172
 - memory enhancement, **2:53**, 206
 - minority health and health disparities, **2:63**, 65, 149, 247-248, 253-254, 255-256, 258-259, **3:6**, 19, 43-44, 78, 118-119
 - mission, **5:7**
 - molecular biology and basic research, **2:64**-65, 178, 247-248, **3:43**-44, 47, 70-71, 72, 75, 78, 83, 89, 90-91, 101, 120-121, 127, 128, 129, 237, 238-239, 257
 - multidisciplinary research, **2:50**, 145
 - multiple sclerosis, **2:56**, 63, 119-120, **3:142**, 143
 - muscle recovery after injury, **2:163**, **3:127**
 - muscular dystrophies, **2:56**, 63, 64, 68-69, 163, **3:122**, 127, **4:19**, 23
 - nanotechnology, **3:240**-241
 - neurofibromatosis, **2:64**-65, **3:72**
 - obesity, **2:159**, 163, 182, 184, 253-254, **3:42**, 172
 - pain research, **2:50**, 178, 179-180, **3:70**-71, 133
 - Parkinson's disease, **2:51**, 53, 58, 63, 220-221, 253-254, **3:122**, 141, 201, 245, **4:5**
 - peripheral neuropathies, **2:64**, **3:71**, 120-121
 - prostheses, **2:51**, 220-221, **3:245**
 - RAID program, **3:122**
 - rare disorders, **2:59**-60, 214, **3:142**, **4:39**
 - registries, databases, and information systems, **2:23**, 57-58, 59, 60, 159, 204-205, **3:42**, 46-47, 142, 156, 190, 197, 199, 201, 207, 225
 - rehabilitation research, **2:51**, 60, 61, 163, 192, 220-221, 222, **3:142**, 245
 - sickle cell disease, **2:179**-180, **3:122**, 133
 - space-related research, **3:100**-101, 238-239
 - spinal muscular atrophy, **2:63**, **3:122**
 - stem cell research, **2:59**-60, 63, 97, **3:50**, 75, 122, 128, 130
 - strategic plans, **2:67**
 - stroke, **2:59**, 63, 65, 67, 182, 258-259, **3:42**, 122, 142, 284-285
 - substance abuse, **3:122**
 - technology development, **2:51**, 57, 58, 62, 116, **3:83**, 101, 129, 171-172, 207, 225, 229, 236, 237, 238-239, 240-241, 245
 - Tourette Syndrome, **2:58**, **3:201**
 - training and career development, **2:57**, 59, 182, **3:169**, 256, 257, 258, 259-260, 261
 - transplantation research, **2:122**, 185, 228
 - traumatic brain injury, **2:60**, 61, 63, 221, 222
 - tuberous sclerosis, **2:63**, 64, **3:72**, 122
 - undiagnosed diseases, **2:147**, **3:154**
 - women's health, **2:117**-118, 247-248, **3:43**-44, 78, 180
- National Institute of Nursing Research
- adolescent health, **2:219**, **3:8**
 - autoimmune diseases, **2:122**
 - behavioral and social sciences research, **2:155**, 189, 246-247, **3:47**, 89, 90-91, 128, 145
 - cancer, **2:3**
 - child health and development, **2:219**, **3:8**
 - chronic diseases and organ systems, **2:145**, 147, 154, 155, 167, 180, 182, 184, 185, 204, 210, 248, 249, **3:90**-91, 128, 145-146, 154
 - chronic fatigue syndrome, **2:145**
 - clinical and translational research, **2:59**-60, 88-89, 154, 155, 203, 248, 261-262, **3:90**-91, 128, 142, 145-146, 154, 156, 157-158, 160, 161, 163, 169, 172, 176, 180, 257, 259
 - communicating health information, **2:167**, 249, 260, 264, **3:161**, 163
 - community-based participatory research, **2:261**-262, **3:172**, 176
 - cost-effectiveness research, **3:156**
 - diabetes, **2:69**, 122, 154, 167, 228, 248, 249, **3:145**, 160
 - digestive diseases, **2:122**, 185
 - end-of-life care, **2:180**, 192, 203, 204, 210, **3:145**-146, 157-158
 - epidemiological and longitudinal studies, **2:219**, **3:7**-8
 - genomics/genetics, **2:59**-60, **3:47**, 91, 263
 - HIV/AIDS, **2:88**-89, **3:158**
 - imaging tools, resources, and applications, **2:57**, 59-60, 203, 222, **3:169**, 207, 225, 257
 - infectious diseases and biodefense, **2:88**-89, **3:158**
 - infrastructure and research resources, **2:57**, **3:157**-158, 172, 207, 225
 - interdisciplinary research, **2:57**, 60, 145, 155, 210, 222, **3:169**, 257
 - international initiatives, **2:246**-247, **3:259**
 - intramural program, **3:263**
 - liver disease, **2:185**
 - minority health and health disparities, **2:154**, 246-247, 248, 249, 260, 261-262, 264, **3:8**, 145, 160, 163, 176
 - mission, **5:9**
 - molecular biology and basic research, **2:155**, **3:47**, 89, 90-91, 128
 - multidisciplinary research, **2:145**
 - nanotechnology, **3:239**
 - neurological research, **2:57**, 58, 59-60, 61, 62, 69, 221, 222, **3:142**, 169, 207, 225, 257
 - obesity, **2:184**
 - population research, **2:219**, **3:7**-8
 - premature delivery, **2:203**, **3:239**
 - quality of life, **2:180**, 203, **3:145**
 - rare diseases, **2:59**-60, **3:142**
 - registries, databases, and information systems, **2:58**, **3:207**, 225
 - rehabilitation research, **1:60**, 61, 222
 - sleep disorders, **2:62**
 - strategic plans, **2:184**, 228
 - technology development, **2:57**, 58, **3:207**, 225, 239, 241-242
 - training and career development, **2:57**, 182, 210, **3:169**, 257, 258, 259, 263
 - traumatic brain injury, **2:61**, 221
 - undiagnosed diseases, **2:147**, **3:154**
 - women's health, **3:180**
- National Institute of Standards and Technology, **3:217**
- National Institute on Aging
- addiction research, **2:23**, 97, 159, **3:130**, 180
 - adolescent health and development, **3:8**
 - Alzheimer's disease, **2:32**, 52-53, 58-59, 206-208, **3:118**, 132, 151-152, 190, 278, **4:3**
 - animal models of disease, **2:97**, **3:129**-130
 - ataxia-telangiectasia, **2:69**
 - autoimmune diseases, **2:122**, **3:180**
 - behavioral and social science research, **2:155**, 246-247, **3:47**, 89, 90-91, 120, 164, 246
 - cancer research, **2:2**, 12, 23, 24-25, 26, 159, 200-201, **3:13**, 42, 77, 172, 180, 199
 - cardiovascular disease, **2:54**, 166, 200-201, **3:42**, 120, 160, 180, 199

National Institute on Aging (*continued*)

cell senescence research, **2:26**, **200**, **3:77**
 child health and development, **3:8**, **77**
 chronic diseases and organ systems, **2:54**,
 145, 149, 153, 154, 158, 159-160, 163,
 164, 166, 183, 184, 185, 209, 212-213,
 248, **3:42**, 90-91, 120, 127, 137, 160, 199
 chronic fatigue syndrome, **2:145**
 clinical and translational research, **2:12**,
 52-53, 54, 58-60, 97, 153, 154, 163, 164,
 166, 206-208, 223, 248, 261-262, **3:90**-
 91, 118, 120, 127, 128, 129-131, 132,
 137, 142, 151-152, 160, 163, 164, 165,
 169, 171, 172, 180, 238, 246, 257
 cognitive status and interventions, **2:54**-
 55, 206-207, 211-212, 214, **3:152**
 collaborative studies, **2:57**-60
 communicating health information,
2:158, 264, **3:91**, 163, 278, 284
 community-based studies, **2:214**
 comparative effectiveness research, **3:165**
 cooperative studies, **2:52**-53, 206-207
 demographic and economic studies,
2:211-212, **3:8**, 9-10
 diabetes research, **2:69**, 122, 154, 166,
 228, 248, **3:73**, 160, 180
 digestive diseases, **2:122**, 185
 Down Syndrome, **2:69**, 214, 228, **3:91**
 drug testing for new indications, **2:54**,
 164
 epidemiological and longitudinal studies,
2:24-25, 149, 200-201, 211-213, 219,
 250, **3:7**-8, 9-10, 13
 exercise/physical activity, **2:158**, **3:91**,
 246, 284
 Fragile X Syndrome and associated
 disorders, **2:69**, 214, 228
 genomics/genetics, **2:23**, 153, 158, 208,
3:39, 42, 47, 91, 180, 199, **4:6**
 ginkgo evaluation, **2:53**, 206
 HIV/AIDS research, **2:97**, **3:130**, 180
 Huntington's disease, **3:130**
 imaging tools, resources, and
 applications, **2:58**-59, 207, **3:132**, 169,
 207, 225, 257
 infectious diseases and biodefense, **2:97**,
3:130, 180, 238-239
 infrastructure and research resources,
2:97, 265, 267-268, **3:91**, 129-130, 164,
 171, 207, 225, 246
 intellectual and developmental
 disabilities, **2:214**, **3:91**
 interdisciplinary research, **2:57**, 145, 155,
3:268
 liver disease, **2:185**
 longevity, **3:39**
 menopausal symptom interventions,
2:206
 metabolic studies, **2:159**-160, 209
 minority health and health disparities,
2:220, 246-247, 248, 250, 264, 265, 267-
 268, **3:8**, 163, 171, 284
 mission, **5:8**

molecular biology and basic research,
2:223, **3:47**, 73, 75, 77, 89, 90-91, 100-
 101, 130-131, 164, 238-239, 246
 multidisciplinary research, **2:145**, 211-
 212
 muscle biology and diseases, **2:163**,
3:127
 nanotechnology, **3:241**-242
 neurological research, **2:32**, 52-53, 54-55,
 57, 58-60, 67, 97, 206-208, 220-221,
3:120, 127, 130, 132, 142, 169, 207, 225,
 257
 obesity, **2:23**, 159, 163, 184, **3:73**, 180
 osteoarthritis, **2:153**, **3:137**
 osteoporosis, **2:149**, 212-213, **3:10**
 Parkinson's disease, **2:54**, 164, **3:120**
 population research, **2:219**, **3:7**-8, 169
 presbycusis (hearing loss), **2:208**
 prevention trials, **2:53**, 54, 154, 206,
3:160
 rare diseases research, **2:59**-60, 214,
3:142
 regenerative medicine, **2:223**, **3:75**, 130-
 131, 238
 registries, databases, and information
 systems, **3:42**, **2:58**, 190, 199, 207, 225
 rehabilitation research, **2:192**, 220-221,
3:75
 spaced-related health research, **3:100**-
 101, 238-239
 stem cell research, **2:97**, 223, **3:75**, 130-
 131, 238
 strategic plans, **2:67**, 69, 183, 184, 185,
 227, 228
 stress response, **3:13**
 stroke research, **2:54**, 164, **3:42**, 120, 199
 taste perception, **3:73**
 technology development, **2:223**, **3:91**,
 100-101, 130-131, 164, 207, 225, 238-
 239, 241-242, 246
 training and career development, **2:57**,
3:169, 171, 256, 257, 258, 265, 266-267,
 268
 trans-NIH research, **2:57**, 69, 122, 145,
 228, **3:89**
 transplantation research, **2:122**, 185, 228
 Werner Syndrome, **2:26**, 200, **3:77**
 women's health, **2:149**, 206, 212-213,
3:10, 13, 180, 268

National Institute on Alcohol Abuse and
 Alcoholism
 action and injury mechanisms of alcohol,
2:184
 addiction research, **2:45**, 47, 66-67, 68,
 148, 170, 184, **3:36**-37, 92-93, 227-228
 adolescent health, **2:219**, **3:8**
 autoimmune diseases, **2:122**
 behavioral and social science research,
2:155, 184, 228, 246-247, **3:7**-8, 47, 89,
 90-92, 128
 cancer research, **2:2**, 7, 28
 cardiovascular disease, **2:142**
 child health and development, **2:219**, **3:8**
 chronic fatigue syndrome, **2:145**

clinical and translational research, **2:47**,
 57, 59-60, 66-67, 160-161, 162, 261-262,
3:90-91, 121, 139, 142, 159, 169, 176,
 180, 198, 256
 collaborative studies, **2:41**-42, 48, 57,
 151, **3:36**
 college drinking, **2:156**-157
 communicating health information,
2:261-262, **3:207**, 225, 288
 community-based participatory research,
2:261-262, **3:176**
 comorbid mental disorders, **2:66**-67, 157-
 158, 160-161, 224, **3:16**, 21, 139
 diabetes research, **2:69**, 122, 228
 digestive diseases, **2:122**, 185
 epidemiological and longitudinal studies,
2:157-158, 213, 219, 224 255, **3:7**-8, 16,
 17, 21
 fetal alcohol effects, **2:213**, 228, 255,
3:17
 genomics/genetics research, **2:41**-42, 45,
 46-47, 141, 148, 151, 162, **3:36**-37, 91-
 93, 227-228
 global health, **2:28**, 100-101, 181-182,
3:3:181
 gut-liver-brain interactions, **2:184**
 HIV-related research, **2:102**, 184, **3:159**
 imaging tools, resources, and
 applications, **2:58**, **3:169**, 207, 225, 257
 interdisciplinary studies, **2:57**, **3:90**-91,
 169, 257, 268
 liver disease, **2:142**, 185
 military veterans and their families,
2:157-158, 224, **3:21**, 159
 minority health and health disparities,
2:213, 246-247, 255, 261-262, **3:8**, 16,
 17, 176
 mission, **5:9**
 molecular biology and basic research,
3:36-37, 47, 89, 90-92, 100-101, 128,
 227-228, 238-239
 multidisciplinary studies, **2:151**, **3:36**
 nanotechnology, **3:241**-242
 neurological research, **2:32**, 41-42, 44-45,
 46-47, 57-58, 59-60, 66-67, 68, 69, 141,
 148, 151, 157, 160-161, 162, 170, 218,
 225, **3:36**-37, 92-93, 121, 139, 142, 169,
 176, 207, 225, 227-228, 257
 obesity research, **2:184**
 pharmacological interventions, **2:47**, 48,
 68, 162, 184, **3:121**
 population health, **2:219**, **3:7**-8, 169
 public policies, **3:204**
 rare diseases research, **2:59**-60, **3:142**
 registries, databases, and information
 systems, **2:58**, **3:198**, 204, 207, 225
 screening and brief interventions, **2:145**-
 146
 sensitivity to alcohol, **2:46**-47, 141, **3:92**
 smoking and alcohol use, **2:48**, 148, 225
 space-related research, **3:100**-101, 238-
 239
 strategic plans, **2:68**, 69, 102, 184-185,
 227-228

- National Institute on Alcohol Abuse and Alcoholism (*continued*)
 stress responses, **2:47**, 170
 technology development, **2:45**, 58, **3:36-37**, 92-93, 100-101, 207, 225, 227-228, 238-239, 241-242
 training and career development, **2:57**, 145-146, **3:169**, 256, 257, 258, 268
 transdisciplinary studies, **2:48**, 148, 225
 trans-NIH research, **2:102**, 145, 184-185, 228
 transplantation research, **2:122**, 185, 228
 underage drinking, **2:44-45**, 157, 218
 women's health, **3:180**, 268
- National Institute on Deafness and Other Communication Disorders
 adolescent health, **2:219**, **3:7-8**
 aging-related hearing loss, **2:208**
 autism, **2:42**, 57-58, 69, 203-205, 214, 228, **3:119**, 197
 autoimmune diseases, **2:122**
 behavioral and social sciences research, **3:47**, 89, 91, 261
 biostatistics, **3:260**
 cancer-related disorders, **2:3**, 28, 100-101, 181-182
 child health and development, **2:202**, 209-210, 219-220, **3:7-8**, 15, 119, 121, 148, 197
 chronic diseases and organ systems, **2:28**, 100-101, 149, 181-182, 255-256
 clinical and translational research, **2:28**, 42, 59-60, 100-101, 181-182, 203-204, 209-210, 261-262, **3:119**, 121, 142, 148, 161, 163, 169, 176, 180, 181, 234, 257
 collaborative research, **2:57**, **3:176**
 communicating health information, **2:264**, **3:161**, 163, 281-282, 287
 community-based participatory research, **2:261-262**, **3:176**
 developmental processes and disorders, **2:57-58**, 202
 diabetes, **2:55**, 69, 122, 228, **3:73**
 Down Syndrome, **2:69**, 214, 228
 epidemiological and longitudinal studies, **2:149**, 219-220, 255-256, **3:6**, 7-8, 15, 19
 eye diseases, **3:121**
 Fragile X Syndrome and associated disorders, **2:69**, 214, 228
 genetics/genomics, **2:57-58**, 59-60, 204-205, 208, 214, **3:47**, 91
 global health, **2:28**, 100-101, 181-182, **3:181**
 hearing and balance disorders, **2:55**, 69, 122, 209-210, 228, **3:67**, 148, 234, 245, 287
 imaging tools, resources, and applications, **2:51**, 57-58, 59-60, 204-205, **3:207**, 225, 257
 infectious diseases and biodefense, **2:28**, 100-101, 181-182
 Information Clearinghouse, **3:281-282**
 infrastructure and research resources, **2:57**, **3:227**
 intellectual and developmental disabilities, **2:214**
 interagency research, **2:69**, 228
 interdisciplinary research, **2:57**, **3:257**
 language impairment, **2:202**, 209-210, **3:148**
 laryngeal tissue regeneration, **2:222-223**
 minority health and health disparities, **2:149**, 219, 255-256, 261-262, 264, **3:6**, 7-8, 19, 163, 176, 281-282
 mission, **5:8**
 molecular biology and basic research, **3:47**, 67, 73, 75, 89, 91, 260, 261
 nanotechnology, **3:241-242**
 neurological research, **2:32**, 42, 51, 55, 57-58, 59-60, 68, 69, 203-205, 220-221, **3:67**, 119, 142, 169, 197, 207, 225, 245, 257
 population research, **2:219**, **3:7-8**
 prosthetics, **2:51**, 220-221
 rare diseases and disorders, **2:59-60**, **3:142**
 registries, databases, and information systems, **2:57-58**, 204-205, **3:197**, 207, 225, 282-282
 rehabilitation research, **2:51**, 192, 222-223, **3:245**
 stem cell research, **2:51**, 59-60, **3:75**
 strategic plans, **2:68**, 227
 taste, **3:73**, 222-223
 technology development, **2:57**, 58, 220-221, 222-223, **3:222-223**, 225, 234, 241-242, 245
 tinnitus, **2:51**
 training and career development, **2:57**, 227, 260, **3:169**, 256, 257, 260, 261
 treatment of hearing loss, **2:51**, 220-221
 women's health, **3:180**
- National Institute on Drug Abuse
 addiction research, **2:46**, 48, 49, 66-67, 158, 163, 225, **3:36-37**, 92-93, 139-140, 227-228, 288
 adolescent health and development, **2:43-44**, 99, 156, 201, 215, 219, **3:8**, 14, 92, 138-139, 288
 alcohol abuse, **2:48**, 225
 asthma, **2:172**
 attention deficit hyperactivity disorder, **2:167-168**, 213, **3:14-15**
 autism, **2:214**
 autoimmune diseases, **2:117**, 119, 122, **3:43**, 44, 200
 behavioral and social science research, **2:155**, 215, 217-218, **3:47**, 89-91, 128, 239
 bioethics, **3:259**
 cancer research, **2:2**, 7, 28, 48, 100-101, 181-182
 child health and development, **2:44**, 156, 167-168, 213, 215, 219, **3:8**, 14-15, 138-139
 chronic diseases and organ systems, **2:28**, 44, 48, 49, 50, 66-67, 100-101, 131, 146, 148, 156, 157-158, 160-161, 163, 167-168, 172, 178, 181-182, 183, 184, 185, 213, 215, 224, **3:14-15**, 21, 70-71, 90-91, 93, 138-140, 224-225
 clinical and translational research, **2:28**, 44, 48, 66-67, 66-67, 91, 92, 98, 99, 100-101, 155, 156, 160-161, 163, 181-182, 201, 215, 261-262, 263, 267-268, **3:15-16**, 50, 90-91, 128, 138-140, 148, 154, 158, 161, 162-163, 169, 170, 171, 176, 180, 181, 256, 257, 259
 communicating health information, **2:146**, **3:161**, 288
 community-based participatory research, **2:261-262**, **3:176**
 developmental processes and disorders, **2:43-44**, 200, 214, 217-218, **3:14**, 92
 diabetes research, **2:69**, 122, 228
 digestive diseases, **2:122**, 185
 Down Syndrome, **2:69**, 214, 228
 drug abuse, **2:43-44**, 156, 157-158, 215, 217-218, 254, 277, **3:7-9**, 14, 15-16, 21, 92, 138-139, 162-163, 224-225, 288
 epidemiological and longitudinal studies, **2:43-44**, 86, 92, 157-158, 167-168, 213, 217-218, 219, 224, 254, **3:7-9**, 14-16, 21, 92, 148, 204
 genetics/genomics, **2:46**, 117, 119, 214, 217-218, 225, **3:36-37**, 41, 43, 44, 47, 49, 50, 83, 91, 92-93, 200, 227-228
 global health, **2:28**, 100-101, 181-182, **3:181**
 HIV/AIDS research, **2:72**, 86, 91, 92-93, 99, 201, 263, **3:15-16**, 148, 158, 162-163, 170, 224-225, 261-262
 imaging tools, resources, and applications, **2:43**, 57, 58, 156, 178, 200, 217-218, 225, **3:169**, 207, 225, 257
 infectious diseases and biodefense, **2:28**, 72, 86, 91, 92-93, 99, 100-101, 102, 181-182, 201, 263, **3:15**, 148, 154, 158, 261-262
 infrastructure and research resources, **2:267-268**, **3:49**, 50, 83, 171, 207, 225
 inmate substance abuse treatment, **2:92**, 263, **3:162-163**
 interdisciplinary research, **2:57**, 98, 155, **3:89-90**, 239, 257, 268
 international initiatives, **2:254**, **3:8-9**, 181, 204, 261-262, 266-267
 liver disease, **2:185**
 mental disorders comorbid with addiction, **2:66-67**, 157-158, 160-161, 224, **3:21**, 139
 minority health and health disparities, **2:91**, 92, 219, 254, 261-262, 263, 267-268, 270, **3:8-9**, 162-163, 171, 176, 204
 mission, **5:9**
 molecular biology and basic research, **2:43-44**, 46, 48, 49, 50, 155, 158, 172, 178, 217-218, **3:14**, 36-37, 47, 49, 83, 70-71, 89-91, 92-93, 227-228, 239

- National Institute on Drug Abuse (*continued*)
 multidisciplinary research, **2**:48, 50, 92-93, 158, 178, 217-218, **3**:14, 93
 nanotechnology, **3**:241-242
 neurological research, **2**:32, 43-44, 46, 48, 49, 50, 57, 58, 66-67, 68, 69, 148, 156, 158, 160-161, 163, 178, 200, 215, 217-218, **3**:14, 36-37, 70-71, 92-93, 138-140, 169, 207, 225, 227-228, 257
 nicotine vaccine, **2**:48, 158, **3**:93
 obesity, **2**:184
 pain management, **2**:50, 178, **3**:70-71
 pharmacology, **2**:48, 49, 50, 92, 99, 148, 163, 167-168, 178, 201, 225, **3**:139-140
 population health, **2**:219, **3**:7-8, 169
 proteomics, **2**:214
 screening methods, **2**:131, 146
 registries, databases, and information systems, **2**:58, 254, **3**:8-9, 43, 200, 204, 207, 225
 strategic plans, **2**:68, 102, 122, 183, 184, 185, 227, 228, 270
 technology development, **2**:46, 58, 172, **3**:36-37, 41, 89-90, 92-93, 224-225, 227-228, 239, 241-242
 telemedicine, **2**:172, **3**:224-225
 tobacco-related research, **2**:2, 7, 48, 148, 158, 225, **3**:93
 training and career development, **2**:57, 92-93, 267-268, **3**:169, 256, 257, 259, 261-262, 266-267, 268
 transplantation research, **2**:122, 185, 228
 veteran drug abuse and comorbidities, **2**:157-158, 224, **3**:21
 women's health, **2**:98, **3**:15, 154, 180, 268
- National Institutes of Health Reform Act of 2006, **1**:5, 6, 7, 18, 19, 35-36, **3**:173, 256, **4**:1, 51, **5**:1-3, 10, 14, 25
- National Kidney Disease Education Program, **2**:193, 259, **3**:114, 162, 281
- National Latino and Asian American Study, **2**:238, 254, **3**:9
- National Library of Medicine
 aging-related resources, **3**:284
 AIDS*Info* service, **2**:258, **3**:290
 behavioral and social science research, **3**:89
 bioinformatics and computational biology, **3**:68
 cataloging and indexing, **1**:40
 ClinicalTrials.gov, **3**:147-148, 198
 collections and acquisition process, **1**:40
 communicating health information, **3**:163, 208, 282-284, 286-287, 289, 290, 291
 Daily Med, **3**:193
 dbGaP, **1**:29, **2**:151, 159, **3**:10, 22, 24, 42-43, 45, 49, 200
 disaster preparedness and information services, **3**:208, 286, 289
 Discovery Initiative, **3**:193, 196, 205
 DSLD, **3**:202-203
 Entrez database linkages, **3**:188, 205
- Genetics Home Reference and gene test information, **3**:165-166, 282
 global health, **3**:226, 263-264
 Individual Fellowship Awards, **3**:248
 Influenza Virus Resource, **2**:94-95, **3**:95, 199
 informatics research, **3**:195, 223
 Institutional Research Training Grants, **3**:248
 MedlinePlus, **1**:40, **2**:95, 256, 257, **3**:95, 188, 193, 199, 201, 276, 283, 286
 minority health information access, **2**:240, 256-258, 264, **3**:163, 276, 283, 286-287, 290
 mission, **3**:274, **5**:10
 nanotechnology, **3**:226-227
 National Network of Libraries of Medicine, **2**:256-257, **3**:286, 297
 Peer Tutor Program, **2**:240, 257-258
 PubChem, **3**:188, 193, 197, 205
 PubMed®/MEDLINE® database, **1**:40, **2**:93, **3**:95, 114, 187, 193, 196, 199, 275
 PubMed Central, **1**:41, **3**:114, 187-188, 196
 public access, **1**:40-41, **2**:78, **3**:114, 188, 196, 280
 public health information resources, **3**:291
 public-private partnerships, **3**:279, 289, 291
 rare disease and disorders, **3**:165-166
 SHARe, **2**:159, **3**:24, 45
 SharePoint for Genome Research, **3**:206
 standards for electronic health records, **3**:193, 204-205, 223-224
 technology development, **3**:205, 223-224, 246-247, 263-264
 TOXNET, **3**:197
 training and career development, **2**:240, 257-258, **3**:195, 205, 209-210, 226, 248, 249, 251, 258, 261, 263-264
 vocabularies, data protocols, and tools, **3**:193-194
 women's health research, **3**:180
- National Longitudinal Study of Adolescent Health, **2**:219, **3**:7-8
- National Lung Screening Trial, **2**:15, **3**:230
- National Nanotechnology Initiative, **3**:219, 241
- National Naval Medical Center, **2**:60, 222, **3**:279
- National NeuroAIDS Tissue Consortium, **2**:60, **3**:197
- National Ophthalmic Disease Genotyping and Phenotyping Network, **3**:190, 200-201
- National Organization for Rare Disorders, **4**:43
- National Primate Research Centers, **2**:97, **3**:106-107, 129-130, 171
- National Quality Forum, **2**:8
- National Registry of Genetically Triggered Thoracic Aortic Aneurysms and Cardiovascular Conditions, **3**:191
- National Research Service Awards, **3**:247, 249, 250-251, 252, 255-256, 258, 265, 266, 267, **5**:37-42
- National Resource for Zebrafish, **3**:58
- National Science Advisory Board for Biosecurity, **1**:49, 50, **2**:72
- National Science Foundation, **2**:215, 265
- National Stem Cell Bank, **3**:66, 75
- National Survey of American Life, **2**:238, 254, **3**:9
- National Survey of Physicians and CAM Providers, **3**:166
- National Toxicology Program, **2**:21-22, 98, 225-226, **3**:64, 87-89, 131, 177, 189
- Native Americans (*see* American Indians and Native Alaskans)
- Native Youth Preventing Diabetes, **4**:32
- Natural History of Acute Kidney Injury study, **2**:172-173
- Navy National Medical Center, **3**:195, 208, 289
- NCBC (*see* National Centers for Biomedical Computing)
- NCBI (*see* National Center for Biotechnology Information)
- NCCAM (*see* National Center for Complementary and Alternative Medicine)
- NCGC (*see* Chemical Genomics Center)
- NCI (*see* National Cancer Institute)
- NCMHD (*see* National Center on Minority Health and Health Disparities)
- NCMHD Centers of Excellence, **4**:27-37
- NCRR (*see* National Center for Research Resources)
- NCS (*see* National Children's Study)
- NDAR (*see* National Database for Autism Research)
- Near-Term Development for Genome Sequencing Grants, **3**:40, 227
- NEI (*see* National Eye Institute)
- NEIGHBOR (NEI Glaucoma Human Genetics CollaBORation), **2**:151, **3**:45
- Neonatal Research Network, **2**:224, **3**:110, 153
- Nephrotic syndromes and nephrosis, **4**:41
- NESARC (*see* National Epidemiologic Survey on Alcohol and Related Conditions)
- Neural interfaces, **2**:51, 220-221, **3**:220, 245
- Neural Prosthesis Program, **2**:63, **3**:122, 220
- Neural regeneration, **2**:50-51, 223-224, **3**:234
- Neural tube defects, **2**:32, 34, 41, 191, 192, 199, 284, **3**:34
- Neuro-Ophthalmology Research Disease Investigator Consortium, **2**:40, 59, **3**:140
- Neuroblastoma, **2**:4-5, 16, 17, 64, 212, **3**:153
- Neurofibromatosis, **2**:16, 17, 32, 64-65, 284, **3**:72, 153
- Neurogenetics DNA Diagnostic Lab, **3**:165
- Neuroimaging Informatics Tools and Resources Clearinghouse, **2**:39-40, 58, **3**:194, 207, 214, 225
- Neurokinin-1, **2**:36, 47, 170

- NeuroLex, **3**:194
- Neurological Emergency Clinical Trials Network, **2**:66, **96**, **3**:120
- Neuronal nitric oxide synthase, **4**:23
- Neuropeptide Y, **2**:47, 170
- Neuroscience and neurological disorders (*see also* Brain; Mental health; National Institute of Neurological Disorders and Stroke; Autism; Pain; Stroke; *other specific disorders*)
- aging-related diseases and disorders, **2**:13, **32**, **34**, **38**, **53**, **54-55**, **77**, **86**, **132**, **153**, **194**, **196**, **200-201**, **203**, **205**, **206**, **207**, **208**, **211**, **253**, **3**:152
- alcohol abuse and alcoholism, **2**:34, **36**, **41-42**, **44-45**, **46-47**, **66-67**, **68**, **141**, **148**, **151**, **156**, **157**, **160-161**, **162**, **170**, **215**, **218**, **225**, **3**:36, **92**
- animal models, **2**:37, **38**, **46-47**, **55**, **97**, **141**, **208**, **3**:92, **108**, **130**, **216**, **4**:21, **22-23**
- ARRA grants, **2**:35, **42**, **63**, **202-203**, **274-290**, **3**:119, **122**, **4**:5, **21**, **22**
- autoimmune diseases, **2**:32, **34**, **35**, **39**, **56**, **63**, **107**, **109**, **110**, **113**, **115**, **119-120**, **126**, **138**, **174**, **281**, **3**:88, **119**, **143**
- Blueprint for Neuroscience Research, **2**:31, **39**, **57-58**
- cancers, **2**:4-5, **16**, **17**, **32**, **63**, **64-65**, **68**, **212**, **286**, **3**:72, **153**
- chemical threat countermeasures, **2**:66, **79-80**, **96**, **3**:120
- chronic diseases, **2**:43, **44**, **46-48**, **49-50**, **137**, **139**, **141-142**, **145**, **148**, **151**, **156**, **157**, **158**, **160-161**, **162-163**, **164**, **170**, **176-180**, **210**, **215**, **225**, **3**:71, **73**, **92**, **93**, **133**, **138-139**
- clinical and translational research, **2**:31, **34**, **36-38**, **39**, **40**, **42**, **43-44**, **45-46**, **47**, **48**, **49**, **52-53**, **54-56**, **57**, **58-60**, **61**, **63**, **64-65**, **66-67**, **97**, **113**, **119-120**, **156**, **158**, **160-161**, **162-163**, **164**, **176-177**, **179-180**, **196**, **203**, **207-208**, **215**, **3**:71, **93**, **107**, **110**, **118**, **120-121**, **122**, **127**, **130**, **132**, **133**, **135-136**, **138-140**, **141-142**, **143**, **151-152**, **153**, **169**, **257**, **4**:20
- cognitive, emotional, and behavioral function, **1**:27, **2**:31, **32**, **33**, **36**, **44**, **45-46**, **53**, **54-55**, **69**, **119**, **128**, **156**, **161**, **176-177**, **192**, **195**, **206**, **207**, **214**, **215**, **228**, **277**, **284**, **3**:135-136, **138-139**, **152**
- collaborative research, **2**:31, **32**, **34**, **35**, **39-42**, **47**, **48**, **56**, **57-61**, **63**, **65**, **132**, **151**, **162**, **221**, **222**, **3**:36, **107**, **121**, **132**, **140**, **142**, **169**, **197**, **201**, **207**, **225**, **257**, **284-285**
- communicating health information, **1**:27, **2**:40-41, **65**, **239**, **258-259**, **3**:284-285
- comorbidities, **2**:66-67, **160-161**, **3**:139
- complementary and alternative medicines, **2**:52, **53**, **57**, **58**, **66**, **68**, **139**, **179**, **206**, **3**:73-74
- computational neuroscience, **2**:57, **3**:169, **257**
- cranial sensory ganglia, **2**:42-43, **214**, **3**:72
- degeneration, **2**:32, **33**, **37-39**, **52-57**, **120-121**, **144**, **164**, **206-208**, **284**, **3**:39, **61**, **73-74**, **85**, **99**, **118**, **120**, **127**, **130**, **141**, **143**, **151-152**, **4**:5
- developmental processes and disorders, **2**:32, **33**, **34-35**, **41-45**, **57**, **63**, **69**, **145**, **151**, **156**, **157**, **191**, **192**, **195**, **199**, **200**, **202-203**, **210**, **214**, **215**, **217-218**, **219**, **228**, **275**, **277**, **284**, **3**:14, **20-21**, **34**, **36**, **72**, **88**, **92**, **119**, **138-139**
- diabetic neuropathies, **2**:38, **55**, **64**, **114**, **125**, **127**, **3**:71, **120-121**
- environmental factors, **2**:34, **42**, **44**, **53-54**, **119**, **144**, **217-218**, **219**, **3**:14, **20-21**, **39**, **85**, **88**, **92**, **130**
- epidemiological and longitudinal studies, **2**:34, **35**, **41-42**, **43-44**, **65**, **66-67**, **132**, **151**, **160-161**, **195-196**, **200**, **217-218**, **219**, **253**, **3**:14, **20-21**, **36**, **92**, **139**
- epigenetics, **2**:36, **44**, **46**
- eye diseases and disorders, **2**:39, **40**, **55-56**, **59**, **128**, **151**, **235**, **3**:45, **140**
- funding, **2**:33, **42**, **56**, **63**, **274-290**, **3**:122
- gene-environment interactions, **2**:38, **42**, **53-54**
- gene therapy, **2**:38, **53**, **55-56**, **59-60**, **63**, **3**:122, **127**, **141**, **142**, **4**:20, **21**, **22**, **23**
- genomics, **2**:32, **34**, **35**, **36**, **38**, **39**, **41-42**, **44-45**, **46-47**, **48**, **49**, **56**, **57**, **58-59**, **63**, **64-65**, **119-120**, **132**, **141**, **148**, **151**, **158**, **159**, **199**, **225**, **3**:34, **36**, **92-93**, **99**, **107**, **132**, **143**, **190**, **201**, **227-228**, **4**:20
- global health, **2**:33, **100-101**, **181-182**
- HIV/AIDS, **2**:35, **45**, **46**, **60**, **64**, **68**, **92**, **176**, **3**:120-121, **135**, **197**
- hypothermia therapy, **2**:61, **221**
- imaging, **2**:31, **35**, **37**, **38**, **39-40**, **43**, **44**, **45**, **47**, **48**, **49**, **50**, **55**, **57-59**, **60-61**, **62**, **63**, **133**, **136**, **141**, **156**, **170**, **176-177**, **178**, **194**, **196**, **200**, **204**, **207**, **215**, **218**, **222**, **225**, **3**:73, **107**, **132**, **135-136**, **169**, **207**, **225**, **229**, **257**, **4**:5, **6**, **7-8**
- immunology and immunotherapy, **2**:36, **38**, **45**, **48**, **52-53**, **56**, **64**, **111**, **120**, **158**, **174**, **206-207**
- inflammation and, **3**:61
- infrastructure and research resources, **2**:31, **39-40**, **41-42**, **45-46**, **47**, **56**, **57-58**, **59**, **66**, **93**, **151**, **204-205**, **3**:36, **92-93**, **115**, **127**, **142**, **194**, **197**, **207**, **214**, **225**, **227-228**
- intellectual and learning disabilities, **2**:32, **34**, **35**, **39**, **42**, **57-58**, **69**, **195**, **214**, **228**, **277**
- interdisciplinary research, **2**:40, **57**, **60**, **222**, **3**:169, **257**
- international initiatives, **2**:34, **37**, **41**, **52-53**, **196**, **199**, **206-207**, **3**:34
- minority health and health disparities, **2**:33, **63**, **65**, **239**, **258-259**, **280**, **3**:141-142, **253**, **284-285**
- molecular biology and basic research, **2**:31, **32**, **36**, **40**, **42-44**, **46-47**, **48**, **49-50**, **51-52**, **53-54**, **61**, **62**, **64-65**, **129**, **141**, **159**, **177-178**, **214**, **217-218**, **3**:14, **36**, **59**, **61**, **70-71**, **72**, **73-74**, **85**, **92-93**, **99**, **120-121**, **227-228**, **4**:20
- multidisciplinary research, **2**:31, **32**, **41-42**, **44**, **48**, **50**, **54**, **151**, **158**, **178**, **179-180**, **217-218**, **3**:14, **36**, **70-71**, **85**, **92**, **93**, **133**
- nanotechnology, **2**:37, **45**, **50-51**, **223-224**, **3**:216, **234**
- obesity and, **2**:32, **36**, **49**, **59**, **129**, **141**, **3**:73, **140**
- older adults, **2**:53, **54-55**, **206**, **207**, **3**:152
- pediatric, **2**:32, **43-45**, **61**, **145**, **200**, **210**
- peripheral neuropathies, **2**:64, **3**:120-121
- personalized medicine, **2**:36, **45**, **176**, **3**:99, **135**
- plasticity, **2**:32, **36-37**, **45-51**, **141**, **148**, **158**, **162-163**, **170**, **176-178**, **220-221**, **223-224**, **225**, **3**:70-71, **73**, **92-93**, **121**, **135-136**, **139-140**, **227-228**, **234**, **245**
- prosthetics, **2**:51, **63**, **220-221**, **3**:122, **220**, **245**
- public-private partnerships, **1**:29-30, **2**:38, **40**, **48**, **54-55**, **58-59**, **207**, **3**:107, **132**, **152**, **4**:21
- radiation countermeasures, **2**:66, **96**
- rare diseases, **2**:32, **33**, **40**, **59-60**, **63**, **64**, **131**, **275**, **277**, **3**:120, **122**, **140**, **142**, **165-166**, **4**:40, **41**, **42**
- regeneration research, **2**:37, **50-51**, **60**, **223-224**, **3**:216, **222**, **234**
- registries, databases, and information systems, **2**:39-40, **41-42**, **43**, **57-58**, **59**, **60**, **200**, **204-205**, **3**:142, **189**, **190**, **197**, **201**, **207**, **225**, **4**:22
- rehabilitation, **2**:51, **61**, **220-221**, **223-224**, **3**:220, **234**, **245**
- sensory impairments, **2**:31, **32**, **38-39**, **42-43**, **51**, **55**, **208**, **214**, **220-221**, **3**:72, **220**, **245**
- sleep disorders and, **2**:61, **4**:22
- statistics and burden of illness, **2**:33
- stem cell research, **2**:37, **51**, **59**, **63**, **97**, **223**, **3**:122, **130**, **142**, **4**:20
- strategic plans, **2**:42, **67-68**
- stress response, **2**:32, **36**, **38**, **44**, **47**, **54**, **170**
- substance abuse and addiction research, **1**:27, **2**:31, **32**, **34**, **35**, **36**, **37**, **43-44**, **46**, **48**, **49**, **50**, **66-67**, **97**, **148**, **158**, **160-161**, **162-163**, **217-218**, **225**, **3**:14, **36**, **92-93**, **227-228**
- technology development, **2**:37, **46**, **50-51**, **58**, **61**, **62-63**, **220-221**, **223-224**, **3**:36, **92-93**, **207**, **216**, **220**, **225**, **227-228**, **229**, **234**, **245**
- training and career development, **2**:31, **39**, **40**, **56**, **57**, **59**, **204**, **3**:142, **169**, **251**, **257**, **4**:21
- trans-agency initiatives, **2**:40, **69**

- Neuroscience and neurological disorders
(*continued*)
trans-NIH research, **1**:18, 29-30, **2**:39, 57, 61, 68-69
transdisciplinary research, **2**:48, 148, 225
vaccines, **2**:36-37, 48, 49, 158, 163, **3**:93
women's health, **2**:40
- Neuroscience Information Framework, **3**:194
- Neutropenia, **3**:38, 114, 156
- New Immigrant Survey, **2**:219, **3**:7-8
- New Innovator Award Program, **3**:98-99, **5**:19
- New York Consortium for Alzheimer's Research and Education, **4**:6
- Newborn Screening Saves Lives Act of 2007, **5**:5
- NExT (*see* Experimental Therapeutics Program)
- NHANES (*see* National Health and Nutrition Examination Survey)
- NHGRI (*see* National Human Genome Research Institute)
- NHIS (*see* National Health Interview Survey)
- NHLBI (*see* National Heart, Lung, and Blood Institute)
- NIA (*see* National Institute on Aging)
- NIAAA (*see* National Institute on Alcohol Abuse and Alcoholism)
- NIAID (*see* National Institute of Allergy and Infectious Diseases)
- NIAMS (*see* National Institute of Arthritis and Musculoskeletal and Skin Diseases)
- NIBIB (*see* National Institute of Biomedical Imaging and Bioengineering)
- NICHD (*see* Eunice Kennedy Shriver National Institute of Child Health and Human Development)
- NIDA (*see* National Institute on Drug Abuse)
- NIDA-Modified Alcohol, Smoking, and Substance Involvement Screening Test, **2**:131, 146, **3**:288
- NIDCD (*see* National Institute on Deafness and Other Communication Disorders)
- NIDCR (*see* National Institute of Dental and Craniofacial Research)
- NIDDK (*see* National Institute of Diabetes and Digestive and Kidney Diseases)
- NIEHS (*see* National Institute of Environmental Health Sciences)
- Niemann-Pick disease, **2**:60, **3**:142, **4**:41, 42
- NIF (*see* Neuroscience Information Framework)
- NIGMS (*see* National Institute of General Medical Sciences)
- NIH Blueprint for Neuroscience Research, **2**:31, 39, 57-58, **3**:169, 194, 207, 225, 251, 257
- NIH Clinical Center
autoimmune diseases, **2**:116, **3**:44-45, 202
Bench-to-Bedside Program, **3**:134
Clinical Research Information System, **3**:198
community-based research, **3**:172
Department of Bioethics, **1**:46, 47
diagnostic microbiology, **2**:98
disaster response, **3**:195, 208, 279, 269
facilities and staff, **1**:13, 14, 23
genomics, **3**:10, 44-45
HIV/AIDS research, **2**:87, 250
image-guided interventions, **3**:228-229
infectious diseases and biodefense, **2**:87, 98, 250
Metabolic Clinical Research Unit, **2**:137, 170-171, **3**:18-19, 111, 150
mission, **5**:10
optimizing programs, **1**:7
ProtoType, **3**:198
registries, databases, and information systems, **3**:44-45, 96, 193, 198, 202, 206, 208, 279, 289
renovations, **1**:23
Sjogren's Syndrome Clinic, **2**:116, **3**:44-45, 202
training and career development, **3**:263, 264-265, **5**:16, 43
traumatic brain injury, **2**:60, 61, 220, 221
Undiagnosed Diseases Program, **1**:14-15, **2**:131, 147, **2**:147, **3**:154
volume of patients, **3**:105
- NIH Data Book, **1**:35
- NIH Image Processing Facility, **1**:28
- NIH Obesity Research Task Force Strategic Plan, **2**:6
- NIH Science of Eliminating Health Disparities Summit, **2**:232-233
- NIHSeniorHealth website, **3**:284
- NIMH (*see* National Institute of Mental Health)
- NINDS (*see* National Institute of Neurological Disorders and Stroke)
- NINR (*see* National Institute of Nursing Research)
- NIOSH (*see* National Institute for Occupational Safety and Health)
- NITRC (*see* Neuroimaging Informatics Tools and Resources Clearinghouse)
- NLM (*see* National Library of Medicine)
- NLST (*see* National Lung Screening Trial)
- NNMC (*see* National Naval Medical Center)
- NNTC (*see* National NeuroAIDS Tissue Consortium)
- Non-dystrophic myotonic disorders, **4**:42
- Non-Hodgkin lymphoma, **2**:23, 113
- Nonalcoholic Steatohepatitis (NASH) Clinical Research Network, **2**:136, 169, **3**:148-149
- NORDIC (*see* Neuro-Ophthalmology Research Disease Investigator Consortium)
- North American AIDS Cohort Collaboration on Research and Design, **3**:159
- North East Cyberinfrastructure Consortium, **2**:244, 268, **3**:170
- NSABB (*see* National Science Advisory Board for Biosecurity)
- NSAL (*see* National Survey of American Life)
- NTP (*see* National Toxicology Program)
- Nuclear/radiological countermeasures, **2**:66, 79, 80, 96-87, 103, **3**:120, 123
- Nurses/nursing, **2**:260, **4**:31
- Nursing Home Comorbid Depression Care Management, **2**:134
- Nutrient Data Laboratory, **3**:201
- Nutrition and fitness (*see also* Dietary supplements; Physical exercise), **2**:74, 132, 134, 136, 137, 149, 158, 159-160, 161, 163, 167, 170, 195, 209, 212-213, 217, 249, 251, 259, 284, **3**:10, 22, 111, 127, 145, 150, 162, 281, 284
- nVision, **1**:28
- O**
- OACU (*see* Office of Animal Care and Use)
- OAIC (*see* Claude D. Pepper Older Americans Independence Centers)
- OAR (*see* Office of AIDS Research)
- OBA (*see* Office of Biotechnology Activities)
- Obesity
adolescents, **2**:137, 170-171, 186, 195, 251, **3**:18-19, 111, 150
bariatric surgery, **2**:135, 137, 170-171, **3**:18-19, 111, 150
behavioral and social sciences research, **2**:136, 195, 251, **3**:65, **4**:31
cancer, **2**:6, 13, 18-19, 24-25, 127, 194, 205, 253
cardiovascular disease, **2**:132, 143, 150, 192, 251, 252, **3**:144-145, **4**:31
childhood, **2**:19, 125, 127, 133, 150, 152, 186, 192-193, 194, 195, 205, 210, 220, **3**:16-17, 143-144, 285
clinical and translational research, **3**:106, 114, 115, 136, 137, 143-145, 154, 160, 170-171, 173, 177, 195, **3**:18-19, 144-145, 150
communicating information on, **2**:239-240, 257, 259, **3**:114, 143-144, 162, 261, 281, 286
comorbidities, **2**:59, 127, 143, 154, 192, 234, 248, **3**:140, 144-145
depression, **2**:127
developmental dimensions, **2**:191, 192
diabetes and, **2**:127, 133, 136, 143, 154, 167, 170, 192, 195, 205, 234, **3**:19, 111, 114, 144-145, 154, 160, 162
epidemiological and longitudinal studies, **2**:5, 13, 18-19, 24-25, 132, 153, 170-171, 205, 253, 262, **3**:12, 16-17, 18-19, 24, 45, 137, 150
estrogen and, **2**:98, **3**:154
etiology and risk factors, **2**:18-19, 150, 152, 153, 154, 210, 220, 252, **3**:12
eye diseases and disorders, **2**:59, **3**:140, 143
exercise and nutrition, **2**:163, 195, 251, 259, **3**:127, 162, 281
funding, **2**:284, **3**:115
genomics, **2**:23, 49, 141, 159, **3**:24, 29, 30, 42, 45, 73, 199, 185, 190, 199
and hypertension, **2**:59

- Obesity (*continued*)
inflammation and fat cell biology, **2**:143, **3**:144-145
international initiatives, **2**:140
liver and gallbladder disease, **2**:127
measure of, **2**:127
minority health and health disparities, **2**:132, 150, 234, 251, 252, 261, **3**:114, 162, 177, 281, **4**:28, 30, 31
molecular biology and basic research, **1**:3, **2**:49, 141, 143, **3**:66, 73, 144-145
neural basis, **2**:32, 36, 49, 59, 129, 141, **3**:73, 140
osteoarthritis, **2**:127
pregnancy and, **2**:192
prevention/intervention, **2**:133, 152, 195, 205, 210, 241, 261, **3**:176-177
registries, databases, and information systems, **2**:23, 159, **3**:42, 199
sleep disorders, **2**:127
statistics and burden of disease, **2**:125, 133, 159, 186, 192, 193, **4**:30
strategic plans, **2**:6, 184
therapies, **2**:130, 135, 137, 141, 143, 163, 170-171
training for researchers, **2**:140, 182
translational research, **2**:154, 163, 248
urinary incontinence, **2**:127, 170, **3**:22, 150
women's health, **2**:98, 152, 170, 192, 195, 210, **3**:22, 150, 154, **4**:30
- Obsessive compulsive disorder, **3**:281
- OBSSR (*see* Office of Behavioral research)
- Obstetric Pharmacology Research Network, **2**:224, **3**:110, 153
- Obstetrical care, **2**:262, **3**:157, 166
- Obstructive sleep apnea, **2**:127, 136, 165-166, **3**:136-137
- OCIO (*see* Office of the Chief Information Officer)
- OCRME (*see* Office of Clinical Research Training and Medical Education)
- OD (*see* Office of the Director)
- ODP (*see* Office of Disease Prevention)
- ODS (*see* Office of Dietary Supplements)
- OEP (*see* Office of Extramural Programs)
- OER (*see* Office of Extramural Research)
- Office of Administrative Operations, **1**:7
- Office of AIDS Research, **1**:8, 9, 18, **2**:27, 29, 68, 71, 72, 85, 86-88, 101, 103, 184, 219, 250, 258, 269, **3**:8, 89, 134, 287, 290, **5**:11
- Office of Animal Care and Use, **1**:7, 46-47
- Office of Behavioral and Social Sciences Research, **5**:11
- Office of Behavioral Research, **1**:8, 9, **2**:57, 58, 145, 152, 154, 155, 184, 210, 219, 247, 248, 262, 264, **3**:7-8, 47, 89-91, 128, 134, 160, 161, 163, 169, 174, 176, 180, 207, 225, 239, 257, 262, 263
- Office of Biotechnology Activities, **1**:48, 49, 50, **3**:133, 161, 172, 182
- Office of Cancer Survivorship, **2**:9
- Office of Clinical Research Training and Medical Education, **1**:14
- Office of Communications and Public Liaison, **1**:8, **3**:173, 258, 271, 274, 277, 280
- Office of Dietary Supplements, **1**:8, **2**:53, 145, 149, 161, 182, 184, 206, 228, 255-256, **3**:6, 19, 47, 91, 147, 156, 161, 169, 180, 201-202, 236, 256, 268, **5**:11
- Office of Disease Prevention, **1**:8, 9, **2**:53, 59-60, 145, 147, 149, 161, 164-165, 182, 184, 206, 255-256, **3**:19, 47, 89, 91, 131-132, 134, 142, 147, 154, 156-157, 161, 165-166, 169, 180, 201-202, 236, 256, 268, 282, 285, 290-291, **5**:11
- Office of Equal Opportunity and Diversity Management, **1**:8
- Office of Extramural Programs, **1**:7, 45
- Office of Extramural Research, **1**:7, 9, 11, 24, 35, 39, 44, 45, 46, **2**:245, **3**:75, 154-155, 252, 253, 254, 255-256, 258-259, 265-266, 267-268, **5**:20
- Office of Financial Management, **1**:24, 39
- Office of Government Ethics, **1**:43
- Office of History, **1**:8
- Office of Human Subjects Research, **1**:7, 45
- Office of Intramural Research, **1**:7, 8, 9, 13-14, 45, 46, **2**:245, **3**:154-155, 172, 257-258
- Office of Intramural Training and Education, **1**:7, 14, **3**:257
- Office of Laboratory Animal Welfare, **1**:7, 46
- Office of Legislative Policy and Analysis, **1**:8
- Office of Management, **1**:8
- Office of Management Assessment, **1**:23-24
- Office of Medical Applications of Research, **1**:8, 9, **3**:115, 156-157, 285, 290-291, **5**:11
- Office of Minority Programs, **2**:231
- Office of Policy for Extramural Research Administration, **1**:7
- Office of Portfolio Analysis and Strategic Initiatives, **1**:8, **5**:10
- Office of Rare Diseases Research, **1**:8, 9, 14-15, **2**:59-60, 147, 164-165, **3**:132-133, 134, 142, 154, 156, 165, 166, 282, **4**:22, **5**:11
- Office of Research Information Systems, **1**:7
- Office of Research Facilities, **1**:7
Division of Environmental Protection, **1**:24
- Office of Research on Minority Health, **2**:231
- Office of Research on Women's Health, **1**:8, 9, **2**:27, 98, 101, 116, 122, 145, 153, 154, 155, 167, 168, 169, 170-171, 178-179, 184, 185, 192, 201, 202, 206, 219, 224, 245, 248, 249, 261-262, **3**:7-8, 18-19, 44-45, 75, 89, 134, 136, 137, 145, 150, 153, 154-155, 160, 167, 176, 180, 202, 236, 258, 268, 280, **5**:11, 45-50
- Office of Science Policy, **1**:8, 29, 30, 48, **2**:72, 184, **3**:75, 133, 161, 165, 172, 182, 242, **5**:17
- Office of Science Policy Analysis, **1**:48, **3**:75, 165, 242
- Office of Strategic Coordination, **1**:8, 9, **5**:10, 25
- Office of Technology Transfer, **1**:7, 39-40
- Office of the Chief Information Officer, **1**:8, 27-28
- Office of the Director
communicating health information, **3**:271, 277
Division of Program Coordination, Planning, and Strategic Initiatives, **1**:8, 9, 17, 18, **2**:155, **3**:91, 128, 165, **5**:10
mission, **5**:10-11
research initiatives, **2**:92-93, **3**:65, 75, 96, 193, 206, 258, 261-262, 268
structure and organization, **1**:7-8, 9
- Office of the Surgeon General, **2**:44-45, 149, 157, 202, 212, 218, 226, 235, **3**:10, 33-34, 164
- OHARA (*see* Oral HIV/AIDS Research Alliance)
- OHSR (*see* Office of Human Subjects Research)
- OIR (*see* Office of Intramural Research)
- OITE (*see* Office of Intramural Training and Education)
- OLAW (*see* Office of Laboratory Animal Welfare)
- Older adults (*see also* Aging; Claude D. Pepper Older Americans Independence Centers)
automobile crash risk, **3**:91, 113, 164, 220, 246
bone health, **2**:132, 149, 212, **3**:91, 113, 164, 220-221, 246, **4**:15
burden of illness, **2**:33, 193, **4**:13-14
chronic diseases, **2**:133, 158, 173-174, **3**:147, 284
clinical research, **2**:54-55, 134, 207, **3**:152, **4**:15
communicating health information to, **2**:65, 158, 239, **3**:284-285
comorbid conditions, **2**:133
developmentally/intellectually disabled, **3**:91, 113, 164, 220-221, 246
donation of corneas, **2**:174-175, **3**:147
epidemiological and longitudinal studies, **2**:211, **3**:4, 9
frailty, **4**:15
HIV/AIDS, **2**:76-77, 86, **3**:15
mental illness, **2**:203
neurological diseases and disorders, **2**:53, 54-55, 206, 207, **3**:152
physical activity and exercise, **2**:134, 158, 191, **3**:91, 113, 164, 220, 246, 284, **4**:14, 15
population ages 65 and older, **4**:4
rehabilitation, **4**:15
stroke, **2**:65, 239, **3**:284-285, **4**:15
- Older Americans Independence Centers (*see* Claude D. Pepper Older Americans Independence Centers)
- OMAR (*see* Office of Medical Applications of Research)

- Omega-3 fatty acids, **2:38**, 52, 127, 206, **3:151**, **4:7**
- OpenSim, **3:230**
- Optical coherence tomography, **2:24**, 67, 183, 227, **3:218**, 228
- Optogenetics, **2:62-63**
- Oral and pharyngeal cancers, **2:26-27**, 235
- Oral-facial clefts, **2:41**, 199, **3:34**
- Oral health care (*see also* Salivary gland), **2:17**, 89-90, 216, 235, 239, 241, 260, 263-264, **3:5**, 13-14, 115, 149, 151, 161-162, 277, 287-289
- Oral HIV/AIDS Research Alliance, **2:89-90**, **3:5**, 13-14, 149
- ORDR (*see* Office of Rare Diseases Research)
- ORWH (*see* Office of Research on Women's Health)
- OSC (*see* Office of Strategic Coordination)
- OSP (*see* Office of Science Policy)
- OSPA (*see* Office of Science Policy Analysis)
- Osteoarthritis, **2:115**, 127, 128, 138, 153, 175, 187, 192, 246, **3:70**, 91, 113, 137, 164, 166, 181, 218, 246
- Osteogenesis imperfecta, **2:129**, 187, 284
- Osteoporosis, **2:13**, 98, 128, 130, 132, 134, 143, 149, 153, 187, 205, 212-213, 217, 253, 262, 282, 285, **3:10**, 12, 30, 74, 154, 275, **4:15**
- Osteoporosis in Women with Rheumatoid Arthritis, **2:134**
- Osteosarcoma, **2:18**
- Otitis media, **2:285**
- OTT (*see* Office of Technology Transfer)
- Outreach (*see* Communicating health information)
- Outreach Partnership Program, **3:278**
- Ovarian cancer, **2:1**, 16-17, 24, 28, 285, **3:47**, 110, 180
- Oxidative stress disease, **2:25**, 54, 130, 144, 200, **3:39**, 77, 130
- P**
- Paclitaxel (Taxol), **3:110**
- Paget's disease, **2:128**, 187, 285, **3:166**
- Pain and its management
- acupuncture, **2:66**, 139, 179
 - brain perception and regulation, **2:37**, 50, 178
 - cannabinoid signaling system, **2:37**, 50, 139, 178, **3:70-71**
 - clinical and translational research, **2:98**, 139, 178-180, **3:112-113**, 133, 154, 167
 - collaborative research, **2:39**, 57
 - dental and craniofacial disorders, **2:128**, 214, 263
 - funding, **2:285**
 - gastrointestinal disorders, **2:168**
 - glucosamine/chondroitin sulfate treatment, **2:138**, 175, **3:70**, 113, 166
 - headaches, **2:32**, 66, 129
 - ICs sponsoring research, **2:32**
 - information resources, **2:126**
 - low back pain, **2:129**, 139, 178-179, **3:112-113**, 167
 - massage therapy, **2:27-28**
 - molecular biology and basic research, **2:45**, 49-50, 139, 177-178, 179-180, **3:59**, 70-71, 133
 - multidisciplinary studies, **2:50**, 139, 170, 178, 179, **3:133**
 - musculoskeletal disorders, **2:128**, 129, 138, 139, 153, 175, 178-179
 - neurofeedback training, **2:31**, 37, 50, 178, **3:70-71**
 - neuropathic, **2:37**, 49-50, 139, 177-178, **3:59**, 70-71, **4:22**
 - neuroplasticity and, **2:36**, 37
 - outcome measures, **2:162**
 - palliative and end-of-life care, **2:49-50**, 125, 126, 139, 170, 177-180, **3:22**, 70-71, 112-113, 150, 167
 - pelvic, **2:170**, **3:22**, 150
 - pharmacotherapeutics, **2:50**, 178, **3:94**, 245
 - placebos, **2:139**
 - sickle cell disease, **2:139**, 179-180, **3:133**
 - statistics and burden of illness, **2:188**
 - surgical interventions, **2:139**, 178-179, **3:112-113**, 167
 - women's health, **2:98**, **3:154**
- Pancreas
- artificial pancreas technologies, **2:114**, 120
 - cancer, **2:2**, 5, **3:6**, 30, 31
 - chronic pancreatitis, **2:128**
 - disorders, **2:168**
 - islet transplant, **2:112**, 113-114, 115, 120, 138, 174, **3:137**
- Pancreatic Cancer Cohort Consortium, **3:6**
- Panic disorder, **3:281**
- Parent Diabetes Prevention Trial, **2:251**
- Parent Project MD, **4:21**
- Parkinson's disease
- biomarkers, **2:38**, 54
 - Centers of Excellence, **2:38**, 53
 - clinical and translational research, **2:38**, 53, 53, 63, 164, **3:120**, 122, 141, 165-166
 - dementia, **4:5**
 - depression and, **2:53**, 134, 160, **3:141**
 - diagnostic criteria, **2:38**, 53, **3:85**
 - DNA repository, **2:58**, **3:201**
 - environmental factors, **2:13**, 38, 53-54, 119, 132, 153, 205, 253, **3:12**, 85, 88, 98-99
 - epidemiological and longitudinal studies, **2:13**, 132, 153, 205, 253, **3:10**, 50, 200
 - funding, **2:285**, **3:98-100**
 - Gene Therapy Study Group, **2:38**, 53, **3:141**
 - genetic factors, **2:34**, 35, 38, **3:10**, 50, 98-99, 100, 190, 200
 - molecular biology and basic research, **2:53-54**, **3:58**, 60, 85, 98-99
 - registries, databases, and information systems, **3:10**, 50, 185, 190, 191, 200
 - stem cell research, **1:1**, **3:60**
 - treatments/therapies, **2:38**, 51, 53, 54, 63, 164, 220-221, **3:99**, 100, 120, 141, 220, 245
 - women's health, **2:13**, 132, 153, 205, 253
- Partners in Information Access for the Public Health Workforce (PH Partners), **3:291**
- Partners in Research initiative, **3:172**
- Partnerships (*see also* Public-private partnerships)
- Pipeline to Partnerships database, **1:39-40**
- Partnerships for Environmental Public Health, **2:258**, **3:279**, 289-290
- PASS (*see* Prenatal Alcohol, Sudden Infant Death Syndrome, and Stillbirth)
- Patents and licenses, **1:39-40**
- Pathogen Functional Genomics Resource Center, **2:82**, **3:48**
- Pathway to Independence Awards, **2:21**, **3:254**, 267
- Patient-Centered Care Management for Seniors with Multiple Morbidities, **2:134**
- Patient Navigation Research Program, **2:19**, 241, 247, **3:100**, 179
- Patient-Reported Outcomes Measurement Information System, **2:125**, 162, **3:214-215**, 224, **5:15**, 16
- Patterns of Care/Quality of Care Studies, **2:9**
- Paul B. Beeson Career Development Awards in Aging Research, **3:265**
- Paul D. Wellstone Muscular Dystrophy Cooperative Research Centers (*see* Wellstone Muscular Dystrophy Cooperative Research Centers)
- PCBs (*see* Polychlorinated biphenyls)
- Pediatric (*see* Adolescent; Infant; Child health and development)
- Pediatric Brain Tumor Consortium, **2:18**, 212
- Pediatric Critical Care Research Network, **2:224**, **3:153**
- Pediatric HIV/AIDS Cohort Study, **2:77**
- Peer-facilitated interventions, **2:133**, 156-157
- Peer review system, **1:5**, 12-13, 33-35, 44, **3:279**, 280
- Peer Tutor High School Program, **2:240**, 257-258
- Pelvic floor disorders, **2:136-137**, 169, 196, 201, 224, **3:110**, 153
- Pelvic Floor Disorders Network, **2:136-137**, 201, 169, 224, **3:110**, 153
- Pelvic inflammatory disease, **2:285**
- PEPFAR (*see* President's Emergency Plan for AIDS Relief)
- Pepper, Claude Denson, **4:13**
- Peptic ulcer disease, **2:128**, 278
- Peptide amphiphile molecules, **2:50-51**, 223-224, **3:216**, 234
- Performance assessment, **1:8**
- Perinatology, **2:21-22**, 34, 77, 155, 202, 225-226, 227, 285-286, **3:49-50**, 153
- Periodontal disease and dental caries, **2:84**, 128, 129, 130, 144, 149, 235, 239, 241, 255-256, 260, 263-264, 270, **3:6**, 19, 30, 41, 64, 82, 84-85, 243-244
- Peripheral arterial disease, **2:127**, 185

- Peripheral neuropathies (*see also specific diseases*), **2:64, 3:71, 120-121**
- Persistent organic pollutants, **2:42, 219, 3:20-21**
- Personalized medicine
 cancer, **2:2, 10-11, 14-15, 23, 25, 3:42, 107-108, 199**
 genomics and, **1:4, 2:47, 97-98, 162, 167, 3:23, 29, 30, 33, 38, 59, 99, 111-112, 114, 121, 143, 156**
 neuroscience and, **2:36, 45, 176, 3:99, 135**
- Pesticides, **2:38, 54, 98, 132, 148, 263, 3:6, 7, 20, 85, 151**
- Pharmacogenetics, **1:4, 3:29, 38, 62, 114, 156**
- Pharmacogenetics and Pharmacogenomics Knowledge Base, **3:38, 114, 156**
- Pharmacogenetics Research Network, **3:29, 38, 114, 156**
- Pharmacology (*see also Drug development; Gene therapy; Translational research; specific drugs and drug classes*)
 alcoholism treatment, **2:36, 46-47, 48, 68, 129, 135, 137, 141, 148, 162, 170, 184, 225, 3:92, 106, 121**
 K-12 educational resources, **1:27**
 obstetric and pediatric, **2:213, 224, 227, 255**
 pain management, **2:50, 139, 178, 179**
 pharmacogenetics, **1:4, 2:47, 97-98, 162, 167, 3:23, 29, 30, 38, 59, 111-112, 114, 121, 143, 156**
 urinary incontinence, **2:170**
- PharmGKB (*see Pharmacogenetics and Pharmacogenomics Knowledge Base*)
- Pemphigus vulgaris, **2:113**
- Phenylketonuria, **2:195, 202**
- Phosphorylation modeling, **3:84**
- Photodynamic therapy, **2:25, 113, 115, 246, 3:181, 220, 245**
- Phthalates, **2:12, 13, 153, 205, 208, 253, 3:4-5, 12-13, 51, 64-65, 86-87, 177-178**
- Phytoestrogens, **2:13, 153, 194, 198, 205, 253, 3:85**
- Physiologically based pharmacokinetic (PBPK) models, **2, 225**
- Pick's disease, **2:286**
- Pima Indians, **2:234**
- Pioglitazone, **2:136, 169, 3:148**
- Pioneer Awards, **2:91, 3:99-100, 5:17, 18**
- Pipeline to Partnerships, **1:39-40, 3:280**
- Pittsburgh compound B, **2:59, 207, 3:107, 132, 4:7-8**
- Placebo treatments, **2:176, 3:23, 94**
- Plague, **2:79, 80, 93, 95, 3:112, 124, 155**
- Plasmapheresis, **3:185**
- Plasmodium vivax*, **3:30**
- PLCO (*see Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial*)
- Point-of-Care Technologies Research Network, **3:212**
- Polychlorinated biphenyls, **2:42, 219, 3:20-21**
- Pompe disease, **4:41**
- Population-Based Palliative Care Research Network, **2:27**
- Population research, **2:132, 170, 218, 219, 3:1-2, 3-4, 7-8, 22, 42-43, 150, 169**
- Porphyrias, **4:41**
- Porphyromonas gingivalis*, **2:84, 130, 144, 3:84-85, 243-244**
- Porter Neuroscience Research Center, **2:23**
- Positive Choice, **2:172, 3:214, 224-225**
- Positron emission tomography, **2:40, 58-59, 207, 4:7-8**
- Post-traumatic stress disorder, **2:32, 40, 60, 133-134, 157, 222, 224, 256, 3:15, 281**
- Postdoctoral Intramural Research Training Award, **3:254**
- PPP (*see Program on Public-Private Partnerships*)
- Practical Oral Care for People with Developmental Disabilities, **2:239**
- Prader-Willi Syndrome, **4:42**
- pRb protein, **2:25, 200, 3:77**
- Precipitating Events Project, **4:15-16**
- Preclinical research (*see also Animal models; Drug development*)
 alcohol treatments, **2:47, 162, 3:106, 121**
 ARRA funding, **3:119, 122, 123, 124, 125**
 autoimmune diseases, **2:110, 117-118, 120, 121, 176-177, 247-248, 3:43-44, 77, 78, 118-119, 144**
 autism and autism spectrum disorders, **2:42, 202-203, 3:119**
 behavior change, **2:155, 3:90-91, 128, 174**
 bioinformatics, **2:18, 22, 84, 89, 91, 116, 3:84, 125, 126, 171-172, 236**
 biomarkers, **2:107-108**
 cancer, **2:6, 8, 12-13, 14-15, 18, 21-22, 26, 225, 3:69, 83, 87-88, 107-108, 129, 132, 133-134, 177, 233, 237**
 chronic diseases, **2:54, 134-135, 144, 148, 156, 161, 162, 164, 176-177, 3:17, 39, 119, 120, 126, 127, 130, 133**
 collaborative science, **3:107-108, 130, 134**
 complementary and alternative medicine, **2:38, 52, 3:73-74**
 developmental disorders, **3:131**
 environmental exposure, **2:225-226, 3:88-89, 131**
 ethical issues, **2:133**
 eye diseases, **2:144, 3:39, 117-118, 121, 130**
 food allergies, **2:155-156, 3:17-18, 128**
 gene therapies, **2:118-119, 121, 3:121**
 genomics, **2:14-15, 58-59, 144, 196, 208, 3:39, 106, 107, 118-119, 120-121, 130, 132, 133-134**
 glycomics, **3:83, 129, 237**
 guidelines for human specimen and data collections, **3:107, 133**
 imaging, **2:58-59, 3:107, 132, 135, 230**
- infectious diseases and biodefense, **2:73, 83, 84, 85, 91, 93, 94-95, 96-97, 3:39-40, 106, 120, 122-126, 130, 155**
 infrastructure, **2:93, 97, 3:107-108, 110, 124, 129-130**
 interdisciplinary research, **2:144, 3:39, 107-108, 130**
 IPCP, **2:45, 3:135**
 minority health and health disparities, **2:117-118, 247-248, 3:43-44, 78, 118-119**
 neurological diseases and disorders, **3:40, 45, 47, 48, 52, 54, 56, 60, 63, 64, 67, 97, 161, 162, 164, 176, 179-180, 196, 207, 222, 225, 3:74, 108, 118, 119, 120-121, 122, 127, 130, 132, 133, 135, 139, 4:22-23**
 oxidative stress disease, **2:144, 3:39, 130**
 pain in sickle cell disease, **2:179-180, 3:133**
 rare and neglected diseases, **2:83, 164-165, 3:124-125, 132-133**
 registries, databases, and information systems, **3:107**
 stem cells and regenerative medicine, **2:130-131, 223, 3:75, 130-131, 238**
 technology development and evaluation, **2:223, 3:75, 83, 97, 128-129, 130-131, 134, 216-217, 235, 237, 238**
 tools and resources, **2:14-15, 93-94, 3:106-107, 121, 122, 125-126, 128, 129-130, 134-135, 230**
- Pregnancy
 adolescent, **2:289**
 alcohol consumption, **2:67, 184, 213, 228, 238, 255, 279, 3:17**
 autism risk study, **2:35, 42, 195-196, 219**
 cesarean delivery vs. vaginal birth, **2:201, 3:157, 290**
 choline supplementation, **2:213, 255, 3:17**
 drug abuse, **2:44-45, 67, 3:139**
 environmental exposures, **2:21-22, 42, 119, 193-194, 198-199, 225, 3:20-21, 85-88, 177**
 epilepsy treatment, **2:61**
 folic acid supplementation, **2:34, 41, 192, 194, 199, 3:34, 85**
 gestational diabetes, **2:122, 127, 155, 192, 194, 199, 3:49-50, 81**
 HIV infection/AIDS, **2:77, 80**
 influenza vaccine, **2:78**
 minority health and health disparities, **2:213, 234, 238, 255, 262, 3:17, 4:32**
 obesity, **2:98, 152, 192, 195, 210**
 obstetrical care, **2:262, 3:166**
 outcome studies, **2:213, 238, 255, 3:17**
 premature delivery, **2:34, 130, 144, 202, 203, 220, 226, 234, 285, 3:239**
 quality of care, **3:166**
 registries, databases, and information systems, **201**
 stillbirth, **2:202, 213, 238, 255, 3:17**
 strategic plans, **2:226**

- Pregnancy (*continued*)
 technology development, **2:203, 3:239**
 vitamin B12 supplementation, **2:34, 41, 199, 3:34**
 weight gain guidelines, **2:202**
- Prenatal Alcohol, Sudden Infant Death Syndrome, and Stillbirth Research Network, **2:213, 238, 255, 3:17**
- President's Emergency Plan for AIDS Relief, **2:80, 92-93, 3:261-262**
- President's Office of National Drug Control Policy, **2:254, 3:8-9, 204**
- Presidential Early Career Award for Scientists and Engineers, **3:247**
- Prevention (*see specific diseases and disorders*)
- Primary ciliary dyskinesia, **4:40**
- Primary hyperoxaluria, **4:41**
- Primary Immune Deficiency Clinic, **2:74, 147-148**
- Primary immune deficiency diseases, **2:74, 147-148, 3:58, 60, 4:41**
- Primary sclerosing cholangitis, **2:128**
- Prion diseases, **2:72**
- Prison inmates, **2:77, 91, 92, 241-242, 263, 3:158, 162-163**
- PRO 2000, **2:76, 86-87**
- Product Showcase database, **1:40**
- Program in Systems Immunology and Infectious Disease Modeling, **3:64**
- Program on Public-Private Partnerships, **1:29**
- Program to Reduce Incontinence by Diet and Exercise, **2:137, 170, 3:22, 150**
- Programs of Excellence in Health Professions Education for Underrepresented Minority Individuals, **2:266-267**
- Project Phidisa, **2:81**
- PROMIS (*see Patient-Reported Outcomes Measurement Information System*)
- Prostate diseases
 benign prostatic hyperplasia, **2:128, 186**
 cancer, **1:4, 2:2, 3, 5, 16, 17, 20, 24, 25, 183, 200, 286, 3:3, 8, 28, 30, 31-32, 46, 63, 90, 153, 209, 215, 222, 4:30**
 chronic prostatitis, **2:128, 170**
- Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial, **2:16-17, 24, 3:8, 46**
- Prostate specific antigen screening, **1:4, 2:16, 200**
- Prostheses, **2:51, 63, 220-221, 222, 3:122, 220, 245**
 for soldiers, **2:71, 220, 222, 3:220, 245**
- Protein Structure Initiative, **3:219, 242**
- Proteins
 antiviral, **3:64**
 biomarkers in infectious diseases, **2:82**
 diagnostic applications, **2:14, 82, 98, 3:55**
 domain analysis, **3:68**
 fluorescent, **3:55**
 folding defects, **3:98, 99**
 immune response, **2:81, 3:80**
 synthesis, **4:22**
 therapeutic targets, **2:26-27, 129, 140-141, 3:68-29, 77, 242-243**
 Wnt family, **2:26-27, 3:68-69, 242-243**
- Proteomic Reagents and Resources Core, **2:8**
- Proteomic Research Centers, **2:98**
- Proteomics, **1:4, 30, 98, 2:2, 5, 7-8, 9, 11, 12-13, 22, 73, 82, 98, 195, 208-209, 214, 3:41, 61, 64-65, 82, 243, 244**
- ProtoType, **3:189, 198**
- PSA (*see Prostate specific antigen*)
- Pseudohypoaldosteronism, **4:40**
- Psoriasis, **1:3, 2:109, 110, 111, 113, 115, 117, 118, 119, 246, 286, 3:34, 43, 44, 79, 82, 115, 181, 200, 4:28**
- PTC Therapeutics, **4:21**
- Public Access Policy, **1:13, 39, 40, 41, 3:188**
- Public Health Service Act, **3:105, 106, 187, 248, 273, 4:3, 13**
- Puerto Ricans, **2:7, 149, 234, 235, 251, 254, 255, 262, 268**
- Public-private partnerships
 biomarkers, **1:29**
 cancer research, **1:29-30, 2:5, 6, 7, 8, 9-10, 11, 20, 240, 258, 266, 3:97, 179**
 epidemiological and longitudinal studies, **3:22, 42-43**
 FNIH, **1:29-30, 2:99-100, 217**
 GAIN, **1:29**
 imaging technologies and applications, **1:29-30**
 infectious diseases and biodefense, **2:83, 95, 99-100, 217, 3:155**
 international, **1:29**
 minority health and health disparities, **2:239-240, 258, 3:280-290**
 neurological research, **1:29-30, 2:38, 40, 48, 54-55, 58-59, 207, 3:107, 132, 152, 4:21**
 Partners in Research initiative, **3:172**
 PEPH initiative, **2:5, 6, 240, 258**
 PPP program, **1:29, 5:17**
 quality-of-care research, **2:8**
 reference guide, **1:29**
- Public Trust Initiative, **3:172**
- Publication policy, **1:13, 39, 40, 41**
- Q**
- Quality of Cancer Care Committee, **2:8**
- Quality of care research, **2:4, 8-9, 22, 160, 166, 263, 3:21, 163-164, 166, 208-209**
- Quality of life research, **2:16, 27-28, 125, 160, 166, 180-181, 263, 3:104, 145**
- Quetiapine, **2:47, 137, 162, 3:121**
- R**
- Radiation countermeasures, **2:96-97**
- Radiation Event Medical Management, **3:208, 289**
- Rat Resource and Research Center, **3:50**
- RAC (*see Recombinant DNA Advisory Committee*)
- Race and Ethnic Disparities in Mental and Cardiovascular Health Disorders, **2:251**
- RAISE (*see Recovery After an Initial Schizophrenic Episode*)
- Rapamycin, **2:26, 64-65, 3:69, 72, 233**
- Rapid Access to Intervention Development program, **3:108, 122, 5:15, 16**
- Rapid Research Notes, **3:188**
- Rapid Response Program, **2:133, 156-157**
- Rare and neglected diseases (*see also Rare Diseases Clinical Research Network; specific diseases*)
 autoimmune, **2:109, 111, 118, 121, 3:79, 119**
 autonomic rare diseases, **4:41**
 cancers, **2:14, 3:203, 4:42**
 chronic, **2:125, 127, 131, 139, 164-165, 3:132-133**
 clinical practice, **3:165-166**
 clinical research, **2:40, 59-60, 83, 169, 3:104-105, 111, 142, 148-149, 4:43**
 drug development, **1:3, 2:97-98, 135, 164-165, 284, 3:132-133**
 eye diseases, **2:195**
 genomics, **3:33, 227**
 infectious diseases and biodefense, **2:81, 83, 97-98, 3:124-125**
 information resources, **3:282**
 intramural research, **2:135, 164**
 kidney disease, **4:41**
 liver diseases, **2:169, 3:148-149**
 neurological, **2:32, 33, 40, 59-60, 63, 64, 131, 275, 277, 3:120, 122, 140, 142, 165-166, 4:40, 41, 42**
 newborn screening, **2:202**
 pain management, **2:139**
- Rare Disease Cooperative Centers, **2:214**
- Rare Diseases Act of 2002, **4:39**
- Rare Diseases Clinical Research Consortia, **4:39**
- Rare Diseases Clinical Research Network, **2:40, 59-60, 3:142, 4:39-46**
- Ras gene, **2:25, 200**
- RCDC (*see Research, Condition, and Disease Categorization system*)
- RCMI (Research Centers in Minority Institutions Program)
- REACH US initiative, **2:262**
- REAP (*see Research Enhancement Awards Program*)
- REasons for Geographic And Racial Differences in Stroke Study, **2:65, 238, 253**
- Recombinant DNA, **1:48, 49, 2:78, 79, 95**
- Recombinant DNA Advisory Committee, **1:49**
- Recovery After an Initial Schizophrenic Episode, **2:177, 3:134-135**
- Reference Epigenome Mapping Centers, **2:199, 3:49-50, 81, 83**
- REGARDS (*see REasons for Geographic And Racial Differences in Stroke Study*)

Index

- Regenerative medicine (*see also* Armed Forces Institute of Regenerative Medicine; Center for Neuroscience and Regenerative Medicine)
ARRA funding, **3**:186
clinical and translational research, **2**:60, 130-131, 223, **3**:75, 130-131, 238
funding, **2**:286
laryngeal tissue, **2**:222-223
neural, **2**:37, 50-51, 60, 223-224, **3**:216, 222, 234
stem cells research, **2**:130-131, 223, **3**:60, 75, 130-131, 238
technology development, **2**:223, **3**:75, 130-131, 238
- Registries, databases, and information systems (*see also* Disease registries and surveillance systems; Genomic information systems; Informatics infrastructure; Information resources and technology; Scientific databases; *specific systems, diseases, and conditions*)
catalog of activities, **3**:187
collaborative research, **2**:9, 10, 11, 18, 28, **3**:194, 206-207, 214, 225
epidemiological and longitudinal studies, **2**:43, 98-99, 109, 200, 254, **3**:9, 191, 202
guidelines for human specimen and data collections, **3**:107, 133
imaging technologies, **2**:43, 59, 153, 194, 200
importance, **3**:185
international collaborations, **3**:193, 196, 206, 225
molecular biology and basic research, **3**:61-62, 75, 95, 96, 193, 195, 206, 208, 236
public access policy, **1**:40-41, **2**:78, **3**:114, 188, 196, 280
standardized vocabularies, data protocols, and tools, **1**:40, **2**:17, 57-58, **3**:96, 185-186, 187, 193, 204-206, 223-224
technology development, **2**:9, 10, 11, 18, 28, 58, 125, 162, 172, 281, **3**:194, 204-207, 214-215, 223-227
trans-NIH activities, **3**:186
- Regulations
animal welfare, **1**:46
biosafety, **1**:49, 50
ethical conduct, **1**:43-44
Federal-Wide Assurance of compliance, **1**:45
human subjects protection, **1**:45, 46
peer review, **1**:12
research misconduct, **1**:44
stem cell research, **1**:48
technology transfer, **1**:39
- Rehabilitation
chronic diseases, **2**:162, 177, **3**:127, 134-135
clinical and translational research, **2**:177, 178-179, **3**:112-113, 134-135, 167
defined, **2**:191
disability defined, **2**:193
funding, **2**:193, 286
ICs supporting research, **2**:192
infection prevention in amputees, **2**:222
interdisciplinary research, **2**:222
laryngeal tissue regeneration, **2**:222-223
molecular biology and basic research, **2**:197
multidisciplinary studies, **2**:221-222
muscle recovery after injury, **2**:163, **3**:137
neural prostheses, **2**:51, 197, 220-222, **3**:220, 237-238, 245
neural regeneration in spinal cord injury, **2**:50-51, 197, 223-223, **3**:234
schizophrenia, **2**:177, **3**:134-135
stem cell research, **2**:197, 223, **3**:75, 130-131, 238
stroke, **2**:32, 192, 197
technology development, **2**:197, 221-223, **3**:237-238
virtual reality systems, **2**:222
- REMBRANDT, **2**:29
- RePORT (*see* Research Portfolio Online Reporting Tool)
- RePORT Expenditures and Results, **1**:35, 36
- RePORTER (*see* RePORT Expenditures and Results)
- Repositories (*see* Disease registries and surveillance systems; Informatics infrastructure; Registries, databases, and information systems; Scientific databases)
- Repository and National Registry of Myotonic Dystrophy Patients and Family Members, **4**:22
- Reproductive health (*see also* Breast cancer; Developmental processes and disorders; Pregnancy; Prostate diseases; Sexually transmitted diseases)
bisphenol A exposure, **2**:225-226, **3**:88-89, 131
cancer, **2**:21-22, 225-226, **3**:30, 87-88, 110, 177
estrogen, **2**:5, 12, 13, 24-25, 132, 153, 194, 205, 206, 208, 253, 262, 278, **3**:12, 154, 180
funding, **2**:277, 279, 281, 282, **3**:180
infertility, **2**:281
mammary gland development, **2**:12-13, 194, 208
menopause, **2**:98, 132, 150, 206, 252, **3**:154
ovarian cancer, **2**:1, 16-17, 24, 28, 282
pelvic floor disorders, **2**:136-137, 169, 196, 201, 224, **3**:110, 153
pelvic inflammatory disease, **2**:282
strategic plans, **2**:226-227
uterine fibroids, **2**:13, 132, 153, 205, 253, 278, **3**:12
- Research Centers in Minority Institutions Program, **2**:243, 267-268, **3**:116, 171
- Research Centers on Minority Aging Research, **4**:6
- Research, Condition, and Disease
Categorization system, **1**:35-36, **2**:3, 33, 73, 109, 126, 193, 236, 273
Research Endowment Program, **2**:265-266
Research Enhancement Awards Program, **3**:180
Research grants (R series)
R01, **1**:11, 21, 34, **2**:45, 157, 218, 266, 269, **5**:18-19
R21, **1**:34, **2**:45, 56, 157, 218, 269
R25T, **2**:20, **3**:260
R34, **1**:34
Research Infrastructure in Minority Institutions program, **2**:243-244, 267
Research misconduct, **1**:44-45
Research Portfolio Online Reporting Tool, **1**:35, **2**:269
Research Scientist Development Award, **3**:267
Research Supplements to Promote Diversity in Health-Related Research, **2**:21, 242, 264-265, **3**:260
ResearchChannel consortium, **3**:279
Resource Centers for Minority Aging Research, **2**:265
Respiratory chain mitochondrial diseases, **4**:42
Respiratory distress syndrome, **2**:285
Responsible research, **1**:7, 12, 13, 27, 29, 43-50, **2**:72, 171, **3**:109
Retinitis pigmentosa, **2**:129, **3**:117-118
Rethinking Drinking website, **3**:278, 288
Retinoblastoma, **2**:25, 200, **3**:77
Retinopathy of prematurity, **2**:130, 144, **3**:39, 130
Rett Syndrome, **2**:32, 286, **4**:42
Revolutionary Genome Sequencing Technologies Grants, **3**:40, 227
Reye's Syndrome, **2**:286
Rheumatic diseases, **2**:121, **3**:278-279
Rheumatoid arthritis, **2**:13, 107, 110, 112, 113, 116, 117, 119, 132, 134, 153, 205, 253, **3**:12, 43, 44, 58, 60, 191, 200, 202, 278-279
Rickets, **2**:115, 246, **3**:180
Right Question Project—Mental Health II, **2**:251
RIMI (*see* Research Infrastructure in Minority Institutions)
- Rituximab, **2**:113, 120, **3**:144
- RNAi, **1**:4
- Roadmap for Medical Research (*see also* Common Fund), **1**:8, 18, 21, 29, 46, **2**:46, 87, 97, 98, 108, 118, 155, 162, 194, 199, 250, **3**:34, 41, 49, 62, 63, 77, 81, 82, 83, 89, 95, 105, 108, 115, 122, 172, 173, 174, 188, 194-195, 208, 209, 212, 214, 226, 230, 236, 239-240, 250, 256, 257, **5**:14-25
- Rocky Mountain Laboratories, **1**:13, 23
- Roll Back Malaria Partnership, **2**:75-76
- ROR2 Robinow Syndrome, **3**:165
- Roundabout4, **2**:129, 140-141, **3**:77
- Roundworm, **1**:4

- Royalties Program, **1:39**
- Royal Centers for Translation Research in the Behavioral and Social Sciences in Aging, **3:91, 113, 164, 220-221, 246**
- RRN (*see* Rapid Research Notes)
- Rural health, **2:67, 101, 161, 231, 240, 241, 244, 257, 260, 263-264, 286, 3:139, 151, 175, 213, 221-222, 277, 278, 286**
- RxNorm, **3:193, 205, 224**
- ## S
- Salivary gland
carcinomas, **4:42**
disorders, **2:116, 3:41-42, 44-45, 82, 202, 243**
proteomics, **3:62, 206**
- Salsalate, **2:143, 3:144-145**
- SAMHSA (*see* Substance Abuse and Mental Health Services Administration)
- San Fillipo disease, **2:60, 3:142**
- Sandhoff disease, **2:60, 3:142**
- Santhera, **2:56, 120, 3:143**
- Sarcopenia (age-related muscle loss), **4:14-15**
- SARS (*see* Severe acute respiratory syndrome)
- Satellite Diagnostic and Treatment Clinics, **4:6**
- SBIR (*see* Small Business Innovative Research)
- Screening
alcoholism, **2:44-45, 130, 133, 146-147, 157, 3:218, 288**
genetic testing, **2:278**
newborn, **2:195, 202**
- Schistosomiasis, **1:4, 2:83, 97-98, 3:30, 124, 125**
- Schizophrenia and psychoses, **2:31, 32, 119, 128, 161, 177, 192, 287, 3:28, 30, 35-36, 88, 134-135**
- Science education and literacy, K-12
career exploration and planning, **1:27**
curriculum supplements, **1:27**
Findings magazine and Website, **1:27**
SEPA, **1:27, 2:239-240, 257, 3:286**
Peer Tutor Program, **2:240, 257-258**
topical publications and school resources, **1:27**
- Science Education Partnership Award program, **1:27, 2:239-240, 257, 3:286**
- Scientific databases (*see also* National Library of Medicine)
BTRIS, **3:189, 198**
ClinicalTrials.gov, **3:105, 109, 147-148, 189, 193, 198**
CRIS, **3:198**
focus of, **3:186**
GeMCRIS, **1:49**
Genetics Home Reference, **3:169, 188, 282**
Hazardous Substances Data Bank, **3:189, 197**
literature, **3:187-188**
MRI Study of Normal Brain Development, **2:43, 200**
Molecular Libraries Initiatives, **3:188, 193, 197, 209, 212, 214, 226, 5:20-21**
NDAR, **2:39, 57-58, 204-205, 3:189, 197, 4:49, 51**
NNTC, **2:60, 3:197**
Protein Data Bank, **3:188**
ProtoType, **3:189, 198**
public access policy, **3:188**
RRN Archive, **3:188**
Scientific Information System, **3:206**
TOXNET, **3:189, 197**
WISER, **3:189, 208, 289**
- Scientific Management Review Board, **1:7**
- Scientific Review Group, **1:12, 13, 34**
- SciLife, **1:27**
- Scleroderma, **2:109, 111, 112, 115, 237, 246, 287, 3:181, 4:28**
- SEARCH for Diabetes in Youth Study, **2:132, 152, 205, 3:143-144**
- Sebaceous carcinoma, **2:23**
- Secretary's Advisory Committee on Genetics, Health, and Society, **3:161**
- SEER (*see* Surveillance, Epidemiology, and End Results)
- Select Agents and toxins, **1:49, 50**
- Selenium and Vitamin E Cancer Prevention Trial, **2:16, 3:153**
- Self-management of health/illness, **2:210, 251, 3:91, 152, 157-158, 163, 164, 246**
- Senator Paul D. Wellstone Muscular Dystrophy Cooperative Research Centers (*see* Wellstone Muscular Dystrophy Cooperative Research Centers)
- Senior Scientist Research and Mentorship Awards, **3:253**
- Seniors (*see* Older adults)
- Sensory impairments (*see also* Eye; Hearing; Taste), **2:31, 32, 38-39, 42-43, 51, 55, 208, 214, 220-221, 3:72, 220, 245**
- SEP (*see* Special Emphasis Panel)
- SEPA (*see* Science Education Partnership Award)
- Sepsis, **2:75, 83-84, 172, 287, 3:76, 216, 233**
- Sequence Read Archive, **3:32, 189-190**
- Service Employees International Union, **2:79**
- Severe acute respiratory syndrome, **2:71, 72, 93, 3:64, 124**
- Severe combined immune deficiency, **2:202**
- Sexual maturation, **2:12-13, 194, 208, 3:5, 12, 51, 86-87, 178**
- Sexually transmitted diseases (*see also* HIV infection/AIDS; *other specific diseases*), **2:72, 73, 76, 85, 287, 3:159, 212, 213, 221**
- SHARe (*see* SNP-Health Association Resource)
- Shared Instrumentation program, **1:23, 2:21, 22-23, 28, 3:66, 98, 168, 215, 230-231**
- SharePoint for Genome Research, **3:206**
- Short-Term Education Program for Underrepresented Persons Program, **2:242**
- Sickle cell disease, **2:125, 128, 139, 179-180, 187, 231, 259, 287, 3:27, 108, 114, 122, 133, 162, 281**
- SIDS (*see* Sudden Infant Death Syndrome)
- Signature initiatives, **1:22, 2:2, 24, 63**
- Sister Study, **2:5, 13, 24-25, 132, 153, 205, 253, 262, 3:12-13**
- Sitosterolemia, **4:42**
- Sjogren's syndrome, **2:109, 113, 116, 3:44-45, 191, 202**
- Sjogren's Syndrome Clinic, **2:113, 116, 3:44-45, 202**
- Sjogren-Larsson syndrome, **4:42**
- Skin disorders
acne, **3:34, 82**
and asthma, **3:38, 79**
atopic dermatitis, **2:129, 130, 143, 187, 3:38, 79**
cancers, **2:2, 18, 23, 3:46, 69, 233**
eczema, **3:35, 38, 79, 82**
infections, **2:132, 143**
microbiomics and, **3:34-34, 82-83**
psoriasis, **1:3, 2:109, 110, 111, 113, 115, 117, 118, 119, 246, 286, 3:34, 43, 44, 79, 82, 115, 181, 200**
- Sleep disorders, **2:32, 61, 62, 77, 86, 128, 132, 133-134, 136, 149, 157, 165-166, 206, 224, 255, 287, 3:6, 15, 19, 21, 136-137, 4:22**
- Small Animal Imaging Program, **2:1, 15, 3:230**
- Small Business Innovation Research program, **1:39-40, 2:222, 3:83, 129, 212, 237**
- Small Business Technology Transfer program, **1:39-40, 3:83, 129, 237**
- Smallpox, **2:71, 78, 79, 95, 287, 3:112, 155, 212**
- Smith-Lemli-Opitz syndrome, **4:42**
- Smithsonian Institute of Museum and Library Services, **2:257**
- Smoking (*see* Tobacco use)
- SMRB (*see* Scientific Management Review Board)
- SNOMED CT (*see* Systematized Nomenclature of Medicine-Clinical Terms)
- SNP-Health Association Resource, **2:149-150, 159, 252-263, 3:3, 5, 19, 24, 40, 45**
- SOF (*see* Study of Osteoporotic Fractures)
- Somatic Hypermutation Group, **2:111**
- South East Asia Infectious Diseases Clinical Research Network, **2:79**
- Southwest Foundation Genetic Analysis Workshop, **2:159, 3:24, 45**
- Space-related research, **3:100-101, 238-239**
- Special Emphasis Panel, **1:12, 13, 34, 4:39, 45**
- Specialized Centers Cooperative Agreement award, **4:19**
- Specialized Centers of Research on Sex and Gender Factors Affecting Women's Health, **2:98, 3:154**
- Specialized Program of Translational Research in Acute Stroke, **2:40, 59, 3:142**

- Specific language impairment, 191, 202
- SPECS (*see* Strategic Partnering to Evaluate Cancer Signatures)
- Spectrum: Building Pathways to Biomedical Research Careers for Girls and Women, 2:240
- Sphincter of Oddi Dysfunction, 2:168, 3:136
- Spina bifida, 2:32, 34, 287
- Spinal cord injury, 1:1, 3, 2:32, 37, 50-51, 197, 198, 223-224, 280, 287, 3:216, 220, 234
- Spinal muscular atrophy, 2:32, 63, 287, 3:108, 122
- Spine Patient Outcomes Research Trial, 2:139, 177-178, 3:112-113, 167
- Spinocerebellar ataxias, 4:42
- Spiral computed tomography, 2:15, 3:230
- SPORT (*see* Spine Patient Outcomes Research Trial)
- Spotlight on Aging Research, 3:284
- SPOTRIAS (*see* Specialized Program of Translational Research in Acute Stroke)
- Squamous cell carcinomas, 2:14, 23, 26-27, 3:68-69, 242-243
- SRA (*see* Sequence Read Archive)
- SRG (*see* Scientific Review Group)
- Statistics and burden of disease (*see also specific diseases, disorders, and life stages*)
rare diseases and disorders, 4:43
- Staphylococcus aureus*, 2:73, 74, 96, 130, 143, 3:31, 39, 57, 122
- Statins, 2:114, 121, 136, 166, 3:119, 160
- Stem cell research
adult stem cells, 1:3, 2:37, 200, 223, 3:60, 74, 75, 130-131, 238
Alzheimer's disease, 3:60
autoimmune diseases, 1:1, 2:113, 120, 3:60, 78, 144
brain, 2:37, 51
cell line registry, 1:48
chronic diseases, 2:143-144, 217, 3:74
clinical and translational research, 2:223, 3:75, 130-131, 238
communicating health information, 2:239, 257, 259, 3:286
developmental biology, 2:194, 200, 3:74
diabetes, 1:1, 2:113, 120, 3:60, 78, 144
Executive Order 13505, 1:1, 48, 3:75
funding, 2:287-288, 3:75
guidelines, 1:48, 3:75, 279
hearing loss treatments, 2:37, 51
hematopoietic, 2:130, 142-143, 217, 4:40-41
human embryonic stem cells, 1:3, 48, 2:194, 200, 287, 3:60, 66, 74, 75
imaging, 3:242
immune response modulation, 2:83
induced pluripotent stem cells, 1:3, 2:200, 3:60
infectious diseases, 2:75, 83-84, 3:76, 233
infrastructure and capacity building, 3:75
mesenchymal (bone marrow stromal cells), 2:75, 83, 3:76, 216, 233, 242
molecular biology and basic research, 2:21, 51, 83-84, 130, 142-143, 200, 217, 223, 3:37, 60, 74, 75, 76, 82, 130-131, 233, 238
neural, 2:37, 51, 59
neurological disorders, 2:37, 51, 59, 63, 97, 223, 3:122, 130, 142, 4:20
niche, 2:142-143, 217
nonhuman, 2:288, 3:50, 128
osteopathic, 2:130, 142-143, 217, 3:74
Parkinson's disease, 1:1, 3:60
policy development, 1:47, 48
regenerative medicine, 2:223, 3:75, 130-131, 238
registries, databases, and information systems, 3:50, 66, 75, 104, 128
spinal cord injury, 1:3
therapeutic applications, 1:3, 2:37, 51, 59, 63, 97, 120, 223, 3:75, 130-131, 238, 4:20
training and career development, 3:253-254
tumor-initiating cells, 2:5-6, 10, 21, 3:69-70
umbilical cord blood/placenta, 2:288
Working Group for Human Embryonic Stem Cell Eligibility Review, 1:48
- Stem Cell Task Force, 3:75
- Stem Cell Therapeutics Outcomes Database, 3:104
- STEP-UP (*see* Short-Term Education Program for Underrepresented Persons Program)
- Sterol and isoprenoid diseases, 4:42
- Stomach cancer, 2:5, 233, 4:32
- Strategic Partnering to Evaluate Cancer Signatures, 2:7, 14-15, 3:107-108, 133
- Strategic planning (*see also specific areas of research*), 1:iv, 17-19, 35, 2:29, 67-68, 102-103, 121-122, 182-185, 226-228, 269-270
- Stress response (*see also* Oxidative stress; Post-traumatic stress disorder), 2:32, 36, 38, 44, 47, 54, 110, 131, 134, 135, 137, 144, 157, 163, 170, 196, 207, 218, 224, 231, 224, 251
alcohol abuse, 2:36, 47, 137, 170, 224
cancer, 2:24-25, 3:13
neurological, 2:32, 36, 38, 44, 47, 54, 137, 170
- Stroke (*see also* Cardiovascular diseases; National Institute of Neurological Disorders and Stroke)
Awareness Month, 2:65, 239, 259
behavioral research, 2:167, 249
Brain Attack Coalition, 2:65, 239, 259
clinical and translational research, 2:40, 54, 59, 63, 65, 164, 166, 167, 173, 249, 3:120, 122, 142
communicating health information, 2:40, 65, 239, 258-259, 3:284-285
diabetes and, 2:107, 127, 164, 167, 173, 234, 249, 3:111
epidemiological and longitudinal studies, 2:65, 132, 149, 238, 253, 255-256
extendin-4 therapy, 2:54, 164, 3:120
funding, 2:288
genetics/genomics, 2:23, 159
imaging tools, resources, and applications, 2:31, 59, 3:142
Know Stroke in the Community program, 2:65, 258-259, 3:284-285
life stages research, 2:194
mental disorders comorbid with, 2:129-130
minority health and health disparities, 2:65, 132, 149, 167, 231, 233-234, 238, 239, 249, 253, 255-256, 258-259, 3:6, 16, 19, 284-285, 4:28, 29
prevention, 2:63, 65, 107, 173, 239, 258-259, 3:142, 284-285
quality-of-care research, 2:40
REGARDS study, 2:65, 238, 253
registries, databases, and information systems, 2:23, 59, 159, 3:142
rehabilitation research, 2:32, 192, 197
risk factors, 2:132, 149, 166, 194, 206, 255-256
secondary stroke, 2:65
SPOTRIAS, 2:40, 59, 3:142
statistics and burden of illness, 2:33, 233-234, 4:29
strategic plan, 2:67
technology development, 2:40
tPA therapy, 2:59, 65, 3:142
training for researcher, 2:59, 182, 3:142
women's health, 2:206
- Strong Heart Study, 2:132, 150, 252
- Structural biology, 3:63, 96, 219, 243
- Structural Biology of Membrane Proteins, 5:22
- Structure and organization of NIH (*see also specific institutes, centers, and offices*), 1:7, 8-9
- STTR (*see* Small Business Technology Transfer program)
- Studies to Advance Autism Research and Treatment, 4:47, 50
- Study of Osteoporotic Fractures, 2:149, 212-213, 3:10
- Sub-Saharan Africa research enterprise, 1:28
- Substance abuse and addiction (*see also* Alcohol; *specific drugs*)
ADHD and, 2:136, 167-168, 213, 3:14-15
adolescents, 2:32, 34, 35, 41-42, 43-45, 130, 133, 151, 156-157, 195, 215, 217-218, 254, 3:3, 8-9, 14-15, 92, 138-139, 163, 192, 204, 288
behavioral factors and therapies, 2:44, 48, 92, 137, 156, 215, 3:15-16, 138-139, 148
children, 2:44-45, 156, 157, 215, 218, 3:138-139
clinical and translational research, 2:44, 49, 66-67, 90, 97, 160-161, 162-163, 261, 3:15-16, 108, 122, 130, 139, 148, 177
clinical practice, 2:92, 263, 3:162-163

Substance abuse and addiction (*continued*)

- communicating health information, **2:44**, 146, 156, 215, **3:138-139**, 278
- comorbid mental conditions, **2:66-67**, 129, 157-158, 160-161, 224, **3:16**, 21, 139
- drugs, **2:33**, 36, 37, 43-44, 46, 49, 50, 66-67, 76, 92, 97, 122, 129, 135, 137, 142, 146, 156, 157-158, 160-161, 162-163, 215, 217-218, 224, 225, 254, 278, 283, **3:8-9**, 14, 92, 108, 130, 204
- endocannabinoid pathway, **2:129**, 142
- environmental risk factors, **2:33**, 44, 131-132, 217-218, **3:14**, 92
- epidemiological and longitudinal studies, **2:43-44**, 66-67, 92, 157-158, 160-161, 217-218, 224, 254, **3:3**, 4, 8-9, 14, 15-16, 92, 139, 148, 192, 204
- epigenetics, **2:36**, 44, 46, 217-218
- families, **2:48**, 133-134, 148, 157-158, 224, 225, **3:21**
- funding, **2:278**, 283, 288
- gene-environment interactions, 34, 35
- genomics, **2:6**, 23, 34, 36, 41-42, 44-45, 46-47, 48, 90, 97, 132, 141, 148, 151, 158, 159, 225, **3:36**, 92-93, 130, 227-228
- Good Behavior Game, **2:44**, 156, 215, **3:138-139**
- HIV/AIDS and, **2:76**, 77, 86, 91, 92, 172, **3:15-16**, 146, 148, 158, 162-163, 170, 224-225
- immunotherapy, **2:36**, 48, 49, 158
- liver disease, **2:129**, 142
- medications, **2:135**
- military veterans and families, **2:157-158**, 224, **3:21**
- minority health and health disparities, **2:92**, 241-242, 254, 261, 263, **3:8-9**, 162-163, 175-176, 177
- molecular biology and basic research, **2:43-44**, 46, 48, 49, 90, 129, 142, 158, 217-218, **3:14**, 36, 92-93, 227-228
- multidisciplinary approach, **2:41-42**, 43-44, 48, 151, 158, 217-218, **3:14**, 92
- neurological research, **1:27**, **2:31**, 32, 34, 35, 36, 37, 43-44, 46, 48, 49, 50, 66-67, 97, 148, 158, 160-161, 162-163, 217-218, 225, **3:14**, 36, 92-93, 227-228
- pain management and, **2:37**, 50, 178
- Positive Action program, **2:44**, 156, 215, **3:138-139**
- prevention, **2:6**, 35, 44, 76, 92, 137, 156, 157-158, 172, 215, 261, **3:15-16**, 138-139, 148, 177, 224-225
- prison inmates, **2:92**, 241-242, **3:162-163**
- registries, databases, and information systems, **2:254**, **3:8-9**, 204
- screening, **2:130**
- statistics and burden of illness, **2:33**, 188
- strategic plans, **2:227**
- stress and, **2:36**, 43-44, 49, 135, 157, 163, 217-218, 224, **3:14**, 92
- technology development, **2:46**, 172, **3:36**, 92-93, 214, 224-225, 227-228
- tobacco/nicotine, **2:2**, 6, 12, 23, 48, 131-132, 148, 157-158, 159, 224, 225, **3:1**, 3, 21, 93, 100, 139, 179, 288
- transdisciplinary research, **2:48**, 148, 225
- treatments, **2:2**, 6, 31, 36, 48, 49, 76, 92, 122, 135, 148, 157-158, 162-163, 241-242, **3:39-40**, 94-95, 106, 108, 139-140, 245
- Web-based interventions, **2:35**, 172, **3:224-225**
- women's health, **2:98**, **3:154**
- young adults, **2:254**, **3:8-9**, 24
- Substance Abuse and Mental Health Services Administration, **2:17**, 69, 188, 228, **3:203**
- Sudden Infant Death Syndrome, **2:202**, 213, 238, 239, 255, 259, 285, 288, **3:17**, 285-286
- Suicide, **2:28**, 235, 238, 254, 261, 289, **3:7**, 9, 20, 62, 99, 146, 177
- Summer Genetics Institute, **3:263**
- Summer Institute on Design and Conduct of Randomized Clinical Trials Involving Behavioral Interventions, **3:262**
- Summer Research Experiences for Students and Science Educators, **2:10**, 269, **3:168**, 231-232
- Superoxide dismutase 2, **3:118**
- Surveillance, Epidemiology, and End Results program, **2:2**, 14, **3:186**, 192, 203
- Synthetic nucleic acid molecules, **1:49**
- Systematized Nomenclature of Medicine-Clinical Terms, **3:193**, 205, 224
- Systemic autoimmunity, **2:111**, 119, **3:88**
- Systemic lupus erythematosus
- animal models, **2:111**, 115, 246, **3:44**, 78, 118-119, 181
 - biomarkers, **2:112**
 - cardiovascular complications, **2:114**, 121, **3:119**
 - characteristics, **2:107**
 - clinical and translational research 113, 115, 121, 237, 246, 247-248, **3:43-44**, 78, 115, 118-119, 180, 181
 - diagnosis and prognosis, **2:110**, 112, 115, 237, 248, **3:44**, 78, 118-119
 - environmental factors, **2:111**, 112, 119, **3:88**
 - funding for research, **2:283**
 - genetic factors, **2:110**, 111, 112, 115, 116, 117, 119, 237, 246, 247-248, **3:43-44**, 78, 118-119, 180, 181, 200
 - immunologic factors, **2:111**, 138, 174, **3:43-44**, 58, 118-119, 136-137
 - infrastructure and resources for research, **2:109**, 111, 115, 246, **3:115**, 180-181
 - international collaborations, **2:237**
 - kidney disease, **2:111**, 112, 117, 235-236, 248, **3:44**, 78, 118-119
 - minority health and health disparities, **2:115**, 117, 231, 235-236, 237, 246, 247-248, **3:43-44**, 78, 118-119, 180
 - molecular biology and basic research, **2:111**, 115, 237, 246, **3:43-44**, 58, 118-119, 180
- neuropsychiatric, **2:111**, 119, **3:88**
- pediatric, **2:109**, 114, 121, **3:119**
- registries, databases, and information systems 109, 248, **3:43**, 191, 200, 202
- statistics and burden of illness, **2:109**
- strategic plans, **2:121**
- treatment, **2:112**, 138, 174, 237, 248, **3:118-119**
- women's health, **2:110**, 117, 235-236, 237, 248, **3:78**, 118-119, 180
- Systems biology, **2:5**, 22, 73, 82, 84, 144, **3:20**, 56, 57, 64, 84-85, 96, 97, 100, 128, 195, 206, 235, 237, 243-244, 251
- Systems Biology Centers for Infectious Diseases, **2:82**, **3:48**
- Systems science, **3:65-66**, 169, 262

T

- Tailored Clinical Trials for Hypertension and Fall Risk, **2:134**
- Tamoxifen, **3:38**, 114, 156
- TARGET (*see* Therapeutically Applicable Research to Generate Effective Treatments)
- Targeting INflammation using SALsalate for Type-2 Diabetes, **2:143**, **3:144-145**
- Task Force on Exercise and Physical Activity, **2:158**, **3:284**
- Taste, **3:73**, 222, 281-282
- Tau proteins, **2:52**, 207-208, **3:152-153**, **4:9**
- Taxol (*see* Paclitaxel)
- Tay-Sachs disease, **2:60**, **3:142**
- TB (*see* Tuberculosis)
- TBI (*see* Traumatic brain injury)
- TCGA (*see* The Cancer Genome Atlas)
- Technology Centers for Networks and Pathways, **5:22**
- Technology development
- aging-related research, **3:91**, 113, 164, 220-221, 246
 - animal models and, **2:26**, 50-51, 83-84, 144-145, 216-217, 223-224, **3:67-68**, 69, 216, 232-235, 244
 - approaches, **3:212**
 - ARRA funding, **3:97-98**, 167-168, 215-216, 230-231
 - artificial pancreas, **2:113**, 114, 120, **3:78**, 144
 - assessment in clinical research on, **2:7-8**, 9, 13, 20, 25
 - assistive technologies, **2:274**
 - autoimmune diseases, **2:114**, 116, **3:171-172**, 236
 - behavioral and social sciences, **3:89-90**, 91, 113, 164, 220-221, 239, 246
 - bioactive nanostructures, **2:50-51**, 223-224, **3:216**, 234
 - biodefense, **3:221**
 - bioengineering, **2:113**, 116, 275, **3:144**, 202, 211, 212, 240, 258
 - bioinformatics, **2:2**, 9, 11, 58, 81-82, 84, 114, 116, 162, **3:80**, 171-172, 236

- Technology development (*continued*)
- biomaterials, **2**:26, 41-42, 84, 144, 151, **3**:76, 84-85, 211, 232-233, 243-244, 246
 - cancer research, **1**:3, **2**:2, 4, 9, 10, 11, 14, 15, 18, 20, 24, 25, 26-27, 28, **3**:68-69, 83, 129, 134, 194, 206-207, 214, 219, 220, 222, 228, 232-233, 237, 241, 242-243, 244-245
 - cardiovascular disease, **3**:242
 - cataract detection, **2**:131, 146-147, **3**:213, 222
 - chemical carcinogenesis model, **2**:26
 - children and clinical studies campaign, **3**:226, 226, 289, 289
 - chronic diseases and organ systems, **2**:84, 125, 131, 144-147, 162, 172, **3**:84-85, 222, 224-225, 229, 243-244
 - circulating tumor cell microchip, **2**:25, **3**:211, 213
 - clinical research, **2**:162, **3**:224
 - collaborative research, **2**:9, 10, 11, 18, 28, **3**:194, 206-207, 214, 225
 - dental, **2**:216
 - diabetes, **3**:213, 222, 240
 - diagnostics and point of care, **2**:25, 93-94, 98, 146-147, 196, 202, 203, **3**:125-126, 211, 212-213, 218, 221-223, 228-229, 239, 245-246
 - disparity-reducing, **2**:247, 269, **3**:168, 231-232, 246, **4**:31, 33
 - e-health and biomedical information technology, **2**:9, 10, 11, 18, 28, 58, 125, 162, 172, 281, **3**:194, 204-207, 213-214, 217, 223-227
 - environmental exposures, **3**:211, 240
 - epigenetics, **3**:41
 - flow cytometry, **2**:116, **3**:171-172, 217, 236
 - funding, **2**:222, 274, 284, **3**:40, 98-100, 218, 227, 237
 - genetics/genomics, **2**:36, 46, 62-63, 216, **3**:32-33, 36, 40-42, 82, 92-93, 211, 214-215, 227-228, 240, 243
 - glycomics, **3**:83, 129, 237
 - high-throughput technologies, **2**:116, **3**:171-172, 211, 217, 236
 - image-guided interventions, **2**:24, 25, 31, **3**:215, 220, 228, 245-246
 - imaging biological systems, **2**:2, 9, 15, 24, 25, 31, 58, 62, 131, 145-147, **3**:15, 41, 96, 215, 218, 219, 222, 229-230, 236, 242
 - immunotherapy, **2**:83-84, **3**:233
 - in situ dendritic cell reprogramming system, **2**:26
 - infectious diseases, **2**:83-84, 98, 144, **3**:84-85, 220, 233, 243-244
 - informatics, **2**:9, 10, 11, 18, 28, 58, 125, 162, 172, 281, **3**:95, 194, 204-207, 214-215, 223-227
 - infrastructure and research resources, **2**:15, 116, 247, 269, **3**: 66, 83, 95, 97-98, 128-129, 167-168, 171-172, 195, 208, 215, 216-217, 230, 231-232, 235, 236, 237
 - intensive care monitoring system, **3**:211, 223
 - large-scale collaborative activities, **2**:116, **3**:95, 97, 128-129, 171-172, 195, 207, 208, 216-217, 235-237
 - levitation, **3**:241
 - metabolemics, **2**:84, **3**:245-246
 - microscope, **3**:211, 213, 218, 221-222
 - molecular theranostics, **2**:25, **3**:220, 244-245
 - multidisciplinary and interdisciplinary research, **2**:203, 221-222, 223, **3**:75, 99-100, 130-131, 173-174, 217-218, 237-240
 - nanotechnology, **2**:9, 14, 25, 45, 50-51, 176, 223-224, 284, **3**:134, 135, 211, 216, 218-219, 220, 234, 241, 245-246
 - neural interfaces, **2**:51, 220-221, **3**:220, 245
 - neurological research, **2**:37, 46, 50-51, 58, 61, 62-63, 220-222, 223-224, **3**:36, 92-93, 207, 216, 220, 225, 227-228, 229, 234, 237-238, 245
 - New Pathways to Discovery initiative, **3**:212
 - obstetrical, **2**:203, 218
 - pharmacological, **3**:94-95, 211, 245
 - portfolio analysis of program performance, **3**:232
 - prostheses, **2**:51, 221-223, **3**:211, 218, 220, 237-238
 - proteins, **2**:9, 26-27, 84, 98, 140-141, 144, **3**: 41, 68-69, 77, 82, 84-85, 219, 232-233, 242-244
 - protocol development, **2**:116
 - psychosocial interventions, **2**:172
 - quality assurance tools, **3**:217, 236
 - regenerative medicine, **2**:223, **3**:75, 130-131, 238
 - shared instrumentation, **3**:98, 168, 215, 230-231
 - simulation of musculoskeletal dynamics, **3**:230
 - space-related research, **3**:100-101, 213, 218, 238-239
 - stem cells, **2**:83-84, 223, **3**:75, 130-131, 216, 238, 242
 - structural biology, **3**:219
 - supercomputer, **3**:209, 214, 226
 - taste test, **3**:222-223
 - training and career development, **3**:195, 226, 251, 263-264
 - trans-NIH research, **3**:217, 219, 236, 241
 - transforming health care, **2**:25, 51, 220-221, 247, toxicology testing, **3**:87
 - virtual reality systems, **2**:222
 - Web- and computer-based interventions, **2**:172, **3**:214, 224-225, 278
 - Technology transfer, **1**:7, 39-40
 - TEDDY (*see* The Environmental Determinants of Diabetes in the Young)
 - Teens (*see* Adolescents)
 - Temporomandibular joint and muscle disorders, **2**:129, 289
 - Teriparatide, **2**:115, 246, **3**:180
 - Testicular cancer, **3**:30, 87, 110, 177
 - The Cancer Genome Atlas, **1**:3, **2**:1, 2, 4, 9, 10, 28, **3**:31, 46-47
 - The Environmental Determinants of Diabetes in the Young, **2**:110, 120, **3**:144
 - Therapeutically Applicable Research to Generate Effective Treatments initiative, **2**:4-5, 18, 212, **3**:31
 - Therapeutics for Rare and Neglected Diseases program, **1**:3, **2**:98, 135, 164-165, **3**:132-133
 - Thyroid diseases, **2**:13, 59, 132, 153, 195, 202, 205, 253, **3**:12
 - Tinnitus, **2**:38, 55
 - Tobacco Product Assessment Consortium, **2**:12
 - Tobacco Research Network on Disparities, **2**:12, 19, 247, **3**:100, 179
 - Tobacco use and related diseases
 - ADHD, **2**:161
 - adolescents, **2**:44, 146, 156, 215, **3**:288
 - alcohol abuse and, **2**:48, 148, 225
 - behavioral research, **2**:12
 - biomarkers of diseases, **2**:6, 12, 48, 148, 225
 - cancer, **2**:2, 6, 7, 10, 12, 13, 19, 23, 159, 247, **3**:12, 42, 100, 178-179, 199
 - cardiovascular disease, **2**:139-140
 - drug treatments, **2**:48, 148, 225
 - epidemiological and longitudinal studies, **2**:149, 255-256, 180-181, **3**:6, 12, 19
 - funding, **2**:287, 289
 - chronic diseases, **3**:125
 - mental disorders and, **2**:67, 133-134, 157, 224, **3**:21
 - minorities, **2**:149, 246, 255, **3**:6, 19
 - nicotine brain receptors, **2**:48, 148, 158, 225
 - military veterans, **2**:133-134, 157, 224, **3**:21
 - mortality from chronic diseases, **2**:180-181
 - nicotine vaccine, **2**:48, 158, **3**:93
 - immunology, **2**:48, 158, **3**:93
 - international research, **2**:10, 139-140, 181
 - minority health and health disparities, **2**:12, 19, 247
 - prevention of smoking, **2**:44, 156, 215
 - screening for, **2**:146, **3**:288
 - statistics and burden of illness, **2**:188
 - vulnerability to addiction, **2**:131-132
 - TODAY (*see* Treatment Options for Type 2 Diabetes in Youth)
 - Topical microbicides, **2**:76, 85-86, 88, 97, 237, 245-246, 273, 289, **3**:130, 158-159
 - Tourette Syndrome, **2**:32, 58, 289, **3**:201
 - Tox21 Collaboration, **2**:98, **3**:87
 - Toxic Release Inventory, **3**:197
 - Toxicology testing, **3**:87
 - TOXLINE, **3**:197
 - TOXNET, **3**:189, 197
 - Trachoma, **2**:81, 101

Training and career development

- aging-related conditions, **2**:204, 265, **3**:265
- Alzheimer's researchers, **4**:6
- ARRA funding, **3**:259-260
- autoimmune diseases, **2**:108, 110
- behavioral and social sciences, **3**:174, 261, 262-263
- bioethics education, **1**:43, 44, 45, 46, 47, **3**:251, 259
- biostatistics, **3**:251, 260
- cancer research, **2**:10, 19, 20-21, 140, 241, 242-243, 247, 266, **3**:97, 100, 178-179, 260, 278
- cardiovascular disease, **2**:181, 251
- Career Development Awards, **3**:253-254, 265, 267
- catalogs of activities, **3**:248
- chronic diseases, **2**:137, 140, 145, 169, 171, 181, 182, **3**:161-162
- clinical research, **2**:17, 20-21, 23, 44-45, 57, 59, 137, 146-147, 157, 171, 181, 218, 263, 268, **3**:105, 112, 116, 142, 157-158, 161-162, 169, 171, 174, 177, 231-232, 254, 256, 257, 259, 262, 264, 288, **4**:31, 44
- communicating information on, **3**:258, 280
- community-based participatory research, **2**:261-262, **3**:176
- coordination and oversight, **3**:254
- CTSA awards, **2**:243, 268, 269, **3**:105, 115, 116, 134, 168, 173, 174-175, 206, 231-232, 250, 253, 256, **5**:14
- curriculum development, **2**:239-240, 257-258
- dentists and dental hygienists, **2**:216, 239, 260, **3**:288-289
- demographic characteristics of NRSA participants, **5**:42
- diabetes, **3**:247
- diversity initiatives, **1**:5, 28, **2**:19, 20, 233, 239-240, 242-243, 265, 266-267, **3**:195, 210, 249-250, 261, **5**:42
- end-of-life care, **2**:210, **3**:263
- ethical conduct, **1**:43, 44, 47
- evaluation/assessment of NIH programs, **3**:252-253, 256, 265-267
- extramural activities, **1**:7, 11, 21, 22, 45, **2**:20-21, 242, 249-254, 267-268, **3**:105, 255-265, 266-268
- faculty development, **1**:22, **2**:20, 57, 242, 243, 244, 265, 266, 267, 268
- genetics/genomics, **3**:263
- global health research, **3**:259-260
- graduate medical education, **3**:247, 254, 264-265, **5**:43
- GRPA goals, **3**:252-253
- health care workers, **2**:78-79
- HIV/AIDS, **2**:92-93, **3**:261-262
- IC-specific programs, **2**:20-21, **3**:250-251, 260-264
- imaging technologies, **2**:57, 78-79, **3**:169, 257
- individual fellowships, **3**:248, 256, 266
- infectious diseases and biodefense, **2**:72, 73, 78-79, 92-93, 99, **3**:261-262
- informatics, **3**:187, 195-196, 209-210, 226, 251, 261, 263-264
- information resources, **1**:35, **3**:248, 252, 256, 265-266
- institutional research training grants, **3**:247, 248, 249, 255, 265, 266
- integrative medicine, **3**:263
- interdisciplinary research, **2**:21, 57, 210, **3**:169, 257, 261, 264, 268, **5**:19-20
- international program/foreign scientists, **1**:5, **2**:92-93, 140, 181, 182, 242, 264, 265, **3**:195, 226, 251, 254, 259, 261-262, 263-264, 266-267
- intramural activities, **1**:7, 11, 13, 14, 46, **2**:20-21, 242, **3**:254-255, 257-258, 263, 266
- laboratory animal welfare, **1**:46-47
- leadership/management programs, **3**:116
- loan repayment programs, **2**:243, 247, 255, 258-259
- mental health workforce, **3**:266
- mentoring programs, **1**:22, **2**:19, 247, 266, 268, **3**:100, 115, 116, 171, 173, 179, 251, 253-254, 256, 257, 259, 262, 264, 265, 266, 267, 268, 280
- minority health and health disparities research, **2**:19, 20-21, 216, 232, 233, 239-240, 241-244, 247, 251, 256, 257-258, 260, 262, 264-265, 266-267, 268, **3**:97, 100, 179, 195, 210, 260, 261, 268, 278, 288-289, **4**:28
- MSTP grants, **3**:251, 256, **5**:15
- multidisciplinary research, **2**:92, **3**:256, 259-260
- training programs for researchers, **2**:92, **3**:256, 259-260
- neuroscience, **2**:31, 39, 40, 56, 57, 59, 204, **3**:142, 169, 251, 257, **4**:21
- NRSA program, **3**:249, 250-251, 252, 255-256, 258, 265, 266, **5**:37-42
- nurse scientists, **3**:263
- obesity, **2**:140, 182
- oral health, **2**:137, 171, 216, 260, **3**:161-162
- peer tutoring, **2**:240, 257-258
- Ph.D.s awarded to NIH fellows and trainees, by field of study, **5**:37-41
- physician scientists, **3**:251, 261, 265
- policy development, **2**:19, 247
- postdoctoral, **3**:249, 251, 252, 254, 255, 256, 257-258, 259, 261, 262, 263, 265, 266, 267
- predoctoral, **3**:169, 249, 251, 255, 256, 257, 260, 261
- public-private partnerships, **3**:116, 251-252, 264-267
- rare diseases, **4**:44
- recruiting and job search tools, **3**:257-258
- regional networks, **2**:247
- senior scientists, **3**:253
- sex and gender differences, **2**:192
- stem cell research, **3**:253-254
- strategic plan, **2**:270
- summer research experiences, **1**:21, 22, 27, 57, **2**:10, 57, 169, 242, 257, 262, 263
- trans-NIH programs, **2**:57, **3**:169, 249-250, 255-260, 267-268
- transdisciplinary, **2**:20-21, **3**:260
- translational research, **2**:21, 57, 59, 108, 204, 268, **3**:169, 257, 260
- undergraduate research training, **3**:249
- Web-based, **1**:35, **2**:145, **3**:263
- women in research careers, **3**:258, 280
- women's health, **3**:253, 268
- workforce analyses, **3**:248, 258
- veterinary, **3**:171, 262
- videoconferencing, **3**:116
- women's health, **2**:192
- Training for a New Interdisciplinary Workforce, **3**:257, **5**:19-20
- Trans-NIH American Indian and Alaska Native Health Communications & Information Work Group, **3**:276
- Trans-NIH Interdisciplinary Research Working Group, **5**:20
- Trans-NIH Nanotechnology Task Force, **1**:48, **3**:219, 241
- Trans-NIH research
 - autoimmune diseases, **1**:18, **2**:108, 112, 116, 122, **3**:61, 217
 - behavioral and social sciences, **2**:133, **3**:65, 89
 - bioethics, **1**:47, **2**:245
 - cancer, **1**:17, 29-30
 - chronic diseases, **2**:49, 126, 133, 141, 145, 147, 184-185, **3**:73, 154
 - Common Fund, **1**:18
 - communicating health information, **3**:276
 - diabetes, **1**:18, **2**:69, 122
 - epidemiological and longitudinal studies, **3**:6HIV/AIDS, **2**:86-87, 92-93, 250, **3**:261-262, **5**:11
 - imaging, **1**:29-30, **2**:141
 - genetics and genomics, **2**:199 **3**:34-35, 41, 50, 82-83
 - immunology and inflammation, **2**:112, 116, **3**:61, 217
 - infectious diseases and biodefense, **2**:87, 103, 250
 - intramural, clinical, **1**:46
 - microbiome, **3**:34
 - minority health and health disparities, **2**:232, 276
 - molecular biology and basic research, **3**:34-35, 82-83, 89
 - neuroscience, **1**:18, 29-30, **2**:17, 29, 49, 39, 57, 61, 64, 68-69, **3**:73
 - rare and neglected diseases, **2**:164
 - strategic plans **1**:17-18, **2**:29, 68-69, 103, 122, 184, 228
 - undiagnosed diseases, **2**:147, **3**:154
 - women's health, **3**:180
- Trans-NIH Working Group for Research of Chronic Fatigue Syndrome, **2**:145
- Transcriptome induced phenotype remodeling, **3**:99

- Transcriptomics, **3:56**, 61, 63
- Transdisciplinary Tobacco Use Research Centers, **2:6**, 48, 131-132, 148, 225
- Transdisciplinary research (*see also* Collaborative research, Interdisciplinary research, Multidisciplinary research, Trans-NIH research), **2:6**, 19, 48, 148, 225, 247, **3:100**, 178-179
- Transdisciplinary Research on Energetics and Cancer research centers, **2:6**, 18
- Translational research (*see also* Clinical and Translational research; Drug development)
- collaborative activities, **3:104**
 - comparative effectiveness research, **3:105**
 - defined, **3:104**
 - outreach approaches, **3:105**
 - trans-NIH, **3:106**
 - veterinarian training, **3:171**, 262
- Translational Research at the Aging/Cancer Interface, **2:12**
- Translational Research Network, **2:267**, **3:116**
- Transmissible spongiform encephalopathy, **2:289**
- Transplant research
- bone marrow, **2:173-174**, **3:81**, **4:40-41**
 - children, **2:138**, 169, **3:148-149**
 - chronic diseases, **2:126**, 138, 173-175, **3:81**, 147
 - clinical and translational research, **2:138**, 173-174, **3:81**
 - corneal, **2:138**, 174-175, **3:147**
 - funding, **2:284**, 289
 - graft-versus-host disease, **4:40-41**
 - immune tolerance strategies, **2:112**, 115, 138, 174, **3:137-138**
 - kidney, **2:115**, 138, 173-174, **3:81**, 138
 - liver, **2:115**, 138, 169, 174
 - molecular biology and basic research, **2:173-174**, **3:60**, 81
 - older donors, **2:138**, 174-175, **3:147**
 - pancreatic islet, **2:112**, 113-114, 115, 120, 138, 174, **3:137**
- Traumatic brain injury, **2:32**, 33, 40, 60, 61, 63, 133-134, 157, 197, 221, 222, 224, 280, **3:21**, 142, 153
- Traumatic Brain Injury Clinical Trials Network, **2:224**, **3:110**, 153
- Treatment Options for Type 2 Diabetes in Youth study, **2:152**, 205, **3:143-144**
- TREC (*see* Transdisciplinary Research on Energetics and Cancer)
- TRENND (*see* Tobacco Research Network on Disparities)
- Triamcinolone, **2:166-167**, **3:141**
- Trimethoprim-sulfamethoxazole, **2:90**
- TRND (*see* Therapeutics for Rare and Neglected Diseases)
- Truvada, **2:68**
- TTURCs (*see* Transdisciplinary Tobacco Use Research Centers)
- Tuberculosis
- adjuvant therapy, **2:74**, 95
 - children, **2:84**, 90, **3:138**
 - clinical and translational research, **2:84**, **3:110**, 122, 138
 - diagnosis, **2:84**, 98
 - drug-resistant, **2:73**, 75, 82, 84, 90, 96, 102, **3:39**, 122, 138
 - drug therapies, **2:75**, 84, **3:138**
 - epidemiological and longitudinal studies, **2:90**, **3:11**
 - funding, **2:72**, 289
 - genomics, **2:82**, 96, **3:39**, 47, 122
 - HIV/AIDS co-infection, **2:75**, 81, 82, 84, 90, **3:11**, 138
 - international collaboration, **2:80**
 - malaria co-infections, **2:90**, **3:11**
 - molecular biology and basic research, **3:58**
 - prophylaxis, **2:90**
 - transmission, **2:71**
 - statistics and burden of illness, **2:72-73**, 139
 - strategic plans, **2:228**
 - technology development, **1:4**
 - vaccines, **2:74**, 75, 84, 95-96, 289, **3:138**
- Tuberous sclerosis complex, **2:17**, 32, 63, 64-65, 68, 286, **3:72**, 122
- Tumor Biology and Metastasis Program, **2:21**, **3:69-70**
- Tumor Microenvironment Network, **2:5**, 21, **3:69-70**
- Tumor Sequencing Project, **3:46**
- Tumor Stem Cells in Cancer Biology, Prevention, and Therapy, **2:10**
- Type 1 Diabetes Genetics Consortium, **2:132**, 152, 237, **3:35**
- Type 1 Diabetes Pathfinder Awards, **2:120**, **3:78**
- Type 1 Diabetes—Rapid Access to Intervention Development program, **2:120**, **3:78**
- Type 1 Diabetes TrialNet, **2:113**, 120, **3:144**
- ## U
- Udall Centers for Excellence in Parkinson's Disease, **2:38**, 53, **3:141**, **4:5**
- UDP (*see* Undiagnosed Diseases Program)
- Ulcerative colitis, **1:3**, **2:128**
- Ultrasound imaging, **2:131**, 147, 149-150, 252, **3:5**, 19, 40, 213, 215, 218, 229, 239
- Underage Drinking Research Initiative, **2:35**, 44-45, 157, 195, 218
- Undiagnosed Diseases Program, **1:14-15**, **2:131**, 147, **3:154**
- Unified Medical Language System, **3:192-193**, 223-224
- Uninsured (*see* Insurance coverage)
- United Health Chronic Disease Initiative, **2:140**, 181
- United Negro College Fund Special Programs Corporation, **2:240**, 256, **3:286**
- United States Renal Data System, **2:171**, **3:18**
- Urea cycle disorders, **3:166**, **4:40**
- Urinary incontinence, **2:127**, 128, 136-137, 169, 170, 186, 201
- Urinary Incontinence Treatment Network, **2:170**, **3:22**, 150
- Urinary tract infections, **2:98**, 128, 186, **3:154**
- Urology research, **2:170**, 289
- Uterine cancer, **2:233**, 289
- Uterine fibroids, **2:13**, 132, 153, 205, 253, 279, **3:12**
- U.S. Army, **3:7**, 20, 21, 146
- U.S. Census Bureau, **4:4**
- U.S. Environmental Protection Agency, **2:98**, 149, 220, 252, **3:2**, 6, 17, 19, 40
- U.S. HIV/AIDS Cancer Match Study, **2:23**
- U.S. Food and Drug Administration, **1:29**, 46, **2:6**, 8, 9, 20, 46, 47, 60, 63, 66, 75, 84, 85, 96, 98, 129, 137, 141, 153, 162, 164, 169, 173, 174, 211, 226, 228, **3:75**, 88, 92, 108, 112, 120, 121, 122, 131, 132, 137, 138, 142, 147, 148-149, 152, 154, 165, 182, 191, 193, 198, 206, 217, 244-245, 260, 287, 290
- U.S. Surgeon General (*see also* Office of the Surgeon General), **4:13**
- ## V
- VA (*see* Department of Veterans Affairs)
- VACS (*see* Veteran's Aging Cohort Study)
- Vaccine Research Center, **2:88**, **3:169-170**
- Vaccines and vaccination
- adjuvant therapy, **2:27**, 74, 95-96, 114
 - anthrax, **2:78**, 79, 82, 95, **3:155**
 - biodefense research, **2:78**, 79, 95, **3:155**
 - biomaterials system, **2:26**
 - botulism, **2:78**, 95
 - cancer, **2:6**, 17, 26, 27, 64, 81, 101, 281, **3:232-233**, 244
 - cell culture-based, **2:78**
 - drug addiction, **2:36**, 49, 163
 - Ebola virus, **1:4**, **2:79**, 95
 - egg-based manufacturing, **2:78**
 - funding for research, **2:**, 281, 283, 289-290
 - genomics, **2:82**, 83
 - Hib, **1:2**, **2:82**, 191
 - HIV/AIDS, **1:22**, **2:76**, 88, 91, 97, **3:124**, 130, 169-170
 - immune profiling, **2:81-82**, 114-115
 - immunosuppression, **2:102**
 - impact study, **2:93**
 - influenza, **2:71**, 78-79, 80, 93-96, 100, **3:125-126**
 - infrastructure for research, **2:71**, 72, 88, 93-94, 97
 - international collaboration, **2:80**, 99-100, 217
 - leishmaniasis, **2:83**
 - malaria, **2:76**, 82, 85, 283, **3:123**
 - Marburg virus, **2:79**, 95, **3:112**, 155
 - nicotine, **2:36-37**, 48, 49, 158, 163, **3:93**
 - nutrition and effectiveness of, **2:99-100**, 217
 - outreach, **2:88**, **3:169-170**
 - proteomics, **2:82**, 83
 - recombinant DNA, **2:78**, 79, 94, 95, **3:155**

- Vaccines and vaccination (*continued*)
 safety, **3:104**
 smallpox, **2:78, 79, 95, 3:155**
 TB, **2:74, 75, 84, 95-96, 286, 3:138**
 technology development, **2:78, 82, 94**
 vectors, **2:78**
 virus-like particle vaccines, **2:27, 81, 101**
 West Nile virus, **2:74, 95-96**
- Valproate, **2:38, 52, 61, 206, 3:151**
- Vancomycin-resistant *Staphylococcus aureus*,
2:74, 96, 3:39, 122
- Varenicline, **2:48, 148, 225**
- Vascular Biology of Hemodialysis Vascular
 Access Consortium, **2:137, 171, 3:18**
- Vascular endothelial growth factor, **2:129,**
140-141, 3:77
- Vascular malformations, **2:40, 60, 3:142, 4:60**
- Vasculitides, **4:40**
- Vector Biology Research Program, **2:83,**
3:124
- Vezf1 protein, **3:37, 62, 82**
- Veterans (*see* Military personnel)
- Veteran's Aging Cohort Study, **3:159**
- Veterinary medicine and research, **3:171, 262**
- Vietnamese Americans, **2:233**
- Violence research, **2:290**
- Visiting Fellowships, **3:254**
- Visual impairment (*see* Eye diseases and
 visual disorders)
- Vitamin B12, **2:34, 41, 199, 3:34, 4:32**
- Vitamin C, **2:132, 149, 212, 3:10**
- Vitamin D, **2:132, 149, 161, 212, 3:10, 147,**
217, 236, 4:15
- Vitamin D Federal Working Group, **2:161**
- Vitamin E, **2:16, 136, 169**
- VIVA! Peer Tutors program, **2:256, 3:287**
- von Willebrand disease, **2:128**
- VRSA (*see* Vancomycin-resistant
Staphylococcus aureus)
- Vulvodinia, **2:290**
- W**
- Walking Activity and the Burden of Multiple
 Morbidities, **2:134**
- Walter Reed Army Medical Center, **2:60, 197,**
222, 223, 3:60, 75, 130, 238
- Warfarin, **1:4, 3:23, 30, 38, 111-112, 114,**
143, 156
- Warren Grant Magnuson Clinical Center (*see*
 Magnuson Clinical Center)
- Web-based interventions, **2:172**
- Weight-Control Information Network, **2:259,**
3:162, 281
- Wellcome Trust, **3:188, 196**
- Wellstone Muscular Dystrophy Cooperative
 Research Centers, **4:19-26**
- Werner Syndrome, **2:25, 200, 3:77**
- West Nile virus, **2:72, 74, 93, 95, 290, 3:80,**
112, 124, 155
- White fat cells/adipose tissue, **2:130, 153**
- White House Office of National Drug Control
 Policy, **3:3**
- Whites/Caucasians, **2:12-13, 65, 87, 117, 132,**
149, 150, 208, 220, 233-236, 237, 238,
247-248, 250, 252, 253, 259, 3:5, 12, 19,
40, 43, 78, 51, 86-87, 118, 178, 250, 285,
4:29-30
- WIHS (*see* Women's Interagency HIV Study)
- Wireless Information System for Emergency
 Responders, **3:189, 208, 289**
- WISE EARS!® campaign, **3:287**
- WISER (*see* Wireless Information System for
 Emergency Responders)
- Wolman disease, **4:41**
- Women
 aging-related research, **4:15**
 autoimmune diseases, **2:108, 110, 117,**
235-236, 237, 248, 3:43, 78, 118-119,
180
 cancer, **1:1, 2:1, 2, 3, 5, 6, 12, 13, 15, 18,**
20, 22, 24, 132, 147, 153, 194, 205, 206,
208, 233, 253, 254, 262, 3:13
 cardiovascular disease, **2:13, 132, 150,**
151, 153, 159, 205, 252, 253, 3:12, 180
 chronic diseases, **2:132, 133, 136-137,**
147, 149, 152, 153, 155, 158, 169-170,
201, 212-213, 3:10
 clinical and translational research, **2:59,**
98, 245, 3:154-155, 180
 communicating information on health
 issues, **3:271, 274, 276**
 diabetes, **2:98, 127, 155, 3:154**
 endometriosis, **2:13, 132, 153, 205, 253,**
279, 3:12
 funding for research, **2:29, 3:180**
 HIV/AIDS, **2:76, 77, 78, 80, 85-86, 88,**
97, 234, 237, 245-246, 273, 3:15, 130,
158-159, 180, 4:32
 inclusion in clinical research, **1:13, 2:245,**
3:154-155, 4:6, 5:27-36
 infectious diseases, **2:85-86, 87, 98, 102,**
3:154, 158-159
 interdisciplinary research, **2:98, 3:154**
 lupus, **2:110, 117, 235-236, 237, 248,**
3:78, 118-119, 180
 mammography screening, **2:233**
 menopause, **2:98, 132, 150, 206, 252,**
3:154
- minority health and health disparities,
2:233, 234, 235-236, 237, 241, 244, 245,
270, 3:154-155, 4:32
 neurological diseases and disorders, **2:40**
 obese/overweight, **2:98, 152, 17, 192,**
195, 210, 3:22, 15, 154, 180, 4:30
 osteoporosis, **2:132, 133, 149, 212-213,**
3:10
 pain research, **2:98, 3:154**
 Pap test, **2:233**
 Parkinson's disease, **2:13, 132, 153, 205,**
253
 pelvic floor disorders, **2:136-137, 169,**
196, 201, 224, 3:110, 153
 report of Advisory Committee on
 Research on Women's Health, **5:45-50**
 rheumatoid arthritis, **2:133**
 Sister Study, **2:5, 13, 24-25, 132, 153,**
205, 253, 262, 3:12
 stress, **3:180**
 substance abuse and addiction, **2:98,**
3:154
 training and career development, **3:253,**
268
 uterine cancer, **2:233, 286**
 uterine fibroids, **2:13, 132, 153, 205, 253,**
279, 3:12
- Women's Health Initiative, **2:2, 132, 149,**
159, 206, 212, 3:10, 24, 45, 5:7
- Working Group on Women in Biomedical
 Careers, **3:258, 280**
- Women's Health Resources Web Portal,
3:274
- Women's Interagency HIV Study, **2:77, 86,**
3:15
- World Health Organization, **2:75, 83, 90, 99,**
139, 182, 217, 3:11, 124
- WormBase, **3:190**
- X**
- X-linked juvenile retinoschisis, **3:121**
- X-linked lymphoproliferative disease, **2:81,**
3:60
- X-ray imaging, **2:15, 278, 3:230**
- xTrain, **3:252-253, 265-266**
- Y**
- Young adults (*see also* Adolescents), **2:32, 33,**
44, 76, 78, 99, 108, 132, 133, 145, 150,
156-157, 201, 215, 235, 252, 254, 3:3, 4,
6-9, 16, 192, 204

**BIENNIAL REPORT OF THE DIRECTOR
NATIONAL INSTITUTES OF HEALTH · FY08-09
VOLUME 5**



U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
NIH Publication No. 11-7701 Volume 5